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Abstract 
Pironetin is a natural product with potent antiproliferative activity against various 
cancer cell lines including ovarian cancer.  Pironetin is proposed to inhibit cell division 
via formation of a covalent adduct with α-tubulin. The disruption of microtubule 
polymerization dynamics via binding to α-tubulin is a novel mechanism of action since 
current chemotherapeutics that target tubulin bind β-tubulin.  α-Tubulin is an attractive 
target for ovarian cancer since the overexpression of the α-tubulin isoform TUBAC3 has 
been reported to be a predictor for short-term survival in ovarian cancer patients who did 
not respond to platinum/paclitaxel chemotherapy. 
While pironetin displays potent in vitro activity, it had poor efficacy in a previous 
in vivo study in mice bearing P388 murine leukemia cells.  Animals treated with 
pironetin also suffered from severe weight loss.  To evaluate if pironetin would be a good 
candidate to develop as a chemotherapeutic agent, we evaluated the natural product’s 
pharmacological properties.  The natural product was found to have poor metabolic 
stability and form covalent adducts with other proteins and/or biomolecules containing a 
reactive thiol.  We hypothesized these properties were the cause of the natural product’s 
poor in vivo efficacy in the previous study.  We therefore decided to synthesize pironetin 
analogs to improve upon the natural product’s pharmacological properties and explore 
the SAR at different parts of the molecule. 
We evaluated the SAR at the α,β-unsaturated lactone of pironetin, which is 
involved in the binding between pironetin and α-tubulin.  We found that modifying the 
different stereocenters of the α,β-unsaturated lactone resulted in a loss of biological 
  v 
activity.  We also explored the addition of a functional group at the α-position of the α,β-
unsaturated lactone to decrease off-target covalent adduct formation. The 
functionalization at this position resulted in a 100-1000 fold decrease in biological 
activity.  We also evaluated the SAR of the substituent at the γ-position of the α,β-
unsaturated lactone in pironetin.  We found that groups with similar steric properties as 
the ethyl group in the natural product are tolerated at this position. 
Along with evaluating the SAR at positions of the α,β-unsaturated lactone in 
pironetin, we also synthesized an analog to potentially improve upon the natural 
product’s metabolic stability.  We exchanged the non-conjugated olefin in the natural 
product, which is the primary site of metabolism, with a phenyl group.  The phenyl-
containing analog has similar antiproliferative activity as the natural product, but did not 
have improved metabolic stability.  We have identified additional sites of metabolism of 
pironetin and the phenyl-containing analog that will need to be modified to improve upon 
the natural product’s metabolic stability.
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CHAPTER 1.  MICROTUBULE-BINDING AGENTS AND OVARIAN CANCER 
1.1 Introduction.  For 2016, the National Institutes of Health estimates ovarian cancer 
will be the 5th leading cause of cancer-related deaths in women with 14,240 associated 
deaths.1  The NIH also estimates 22,280 new diagnoses in 2016 and approximately 80% 
of ovarian cancer patients will relapse following treatment with first line taxane/platinum 
combination therapy.1,2  Based on these statistics, novel ovarian cancer chemotherapeutic 
agents with new mechanisms of action are required.  In 2011, Nikas and coworkers 
performed a bioinformatics study to identify genes overexpressed in short term ovarian 
cancer patients who survived < 3 years (short-term survivors) following platinum/taxol 
chemotherapy to patients who survived > 7 years (long-term survivors) after treatment.3  
One of the top predictive genes overexpressed in short-term survivors was TUBA3C, 
which encodes for α-tubulin.  The overexpression of TUBA3C in short-term ovarian 
cancer survivors led us to believe α-tubulin would be a good target for new 
chemotherapeutic agents. 
1.2 Microtubule-binding agents as chemotherapeutic agents.  α-Tubulin and β-tubulin 
are structural proteins that polymerize to form microtubules.  Microtubules play key roles 
in maintaining cell shape, organelle movement, and cell division.4  During mitosis, 
microtubules are responsible for separating daughter chromatids during anaphase.  
Disruption of the polymerization dynamics between α-tubulin and β-tubulin to form 
microtubules during mitosis can result in cell cycle arrest at the G2/M phase and 
subsequent apoptosis.  A number of FDA approved chemotherapeutic agent’s mechanism 
of action involves the disruption of the polymerization dynamics by either stabilizing or 
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destabilizing microtubules;5-7 these include the drugs derived from the taxanes, 
epothilones, and vinca alkaloid natural products as shown in Figure 1-1.  More recently, 
analogs of the tubulin-binding natural products dolastatin 10 and maytansine have been 
utilized as the active small molecule in antibody-drug conjugates (Figure 1-2).8,9 
 
 
While these chemotherapeutic agents have diverse chemical structures, they have 
been shown to bind to β-tubulin via X-ray crystallography at different sites of the protein 
as shown in Figure 1-4.10-14  While some compounds have overlapping binding sites, 
distinct binding sites have been identified; these include the taxane binding site, the vinca 
binding site, and the maytansine site. 
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Although tubulin-binding chemotherapeutic agents have been successful for the 
treatment of a variety of cancers, drug-resistance has been reported for these agents.7,15,16  
In ovarian cancer patients, drug-resistance to paclitaxel has been associated with changes 
in the expression level of the different isoforms of β-tubulin; increased levels of class III 
β-tubulin was shown to correlate with shorter survival in ovarian cancer patients.17,18  
While a number of drugs have been developed that target β-tubulin, no current 
chemotherapeutic agents disrupt tubulin polymerization via binding to α-tubulin.  A few 
natural products have been shown to bind to α-tubulin.  One class of natural products 
shown to bind to α-tubulin is the hemiasterlins (Figure 1-4).19-21  Hemiasterlin analogs 
Taltobulin/HTI-286 (1.7) and E7974 (1.8) have independently been developed as drug 
candidates and proceeded to Phase I clinical trials.22,23  While the hemiasterlin analogs 
were shown to bind to α-tubulin via photo cross-linking studies, taltobulin (1.7) was 
shown to bind to the vinca binding site in β-tubulin via X-ray crystallography.24  
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Haematological toxicity was reported for analog 1.8.  In addition to the hemiasterlins, the 
natural product pironetin (Figure 1-4, 1.9) has been shown to bind α-tubulin. 
 
 
1.3 Background on pironetin.  Pironetin is a polyketide natural product independently 
isolated from the fermentation of different Streptomyces strains in 1993 and 1994.25-27 
1.3.1 Biological activity.  While pironetin was initially reported as a plant growth 
inhibitor and immunosuppressant, it was subsequently shown to have potent in vitro 
antiproliferative activity with nanomolar GI50 values against a variety of cancer cell lines 
including ovarian cancer cells which overexpress the Pgp transporter.28-32  The 
overexpression of Pgp transporters is another mechanism by which cancer cells can 
develop resistance to chemotherapeutic agents via efflux of chemotherapeutic agents out 
of the cell.15  While pironetin has potent in vitro activity, it showed poor activity in vivo 
in mice bearing P388 murine leukemia cells.33  A 6.25 mg/kg IP dose resulted in 
increased survival time from 11.2 days to 14.3 days.  Animals treated with pironetin also 
showed severe weight loss. 
1.3.2 Mechanism of action.  In initial studies into pironetin’s mechanism of action, the 
natural product was found to induce G2/M phase cell cycle arrest in 3Y1 normal rat 
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fibroblast cells.33  This activity was similar to other chemotherapeutics which disrupt 
microtubule polymerization.  In tubulin polymerization assays, pironetin has been 
reported in the literature to disrupt the polymerization dynamics by either stabilizing31 or 
destabilizing34 microtubules.  To further study pironetin’s mechanism of action, groups 
have identified the pironetin binding site.  In 2004, Usui and coworkers incubated 
pironetin with α- and β-tubulin and found that pironetin labeled a 100 amino acid 
sequence of α-tubulin.35  Lysine 352 was identified as the residue involved in the binding 
with α-tubulin after alanine scanning of nucleophilic residues in this 100 amino acid 
sequence; the K352A mutation in α-tubulin resulted in an 80% decrease in pironetin 
binding.  The group proposed pironetin’s mechanism of action involved formation of a 
covalent adduct via conjugate addition of lysine 352 of α-tubulin as shown in Figure 1-6. 
In 2016, the X-ray crystal structures of pironetin bound to α-tubulin was 
independently reported by two groups.36,37  In these crystal structures, the natural product 
binds in an unique pocket not observed in the apo structure as shown in Figure 1-7.  
Pironetin formed a covalent adduct with cysteine 316 instead of lysine 352.  The covalent 
adduct formed between pironetin and α-tubulin was also detected by MS/MS 
spectrometry following incubation of pironetin with α- and β-tubulin.  The previous 
observation of the K352A mutation in α-tubulin resulting in loss of pironetin binding 
could be due to lysine 352 being involved in the binding by deprotonating cysteine 316 or 
having a role in stabilizing pironetin’s unique binding pocket. 
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1.4 Summary.  Pironetin is a natural product that has potent antiproliferative activity and 
a novel mechanism of action via its binding to α-tubulin.  These properties make it a 
potential candidate for development as a chemotherapeutic agent. 
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CHAPTER 2. EVALUATION OF PIRONETIN’S BIOLOGICAL ACTIVTY AND 
PHARMACOLOGIAL PROPERTIES. 
2.1 Introduction. While pironetin (2.1) is reported to have potent antiproliferative 
activity in vitro against various cancer cell lines, the natural product has not been further 
developed as a drug candidate.  The initial goal of our research was to evaluate whether 
the natural product would be a good candidate to develop into an ovarian cancer 
chemotherapeutic agent.  Thus we sought to confirm pironetin’s previously reported 
biological activity and evaluate its pharmacokinetic and pharmacodynamic properties, 
which had not been previously reported in the literature. 
2.2 Isolation of pironetin.  Since significant amounts of pironetin could potentially be 
required for development of the natural product into a drug, we sought to obtain pironetin 
from a biological source instead of through commercial vendors.  Our group obtained the 
previously reported pironetin-producing Streptomyces prunicolor strain PA-48153.25  The 
culture was given to the University of Minnesota Institute for BioTechnology for 
fermentation in a 200 L reactor.  The fermentation resulted in 165 kg of fermentation 
broth and also 40 kg of cell paste.  Pironetin was isolated from both the fermentation 
broth and cell paste.  While the extraction of pironetin from the cell paste was adapted 
from previously reported procedures, we performed the extraction from the fermentation 
broth through an alternative procedure.25  In the previously published procedure for the 
extraction of pironetin, the fermentation broth was extracted with ethyl acetate in a 2:1 
ratio of fermentation broth to ethyl acetate.  Due to the large volume of fermentation 
broth generated in our 200 L fermentation, large volumes of ethyl acetate and specialized 
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equipment would be required for the extraction following this procedure.  To facilitate 
the extraction of pironetin from our large volume of fermentation broth, we performed 
the extraction from the fermentation broth with a solid-phase resin that absorbs organic 
compounds from aqueous mixtures.  After incubating overnight in the fermentation broth, 
the resin was recovered following filtration of the resulting suspension.  The resin was 
rinsed with methanol to release absorbed organic compounds.  Crude extracts from both 
the cell paste and the fermentation both could be purified via standard normal-phase and 
reverse-phase chromatography to obtain pironetin in ≥95% purity. 
2.3 Evaluation of pironetin’s antiproliferative activity. The initial step in evaluating 
pironetin as a drug candidate was to confirm its previously reported antiproliferative 
activity.  We obtained drug-sensitive OVCAR5 ovarian cancer cell lines along with a 
cisplatin-resistant A2780-CP ovarian cancer cell line and its drug-sensitive parent A2780 
cell line.  The antiproliferative activity of pironetin in these cell lines was evaluated along 
with the ovarian cancer chemotherapeutic agents cisplatin and paclitaxel.  In addition to 
paclitaxel, we also compared pironetin’s biological activity to the tubulin-binding agents 
vinblastine and Taltobulin/HTI-286.  Taltobulin/HTI-286 is a hemiasterlin analog and 
Phase I clinical candidate previously shown to bind to α-tubulin binding.  The measured 
GI50 values for each compound are reported in Table 2-1. 
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Pironetin (Table 2-1, entry 1) was found to have nanomolar GI50 values against the 
various cell lines with comparable activity to paclitaxel (Table 2-1, entry 3).  Our 
measured GI50 value in the A2780 cell line was higher than the previously reported value 
of 2.9 nM for this cell line.28  Although pironetin was less active than other tubulin 
binding agents vinblastine (Table 2-1, entry 4) and Taltobulin (Table 2-1, entry 5), we 
believed the natural product had sufficient in vitro potency to warrant further evaluation 
as a drug candidate. 
2.4 Evaluation of pironetin’s pharmacokinetic and pharmacodynamic properties.  
After confirming pironetin’s in vitro antiproliferative activity, we were interested in 
evaluating its efficacy in vivo.  In a previously reported in vivo study, pironetin had poor 
efficacy in mice bearing murine P388 leukemia.33  Significant weight loss was also 
observed in mice dosed with pironetin.  Pironetin’s poor in vivo efficacy could be due to 
the natural product having poor ADME properties such as poor bioavailability, poor 
stability, poor distribution, and/or rapid clearance.  To evaluate if these properties were a 
cause for pironetin’s poor in vivo efficacy, we chose to evaluate the natural product’s 
PK/PD properties prior to performing in vivo efficacy studies. 
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2.4.1 Evaluation of pironetin’s solubility and protein binding.  One potential cause of 
pironetin’s poor in vivo efficacy could be the natural product’s poor solubility in 
biological media.  If pironetin had poor solubility, the natural product could precipitate 
following administration and result in the poor drug adsorption and in vivo efficacy.  To 
evaluate its solubility, pironetin was sent CEREP, a CRO, for solubility assays in pH = 
7.4 PBS, simulated intestinal fluid and simulated gastric fluid.  The solubility of pironetin 
was evaluated at 200 µM in these different solutions.  In the simulated intestinal fluid and 
simulated gastric fluid, pironetin was found to have solubility of 141.3 µM and 198.4 µM 
respectively.  For the pH = 7.4 PBS, pironetin soluble at the highest measured 
concentration of 200 µM.  Based on the high solubility of pironetin in the various fluids, 
we did not believe the natural product’s solubility was a significant factor in pironetin’s 
poor in vivo efficacy. 
Another factor which could impact pironetin’s in vivo efficacy could be its drug 
distribution following dosing.  One factor which could impact distribution is protein 
binding; if pironetin is predominately bound to plasma proteins in animals, the natural 
product would not be circulating at sufficient concentrations to inhibit tumor growth.  We 
contracted CEREP to evaluate protein’s protein binding in plasma in human, mouse and 
rat plasma.  We chose to evaluate the property in both mouse and rat plasma in addition 
to human plasma since future in vivo studies could be performed in either rats or mice.  
The calculated percent of protein-bound of pironetin ranged from 87% in human plasma 
to 98% in mouse plasma; the calculated percent of pironetin bound to proteins in rat 
plasma was 93%.  While we initially hypothesized the high percent protein binding in 
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mouse plasma could be the cause of pironetin’s poor in vivo efficacy in mice, a survey in 
2014 reported compounds with high protein binding have been approved as drugs by the 
FDA.  The survey reported 45% of newly approved drugs have >95% protein binding 
while 24% of new drugs have >99% protein binding.38  Based on this survey, we did not 
believe pironetin’s high protein binding was a significant factor for the poor in vivo 
efficacy and thus decided to explore additional pharmacokinetic properties of pironetin. 
2.4.2 Evaluation of pironetin’s stability.  Another potential cause for pironetin’s poor in 
vivo efficacy could be the natural product’s stability when dosed in animals.  Pironetin 
could potentially decompose in biological fluids and/or be metabolized by the liver.  
Although stability assays could be performed in vivo, we chose to evaluate this property 
in vitro since in vitro assays would provide preliminary data and require smaller 
quantities of material relative to in vivo assays. 
2.4.2.1 Synthesis of a model system.  For our studies on the stability of pironetin, we 
required a reference standard for quantitative measurements during our assays.  Since 
many analytical analysis methods for assays are performed on a HPLC instrument 
equipped with a UV detector, we chose to synthesize a standard with similar UV 
absorbance as pironetin.  We chose to synthesize reference 2.2 (Figure 2-1), which 
contains both an E-non-conjugated olefin along with an α,β-lactone similar to pironetin.  
We proposed the lactone in standard 2.2 could be synthesized following lactonization of 
Z-olefin 2.3, as shown in Scheme 2-1.  Intermediate 2.3 could be synthesized via a Z-
selective olefination reaction of aldehyde 2.4, which could be derived from methyl 
acetoacetate (2.5). 
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The forward synthesis of standard 2.2 began with the alkylation of the dianion of 
methyl acetoacetate (2.5) with a predominately trans- mixture of crotyl bromide as 
shown in Scheme 2-2.  β-Keto-ester 2.6 was reduced to secondary alcohol 2.7, and 
subsequently protected as the TBS ether.  The methyl ester in intermediate 2.8 was 
reduced to the aldehyde 2.9.  Olefination of aldehyde 2.9 with phosphonate ester 2.10 
resulted in the Z-olefin.  Ando and coworkers previously reported the olefination of β-
silyloxy aldehydes with phosphonate ester containing aromatic groups such as 2.10 to 
proceed in >90% yield with 95:5 selective for the Z-olefin over the E-olefin.39  Treatment 
of intermediate 2.11 with PPTS resulted in a one-pot deprotection of the silyl ether and 
lactonization to form standard 2.12 as a mixture of diastereomers.  The two diastereomers 
could be separated via silver-nitrate embedded silica gel column chromatography to yield 
the desired standard 2.2. 
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2.4.2.2 Evaluation of pironetin’s serum stability.  To evaluate pironetin’s stability in 
biological systems, we first chose to evaluate the natural product’s serum stability.  
Similar to the protein binding assays, the serum stability was evaluated in human, mouse 
and rat sera.  Pironetin was incubated in the sera of the different species at 37 °C.  The 
amount of pironetin remaining in serum was calculated by quenching aliquots of serum 
with a solution of standard 2.2.  The percentage of pironetin remaining in serum at 
multiple time points over a 24 h incubation are shown in Table 2-2. 
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Pironetin was found to have moderate serum stability with 35-57% of the natural product 
remaining after incubation at 37 °C for 24 h.  Since pironetin was found to be stable in 
biological media, we continued to evaluate additional pharmacological properties of 
pironetin. 
2.3.2.3 Evaluation of pironetin’s metabolic stability.  Another potential cause for 
pironetin’s poor in vivo efficacy could be the rapid metabolism of the natural product to 
an inactive metabolite.  Preliminary in vitro metabolic stability assays were performed in 
human, mouse, and rat liver microsomes by CEREP.  Liver microsomes consist of 
fractions derived from the liver containing metabolic enzymes and mimic the in vivo 
metabolism by the liver.  In human liver microsomes, the half-life of pironetin was 
calculated to be 7 min; the half-lives were not calculated in mouse or rat liver 
microsomes due to complete metabolism of the natural product within 15 min.  Due to 
these short half-lives, we hypothesize the poor metabolic stability of pironetin was the 
primary cause of the poor activity in the previous in vivo study in mice. 
2.3.3 Evaluation of non-selective covalent adduct formation with pironetin.  Along 
with evaluating the PK properties of pironetin which could impact the natural product’s 
efficacy, we also sought to determine potential causes of pironetin’s in vivo toxicity.  
Since pironetin is a covalent inhibitor, we hypothesized the toxicity could be due to the 
natural product forming covalent adducts in a non-selective manner with other proteins.  
To evaluate if pironetin could form covalent adducts with other biomolecules, we 
monitored covalent adduct formation between pironetin and the monoethyl ester of 
glutathione, which contains a reactive thiol.  Following incubation of pironetin with an 
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excess of glutathione monoethyl ester in pH 7 PBS at 37 °C, a 1:1 mixture of pironetin to 
glutathione-pironetin adduct was detected by LC-MS/MS.  Since pironetin formed 
adducts with glutathione, we hypothesized it could also form adducts with additional 
proteins containing a reactive cystine residue.  This off-target binding could be the cause 
of the severe weight loss in animals dosed with the natural product. 
2.5 Conclusion.  Following isolation of pironetin from a fermentation of Streptomyces 
prunicolor strain PA-48153, we confirmed its previously reported antiproliferative 
activity.  Pironetin was found to have nanomolar GI50 values against a panel of ovarian 
cancer cell lines with comparable antiproliferative activity as paclitaxel.  To determine if 
pironetin would be a good drug candidate, we evaluated multiple PK/PD properties of the 
natural product.  Pironetin was found to be rapidly metabolized in human liver 
microsomes and to form covalent adducts with reactive thiols.  These poor PK/PD 
properties could be the cause for the previously observed poor in vivo efficacy in mice 
bearing P388 murine leukemia cells.  Due to its poor PK/PD properties, we chose not to 
pursue developing pironetin as a single agent drug candidate.  However, we believed 
pironetin’s PK/PD properties could be improved via modification at different positions of 
pironetin.  Pironetin analogs with potent antiproliferative activity and with improved 
PK/PD properties could provide a potential candidate for development into a 
chemotherapeutic agent. 
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CHAPTER 3.  SYNTHESIS AND EVALUATION OF α-FUNCTIONALIZED 
PIRONETIN ANALOGS 
3.1 Introduction.  In our studies into the PK/PD properties of pironetin (3.1), we found 
the natural product could form covalent adducts with proteins and other biological 
molecules containing a reactive thiol.  We hypothesized that the non-selective covalent 
adduct formation could be the cause of the previously observed in vivo toxicity.  To 
decrease its toxicity, we sought to synthesize pironetin analogs with decreased off-target 
covalent adduct formation. 
In previous reports on improving the drug properties of Michael acceptors, 
researchers reported that the addition of functional groups at the α-position of Michael 
acceptors can decrease covalent-adduct formation.  Taunton and coworkers initially 
reported α-nitrile containing Michael acceptor 3.2 formed reversible covalent adducts 
with thiols, whereas non-substituted Michael acceptor 3.4 formed irreversible adducts 
(Scheme 3-1).40 
 
Taunton and coworkers proposed the Michael addition of the nitrile at the α-position of 
Michael acceptor 3.2 is reversible since the increased acidity of the α-hydrogen in adduct 
3.3 can undergo deprotonation allowing for a more rapid elimination of the thiol to 
regenerate the conjugated ester.  Taunton and coworkers subsequently found Michael 
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acceptors containing electron-deficient aromatic groups including heterocycles at the α-
position also form reversible covalent bonds with thiols.41  A reversible covalent inhibitor 
would have decreased off-target binding compared to the irreversible inhibitor.  In a 
separate study into modifying the electronic properties of Michael acceptors, Yu and 
coworkers evaluated the effect of adding a fluorine to the EGFR-TK covalent inhibitor 
afatinib (3.6) (Figure 3-1);42 the group found that the fluorine-containing analog 3.7 had 
significantly decreased covalent adduct formation when incubated with glutathione over 
the parent drug.  Based on these previous studies, we sought to synthesize pironetin 
analogs containing different functional groups at the α-position of the α,β-unsaturated 
lactone to decrease off-target binding.  SAR studies at the α-position of pironetin have 
not been previously reported in the literature. 
 
3.2 Potential synthetic routes to α-functionalized pironetin analogs via semi-
synthesis.  Due to the complexity of the natural product’s structure, the most rapid 
method to synthesize α-functionalized pironetin analogs 3.8 would be via semi-synthesis 
from pironetin isolated from our previous fermentation.  We hypothesized two potential 
routes for the semi-synthesis of desired analogs as shown in Scheme 3-2. 
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One potential route involves installation of desired functional group at the α-position via 
a direct C-H activation at the α-position.  An alternative synthetic route for analogs 3.8 
involved initial halogenation of the α-position resulting in intermediate 3.9.  The desired 
functional groups at the α-position could subsequently be introduced via a cross-coupling 
reaction.  Although the direct C-H functionalization route would be the most efficient 
route to install a functional group at the α-position, methods for the direct C-H 
functionalization are not well developed for complex natural products.  Thus, we sought 
to explore synthesis of analog 3.8 via the later 2-step halogenation/cross-coupling 
synthetic route. 
To explore the feasibility of synthesizing pironetin analogs 3.8 via a 
halogenation/cross-coupling route, we screened potential reaction conditions using model 
substrate 3.10, which contains both a non-conjugated olefin and α,β-unsaturated lactone 
similar to pironetin (Scheme 3-3). 
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The initial challenge in this synthetic route was the selective halogenation of the 
conjugated-olefin over the non-conjugated olefin.  We hypothesized that the α,β-
unsaturated lactone could be selectively-activated for halogenation by a tertiary amine 
similar to the activation of α,β-unsaturated carbonyl compounds in Bayliss-Hillman 
reactions.  A potential mechanism for the activation of the conjugated olefin is shown in 
Scheme 3-4.  We hypothesized the tertiary amine would activate the conjugated olefin via 
hetera-Michael addition into substrate 3.10; the resulting enolate 3.13 could be 
halogenated by an electrophilic halogen source.  Elimination of the amine adduct from 
intermediate 3.14 would result in the desired halogenated substrate 3.11. 
 
We explored the halogenation of substrate 3.10 with electrophilic halogenation 
reagents Br2, I2, NBS, or NIS in the presence of tertiary amine additives DABCO, TEA 
or DMAP.  These reactions resulted in a complex mixture of products resulting from the 
non-selective halogenation of either olefin along with unreacted starting material.  Due to 
the lack of selectively for the halogenation of the model substrate 3.10 and the limited 
quantities of pironetin we had obtained from our fermentation, we chose to synthesize α-
functionalized pironetin analogs 3.8 via total synthesis instead of semi-synthesis. 
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3.3 Synthesis towards α-cyanopironetin via total synthesis.  Because Taunton’s initial 
reports on reversible covalent inhibitors involved α-nitrile containing Michael acceptors, 
the first α-functionalized pironetin analog we sought to synthesize via total synthesis was 
α-cyanopironetin 3.15. 
3.3.1 First generation route.  Since a number total syntheses of pironetin have been 
reported in the literature,43-55 we chose to adapt previously reported syntheses for the 
synthesis of α-cyanopironetin 3.15. 
3.3.1.1. Keck’s pironetin total synthesis.  After surveying the different total syntheses 
of pironetin, we chose to adapt synthetic strategies previously utilized by Keck and 
coworkers for the total synthesis of pironetin (Scheme 3-5).50  In Keck’s total synthesis of 
pironetin, the α,β-unsaturated lactone was synthesized via lactonization methodology of 
β-acetoxy aldehydes developed in his group.56  Aldehyde 3.16 was synthesized from 
intermediate 3.18 via a series of functional group transformations.  β-Hydroxy ketone 
3.18 was synthesized via a stereoselective Mukaiyama aldol reaction between aldehyde 
3.19 and silyl enol ether 3.20. 
 
3.3.1.2. Retrosynthesis.  We believed that the Keck total synthesis would be amenable 
for the synthesis of analog 3.15 since we proposed to synthesize the α-cyano-α,β-
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unsaturated lactone via an intramolecular Knoevenagel condensation between the 
cyanoacetate and aldehyde in intermediate 3.21 as shown in Scheme 3-6.  Intermediate 
3.21 is similar to aldehyde 3.16 from Keck’s total synthesis with the main difference 
being the cyanoacetate group in intermediate 3.21 compared to the acetate group in 
Keck’s intermediate 3.16.  Aldehyde 3.21 would be derived from alkyne 3.22.  
Intermediate 3.22 differs from Keck’s intermediate 3.17 in that the former contains an 
alkyne instead of a trans-olefin.  In our proposed route, we planned to install the trans-
olefin from the alkyne during the late stages of the synthesis.  The alkyne could be 
converted to the trans-olefin under dissolving metal reduction conditions that also remove 
the PMB protecting group in intermediate 3.22.  A similar transformation was previously 
utilized by the Dias group in their total synthesis of pironetin.46  Intermediate 3.22 would 
be derived from the β-hydroxy ketone 3.23, which would result from a Mukaiyama aldol 
between alkyne containing aldehyde 3.24 and the previously reported silyl enol ether 3.20 
form Keck’s total synthesis. 
 
For the synthesis of aldehyde 3.24, we proposed that the aldehyde could be synthesized 
from primary olefin intermediate 3.25 as shown in Scheme 3-7.  The alkyne could be 
introduced via a displacement of the primary tosylate in intermediate 3.26.  Similar 
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strategies for introduction of an alkyne have been utilized in previous total syntheses of 
pironetin.43,46,54  Tosylate 3.26 would be synthesized from previously reported secondary 
alcohol 3.27 which can be derived from commercially available (S)-Roche ester (3.28). 
 
3.1.1.3 Forward Synthesis.  Our forward synthesis began with the protection of the 
primary alcohol of (S)-Roche ester (3.28) as the TBS ether followed by a 2-step 
conversion of the methyl ester to the aldehyde as shown in Scheme 3-8.  Aldehyde 3.31 
was reacted with the Roush organoboron crotylation reagent 3.3257,58 to give the desired 
secondary alcohol 3.27 in good yield.  Alkylation of the secondary alcohol with 
iodomethane and conversion of the TBS ether to the primary tosylate resulted in the 
desired intermediate 3.26 in 86% yield over 3 steps.  The alkyne was installed via 
displacement of the tosylate with commercially available lithium acetylide complex 3.34.  
The terminal alkyne was alkylated with iodomethane after reaction with n-BuLi to give 
intermediate 3.25. 
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We initially attempted to convert intermediate 3.25 directly to the desired aldehyde 3.24 
via ozonoylsis, but only obtained the desired product in 16% yield even when the 
reaction was performed in the presence of an ozonizable dye.59  An alternative strategy to 
convert the terminal olefin to the aldehyde, we proposed to perform the dihydoxylation of 
intermediate 3.25 followed by oxidative cleavage of the resulting diol 3.36 to the desired 
aldehyde.  We screened various conditions for both the dihydroxylation and oxidative 
cleavage as shown in Table 3-1 and Table 3-2 respectively. 
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We found the optimal reactions conditions for the conversion of intermediate 3.25 to 
aldehyde 3.24 to be via dihydroxylation with AD-mix-α60 (Table 3-1, entry 3) followed 
by oxidative cleavage with (diacetoxyiodo)benzene61 (Table 3-2, entry 2).  The reaction 
sequence could be performed without purification of the intermediate diol 3.36 to give 
the desired product in 60% yield over 2 steps (Scheme 3-9).  Although the 
stereochemistry of secondary alcohol intermediate diol 3.36 is insignificant in the 
dihydroxylation/oxidative cleavage sequence, we were interested if different AD-mix 
mixtures would impact the dihydroxylation and oxidative cleavage of olefin 3.25.  The 
same reactions in Scheme 3-9 performed with AD-mix-β instead of AD-mix-α resulted in 
the synthesis of aldehyde 3.24 in decreased yield of 40%; these results suggest potential 
substrate preference for the dihydroxylation of olefin 3.25 with the AD-mix-α. 
 
Following completion of the synthesis of the aldehyde 3.24, the desired 
Mukaiyama aldol silyl enol 3.20 was synthesized following minor modification of Keck’s 
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reported route as shown in Scheme 3-10.50  The synthesis of the silyl enol ether began 
with the diastereoselective alkylation of the dienolate of amide 3.38 to give olefin 3.39.  
Pseudoephedrine amide 3.39 was reduced to the primary alcohol and protected as the 
PMB ether.  Methyl ketone 3.40 was synthesized following by dihydoxylation/oxidative 
cleavage of the 1,1-disubsituted olefin.  Our synthesis of ketone 3.40 varied from Keck’s 
synthesis in that we performed the PMB ether synthesis with commercially available 
PMBCl instead of PMBBr.  Following Keck’s previously reported reaction conditions, 
silyl enol ether 3.20 was synthesized via trapping of the lithium enolate of ketone 3.40 
with TMSCl.  The crude silyl enol ether was used without further purification. 
 
Crude silyl enol ether 3.20 was reacted with aldehyde 3.24 in the presence of BF3•Et2O 
to give the desired β-hydroxy ketone 3.23 in good yield (Scheme 3-11).  Evans and 
coworkers developed models for the Mukaiyama aldol between silyl enol ethers and 
aldehydes containing either an α-substituent and/or a β-alkoxy substituent.62  The model 
predicts the addition of silyl enol ether 3.20 would be directed to the desired Re face of 
aldehyde 3.24 in the presence of BF3•Et2O by both the α-and β-stereocenters to give 
desired product 3.23. 
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A samarium-catalyzed Evans-Tischenko63 disproportionation reaction between β-hydroxy 
ketone 3.23 and acetaldehyde resulted in the simultaneous protection of the secondary 
alcohol as the acetate ester and directed reduction of the ketone.  Enders and coworkers 
previously used a similar reaction in their total synthesis of pironetin.47  To confirm the 
relative configuration from the disproportionation reaction, intermediate 3.41 was 
converted to acetonide 3.42 over 2 steps as shown in Scheme 3-12.  The 13C NMR 
resonances of for the acetonide (Figure 3-2) were consistent with chemical shifts reported 
by Rychnovsky and coworkers for the corresponding anti-1,3-diol acetonide.64 
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The synthesis towards α-cyanopironetin analog 3.15 continued with the DCC coupling of 
the secondary alcohol 3.41 with cyanoacetic acid.  In our attempt to covert the alkyne in 
intermediate 3.43 to the trans-olefin and remove the PMB protecting group under 
dissolving metal reduction conditions, we did not obtain desired intermediate 3.44.  The 
reaction conditions not only resulted in our desired transformations but also the cleavage 
of the ester groups.  Due to the cleavage of the acetyl esters, we abandoned our initial 
route and sought an alternative synthetic route for the synthesis of α-cyanopironetin 3.15. 
3.3.2 Second generation route.  While we were originally unsuccessful in synthesizing 
desired analog 3.15, we hypothesized we could complete the synthesis by rearranging the 
functional group transformations from the original route. 
3.3.2.1 Retrosynthesis. To avoid late-stage cleavage of the acetate esters during the 
conversion of the alkyne to the trans-olefin in our original route, we proposed a revised 
route in which the non-conjugated olefin would be introduced prior to the stereoselective 
Mukaiyama coupling as shown in Scheme 3-13.  The updated route maintained our 
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original synthetic strategy of synthesizing the α-cyano, α,β-unsaturated lactone via an 
intramolecular Knoevenagel condensation from intermediate 3.45.  Aldehyde 3.45 could 
be synthesized from previously reported intermediates 3.18, 3.19, and 3.20 from Keck’s 
pironetin total synthesis utilizing reactions from our original route.50 
 
For the synthesis of aldehyde 3.19, we did not think that our previously utilized 
route for the synthesis of aldehyde 3.24 could be applied for the synthesis of aldehyde 
3.19.  In our original route, aldehyde 3.24 was synthesized via the dihydroxylation and 
oxidative cleavage of a terminal olefin.  Aldehyde 3.19 could not be synthesized from the 
corresponding terminal olefin due to the presence of the 1,2-disubustituted trans-olefin.  
The dihydroxylation and oxidative cleavage would not be selective between the two 
olefins since the dihydroxylation with AD-mix-α can occur at both the terminal olefin 
and the 1,2-disbutituted E-olefin.60  Thus, we sought alternative routes for the synthesis 
of aldehyde 3.19. 
In our synthetic route for aldehyde 3.19, we followed a similar strategy used by 
Keck and coworkers for the synthesis.50  Similar to Keck’s synthesis of aldehyde 3.19, 
we proposed the aldehyde could be synthesized from intermediate 3.46 as shown in 
Scheme 3-14.  For the synthesis of alkyne 3.46, we chose to deviate from Keck’s 
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synthetic route of the common intermediate.  We proposed to synthesize the intermediate 
3.46 from intermediates from our previous synthesis.  The alkyne would be introduced 
via displacement of the primary tosylate in intermediate 3.47, which could derived from 
previously utilized silyl ether 3.33. 
 
3.3.2.2 Forward synthesis of the carbon-skeleton.  The synthesis of aldehyde 3.19 
began with the ozonolysis of olefin 3.33 followed by reduction of the intermediate 
ozonide with NaBH4 to yield the primary alcohol as shown in Scheme 3-15.  Primary 
alcohol 3.48 was subsequently protected as the benzyl ether.  The silyl ether in 
intermediate 3.49 could be converted to intermediate 3.46 following previous reactions 
for the synthesis of alkyne 3.25.  Under dissolving metal reduction conditions previously 
reported by Keck and coworkers, the one-pot conversion of the alkyne to the trans-olefin 
and deprotection of the benzyl ether of intermediate 3.46 resulted in the previously 
reported primary alcohol 3.51.50  The primary alcohol was oxidized to aldehyde 3.19 and 
reacted with silyl enol ether 3.20 to give previously reported β-hydroxy ketone 3.18.50  
Intermediate 3.52 was synthesized from β-hydroxy ketone 3.18 following samarium-
catalyzed Evans-Tischenko disproportionation reaction with acetaldehyde.  The relative 
configuration of the secondary alcohol from the disproportionation reaction was 
confirmed following hydrolysis of the acetate ester 3.52 to previously reported diol 3.54 
as shown in Scheme 3-16.50  We completed the synthesis of the desired intermediate 3.44 
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following DCC coupling of the secondary alcohol of intermediate 3.52 and DDQ removal 
of the PMB ether. 
 
 
3.3.2.3 Model systems to evaluate the intramolecular Knoevenagel condensation.  
Following the synthesis of the carbon skeleton of the desired α-cyanopironetin analog 
3.15, we needed to evaluate conditions for both the oxidation of intermediate 3.44 to 
aldehyde 3.45 and the subsequent Knoevenagel condensation for the synthesis of α-
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cyano-α,β,-unsaturated lactone 3.55 (Scheme 3-17).  Since both reactions would need to 
be optimized, we chose to screen reaction conditions for the synthesis of α-cyano-α,β,-
unsaturated lactone 3.56 from model substrate 3.57 (Scheme 3-18). 
 
 
3.3.2.3.1 First generation model substrate.  We initially synthesized model substrate 
3.59 over 3 steps from aldehyde 3.60 as shown in Scheme 3-19.  Following vinyl 
Grignard addition into aldehyde 3.60, the resulting secondary alcohol was coupled with 
cyanoacetic acid to give intermediate 3.62.  Hydroboration of olefin 3.62 resulted in the 
desired model substrate.  During our screen of different oxidants for the conversion of 
alcohol 3.59 to aldehyde 3.63, we found that Dess-Martin periodinane oxidation of 
alcohol 3.59 resulted in the synthesis of desired aldehyde along with the α-cyano, α,β-
unsaturated lactone condensation product 3.64.  These results suggested that the 
intramolecular Knoevenagel condensation of aldehyde 3.63 could occur under mild 
conditions. 
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The facile intramolecular condensation was not unexpected since the aldehyde was not 
isolated in our previous attempts to synthesize aldehyde 3.63.  In an earlier synthesis of 
aldehyde 3.63 to evaluate conditions for the intramolecular Knoevenagel condensation, 
we attempted the synthesis of our desired aldehyde via ozonolysis of olefin 3.66. Olefin 
3.66 was synthesized over 2 steps from aldehyde 3.60 as shown in Scheme 3-20.  Instead 
of isolating aldehyde 3.63, the ozonolysis resulted in synthesis of α-cyano-α,β-
unsaturated lactone 3.64 in good yield following intramolecular condensation of aldehyde 
3.63 under the reaction conditions. 
To improve upon the oxidation/Knoevenagel condensation of model substrate 
3.59, we attempted to facilitate the Knoevenagel condensation with the addition of an 
external base.  The addition of base following the oxidation of alcohol 3.59 resulted in a 
mixture of products including α,β-unsaturated aldehyde 3.67 resulting from the β-acetoxy 
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elimination of aldehyde 3.63 (Scheme 3-21).  Although we discovered the desired 
intramolecular Knoevenagel condensation could occur under mild conditions, we 
believed our initially screened reaction conditions could not be applied for the synthesis 
of desired lactone 3.55 due to the generation of a mixture of products. 
 
3.3.2.3.2 Second generation model substrate.  To improve reaction conditions for the 
oxidation/Knoevenagel condensation reactions, we hypothesized that the formation of the 
α,β-unsaturated aldehyde byproduct could be suppressed if the reaction was performed 
with the more elaborate model substrate, 3.57, containing an alkyl group along the 
backbone.  The addition of an alkyl group in the model system could decrease the rate of 
β-acetoxy elimination from aldehyde 3.58.  Screening reaction conditions with model 
substrate 3.57 containing an alkyl group would also accurately mimic our substrate 3.44 
due to the similarities between the two structures. 
We completed the synthesis of a second generation model substrate 3.70 
containing an ethyl group at the desired position.  The synthesis of the updated model 
substrate was accomplished using the previous synthetic route for the synthesis of model 
substrate 3.59 as shown in Scheme 3-22.  α-Cyano-α,β-unsaturated lactone 3.71 was 
synthesized in moderate yield following the Dess-Martin periodinane oxidation of model 
substrate 3.70 and stirring the resulting aldehyde with basic alumina; the potential α,β-
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unsaturated aldehyde elimination byproduct was not observed under these reaction 
conditions. 
 
With these updated conditions, we attempted the oxidation/Knoevenagel condensation of 
our synthetic intermediate 3.44.  Although aldehyde 3.45 was synthesized via Dess-
Martin periodinane oxidation of alcohol 3.44, treatment of the crude aldehyde with basic 
alumina did not yield desired lactone 3.55; the primary product observed by 1H NMR 
analysis of the crude material was the α,β-unsaturated aldehyde 3.72 as shown in Scheme 
3-23.  Although the α-cyano-α,β-unsaturated lactone 3.71 was synthesized under these 
conditions, we hypothesized that lactone 3.55 was not synthesized due to the different 
relative configuration of the groups of intermediate 3.44 and model substrate 3.70.  The 
relative configuration of these intermediates could affect the relative rates for the desired 
Knoevenagel condensation over the observed β-acetoxy elimination. 
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3.3.2.3.3 Third generation model substrate.  Since the relative configuration of model 
substrate 3.58 can effect the product distribution during the intramolecular Knoevenagel 
condensation, we chose to rescreen reaction conditions with a third model substrate, 3.73, 
containing similar relative configuration as our synthetic intermediate 3.44.  The relative 
configuration in substrate 3.73 was established via syn-selective aldol reaction between 
methyl propionate (3.74) and aldehyde 3.60 under reaction conditions reported by 
Masamune and coworkers (Scheme 3-24).65  The reduction of ester 3.75 with LAH 
resulted in diol 3.76.  The primary alcohol was protected as the PMB ether allowing for 
selective coupling of the secondary alcohol with cyanoacetic acid to give intermediate 
3.78.  The desired model substrate 3.73 was obtained following DDQ removal of the 
PMB protecting group. 
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We screened a variety of bases for the desired oxidation/Knoevenagel condensation of 
alcohol 3.73 for the synthesis of lactone 3.79 as shown in Table 3-3.  Although we 
observed the desired lactone following the Knoevenagel condensation in the presence of 
basic alumina following the oxidation of alcohol 3.73 (Table 3-3, entry 1), the major 
product was the β-acetoxy elimination byproduct, aldehyde 3.80.  This result is consistent 
with the observation of α,β-unsaturated aldehyde 3.72 as the product following the 
oxidation and Knoevenagel condensation of intermediate 3.44 under similar reaction 
conditions (Scheme 3-23).  In addition to basic alumina, we screened other bases for the 
desired intramolecular condensation.  We found sodium hydride to be the optimal base 
for the desired condensation (Table 3-3, entry 4).  Although lactone 3.79 was isolated in 
low yield, the lactone was synthesized with high preference over the α,β-unsaturated 
aldehyde 3.80 byproduct. 
With our updated Knoevenagel condensation conditions, we attempted to 
synthesize desired lactone 3.55 to continue the synthesis of desired α-cyanopironetin 
3.15.  The DMP-oxidation of intermediate 3.45 and subsequent Knoevenagel 
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condensation with sodium hydride resulted in the synthesis of the desired lactone as 
shown in Scheme 3-25. 
 
Lactone 3.55 was found to epimerize at the γ-position during purification and was 
isolated as a mixture of diastereomers.  We hypothesized that the addition of the nitrile at 
the α-position increased the acidity of the γ-hydrogen resulting in epimerization under 
both normal phase and reverse phase column chromatography conditions.  We attempted 
to complete the synthesis of analog 3.15 as a mixture of epimers at the γ-position , but 
found the hydrolysis of the acetate protecting group of penultimate intermediate 3.55 to 
be difficult because of the activated Michael acceptor in α-cyano-α,β-unsaturated lactone.  
Due to the epimerization of the γ-position and challenging late-stage removal of the 
acetate protecting group in intermediate 3.55, this route was also abandoned for the 
synthesis of the α-cyanopironetin 3.15. 
3.4 Synthesis and evaluation of α-functionalized pironetin analogs containing 
various functional groups. While we were initially unsuccessful with the synthesis of α-
cyanopironetin 3.15, other functional groups such as fluorine or electron-deficient 
aromatic groups at the α-position of pironetin could also decrease off-target covalent 
adduct formation.  Thus, we chose to synthesize analogs 3.8 containing varying 
functional groups at the α-position. 
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3.4.1 Retrosynthesis.  Since we proposed to synthesize a series of pironetin analogs 3.8 
containing different functional groups at the α-position, we did not believe an 
intramolecular Knoevenagel condensation could be applied for the synthesis of α,β-
unsaturated lactones with varying groups at the α-position.  Although our previous 
synthesis of analog 3.15 used the same retrosynthetic disconnection as Keck for the 
synthesis of the α,β-unsaturated lactone, the mechanisms for the different reactions used 
to synthesize the lactone are significantly different. 
 
 
In our synthesis of the α-cyano-α,β-unsaturated lactone 3.55, we proposed the 
intramolecular condensation proceeds through a traditional Knoevenagel condensation as 
shown in Scheme 3-26.  In Keck’s synthesis for the α,β-unsaturated lactone of pironetin, 
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the mechanism for the synthesis of the lactone begins with an intermolecular acetate aldol 
between the lithium enolate of methyl acetate and aldehyde 3.16 as shown in Scheme 3-
27.50,56  The α,β-unsaturated lactone is synthesized following an acyl migration in 
intermediate 3.83, lactonization of intermediate 3.84, and elimination of the β-acetate 
ester.  Due to the different mechanisms for the same retrosynthetic disconnection for the 
synthesis of α,β-unsaturated lactones 3.55 and 3.86, a significant amount of optimization 
of reaction conditions could be required for the synthesis of α-functionalized-α,β-
unsaturated lactone of pironetin analogs 3.8 thru a similar retrosynthetic disconnection.  
Thus, we sought an alternative strategy that could be applied for the synthesis of a variety 
of α-functionalized-α,β-unsaturated lactones. 
In previously reported total syntheses of pironetin, the most common strategy for 
the synthesis of the α,β-unsaturated lactone is thru an intramolecular lactonization of a Z-
α,β-unsaturated ester with a hydroxyl group.45,46,48,49,53,54  We propose to utilize this 
method for the synthesis of our α–functionalized-α,β-unsaturated lactone in analogs 3.8 
as shown in Scheme 3-28. 
 
Intermediate 3.87 could be synthesized via a selective olefination of the aldehyde 3.88.  
A variety of different olefination conditions have been reported for the synthesis of the 
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tri-substituted olefin of intermediate 3.87 with the desired olefin geometry; conjugated 
esters containing halides and alkyl groups at the α-position have been synthesized thru 
this method.66-70  Since intermediate 3.88 contains the polyketide backbone of pironetin, 
we believed this could be synthesized via iterative aldol reactions from previously 
utilized alcohol 3.51.  A similar iterative aldol/lactonization strategy was utilized by 
Crimmins and coworkers for the total synthesis of pironetin as shown in Scheme 3-29.45  
The Crimmins group utilized thiazolidinethiones 3.90 and 3.93 for the diastereoselective 
aldol reactions to synthesize pironetin’s polyketide backbone with the appropriate 
stereochemistry.  One advantage of the diastereoselective aldol reactions with 
thiazolidinethiones over similar Evans oxazolidinones is that thiazolidinethione amides 
can be converted directly to the corresponding aldehyde, whereas conversion of the 
oxazolidinone amides to the corresponding aldehydes is performed over two-steps. 
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3.4.2 Forward synthesis.  3.4.2.1 Synthesis of the polyketide backbone.  Similar to 
Crimmins’ synthetic route, the first aldol reaction for the synthesis of the backbone of 
analogs 3.8 is a stereoselective acetate aldol with aldehyde 3.19.  Conditions for the 
boron and titanium enolate additions of N-acetyl thiazolidinethiones have been reported 
to occur with high diastereoselectivity.71-73  The facial selectivity of the acetate addition 
varies with the reactions conditions for the generation of the enolate.  We chose to 
perform the acetate aldol with tert-leucine derived thiazolidinethione 3.97 instead of 
Crimmins’s thiazolidinethione 3.90 since the former thiazolidinethione precursor is 
readily synthesized from the commercially available unnatural amino acid.71 
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The oxidation of alcohol 3.51 to aldehyde 3.19 and the subsequent addition of the boron 
enolate of thiazolidinethione 3.97 proceeded in moderate yield to give intermediate 3.98 
(Scheme 3-28).  Protection of the secondary alcohol as the TBS silyl ether followed by 
diisobutylaluminum hydride cleavage of the chiral auxiliary resulted in aldehyde 3.100.  
A second diastereoselective aldol addition was performed with thiazolidineone 3.93 
under similar conditions reported by the Crimmins45 and Marco74 groups for synthesis 
pironetin and related analogs.  We completed the synthesis of the polyketide backbone 
following conversion of intermediate 3.101 to aldehyde 3.103 following previously 
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utilized conditions for the protection of the secondary alcohol and removal of the chiral 
auxiliary. 
3.4.2.2 Olefination conditions.  Although we initially planned to introduce a variety of 
different groups at the α-position of analogs 3.8 via a diastereoselective olefination of 
intermediate 3.103, previous reports on the selective olefination reaction for the synthesis 
of tri-substituted olefins include the synthesis of α-functionalized conjugated esters 
containing alkoxides,75 halides67-70 or alkyl groups66 at the α-position.  Based on the 
limited literature precedent, we initially chose to synthesize analogs containing these 
previously reported groups. 
3.4.2.2.1 Olefination with commercially available 2-fluoro-2-phosphonoacetate.  
Although different olefination regents have been reported for the synthesis of tri-
substituted olefins, only one phosphonate ester suitable for our desired olefination 
reaction was available thru commercial vendors.  In 1964, Machleidt and Wessendorf 
reported the synthesis of E-α-fluoro-α,β-unsaturated esters from the olefination reaction 
with commercially-available triethyl 2-fluoro-2-phosphonoacetate (3.104);68 the 
commercial availability of the reagent is advantageous for our analog syntheses since the 
fluorinated analog is one desired analog.  Fluorine at the α-position of Michael acceptors 
has been shown to decrease covalent adduct formation with glutathione.42 
Following previously reported olefination conditions with phosphonate 3.104, we 
synthesized tri-substituted olefin 3.105 from aldehyde 3.103 as shown in Scheme 3-31.  
While the 1H NMR analysis of the 1H-19F coupling constants68 of the β-hydrogen of the 
α,β-unsaturated ester 3.105 in the crude product showed selective synthesis of the desired 
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E-olefin, the 1H NMR spectrum also showed the presence a second E-olefin byproduct.  
The mixture of products ranged from a 7:1 to 2:1 with the major product being the 
desired olefin 3.105.  Although the isomers could be separated via silica gel flash 
chromatography, we proceeded to evaluate alternative olefination conditions for the 
synthesis of ester 3.105 as a single product. 
 
3.4.2.2.2. Synthesis of phosphonate esters.  Although only one selective olefination 
reagent for the synthesis of α-substituted α,β-unsaturated ester was commercially-
available, additional phosphonate esters could be synthesized in one or two steps from 
commercial starting materials.  Ando and coworkers previously reported the synthesis of 
Z-α-methyl-α,β-unsaturated esters via the olefination with phosphonate ester 3.101a.66  
Similar aryl phosphonate esters containing either a bromine or chlorine at the 2-position 
have utilized for the synthesis of desired E-α-halo-α,β-unsaturated esters.67,69,70  Although 
the addition of a methyl group, chlorine, or bromine at the α-position of Michael 
acceptors have not been previously reported to decrease off-target covalent adduct 
formation, we chose to install these groups at the α-position of analogs 3.8 to evaluate the 
effect of adding groups with varying electronic properties to the α-position of pironetin. 
Due to precedent for the selective olefination with aryl phosphonate esters, we 
synthesized phosphonate esters 3.106 containing different group at the 2-position from 
  45 
previously utilized phosphonate ester 3.107 in varying yield (Table 3-4).  Quenching the 
sodium enolate anion of phosphonate 3.107 with electrophilic reagents also resulted in 
the synthesis of difunctionalized phosphonate esters 3.108 as a byproduct; the 
disubstituted phonate esters 3.108 were separated from desired phosphonate esters 3.106 
via silica gel chromatography. 
 
Although the olefination with aryl 2-fluorophosphoante esters has not been reported in 
the literature, we attempted to synthesize fluorine-containing ester 3.106d following 
previously reported methods for the electrophilic fluorination of phosphonate esters;76 
impure phosphonate ester 3.106d was only obtained in low yield.  We were, however, 
able to synthesize phosphonate ester 3.106d from phosphite 3.109 as shown in Scheme 3-
32.  The desired phosphonate ester was synthesized in moderate yield via substitution of 
the chloro groups of phosphite 3.109 with o-cresol and subsequent Arbuzov reaction with 
ethyl bromofluoroacetate (3.110). 
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3.4.2.3 Completion of the synthesis of the first series of α-functionalized pironetin 
analogs. Following the synthesis of phosphonate esters 3.106, we performed the 
olefination reactions between aldehyde 3.103 and our synthesized phosphonate esters 
(Scheme 3-33).  The desired α-functionalized-α,β-unsaturated esters 3.105 and 3.111 
were synthesized in varying yield.  The olefination with phosphonate ester 3.106a 
proceeded with the highest yield; the relative geometry of the α,β-unsaturated ester in 
intermediate 3.111a was confirmed from an observed NOE correlation between the α-
methyl group and the β-hydrogen.  Although the olefination of the chloro- and bromo-
phosphonate esters proceeded in low yield, we were able to recover a significant amount 
of unreacted aldehyde 3.103.  For the olefination with 2-fluorophosphonate ester 3.106d, 
we obtained the α-fluoro-α,β-unsaturated ester 3.105 as a single isomer with the desired 
E-geometry of the conjugated olefin; this was an improvement upon our previous 
olefination attempt with commercial phosphonate ester 3.104.  Following the olefination 
reaction, we completed the synthesis our first series of pironetin analogs 3.112 following 
lactonization of the α,β-unsaturated esters under acidic conditions. 
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3.4.2.4 Functionalization via cross-coupling with α-bromopironetin.  Although we 
were limited in the different type of the functional groups we could install directly via our 
olefination strategy, we hypothesized that we could introduce additional functional 
groups at the α-position via a transition metal catalyzed cross-coupling reaction with α-
bromopironetin 3.112c.  We previously proposed to introduce groups via cross-coupling 
in our earlier proposed semi-synthesis routes for the synthesis of α-functionalized 
pironetin analogs.  Although we could also perform the cross-coupling reaction with α-
chloropironetin 3.112b, we chose to focus on the cross-coupling with analog 3.112c due 
to the increased reactivity of vinyl bromides over vinyl chlorides.  In addition to the 
coupling with aromatic nucleophiles via a Stille, Suzuki, or Negeshi coupling, a wide 
variety groups could be installed via a transition-metal cross-couplings reaction since 
methods have been reported for the conversion of aryl or vinyl bromides to a variety of 
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groups such as an aniline,77 phenol,78 ester,77 amide,77 nitrile,79 or CF3 group.80-82  
However, a number of these methods require harsh reaction conditions such as elevated 
temperatures or the addition of a strong base.  These conditions could potentially result in 
the decomposition of analog 3.112c and/or epimerization at the γ-position of the α,β-
unsaturated lactone during the cross-coupling reaction. 
3.4.2.4.1 Cross-coupling model substrate synthesis.  Due to the numerous published 
cross-coupling reaction conditions and the limited amount of α-bromopironetin 3.112c, 
we chose to evaluate potential cross-coupling conditions with model substrate 3.113 
containing a α-bromo-α,β-unsaturated lactone.  As shown in Scheme 3-34, the model 
substrate was synthesized via an analogous olefination/lactonization route utilized for the 
synthesis of our pironetin analogs.  β-Hydroxy ester 3.75 was converted to aldehyde 
3.115 following protection of the secondary alcohol and reduction of the methyl ester to 
the corresponding aldehyde.  Olefination and subsequent lactonization under previously 
utilized conditions resulted in the synthesis of model substrate 3.113. 
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3.4.2.4.2 Cyanation cross-coupling.  One of the initial groups we sought to install via a 
cross-coupling reaction was a nitrile.  We had been unsuccessful in the synthesis of α-
cyano analog 3.15 from previous routes, and hypothesized that the cross-coupling 
between vinyl bromides 3.111c or 3.112c and cyanide could be an alternative route for 
the synthesis of the desired analog.  The palladium-catalyzed coupling between aryl 
halides and zinc cyanide has been reported to occur at ambient temperature in the 
presence additional zinc metal.83  Cyanation reactions have been reported with palladium 
catalysts containing PtBu3 as a ligand.  Researchers at AstraZeneca previously utilized the 
[(tBu)3PPdBr]2 complex as a precatalyst for the cyanation of aryl bromides for the 
synthesis of an active pharmaceutical ingredients.84 
Although we synthesized model substrate 3.113, initial studies into the cyanation 
coupling reaction were performed with α-bromo-α,β-unsaturated ester 3.116.  We 
proposed that following the coupling of vinyl halide 3.116 with zinc cyanide, we could 
complete the synthesis of the α-cyano, α,β-unsaturated lactone 3.117 following 
lactonization of cross-coupling product 3.118 as shown in Scheme 3-35.  If this route was 
successful, we could apply our reaction conditions for the synthesis of α-cyanopironetin 
3.15 from vinyl halide 3.111c.  Following previously reported cyanation conditions, the 
coupling of 3.111 with 1.8 equiv zinc cyanide catalyzed by 5% [(tBu)3PPdBr]2 in the 
presence of 0.12 equivalents Zn metal resulted in intermediate 3.118 in 87% yield.  
Although the cyanation coupling proceeded in high yield, we were unable to cyclize α-
cyano-α,β-unsaturated ester 3.118 to lactone 3.117 even in the presence of a Brønsted or 
Lewis acid. 
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Although we couldn’t synthesize the desired α-cyano-α,β-unsaturated ester 3.117, the 
successful coupling of vinyl halide 3.116 with zinc cyanide suggested we could 
synthesize the α-cyanopironetin 3.15 via a palladium catalyzed cyanation reaction.  We 
attempted the cyanation with α-bromopironetin 3.112c under similar reaction conditions 
as shown in Scheme 3-36.  α-Cyanopironetin 3.15 was obtained in moderate yield as 
mixture of products.  Although epimerization at the γ-position was foreseen from our 
previous attempts to synthesis analog 3.15, additional inseparable byproducts were 
generated under the reaction conditions.  We hypothesized that these additional 
byproducts could be due to side reactions between the secondary alcohol of α-
bromopironetin 3.112c and the palladium catalyst.  We subsequently protected the 
secondary alcohol of α-bromopironetin 3.112c as the TBS ether and submitted vinyl 
halide 3.119 to similar cyanation conditions as shown Scheme 3-37.  To our surprise, 
only trace amounts of coupling product 3.120 were observed.  Due to requirement for 
additional optimization of cyanation conditions of either vinyl halide 3.112c or 3.119 and 
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the epimerization at the γ-position of α-cyano-α,β-unsaturated lactones, we abandoned 
the synthesis of analog α-cyanopironetin 3.15 altogether. 
 
3.4.2.4.3 Suzuki cross-coupling.  Since Taunton and coworkers had reported that the 
Michael acceptors containing electron-deficient aromatic groups at the α-position were 
also reversible covalent inhibitors, we hypothesized that α-aryl pironetin analogs could 
also have decreased off-target covalent adduct formation.41  These analogs could be 
readily synthesized via cross-coupling reaction between α-bromopironetin 3.112c and an 
aryl nucleophile.  Although various aryl nucleophiles could be utilized for the cross-
coupling reactions, we focused on exploring Suzuki couplings with an arylboron reagent 
due to the commercial-availability and functional-group tolerance of these reagents.  
Various catalysts and reaction conditions have been reported for the Suzuki coupling of 
aryl halides under mild conditions.  Our initial survey of various Suzuki coupling 
conditions focused on catalyst and reaction conditions that occur at room temperature and 
did not require the addition of a strong base.  Fu and coworkers previously reported the 
Pd2(dba)3/PtBu3 catalyzed coupling of aryl bromide with boronic acid at room 
temperature in the presence of potassium fluoride as a base.85  More recently, Buchwald 
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and coworkers reported the coupling of aryl halides with fluorinated boronic acids at 
room temperature in the presence of potassium phosphate catalyzed by cyclometalled 
Xphos Pd G2 complex.86  Based on these two reports, we screened previously reported 
Suzuki coupling conditions utilizing either Pd/PtBu385,87,88 or Pd/Xphos86 catalysts for the 
coupling of model substrate 3.113 with phenyl boronic acid as shown in Table 3-5. 
 
The α-phenyl-α,β-unsaturated lactone 3.121 was synthesized in high yield under various 
reaction conditions in which water was either an additive or a co-solvent.  We chose to 
proceed with the [(tBu)3PPdBr]2 catalyzed coupling in the presence of potassium 
phosphate in a water:acetonitrile:THF solvent mixture due to the high yield and short 
reaction time (Table 3-5, entry 3).  Reactions catalyzed by [(tBu)3PPdBr]2 also did not 
show additional byproducts associated with the palladium precatalyst complex unlike the 
Xphos Pd G2 catalyst (Table 3-4, entry 4).  Since we hypothesized that the free hydroxyl 
group in α-bromopironetin 3.112c could result in undesired side reactions and/or catalyst 
decomposition, we chose to apply our optimized Suzuki coupling conditions for the 
coupling of TBS-protected α-bromo-α,β-unsaturated lactone 3.119 with phenylboronic 
acid.  Although Taunton and coworkers only evaluated the effect of an electron-deficient 
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aromatic group at the α-position of Michael acceptors,41 we chose to synthesize the α-
phenylpironetin 3.122 to initially evaluate if aryl groups would be tolerated at the α-
position of pironetin.  The desired Suzuki coupling reaction proceeded in moderate yield 
as shown in Scheme 3-38.  We completed the synthesis of our desired analog following 
removal of the TBS protecting group in intermediate 3.123 with BF3•Et2O. 
 
3.4.2.4.4 Additional cross-coupling reactions.  Along with introducing a nitrile and 
aromatic group at the α-position of pironetin via a cross-coupling reaction, we were 
interested in installing other groups at the α-position with similar electronic properties as 
the nitrile.  Two groups we proposed to introduce through cross-coupling reactions were 
either an ester or amide.  We proposed to introduce these groups via a carbonylation 
reaction of vinyl halide 3.119 in the presence of either an alcohol or amine under a 
carbon monoxide atmosphere.  To evaluate the possibility of converting an α-bromo-α,β-
unsaturated lactone to an α-carbonyl-α,β-unsaturated lactone, we evaluated the 
carbonylation reaction of model substrate 3.113 with methanol as shown in Scheme 3-39.  
We screened a variety of palladium catalysts previously reported for the carbonylation of 
aryl halides under atmospheric pressure of carbon monoxide.89-92  We did not obtain 
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desired ester 3.124 under screened conditions with either Pd/dppe or Pd/Xantphos 
catalyst systems.  These preliminary results suggested that further optimization of the 
carbonylation reaction conditions is required for the synthesis of α-carbonyl-pironetin 
analogs from vinyl bromide 3.119. 
 
Although we initially-focused on the addition of electron-deficient groups at the 
α-position of pironetin to decrease off-target covalent adduct formation, we became 
interested in evaluating the effect of an electron-donating group at this position to further 
explore the SAR at this position.  Thus, we chose to explore the synthesis of α-
aminopironetin 3.125 via coupling of vinyl bromide 3.119 with an ammonia source as 
shown in Scheme 3-40. 
 
Although the transition-metal catalyzed coupling of aryl bromides with ammonia has 
been reported in the literature, these reactions require high temperature and the addition 
of a strong base such as sodium tert-butoxide.93,94  Thus, we chose to explore the 
coupling of vinyl bromide 3.119 with an ammonia surrogate, which have been reported to 
occur under milder conditions.  Hartwig and coworkers previously reported the Pd/PtBu3-
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catalyzed coupling between aryl halides with Zn(HMDS)2 as the ammonia surrogate for 
the synthesis of anilines at either ambient temperature or 45 °C.  Zn(HMDS)2 could be 
generated in situ from commercial solutions of ZnCl2 and LiHMDS.95  Researchers at 
GlaxoSmithKline had also reported the synthesis of anilines via Pd/tBu-Xphos-catalyzed 
coupling of aryl bromides with the ammonia surrogate, benzophenone imine, in the 
presence of potassium phosphate at 30 °C.96 
We initially explored the Pd/PtBu3-catalyzed amination of model substrate 3.113 
with in situ generated Zn(HMDS)2 but we did not observe the desired coupling product 
from these reactions and only recovered unreacted starting material.  We subsequently 
explored the coupling of our model substrate with benzophenone imine as shown in 
Scheme 3-41.  Even under previously reported amination conditions, we did not observe 
the synthesis of imine 3.126 in yields greater than two turnovers of the catalyst even with 
40% palladium catalyst.  Although imine 3.126 was obtained in low yield, we found the 
imine could be hydrolyzed in the presence of hydroxylamine hydrochloride; hydrolysis of 
the benzophenone imine 3.126 resulted in imine 3.127 instead of the conjugated enamine 
isomer. 
 
Although the coupling with benzophenone imine and subsequent hydrolysis did not occur 
in high yield, we attempted these reactions with TBS-protected α-bromo-α,β-unsaturated 
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lactone 3.119 as shown in Scheme 3-42.  Due to the low-catalyst turnover in the coupling 
with model system 3.113, the amination reaction was attempted with stoichiometric 
amount of palladium and ligand to potentially increase the yield of the desired coupling 
product.  However, the desired imine product 3.128 was only isolated in 9% yield.  Due 
to the low yield of the amination product under these conditions, further optimization of 
the amination reaction conditions is required for the coupling of α-bromo-α,β-unsaturated 
lactone with an ammonia surrogate.  Thus, we chose to postpone the synthesis of the α-
amino analog 3.125 via the amination route of vinyl bromide 3.119. 
 
3.4.3 Biological activity.  Following the synthesis of our α-functionalized pironetin 
analogs, we investigated their biological activity to evaluate the structure-activity 
relationship of the α-position.  The antiproliferative activity was evaluated in a drug-
sensitive OVCAR5 ovarian cancer cell line, drug-sensitive A2780 ovarian cancer cell line 
along with the cisplatin-resistant A2780-CP ovarian cancer cell line (Table 3-6).  The 
addition of a group at the α-position of pironetin resulted in decreased antiproliferative 
activity.  While the addition of a methyl group to the α-position of pironetin (Table 3-6, 
entry 4) resulted in an approximate 200-fold decrease in biological activity, the α-phenyl 
analog 3.122 was found to be inactive (Table 3-6, entry 8).  The α-methyl, α-chloro, and 
α-fluoro analogs (Table 3-6, entries 4-5 and entry 7) were calculated to have similar GI50 
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values even though these groups have different electronic properties; these results suggest 
the decreased biological activity of our α-functionalized analogs was primarily due to the 
steric properties of the group at the α-position instead of the electronic properties of the 
various groups. Although α-cyanopironetin analog 3.15 was synthesized as a mixture of 
products, we chose to evaluate the antiproliferative activity of the mixture; the mixture 
was found to be inactive in our assay (Table 3-6, entry 3). 
 
Although our α-functionalized pironetin analogs were found to have decreased biological 
activity relative to the natural product, α-bromopironetin 3.112c had unique activity 
(Table 3-6, entry 6). While analog 3.112c had sub-micromolar GI50 values against all 
three cell lines, the dose response curves suggest the analog may act through an 
alternative mechanism of action (Figure 3-3).  In the OVCAR5 cell lines, the dose 
response curve for α-bromopironetin 3.112c showed biphasic character; this was not 
  58 
observed in the A2780 cell lines or with any of our other tubulin-binding agents including 
pironetin and our synthesized analogs in either cell lines. 
 
 
 
Another interesting aspect for the dose-response curves of α-bromopironetin 
3.112c, was the percentage of cells remaining at the high drug concentrations.  In the 
dose-response curves of tubulin-binding agents paclitaxel, vinblastine, and pironetin in 
the A2780 cell line, the dose-response curve plateaus at approximately 10% to 30% of 
the control population at the higher tested drug concentrations.  In the dose response 
curves of α-bromopironetin 3.112c in the A2780 cell line, the highest doses of the analog 
resulted in <10% of the control population; this was significantly lower than other 
evaluated tubulin-binding agents.  The only compound we previously evaluated which 
resulted in similar levels of the cell population remaining at the high drug doses was 
cisplatin.  Cisplatin’s mechanism of action does not involve the binding to tubulin, but 
involves forming crosslinks within DNA.  Similar activity of α-bromopironetin 3.112c 
was observed in the dose-response curve in the OVCAR5 cell line albeit to a lower 
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extent.  Due to the similar degree at which α-bromopironetin 3.112c and cisplatin can 
decreases cell population at high doses along with its bimodal dose-response curve in the 
OVCAR5 cell line, we hypothesize α-bromopironetin analog 3.112c may have an 
alternative and/or additional mechanism of action other than binding to α-tubulin. 
3.5 Conclusion.  Based on previous studies on the effect of functional groups at the α-
position of Michael acceptors, we sought to synthesize α-functionalized pironetin analogs 
with the goal of decreasing the natural product’s off-target covalent adduct formation.  
The structure-activity relationship at this position had not been previously reported in the 
literature.  Although our initial attempts to synthesis α-cyanopironetin 3.15 via total 
synthesis were unsuccessful, we completed the synthesis of an initial series of analogs 
containing either a halogen or methyl group at the α-position.  Additional groups at the α-
position were introduced following cross-coupling reaction with either the α-bromo 
analog 3.112c or 3.119.  The addition of a functional group at the α-position of pironetin 
resulted in significant decreased antiproliferative activity of at least 100-fold for the 
majority of our analogs.  However, α-bromopironetin 3.112c was found to have only a 
10-40 fold decrease in biological activity relative to pironetin.  This increased activity of 
analog 3.112c relative to our other α-functionalized pironetin analogs could be due to the 
analog acting through a different mechanism(s) of action in addition to binding to α-
tubulin.  Further studies are required to identify potential mechanisms of action of this 
analog.  Due to the overall lower biological activity of our synthesized analogs, we chose 
not the further evaluate the effect of the functional group at α-position of pironetin upon 
the off-target covalent-adduct formation of the natural product. 
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CHAPTER 4.  EVALUATION OF THE STRUCTURE-ACTIVITY 
RELATIONSHIP OF THE C4- AND C5-POSITIONS OF THE α,β-
UNSATURATED LACTONE OF (-)-PIRONETIN 
4.1 Introduction.  During our previous studies on the SAR of the α-position of pironetin 
(Figure 4-1, 4.1), we observed epimerization at the C4-position upon addition of a nitrile 
at the α-position.  Due to this observation, we became interested in evaluating the 
structure-activity relationship at other positions of the α,β-unsaturated lactone of 
pironetin.  While a number of total syntheses of the natural product have been reported, 
few reports have evaluated the SAR at the various positions of the lactone.  
 
Previously reported pironetin analogs containing modification at different positions of the 
lactone are shown in Figure 4-2.   Kitahara and coworkers reported that analog 4.2 
containing a saturated lactone showed a 1000-fold decrease in biological activity in 
microtubule disassembly assays compared to the natural product.97  The decreased 
activity of this analog would be expected since pironetin’s mechanism of action involves 
the Michael addition of cysteine 316 into the α,β-unsaturated lactone.  Vogt and 
coworkers reported that the addition of a hydroxyl group to the β-position of the 
unsaturated lactone (4.3) results in a 10-75 fold decrease in antiproliferative activity in 
various cancer cell lines.31  Qing and coworkers synthesized gem-difluorinated analog 4.4 
and the corresponding C5-epimer epi-4.4.98  The GI50 values for these analogs were 
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measured at 600 to 1500 nM against MGC803 and A375 cancer cell lines respectively.  
More recently, Marco and coworkers have synthesized simplified pironetin analogs 4.5 
and evaluated the structure-activity relationship at the C4- and C5-position of their 
simplified scaffold.28,74  The group hypothesized that the C4-ethyl group is necessary for 
biological activity since analog 4.5c had a GI50 value of 10 µM in A2780 ovarian cancer 
cell line whereas methyl analog 4.5b was found to be inactive with a GI50 value >200 
µM.  Analogs 4.5a and epi-4.5a were found to have comparable GI50 values of 22.9 µM 
and 44 µM respectively; these results suggest the stereochemistry at the C5-position did 
not significantly influence the biological activity of their analogs. 
 
We hypothesized that the groups and stereochemistry at the C4- and C5-positions 
of pironetin could play keys roles in the binding of pironetin to α-tubulin prior to covalent 
adduct formation, and thus chose to focus on evaluating the SAR at these positions.  
Although Marco and coworkers hypothesized the C4-ethyl group of pironetin was 
required for biological activity from their studies on the C4- and C5-positions of the α,β-
unsaturated lactone in their simplified analogs 4.5, their analogs were all found to be 
1000-fold less active than pironetin in their antiproliferative assays.  The significant 
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decreased activity of these simplified analogs could be due to the oversimplification of 
the pironetin structure.  To explore the structure activity relationship at the C4- and C5-
positions of pironetin, we sought to synthesize and evaluate pironetin analogs containing 
modification only at the C4- and C5-positions. 
4.2 Synthesis of C4- and C-5 pironetin analogs.  4.2.1. Synthesis and evaluation of 
analogs lacking a C4-stereocenter.  To initially evaluate the SAR at the C4-position, we 
sought to determine if a substituent and/or a stereocenter is required at this position for 
biological activity.  We thus sought to synthesize desethyl pironetin (4.6a) and the gem-
dimethyl analog 4.6b.  In many of the previous total syntheses of pironetin, the 
stereoselective introduction of the ethyl group at the C4-position was more challenging 
than installing the methyl groups along the natural product’s backbone. Methods for 
introducing the ethyl group in these total syntheses include the diastereoselective 
alkylation,44,50 pentylation,43 or aldol reactions45-47,49 with reagent containing chiral 
auxiliaries.  The ethyl group has also been introduced via a selective ring opening of a 
scalemic epoxide.48,52,53,55  If the removal of the stereocenter at the C4-position is 
tolerated, this would significantly simplify the synthesis of future analogs. 
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4.2.1.1 Retrosynthesis. For the synthesis of analogs 4.6, we chose to follow the synthetic 
route from Keck’s pironetin total synthesis.50  The lactone would be synthesized via 
methodology developed by Keck and coworkers for the synthesis of α,β-unsaturated 
lactones from β-acetoxy aldehydes 4.7 as shown in Scheme 4-1.  This intermediate would 
be derived following functional group transformations of β-hydroxy ketones 4.8.  
Intermediates 4.8 would be synthesized via the stereoselective Mukaiyama reaction 
between aldehyde 4.9 and silyl enol ethers 4.10.   The main difference between our route 
and Keck’s reported route would be the silyl enol ether for the Mukaiyama aldol reaction.  
By following Keck’s synthetic route, we could rapidly synthesize desired analogs 4.6 
following previously reported conditions for the various transformations. 
4.2.1.2 Forward synthesis.  Since we previously synthesized aldehyde 4.9 for our 
previous SAR studies into the α-position of pironetin, we initially focused on the 
synthesis of silyl enol ethers 4.10.  The desired silyl enol ethers were synthesized 
following trapping of the lithium enolates of ketones 4.11 with TMSCl as shown in 
Scheme 4-2.  The synthesis of silyl enol ether 4.10a resulted in a mixture of products 
since ketone 4.11a contained sterically accessible acidic protons at both α-positions of the 
ketone.  Deprotonation of ketone 4.11a with LDA and rapid quenching with TMSCl 
resulted in the synthesis of desired silyl enol ether 4.10a along with silyl enol ether 4.12 
as a 1.1:1 mixture.  Byproduct 4.12 was generated due to deprotonation at the 
thermodynamically favored position of ketone 4.11a.  The silyl enol ethers were unstable 
to chromatography and used as a crude mixture without further purification.  Since 
ketone 4.11b only contained acidic protons at one α-position, the synthesis of silyl enol 
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ether 4.10b proceeded without significant formation of additional byproducts.  This silyl 
enol ether was also used without further purification. 
 
Following the synthesis of the required silyl enol ethers, we performed the desired 
stereoselective Mukaiyama aldol reaction with aldehyde 4.9 as shown in Schemes 4-3 
and 4-4.  The desired aldehyde was synthesized following oxidation of alcohol 4.13 
which we previously synthesized during our syntheses of α-functionalized pironetin 
analogs.  The aldehyde was reacted with silyl enols ethers 4.10 in the presence of 
BF3•Et2O to give β-hydroxy ketones 4.8 in moderate yield.  The stereochemistry at the 
secondary alcohol was assigned based on models Evans and coworkers developed for the 
Mukaiyama reaction of aldehydes containing an α-substituent and/or a β-alkoxy 
substituent.62  For the reaction between silyl enol ethers 4.10a and 4.12 with aldehyde 
4.9, the desired product 4.8a was synthesized along with byproduct 4.14 resulting from 
the Mukaiyama aldol with silyl enol ether 4.12.  Even though the reaction was performed 
with near statistical mixture of silyl enol ethers, we hypothesized β-hydroxy ketone 4.8a 
was the major product due to faster rate of addition of silyl enol 4.10a over 4.12 to the 
aldehyde. 
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From intermediates 4.8, we continued the synthesis of the desired analogs 4.6 following a 
similar synthetic route reported by Keck and coworkers as shown in Scheme 4-5.   A 
SmI2-catalyzed anti-selective disproportionation63 between β-hydroxy ketone 4.8 and 
acetaldehyde resulted in the formation of the desired intermediates 4.15.  The relative 
geometries of the secondary alcohols of intermediates 4.15 were assigned following 
hydrolysis of the acetate esters and conversion of the resulting diol to the corresponding 
acetonides 4.16 as shown in Scheme 4-6.  The 13C NMR resonances of the acetonide 
carbons in acetonides 4.16 (Figures 4-3 and 4-4) were consistent with the chemical shifts 
of the anti-1,3-diol acetonide.64 
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Intermediate 4.15 was converted to primary alcohol 4.18 following protection of the 
secondary alcohol as the acetate ester and removal of the PMB protecting group.  The 
primary alcohol was oxidized to desired aldehydes 4.7 and reacted with the lithium 
enolate of methyl acetate to yield α,β-unsaturated lactones 4.19.  The acetate group was 
hydrolyzed under acidic conditions to yield the desired desethyl and gem-dimethyl 
pironetin analogs 4.6a and 4.6b respectively. 
4.2.1.3 Biological activity.  The antiproliferative activity of analogs 4.6 was evaluated 
against drug-sensitive OVCAR5 and A2780 ovarian cancer cell lines and a cisplatin-
resistant A2780-CP cell line.  Analogs 4.6a and 4.6b were found to be inactive with GI50 
values >10 µM and >100 µM respectively.  These results reveals that the C4-ethyl group 
cannot be replaced by a hydrogen or a gem-dimethyl moiety. 
4.2.2 Synthesis and evaluation of the analogs with varying stereochemistry at the 
C4-, and C5-positions.  To further explore the structure activity relationship of the α,β-
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unsaturated pironetin lactone, we sought to synthesize analogs 4.20-4.22 (Figure 4-5), 
which are C4- and/or C5-stereoisomers of pironetin.  
 
4.2.2.1 Retrosynthesis.  For the synthesis of our desired analogs, we proposed the α,β-
unsaturated lactones would be synthesized via lactonization of intermediate 4.23, which 
results from a Z-selective olefination of aldehyde 4.24 as shown in Scheme 4-7.  This 
synthetic strategy has been utilized by multiple groups for the synthesis of the α,β-
unsaturated lactone of pironetin.44-46,48,49,52,53  We previously utilized this strategy for the 
synthesis of our α-functionalized pironetin analogs.  We proposed the desired 
stereochemistry at the C4- and C5-positions of our analogs could be established via the 
appropriate syn- or anti-aldol reaction with aldehyde 4.25.   We previously synthesized 
aldehyde 4.25 during our studies into the SAR of the α-position of pironetin. 
 
4.2.2.2 Synthesis of C4-epi and C5-epi pironetin analogs.  For the synthesis of the C4-
epi-pironetin analog 4.20, the relative configuration between the C4- and C5- positions 
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requires an anti-selective aldol with aldehyde 4.25.  Evans and coworkers have reported 
the anti-selective aldol between thiazolidinethiones and conjugated aldehydes or 
benzaldehydes.99  The anti-selective thiazolidinethione aldol reaction with aldehyde 4.25 
under these previously reported reaction conditions were unsuccessful.  The anti-
selective reactions have been reported with norephedrine esters developed by Masamune 
and coworkers.100 
 
Aldehyde 4.25 was reacted with the boron enolate of norephedrine ester 4.26 to give β-
hydroxy ester 4.27 as shown in Scheme 4-8.  Subsequent protection of the secondary 
alcohol as the TBS ether and diisobutylaluminum aluminum hydride reduction of the 
ester resulted in intermediate 4.29.  The primary alcohol was oxidized to the aldehyde 
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4.30 and carried forward to intermediate 4.32 following the Z-selective olefin with Ando 
type phosphonate 4.31.  We completed the synthesis of our desired analog 4.20 via a one-
pot lactonization and TBS-deprotection of ester 4.32 for the synthesis of the α,β-
unsaturated lactone.  The C5-epi-pironetin analog 4.21 was synthesized following the 
same route but with the anti-selective aldol reaction being performed with ester 4.33 as 
shown in Scheme 4-9. 
 
4.2.2.3 Synthesis of C4-, C5-epi pironetin analog.  Since the C4, C5-epi-pironetin 
analog 4.22 contains a syn-relationship between the C4- and C5- positions, 
thiazolidinethione based syn-aldol methodologies could be applied for the synthesis of 
the desired analog.101   Aldol reaction between aldehyde 4.25 and thiazolidinethione 4.39 
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established the desired stereochemistry at the C4- and C5- positions as shown in Scheme 
4-10.  Following protection of the secondary alcohol in intermediate 4.40 as the TBS 
ether, thiazolidinethione 4.41 was converted to aldehyde 4.42 following DIBAL-H 
cleavage of the chiral auxiliary.  The synthesis of analog 4.22 was completed from 
aldehyde 4.42 via previously utilized Z-olefination and lactonization methodology for the 
synthesis of the α,β-unsaturated lactone. 
 
4.2.2.4. Biological activity.  The antiproliferative activity of analogs 4.20-4.22 were 
evaluated against drug-sensitive OCVAR5 and A2780 ovarian cancer cell lines and a 
cisplatin-resistant A2780-CP cell line.  These analogs were also found to be inactive with 
GI50 values >30 µM.  These results suggest modifying either the stereochemistry at either 
the C4- and C5-position results in loss of biological activity. 
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4.2.3 Synthesis of C4-pironetin analogs.  Since our initial SAR into the C4- and C5-
positions of pironetin suggests a group at the C4-position with the same absolute 
stereochemistry as the natural product is required for biological activity, we proposed to 
synthesize additional pironetin analogs 4.44 containing different substituents at C4-
position to further evaluate the SAR at the this position. 
4.2.3.1 Retrosynthesis.  For the synthesis of our desired analogs, we propose to 
synthesize our analogs following the synthetic route used for the synthesis of C4-,C5-epi-
pironetin analog 4.22 as shown in Scheme 4-11.  The α,β-unsaturated lactone would be 
synthesized following the previously utilized olefination/lactonization strategy from 
aldehyde 4.46.  We proposed to introduce different functional groups at the C4-position 
via a diastereoselective aldol reaction between aldehyde 4.25 and thiazolidinethione 4.45 
containing various groups. 
 
4.2.3.2 Forward synthesis general route.  Similar to our synthesis of analog 4.22, 
groups at the C4-position were introduced with the correct stereochemistry following 
syn-aldol addition of the titanium enolate of thiazolidinethiones 4.45 into aldehyde 4.25 
as shown in Scheme 4-12.  We focused on only introducing hydrophobic groups at this 
position to evaluate the effect of groups with different steric properties.  We successfully 
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performed the diastereoselective aldol reaction with thiazolidinethione 4.45 containing 
groups such as the linear and branched alkyl groups, and also a cyclopropyl group.  We 
completed the synthesis of analogs 4.44 from intermediates aldehyde 4.48 following the 
same synthetic routes utilized for the synthesis of C4-, C5-epi pironetin analog 4.22. 
 
4.2.3.3 Synthesis of the isopropyl pironetin analog.  While we completed the syntheses 
of analogs containing a branched substituents at the C4-position such as the cyclopropyl 
and the isobutyl group, the synthesis of the isopropyl analog 4.44g required different 
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methodologies for the synthesis of the α,β-unsaturated lactone.  We successfully 
introduced the isopropyl group following the aldol reaction and the between aldehyde 
4.25 and thiazolidinethione 4.45g as shown in Scheme 4-13. 
 
The diisobutylaluminum hydride reduction of intermediate 4.49g, however, resulted in 
aldehyde 4.46g in only 8% yield along with alcohol 4.50 in 21% yield and 62% 
recovered starting material.  We hypothesized that the steric properties of the isopropyl 
group hindered the diisobutylaluminum hydride cleavage of the chiral auxiliary.  Due to 
the mixture of products from the diisobutylaluminum hydride reduction, we chose to 
cleave the chiral auxiliary of intermediate 4.49g with a less sterically-bulky reagent.  The 
reduction of sterically-hindered oxazolidineone amides and thiazolidineone amides to the 
corresponding aldehyde has been reported with lithium borohydride.102-104  The lithium 
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borohydride reduction of amide 4.49g resulted in alcohol 4.50 in moderate yield.  The 
primary alcohol was subsequently oxidized to the desired aldehyde 4.46g.  Our previous 
strategy for synthesizing the α,β-unsaturated lactone via a Z-selective olefination and 
lactonization reactions were unsuitable for the synthesis of the isopropyl analog.  The 
reaction between phosphonate ester 4.31 and aldehyde 4.46g did not occur even in the 
presence of 10 equivalents of the phosphonate ester.  The steric properties of the 
isopropyl group could also hinder the addition of the phosphonate ester into the aldehyde.  
Thus, we sought an alternative method for the synthesis of the α,β-unsaturated lactone 
involving less sterically demanding reagents.  Nelson and coworkers previously reported 
the synthesis of the pironetin α,β-unsaturated lactone via a one pot ester hydrolysis, 
lactonization, and subsequent β-hydroxyl group elimination of a β,δ ester diol.51  
Following a similar strategy for the synthesis of the isopropyl analog, the acetate aldol 
between aldehyde 4.46g and the lithium enolate of ethyl acetate resulted in β-hydroxy 
ester 4.51.  Heating intermediate 4.51 in the presence of toluenesulfonic acid afforded a 
one pot silyl ether deprotection, ester hydrolysis, lactonization and elimination resulting 
in desired analog 4.44g.  The α,β-unsaturated lactone was synthesized from aldehyde 
4.46g in comparable yield through this alternative route as our general 
olefination/lactonization route. 
4.2.3.4. Biological Activity.  The antiproliferative activities of analogs 4.44 were 
evaluated in our previously used panel of ovarian cancer cell lines; the measured GI50 
values are shown in Table 4-1. 
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In our assay, pironetin (Table 4-1, entry 2) had comparable activity to paclitaxel (Table 4-
1, entry 1) across our panel of ovarian cancer cell lines.  We found limited substitution is 
also tolerated at the C4-position, smaller group such as the methyl group (Table 4-1, 
entry 3) or larger groups such as the isobutyl (Table 4-1, entry 7) and benzyl (Table 4-1, 
entry 8) group at this position resulted in decreased biological activity.  While a propyl 
(Table 4-1, entry 4) and cyclopropyl (Table 4-1, entry 6) containing analogs have 
comparable activity to pironetin, the isopropyl analog 4.44g (Table 4-1, entry 9) showed 
a 100-fold decrease in biological activity compared to the natural product. 
4.3 Molecular modeling of synthesized pironetin analogs.  After we completed the 
syntheses and evaluation of the biological activity of our various C4- and/or C5- 
pironetin analogs, the crystal structures of pironetin bound to α-tubulin in an α-tubulin/β-
tubulin/statmin-4/tubulin tyrosine ligase complex were reported by multiple groups.36,37  
Pironetin was shown to bind in an induced binding site in α-tubulin with the C4-ethyl 
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group of the natural product occupying a hydrophobic pocket in the binding site (Figure 
4-6).  This size of the hydrophobic pocket occupied by the C4-ethyl group of pironetin 
could be cause for the limited steric properties of groups tolerated at the C4-position of 
our pironetin analogs. 
  
 
Since our analogs had a range of antiproliferative activity, we sought to determine 
if molecular modeling could be used as a tool for the design of future analogs.  Analogs 
4.6, 4.20-4.22 and 4.44 were docked into the identified pironetin binding site in α-
tubulin.36,37  Since pironetin is a covalent inhibitor, docking scores were calculated using 
CovDock module in the Schrödinger® Maestro software package;105 the CovDock 
module provides docking score, glide score and covdock affinity for each ligand pose.  
We were interested if either of these values correlated with the measured biological 
activity; the best docking score, glide score and covdock affinity from multiple poses of 
each analog were compared to the antiproliferative activity in OVCAR5 ovarian cancer 
cell line as shown in Table 4-2.  A correlation was not observed between either of the 
CovDock scores and the observed biological activity.  Although molecular modeling is a 
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useful tool for drug discovery, computer-based drug design may have limited application 
for the design of pironetin analogs. 
 
4.4 Conclusion.  We have synthesized a series of pironetin analogs containing 
modification only at the C4- and C5- position of the α,β-unsaturated lactone and 
evaluated their antiproliferative activity.  By modifying only these positions, we 
systematically evaluated the structure-activity relationship at these positions of pironetin.  
Since analogs 4.44 containing either a propyl or cyclopropyl group at the C4-position 
were shown to have comparable antiproliferative activity to pironetin with nanomolar 
GI50 values, the binding pocket may not be able to accommodate larger groups at this 
position.  We have also found that modifying the stereochemistry at either of these 
positions results in the loss of biological activity.  These results suggest that the 
confirmation of the α,β-unsaturated lactone is important for biological activity  Unlike 
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previous studies by Marco and coworkers with simplified analogs 4.5 (Figure 4-2),28,74 
we found that modification of the C5-stereocenter in pironetin also results in a loss of 
biological activity.  From our SAR studies, we have shown that a single substitution at 
the C4-position of pironetin with the same stereochemistry of the α,β-unsaturated lactone 
as the natural product is required for biological activity. 
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CHAPTER 5.  SYNTHESIS AND EVALUATION OF ANALOGS TO IMPROVE 
PIRONETIN’S METABOLIC STABILITY 
5.1 Introduction.  While pironetin (5.1) has potent in vitro activity against a variety of 
cancer cell lines, the natural product was found to have poor efficacy in vivo in mice 
bearing P388 murine leukemia cells.33  We hypothesized that the poor in vivo activity 
could be due to pironetin’s poor metabolic stability.  In our initial evaluation of 
pironetin’s PK/PD properties, the natural product was found to be rapidly metabolized in 
human and mouse liver microsomes.  To improve pironetin’s in vivo activity, we sought 
to synthesize analogs with improved metabolic stability. 
5.2 Evaluation of pironetin’s metabolism and potential metabolites.  In order to 
design pironetin analogs with increased metabolic stability, we needed to identify the 
natural product’s sites of metabolism. 
5.2.1 Predicted sites of metabolism.  Due to the instrumentation required for metabolite 
identification studies, we initially predicted the sites of metabolism using the 
SMARTCyp program.  SMARTCyp is a online tool developed by researchers at the 
University of Copenhagen to predict sites of cytochrome P450 metabolism.106-110  
Cytochrome P450s are enzymes containing a heme iron which oxidize substrates using 
molecular oxygen.111  The software predicts sites which undergo metabolism by the 
various isoforms of cytochrome P450 along with sites specific for metabolism via 
CYP2C and CYP2D6 isoforms; the top predicted sites of metabolism are shown in Figure 
5-1. 
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The models predicted sites of metabolism on the α,β-unsaturated lactone of pironetin.  
The model predicting sites of metabolism for the various P450 isoforms also predicted 
the methyl ether to undergo P450 metabolism.  Predicted sites of metabolism specific for 
the CYP2C and CYP2D6 isoforms include the non-conjugated olefin and neighboring 
allylic positions. 
 
5.2.2 Previous studies on predicted metabolites.  Based on these predicted sites of 
metabolism, we hypothesized the structure of the potential metabolites.  Two potential 
metabolites are demethylpironetin/NK10958P (5.2) and epoxypironetin (5.3) (Figure 5-
2).  Demethylpironetin could result from demethylation of pironetin via P450 oxidation 
of the methyl ether to the formaldyde hemiacetal and subsequent elimination of 
acetaldehyde.  Epoxypironetin would result from P450 oxidation of the non-conjugated 
olefin.  We focused on these two potential metabolites since the biological activity of 
both compounds had previously been reported in the literature. 
Demethylpironetin/NK10958P (5.2) is a natural product previously isolated from 
a fermentation of a pironetin-producing Streptomyces strain.112  The demethyl analog 5.2 
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was previously found to have comparable activity as pironetin in tubulin disassembly 
assays and cell cycle arrest assays.33,34  Epoxypironetin (5.3) was reported to be less 
active than the natural product.33,34  In assays measuring cell cycle arrest, the percentage 
of the cell population arrested in the G2/M-phase in cells treated with 500 ng/mL of 
epoxide 5.3 were similar to cells treated with 50 and 100 ng/mL of pironetin..  
Epoxypironetin was also reported to disrupt tubulin polymerization at 50-fold greater 
concentrations than the natural product. 
5.2.3 Synthesis and evaluation of demethylpironetin.  Since demethylpironetin is a 
potential bioactive metabolite, we were interested in obtaining demethyl analog 5.2 as a 
standard for future metabolite identification studies.  Kitahara and coworkers previously 
reported the semi-synthesis of demethylpironetin in 80% yield following the 
demethylation of pironetin.52  We attempted to repeat the synthesis of demethylpironetin 
following previously reported conditions; the reaction resulted in a mixture of products 
and we only obtained desired product in 13% as shown in Scheme 5-1. 
 
Although the analog 5.2 was obtained in low yield, we obtained sufficient amount of 
material to evaluate its antiproliferative activity which had not been previously been 
reported in the literature.  We evaluated its antiproliferative activity against drug sensitive 
OVCAR5 cell line; demethylpironetin (5.2) was found to have comparable activity to 
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pironetin with a GI50 value of 64.2 ± 2.9 nM compared to GI50 value of 21.5 ± 0.7 nM for 
pironetin. 
5.2.4 Identification of the sites of metabolism.  Although we predicted the sites of 
metabolism of pironetin through the SMARTCyp program, we chose to experimentally 
identify the sites of metabolism of pironetin; metabolite identification studies were 
performed with human liver microsomes as an in vitro method to identify potential 
human metabolites.  Sara Coulup in our group collaborated with Dr. Natalia Tretyakova 
for initial metabolite identification studies.  LC-MS/MS analysis of aliquots taken from 
the incubation of pironetin in human liver microsomes showed the primary metabolite 5.4 
to result from oxidation at a position around the non-conjugated olefin as shown in Figure 
5-3.  We hypothesized the structure of metabolite 5.4 could be epoxypironetin (5.3) or 
allylic alcohols 5.5 and 5.6 (Figure 5-4); the MS/MS fragmentation pattern of metabolite 
5.4 matched that of epoxide 5.3 independently synthesized in our group.  We have not 
excluded alcohols 5.5 and 5.6 as the primary metabolite due to the difficulty of 
synthesizing these analogs via semi-synthesis.  The demethylpironetin 5.2 was only 
observed in trace amounts during these studies. 
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We also submitted pironetin to Pharmaron, a CRO, for similar metabolite identification 
studies form human liver microsomes.  In these parallel studies, 14 metabolites of 
pironetin were identified over a 15 min incubation of pironetin in human liver 
microsomes.  These studies also suggest the primary initial site of metabolism to be the 
non-conjugated olefin.  A number of the metabolites identified by Pharmaron were 
proposed to result from further oxidation of metabolite 5.4; the general structure of these 
metabolites is shown in Figure 5-5.  Demethylpironetin 5.2 was also not detected in the 
assay performed by Pharmaron.  Demethylation of the methyl ether of pironetin was only 
observed in metabolites 5.9 and 5.10 which had undergone oxidation at other positions of 
the natural product. 
 
5.3 Synthesis and evaluation of phenylpironetin.  Since the primary site of metabolism 
identified from both metabolite identification studies was the non-conjugated olefin, we 
sought the replace this group with one which would be less prone to undergo metabolism. 
5.3.1 Previous SAR on the non-conjugated olefin.  In addition to epoxypironetin (5.3), 
a limited number of pironetin analogs containing modifications at the non-conjugated 
olefin have been reported in the literature (Figure 5-6).  Analog 5.11 was synthesized by 
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Kitahara and coworkers following TMSI-promoted demethylation and cyclization of 
pironetin; this analog was found to be 1,000 fold less active than the pironetin in 
microtubule disassembly assays.97  Marco and coworkers have synthesized simplified 
analogs 5.12 containing either long alkyl chains or a phenyl group instead of a non-
conjugated olefin; these analogs were found to be 10,000-fold less active than pironetin 
in antiproliferative assays.28,113  More recently, the same group has synthesized a series of 
hybrid molecules 5.13 containing colchicine/combrestatin A-4 analogs conjugated to a 
simplified pironetin scaffold.29,30,114  These analogs were also found to be 1,000 to 10,000 
fold less active than pironetin.  While the Marco group synthesized a series of simplified 
analogs with groups other than non-conjugated olefin, the overall poor biological activity 
of these analogs could be due to the over-simplification of the pironetin scaffold.  Due to 
the limited scope of the studies with analogs 5.3, 5.11-5.13 and lack of systematic SAR 
studies around the non-conjugated olefin of pironetin, these previous reports did not 
provide significant insight into groups that would be tolerated instead of the non-
conjugated olefin. 
 
5.3.2 Analog design and retrosynthesis.  Since the SAR around the non-conjugated 
olefin had not been systematically evaluated, the first analog we sought to synthesize was 
phenylpironetin (5.14), as shown in Figure 5-7.  Although an unsubstituted phenyl group 
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can also undergo cytochrome P450 metabolism, we decided to synthesize analog 5.14 to 
determine if an aromatic group would be tolerated at that position.  If the phenyl analog 
5.14 was found to be biologically active, we could synthesis additional analogs 
containing different substituent on the aromatic group.  The addition of substituents on 
the phenyl group of analog 5.14 could potentially improve upon both the metabolic 
stability of the phenyl group and the overall potency of the molecule. 
 
We proposed that analog phenylpironetin (5.14) could be synthesized from 
alcohol 5.15 (Scheme 5-2).  In our previous SAR studies, we have completed the 
synthesis of pironetin analogs from alcohols with similar structure to alcohol 5.15.  We 
proposed alcohol 5.15 could be derived from ether 5.16.  Intermediate 5.16a was a 
previous intermediate in our synthesis in of pironetin analogs to evaluate the SAR at 
various positions of the α,β-unsaturated lactone. 
 
5.3.3 Forward Synthesis.  The primary challenge for the synthesis of analog 5.14 was 
the introduction of the phenyl ring.  We initially proposed to introduce the phenyl group 
via a copper-catalyzed substitution reaction with a Grignard reagent.  The silyl ether in 
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intermediate 5.16b was converted to the primary tosylate 5.18, as shown in Scheme 5-3; 
however, we were unable to couple the tosylate with phenyl magnesium bromide even in 
the presence of stoichiometric amounts of copper. 
 
Since we were unable to introduce the phenyl group via a substitution reaction, we 
explored alternative methods to introduce the phenyl group.  As an alternative synthetic 
strategy, we proposed to introduce this group via Grignard addition to aldehyde 5.21 as 
shown in Scheme 5-4.  Aldehyde 5.21 could be readily synthesized from intermediate 
5.16.  Deoxygenation of the secondary alcohol 5.22 would result in intermediate 5.15 or 
5.22. 
 
When reviewing different methods for the deoxygenation of alcohol 5.22, we found the 
deoxygenation of benzylic alcohols could be performed under a H2 atmosphere in the 
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presence of a palladium catalyst.  The palladium-catalyzed deoxygenation of the 
secondary benzylic alcohol would also remove the benzyl or PMB protecting group of 
intermediate 5.22.  Evans and coworker previously used this Grignard/deoxygenation 
strategy for the introduction of the phenyl group during their total synthesis of zaragozic 
acid C as shown in Scheme 5-5.115  While the direct deoxygenation of secondary benzylic 
alcohols has been reported in the literature, Evans and coworkers converted benzylic 
alcohol 5.25 to the trifluoroacetate ester prior to hydrogenolysis.  We chose to follow 
Evans’ reported method since the hydrogenolysis was performed at room temperature 
under an atmospheric pressure of hydrogen. 
 
Our forward synthesis of phenylpironetin 5.14 (Scheme 5-6), began with the removal of 
the TBS group in protected alcohol 5.16a.  Primary alcohol 5.20a was oxidized to the 
aldehyde and treated with phenyl magnesium bromide to give benzylic secondary alcohol 
5.22a.  Following Evans’ method for the hydrogenolysis of benzylic secondary alcohols, 
the hydrogenolysis of the intermediate 5.22a also resulted in hydrogenolysis of benzyl 
group resulting in desired alcohol 5.15. 
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At the time we completed the synthesis of alcohol 5.15, we were synthesizing 
additional pironetin analogs for our SAR studies of the other positions of the molecule 
utilizing Keck’s synthetic route for the total synthesis for pironetin.  Thus, we chose to 
complete the synthesis of analog 5.14 following Keck’s synthetic route.50  Similar to 
Keck’s pironetin total synthesis, the carbon backbone of intermediate phenylpironetin 
was synthesized via a Mukaiyama aldol between silyl enol ether 5.27 and the aldehyde 
resulting from the oxidation of alcohol 5.15.  Following the SmI2-catalyzed disproportion 
reaction of β-hydroxyketone 5.28 to intermediate 5.29, we confirmed the stereochemistry 
of secondary alcohol in intermediate 5.29 by converting this intermediate to the 
corresponding 1,3-diol acetonide 5.30 (Scheme 5-7); The 13C NMR resonances of the 
acetonide were consistent with the chemical shifts reported for anti-1,3-diol acetonides 
(Figure 5-8).64  The synthesis of phenylpironetin was completed following protection of 
  90 
the secondary alcohol of 5.29 as the acetate ester and removal of the PMB protecting 
group.  α,β-Unsaturated lactone 5.33 was synthesized from primary alcohol 5.32 
following methodology developed by Keck and coworkers via a reaction between an β-
acetoxy aldehyde and the lithium enolate of methyl acetate.56  We completed the 
synthesis of analog 5.14 following acetate ester hydrolysis of intermediate 5.33. 
 
 
 
5.3.4 Biological activity and metabolic stability.  We initially evaluated the 
antiproliferative of phenylpironetin against our previously utilized panel of ovarian 
cancer cell lines.  Phenylpironetin was found to have comparable activity as pironetin as 
shown in Table 5-1 (Entries 1-3).  Since phenylpironetin was an active analog, we sought 
to determine if replacing the non-conjugated olefin in pironetin with the phenyl group 
improved the natural products metabolic stability in human liver microsomes.  While 
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phenylpironetin had minor improved stability in mouse liver microsomes, exchanging the 
non-conjugated olefin to a phenyl group decreased the metabolic stability; the calculated 
half-life in human liver microsomes decreased from 7 min to 5 min.  We hypothesized 
the poor metabolic stability of phenylpironetin could be due to the rapid oxidation of the 
phenyl group.  To evaluate if the phenyl group was the primary site of metabolism of 
analog 5.14, we submitted phenylpironetin to Pharmaron for metabolite identification 
studies in human liver microsomes. 
 
Pharmaron identified 17 metabolites following incubation of phenylpironetin in 
human liver microsomes over 15 min.  The structures of some of the major metabolites 
are shown in Figure 5-9.  Metabolites resulting from metabolism only on the phenyl 
group were detected in trace amounts.  The primary site of metabolism was positions 
around the α,β-unsaturated lactone as shown metabolite 5.34.  Metabolites resulting from 
oxidation at the α,β-unsaturated lactone along with the side chains of the molecules, such 
as 5.35-5.37, were also detected.  While we did not predict metabolism at the α,β-
unsaturated lactone and methyl side chains of phenylpironetin, this was not unexpected.  
In our previous metabolite identification study of pironetin performed by Pharmaron, 
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metabolite 5.7 resulting from oxidation around the non-conjugated olefin and other 
positions along the carbon skeleton increased over time during the 15 minute incubation 
in human liver microsomes. 
 
5.4. Conclusion.  To increase the in vivo efficacy of pironetin, we sought to synthesize 
analogs with improved metabolic stability.  After identifying the non-conjugated olefin of 
pironetin as the primary site of metabolism, we synthesized analog 5.14 in which the non-
conjugated olefin was replaced with a phenyl group.  Phenylpironetin was found to have 
comparable antiproliferative activity as pironetin, but did not have improved metabolic 
stability.  Metabolite identification assay with phenylpironetin 5.14 revealed the 
metabolism to occur at multiple positions around the α,β-unsaturated lactone and at the 
methyl side chains along the natural product’s backbone.  Although we modified the 
primary site of metabolism pironetin, additional modifications around the α,β-unsaturated 
lactone and substituents along the carbon backbone of pironetin are required to increase 
the natural product’s metabolic stability. 
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Chapter 6. Experimental Procedures 
6.1. General Experimental Procedures 
6.1.1 General Materials and Chemistry Procedures.  Normal-phase silica gel flash 
chromatography was conducted with Silicycle SilicaFlash® P60 silica gel or with 
preloaded Redisep® normal-phase silica flash columns.  TLC was performed with 
Millipore Silica Gel 60 F254 or Analtech TLC Uniplates silica plate with florescent 
indicator (250 µm layer thickness).  The product was visualized by UV light and/or 
staining with KMnO4. 
 All NMR spectroscopy was conducted using either a Bruker Avance II 400 MHz 
instrument equipped with a BBO broadband probe or a Bruker Avance III 900 MHz 
instrument equipped with a TCI cryoprobe.  NMR spectra were processed using 
MestReNova 9.0 (Metrelab Research S.L).  Chemical shifts are reported in ppm and 
referenced to residual solvent peaks: CHCl3 in CDCl3: 7.26 ppm for 1H NMR 
spectroscopy, 77 ppm for 13C NMR spectroscopy.  C6H6 in C6D6: 7.16 1H NMR 
spectroscopy, 128 ppm for 13C NMR spectroscopy.  CH2Cl2 in CD2Cl2: 5.32 1H NMR 
spectroscopy, 54 ppm for 13C NMR spectroscopy.  DMSO in DMSO-d6: 2.50 ppm for 1H 
NMR spectroscopy, 39.52 for 13C NMR spectroscopy.  Coupling constants are reported 
in Hertz.  Mass spectrometry was performed on a Bruker BioTOF II.  Optical rotations 
were measured on a Rudolph Research Analytical Autopol V polarimeter with a 100 mm 
sample cell.  Melting points were measured on an Electrothermal IA9100. 
 All starting materials were purchased from commercial vendors and used without 
further purification unless noted.  Phenylboronic acid was recrystallized from water.  
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Ethyl 2-(bis(o-tolyloxy)phosphoryl)acetate and samarium iodide were synthesized from 
commercial reagents instead of being purchased from commercial vendors.  All reactions 
were performed with anhydrous solvent unless noted.  Anhydrous solvents were degassed 
with nitrogen and passed through a column of activated alumina or molecular sieves 
(Solvent system from Inert Technologies). 
6.1.2 HPLC and UPLC analysis methods.  HPLC analysis was performed on the Water 
2695 HPLC equipped with a Phenomnex Luna® 5 µm C18 100 Å, LC Column 150 × 4.6 
mm.  Samples were maintained at 10 °C and column was maintained at 25 °C.  HPLC 
analyses were performed using the following method: 
 The mobile phase at a flow rate of 1 mL /min was increased from 50% 
MeCN/water to 70% MeCN/water over 30 min.  The gradient was held at 70% 
MeCN/water for 1 min and then increased to 99% MeCN/water over 5 min and held for 5 
min.  The gradient was decreased back to 50% MeCN/water over 15 min and held for 10 
min.  Absorbance was monitored at 220 nm. 
 UPLC analysis was performed on the Water Acquity UPLC equipped with a BEH 
C18 column 1.7 µm, 2.1 × 50 mm.  The column was maintained at 25 °C.  The analyses 
were performed with mobile phase A (95% water, 5% MeCN, 0.1% formic acid) and 
mobile phase B (95% MeCN, 5% water, 0.1% formic acid) at a flow rate of 0.25 µL /min 
using the following gradient: 
 The mobile phase was increased from 95% mobile phase A and 5% mobile phase B 
to 50% mobile phase A and 50% mobile phase B over 1 min.  The gradient was then 
increased to ramping to 5% mobile phase A and 95% mobile phase B over 4.5 min.  The 
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mobile phase was then returned to 95% mobile phase A and 5% mobile phase B over 0.5 
min.  Absorbance was monitored at 214 nm. 
6.1.3 Antiproliferative assays protocol.  OVCAR5 cells were grown in Gibco ® RPMI 
1640 media supplemented with 10% fetal bovine serum and 50 U/mL penicillin-
streptomycin in at 37 °C incubator with 5% CO2 atmosphere.  A2780 and A2780-CP 
cells were grown in Gibco ® DMEM/F-12 media supplemented with 7.5% fetal bovine 
serum, 7.5% newborn calf serum, 1% non-essential amino acids, 4.8g/L HEPES, and 50 
U/mL penicillin-streptomycin in at 37 °C incubator with 5% CO2 atmosphere. 
 Assays were performed in Corning® 96 well clear flat bottom cell culture plates.  
Cells were plated at 2500 cell per well and incubated overnight to allow cells to adhere to 
the well.  Solutions were of assayed compounds ranging from 200 µM to 0.2 nM were 
prepared in the growth media supplemented with 0.2% DMSO.  Plated cells were dosed 
with each compound with final concentrations of compound ranging from 100 µM to 0.2 
nM in growth media with 0.1 % DMSO and incubated for 48 h.   Cell proliferation was 
measured with Promega CellTiter 96® Non-radioactive cell proliferation assay (cat. # 
G4100) following published protocols.116  Absorbances were measured at 538 nm on a 
Molecular Devices Spectromax M2 plate reader.  GI50 values were calculated by 
GraphPad Prism 5. 
6.2 Chapter 2 experimental procedures 
6.2.1 Pironetin extraction procedures 
Sample extraction procedure from cell paste:  The extraction procedure was adapted from 
a previously published procedure.25  Frozen cell paste (2.3 kg) was suspended in acetone 
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(9 L) and stirred overnight via an overhead mechanical stirrer.  The suspension was 
filtered and volatile materials were removed using a rotary evaporator to yield ~1.9 L of 
aqueous extract.  The aqueous extract was divided into two aliquots of 0.95 L. 
 Each 0.95 L aliquot of aqueous extract was adjusted to pH = 7 with 3 M HCl.  The 
aqueous layer was extracted once with EtOAc (0.8 L) and twice with EtOAc (0.5 L).  The 
combined organic layers were washed with brine and dried with anhydrous Na2SO4.  The 
salts were removed via vacuum filtration and volatile materials were removed using a 
rotary evaporator.  The organic residues from each aliquot extraction were combined and 
stored in benzene prior to further purification. 
 The residues from separate extractions of 2.3 kg, 2.1 kg, 2.3 kg, and 2.4 kg were 
combined and suspended in hexanes (0.5 L).  The solution was decanted through a 
Buchner funnel.  The residual solid was dissolved in EtOAc (50 mL); Hexanes (0.5 L) 
was added to this solution.  The removed via vacuum filtration and the residual solid was 
washed with hexanes.  The filtrates from the different filtrations were combined and 
concentrated using a rotary evaporator.  The crude extract was frozen in benzene prior to 
purification. 
Sample extraction of fermentation broth:  Frozen fermentation broth (17 kg) was thawed 
and filtered through cheese cloth followed by filtration through a coarse fritted funnel.  
The filtered fermentation broth was adjusted to pH 7 with 2 M HCl.  Amberlite® XAD-
16 resin (190 g) was shaken in water for 2 h.  The resin suspension was filtered and the 
resin was washed three times with water.  The resin was resuspended in methanol and 
shaken for 2 h.  The resin suspension was filtered and washed three times with methanol.  
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The resin was added to the filtered fermentation broth.  The resulting suspension was 
slowly stirred overnight via an overhead mechanical stirrer.  The resin was recovered 
following filtration of the suspension through a coarse fritted funnel. 
 The recovered resin was split into 3 portions.  Each portion was shaken in methanol 
for 2 h.  The resin was recovered following filtration through a coarse fit and washing 
with methanol.  The resin was resuspended in methanol and shaken for 2 h.  The resin 
was recovered following filtration through a coarse fit and washed with methanol.  The 
combined methanol filtrates from each portion of recovered resin were combined and 
filtered through a plug of Celite®.  The resulting filtrate was concentrated using a rotary 
evaporator to ~200 mL.  The resulting mixture was extracted six times with hexanes.  
The combined hexanes extracts were dried with anhydrous Na2SO4.  The resulting salts 
were removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was frozen in benzene prior to purification. 
 Purification of pironetin extracts: Extracts from the cell paste and fermentation 
broth were combined prior to purification.  Extracts were initially purified via silica gel 
column chromatography (multiple columns of 40% EtOAc in hexanes).  Final 
purification was performed via Combiflash equipped with a Biotage® C18 SNAP 
cartridge (10% 100% MeCN in water to 100% MeCN).  The extraction from 165 kg of 
fermentation broth and 3 kg of frozen cell paste resulted in approximately 50 mg of 
pironetin. 
6.2.2 Synthetic procedures and compound characterization data 
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Methyl 3-Oxooct-6-enoate (2.6).  To a suspension of sodium hydride (60% in mineral 
oil, 0.58 g, 15 mmol) in THF (33 mL) at 0 °C was added methyl acetoacetate (2.5, 1.4 
mL, 13 mmol) dropwise.  After stirring for 10 min, a solution of n-butyllithium (2.5 M in 
hexanes, 5.6 mL, 14 mmol) was added dropwise.  After stirring an addition 10 min at 0 
°C, a solution of crotyl bromide (1.5 mL, 15 mmol) in THF (3 mL) was added to the 
reaction.  The reaction was warmed to room temperature and allowed to stir overnight.  
The reaction was quenched with saturated aqueous NH4Cl and diluted with EtOAc.  The 
layers were separated and the aqueous layer was extracted twice with EtOAc.  The 
combined organic layers were washed with brine and dried with anhydrous MgSO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatograph 
(5% EtOAc in hexanes) to yield 1.60 g of product as a colorless oil (71% yield).  1H 
NMR (400 MHz, CDCl3) δ 5.59 – 5.30 (m, 2H), 3.73 (s, 3H), 3.44 (s, 2H), 2.59 (t, J = 7.3 
Hz, 2H), 2.39 – 2.16 (m, 2H), 1.63 (dq, J = 6.2, 1.2 Hz, 3H).  13C NMR (100 MHz, 
CDCl3) δ 202.2, 167.6, 128.9, 128.1, 126.3, 125.47, 52.3, 49.1, 42.8, 26.4, 17.9. 
 
Methyl 3-Hydroxyoct-6-enoate (2.7).  To a solution of β-keto-ester 2.6 (1.53 g, 8.88 
mmol) in methanol (33 mL) in 0 °C was added sodium borohydride (0.44 g, 12 mmol).  
The reaction was warmed to room temperature and stirred for 6 h.  The reaction was 
diluted with acetone (12 mL).  Volatile materials were removed using a rotary 
evaporator.  The crude material was diluted with EtOAc and saturated aqueous NH4Cl.  
The layers were separated and the aqueous layer was extracted three times with EtOAc.  
  99 
The combined organic layers were washed with brine and dried with anhydrous MgSO4.  
The salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatograph 
(15% EtOAc in hexanes) to yield 1.23 g of product as a colorless oil (80% yield).  1H 
NMR (400 MHz, CDCl3) δ 5.59 – 5.31 (m, 2H), 4.01 (td, J = 8.0, 4.0 Hz, 1H), 3.71 (d, J 
= 1.1 Hz, 3H), 2.87 (dd, J = 12.6, 4.0 Hz, 1H), 2.60 – 2.32 (m, 2H), 2.26 – 1.89 (m, 2H), 
1.73 – 1.40 (m, 5H).  13C NMR (100 MHz, CDCl3) δ 173.4, 130.4, 129.6, 125.6, 124.7, 
77.2, 67.5, 51.7, 41.1, 41.1, 36.2, 36.1, 28.6, 17.9. 
 
Methyl 3-((tert-Butyldimethylsilyl)oxy)oct-6-enoate (2.8).  To a solution of alcohol 2.7 
(1.23 g, 7.14 mmol) in DMF (7.5 mL) was added imidazole (1.41 g, 20.7 mmol) followed 
by TBSCl (1.25 g, 8.29 mmol).  After stirring at room temperature for 1.5 days, the 
reaction was diluted with saturated aqueous NH4Cl.  The mixture was extracted four 
times with EtOAc.  The combined organic layers were washed with brine and dried with 
anhydrous MgSO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatograph (8% EtOAc in hexanes) to yield 1.95 g of product as a colorless oil 
(95% yield).  1H NMR (400 MHz, CDCl3) δ 5.54 – 5.33 (m, 2H), 4.23 – 4.06 (m, 1H), 
3.66 (s, 2H), 2.57 – 2.37 (m, 2H), 2.10 – 1.93 (m, 2H), 1.71 – 1.47 (m, 5H), 0.86 (s, 6H), 
0.06 (s, 3H), 0.03 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 172.2, 130.7, 125.1, 69.0, 
51.4, 42.5, 37.5, 28.1, 25.8, 17.9, -4.5, -4.8. 
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3-((tert-Butyldimethylsilyl)oxy)oct-6-enal (2.9).  To a solution of methyl ester 2.8 (1.88 
g, 6.56 mmol) in DCM (47 mL) at -78 °C, was added a solution of DIBAL-H (1 M in 
toluene, 13.1 mL, 13.1 mmol).  After stirring at -78 °C for 30 min, the reaction was 
diluted with acetone (30 mL).  The reaction was quenched with a solution of Rochelle (10 
g) salt in water (22 mL).  The reaction was warmed to room temperature and diluted with 
water and DCM.  The layers were separated and the aqueous layer was extracted three 
times with DCM.  The combined organic layers were washed with brine and dried with 
anhydrous MgSO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatograph (5% to 33% EtOAc in hexanes) to yield 1.42 g of product as a 
colorless oil (85% yield).  1H NMR (400 MHz, CDCl3) δ 9.81 (t, J = 2.5 Hz, 1H), 5.53 – 
5.33 (m, 2H), 4.25 – 4.14 (m, 1H), 2.53 (ddd, J = 8.2, 5.8, 2.6 Hz, 2H), 2.09 – 1.96 (m, 
2H), 1.71 – 1.51 (m, 5H), 0.87 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H). 
 
Ethyl 2-(Bis(o-tolyloxy)phosphoryl)acetate (2.10).  The synthesis was adapted from 
previously published procedures.117  To a solution of o-cresol (6.3 mL, 61 mmol) and 
triethylamine (8.9 mL, 64 mmol) in toluene (46 mL) at 0 °C was cannula transferred a 
solution of ethyl dichlorophosphite (4.6 g, 31 mmol) in ether (19 mL).  The reaction was 
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warmed to room temperature and stirred overnight.  The reaction was filtered through a 
fritted funnel and washed with toluene.  The filtrate was filtered through a plug of basic 
alumina.  Volatile materials were removed using a rotary evaporator.  To the crude 
phosphite at 120 °C was added ethyl bromoacetate (5.2 mL, 47 mmol) dropwise.  After 
heating at 120 °C, the reaction was determined to be complete by 31P NMR spectroscopy.  
The crude material was purified via silica gel flash chromatograph (25% EtOAc in 
hexanes) to yield 4.85 g of product as a colorless oil (45% yield).  The resonances in the 
1H NMR of the product matched previously reported chemical shifts.39 
 
Ethyl 5-((tert-Butyldimethylsilyl)oxy)deca-2,8-dienoate (2.11).  To a suspension of 
sodium hydride (60% in mineral oil, 0.21 g, 5.3 mmol) in THF (2 mL) at 0 °C was added 
a solution of phosphonate ester 2.10 (1.31 g, 3.76 mmol) over 5 min.  The reaction was 
stirred at 0 °C for 15 min before cooling to -78 °C.  A solution of aldehyde 2.9 (0.88 g, 
3.4 mmol) in THF (1.7 mL) was added to reaction over 10 min.  The reaction was stirred 
at -78 °C for 1 h before warming to room temperature.  After an additional 1 h, the 
reaction was quenched with saturated aqueous NH4Cl.  The mixture was extracted three 
times with EtOAc.  The combined organic layers were washed with brine and dried with 
anhydrous MgSO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatograph (5% EtOAc in hexanes) to yield 0.85 g of product as a 1:4 mixture 
of E:Z ratio for the conjugated olefin as a colorless oil (76% yield). 
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(2Z)-isomer: 1H NMR (400 MHz, CDCl3) δ 6.49 – 6.26 (m, 1H), 5.84 (dt, J = 11.6, 1.8 
Hz, 1H), 5.57 – 5.24 (m, 2H), 4.17 (q, J = 7.0 Hz, 2H), 3.81 (p, J = 5.6 Hz, 1H), 3.03 – 
2.68 (m, 2H), 2.20 – 1.88 (m, 2H), 1.63 (dt, J = 4.7, 1.3 Hz, 2H), 1.58 – 1.41 (m, 3H), 
1.28 (t, J = 7.1 Hz, 5H), 0.89 (d, J = 2.8 Hz, 10H), 0.05 (d, J = 2.6 Hz, 6H).  13C NMR 
(100 MHz, CDCl3) δ 166.4, 146.6, 131.0, 124.9, 120.8, 100.0, 77.3, 77.2, 77.0, 76.7, 
71.1, 71.0, 59.8, 37.1, 36.3, 28.5, 25.8, 22.9, 18.1, 17.9, 14.3, -4.5, -4.5. 
 
6-(Pent-3-en-1-yl)-5,6-dihydro-2H-pyran-2-one (2.12).  A solution of ester 3.11 (200. 
mg, 0.612 mmol) and PPTS (48 mg, 0.19 mmol) in EtOH (3 mL) was heated at 55 °C for 
48 h.  The reaction was cooled to room temperature and volatile materials were removed 
using a rotary evaporator.  The crude material was purified via silica gel flash 
chromatograph (20% EtOAc in hexanes) to yield 71.7 mg of product as a colorless oil 
(70% yield).  1H NMR (400 MHz, CDCl3) δ 6.87 (ddd, J = 9.8, 5.2, 3.3 Hz, 1H), 6.02 (dt, 
J = 9.8, 1.8 Hz, 1H), 5.65 – 5.28 (m, 2H), 4.43 (ddt, J = 9.7, 7.3, 5.6 Hz, 1H), 2.42 – 2.29 
(m, 2H), 2.31 – 2.05 (m, 2H), 1.88 (dtd, J = 14.1, 8.2, 6.2 Hz, 1H), 1.74 – 1.61 (m, 4H).  
13C NMR (100 MHz, CDCl3) δ 164.5, 144.9, 129.6, 126.2, 121.5, 77.3, 77.2, 77.0, 76.7, 
34.6, 29.4, 27.7, 17.9. 
 
(E)-6-(Pent-3-en-1-yl)-5,6-dihydro-2H-pyran-2-one (2.2).  The mixture of lactone 
isomers 2.11 were separated with silica gel column chromatography with 10% wt silver 
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nitrate embedded silica gel.  1H NMR (400 MHz, C6D6) δ 5.95 (ddd, J = 9.7, 5.9, 2.3 Hz, 
1H), 5.92 – 5.81 (m, 1H), 5.54 – 5.29 (m, 2H), 3.91 (dddd, J = 11.7, 8.3, 4.8, 3.7 Hz, 1H), 
2.22 – 1.92 (m, 2H), 1.66 (dq, J = 6.2, 1.3 Hz, 3H), 1.64 – 1.48 (m, 3H), 1.41 – 1.23 (m, 
2H).  13C NMR (100 MHz, C6D6) δ 163.2, 143.7, 143.7, 130.3, 125.9, 121.8, 76.5, 34.9, 
29.1, 28.1, 18.0.  13C NMR (100 MHz, C6D6) δ 163.2, 143.7, 130.3, 125.9, 121.8, 76.5, 
34.9, 29.1, 28.1, 18.0. 
6.2.3  Serum Stability Assay.  Human and mouse serum were purchased from Sigma 
Aldrich.  Pironetin was analyzed by HPLC to be > 95% pure. 
Sample procedure for serum stability assays.  Pironetin (1.10 mg) in mouse serum (1.3 
mL) and DMSO (1.3 µL) was shaken at 37 °C.  Aliquots (100 µL) were taken after 10 
min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h for analysis of percent pironetin remaining in 
serum.  Each aliquot was treated with a methanol solution (150 µL) of standard 2.2 (3.98 
mg of lactone 2.2 in 5 mL methanol).  The supernatant was separated from precipitated 
proteins via filtration using an Amicon ® Ultra 10K - 0.5 Centrifugal Filter Device.  75 
µL of the filtrate was diluted with 75 µL of acetonitrile and analyzed via HPLC to 
calculate the amount of pironetin remaining in serum. 
6.2.4 Incubation of pironetin with glutathione protocol.  A solution of pironetin (6 
mM) was prepared by dissolving pironetin (1.2 mg) in PBS (1x, pH 7.4, 0.6 mL) 
containing DMSO (0.1%).  A solution of mono-ethyl glutathione (60 mM) was prepared 
by dissolving mono-ethyl glutathione (16 mg) in PBS (1x, pH 7.4, 0.8 mL) containing 
DMSO (0.1%).  The pironetin solution (0.25 mL) was combined with the mono-ethyl 
glutathione solution (0.25 mL).  The sample was shaken at 37 °C for 1 h.  The sample 
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was extracted three times with EtOAc.  The combine organic extracts were filtered 
through a plug of Celite®.  The Celite® plug was rinsed with EtOAc.  The filtrate was 
concentrated using a rotary evaporator.  The residue was submitted to Sara Coulup for 
LC-MS/MS analysis for the detection of glutathione adducts. 
6.3 Chapter 3 experimental procedures 
 
(S)-Methyl 3-((tert-Butyldimethylsilyl)oxy)-2-methylpropanoate (3.29).  The product 
was synthesized following a previously reported procedure.118  To a solution of (S)-
Roche ester 3.28 (1.25 g, 10.6 mmol) in DCM (44 mL) was added imidazole (0.86 g, 13 
mmol) followed by TBSCl (1.75 g, 11.6 mmol).  The reaction was stirred at room 
temperature overnight.  The reaction was filtered through a fritted funnel.  The filtrate 
was concentrated using a rotary evaporator.  The crude material was purified via silica 
gel flash chromatograph (5% ether in hexanes) to yield 2.36 g of product as a colorless 
oil (96% yield).  The resonances in the 1H NMR and 13C spectrum of the product 
matched previously reported chemical shifts.118 
 
(R)-3-((tert-Butyldimethylsilyl)oxy)-2-methylpropan-1-ol (3.30).  The product was 
synthesized following a previously reported procedure for the (S)-enantiomer.119  To a 
solution of ester 3.29 (1.74 g, 7.47 mmol) in DCM (75 mL) at -78 °C was cannula 
transferred a solution of DIBAL-H (1 M in toluene, 15.7 mL, 15.7 mmol) over 25 min.  
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The reaction was stirred at -78 °C for 10 min and then warmed to -40 °C and stirred for 
an additional 1 h.  The reaction was cooled to -78 °C and then quenched with MeOH (2.1 
mL) and stirred for 10 min.  The reaction was poured into DCM (50 mL) and saturated 
aqueous Rochelle salt (50 mL) and stirred for 2 h.  The layers were separated and the 
aqueous layer was extracted three times with DCM.  The combined organic layers were 
washed with brine and dried with anhydrous MgSO4.  The salts were removed via gravity 
filtration and volatile materials were removed using a rotary evaporator.  The crude 
material was purified via silica gel flash chromatograph (10% to 15% EtOAc in hexanes) 
to yield 1.41 g of product as a colorless oil (92% yield).  The resonances in the 1H NMR 
and 13C spectrum of the product matched previously reported chemical shifts.119 
 
(S)-3-((tert-Butyldimethylsilyl)oxy)-2-methylpropanal (3.31).  The product was 
synthesized following previously a reported procedure for the (R)-enantiomer.120  To a 
solution of oxalyl chloride (2.1 mL, 24 mmol) in DCM (154 mL) at -78 °C was added 
dimethylsulfoxide (3.4 mL, 48 mmol) dropwise.  After stirring the reaction at -78 °C for 
10 min, a solution of alcohol 3.30 (3.30 g, 16.2 mmol) in DCM (6.4 mL) was added 
dropwise.  After stirring the reaction at -78 °C for an additional 30 min, TEA (14.6 mL, 
105 mmol) was added dropwise and stirred at -78 °C for an additional 1 h.  The reaction 
was warmed to -40 °C and diluted with DCM and quenched with saturated aqueous 
NH4Cl.  The reaction was warmed to room temperature and diluted with ether.  The 
layers were separated and the aqueous layers were extracted twice with ether.  The 
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combined organic layers were washed with brine and dried with anhydrous Na2SO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatograph 
(6% EtOAc in hexanes) to yield 3.01 g of product as a colorless oil (92% yield).  The 
resonances in the 1H NMR and 13C spectrum of the product matched previously reported 
chemical shifts.120 
 
Diisopropyl (4R,5R)-2-((E)-But-2-en-1-yl)-1,3,2-dioxaborolane-4,5-dicarboxylate 
(3.32).  The product was synthesized following a previously reported procedure121  To a 
suspension of potassium tert-butoxide (7.04 g, 62.7 mmol) in THF (52 mL) at -78 °C was 
cannula transferred trans-2-butene (~6.2 mL).  To the reaction was cannula transferred a 
solution of n-butyllithium (1.95 M in hexanes, 32.2 mL, 62.7 mmol) over 20 min.  The 
reaction was warmed to -50 °C and stirred for 15 min and recooled to -78 °C.  
Triisopropyl borate (14.6 mL, 62.7 mmol) was cannula transferred to the reaction over 30 
min and stirred at -78 °C for 15 min.  The reaction was poured into at separatory funnel 
containing 1 M HCl (110 mL) saturated with NaCl.  The pH of the solution was 
measured to ensure it was pH = 1.  A solution of (+)-diisopropyl L-tartrate (14.7 g, 62.7 
mmol) dissolved in ether (22 mL) was added to the separatory funnel.  The layers were 
separated and the organic layer was extracted four times with ether (30 mL).  The 
combined organic layers were stirred with anhydrous MgSO4 for 2 h.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
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evaporator.  Residual volatile materials were removed under high vacuum to yield 17.1 g 
of crude material.  The crude material was dissolved in toluene (20 mL) to give 34 mL of 
solution of crotylation reagent 3.32. 
 For determining the concentration of reagent 3.32, to 1,3,5-trimethoxybenzene (14 
mg, 0.083 mmol) and cyclohexanescarboxaldehyde (0.10 mL, 0.83 mmol) was added a 
the solution of crotylation reagent 3.32 (0.2 mL) and stirred at room temperature for 45 
min.  A suspension of NaBH4 (34 mg, 0.90 mmol) in EtOH (1 mL) was added to the 
reaction and stirred for an additional 45 min.  A solution of sodium hydroxide (3 M, 2 
mL) was then added to the reaction and stirred for an additional 1 h.  The reaction was 
diluted with ether and the layers were separated.  The organic layer was concentrated 
under reduced pressure.  1H NMR analysis of the crude material showed the solution of 
reagent 3.32 to be 0.6 M based on the relative amount of (1,2-anti)-1-cyclohexyl-2-
methylbut-3-en-1-ol and 1,3,5-trimethoxybenzene. 
 
(2S,3S,4S)-1-((tert-Butyldimethylsilyl)oxy)-2,4-dimethylhex-5-en-3-ol (3.27).  The 
product was synthesized following a previously reported procedure.58  A solution of 
crotylation reagent 3.32 (0.6 M in toluene, 29 mL, 18 mmol) was stirred over powdered 4 
Å molecular sieves (2 g) for 10 min then cooled to -78 °C.  A solution of aldehyde 3.31 
(2.37 g, 11.7 mmol) in toluene (10 mL) was cannula transferred to the reaction over 25 
min.  The reaction was stirred at -78 °C for 7 h.  The reaction was filtered through a plug 
of Celite® and the filtrate was diluted with ether and water.  The layers were separated 
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and the aqueous layer was extract three times with ether.  The combined organic layers 
were washed with brine and dried with anhydrous Na2SO4.  The salts were removed via 
gravity filtration and volatile materials were removed using a rotary evaporator.  The 
crude material was dissolved in ether (150 mL) and aqueous KOH (1 M, 150 mL) and 
stirred overnight.  The layers were separated and the aqueous layer was extracted three 
times with ether.  The combined organic layers were washed with brine and dried with 
anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatograph (5% ether in hexanes).  Impure material was further purified three 
times with via silica gel flash chromatograph (5% ether in hexanes).  The combined 
product from 4 columns yielded 2.35 g of as a colorless oil product as a colorless oil 
(78% yield).  The resonances in the 1H NMR spectrum of the product matched previously 
reported chemical shifts.121 
 
tert-Butyl(((2S,3S,4S)-3-methoxy-2,4-dimethylhex-5-en-1-yl)oxy)dimethylsilane 
(3.33).  To a suspension of sodium hydride (60% in mineral oil, 2.1 g, 52 mmol) in THF 
(90 mL) was added a solution of alcohol 3.27 (2.32 g, 8.98 mmol) in THF (10.5 mL).  
After stirring for 1.5 h, iodomethane (2.8 mL, 45 mmol) was added to the reaction and 
the reaction was stirred overnight.  The reaction was quenched with saturated aqueous 
NH4Cl and diluted with EtOAc.  The layers were separated and the aqueous layer was 
extracted three times with EtOAc.  The combined organic layers were washed with brine 
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and dried with anhydrous MgSO4.  The salts were removed via gravity filtration and 
volatile materials were removed using a rotary evaporator.  The crude material was 
purified via silica gel flash chromatograph (2% ether in hexanes) to yield 2.28 g of 
product as a colorless oil (93% yield).  1H NMR (400 MHz, CDCl3) δ 5.89 (ddd, J = 17.7, 
10.3, 7.8 Hz, 1H), 5.19 – 4.89 (m, 2H), 3.65 – 3.42 (m, 2H), 3.40 (s, 3H), 3.08 (dd, J = 
6.8, 4.1 Hz, 1H), 2.40 (q, J = 7.1 Hz, 1H), 1.96 – 1.68 (m, 1H), 0.99 (d, J = 6.9 Hz, 3H), 
0.90 (s, 9H), 0.86 (d, J = 6.9 Hz, 3H), 0.05 (s, 6H).  13C NMR (100 MHz, CDCl3) δ 
141.8, 114.0, 85.2, 77.3, 77.0, 76.7, 65.5, 60.9, 40.9, 38.3, 25.9, 25.9, 18.2, 17.1, 11.1, -
5.4.  HRMS calc m/z [C15H32O2Si + Na]+: 295.2064, found: 295.2048. 
 
(2S,3S,4S)-3-Methoxy-2,4-dimethylhex-5-en-1-yl 4-Methylbenzenesulfonate (3.26).  
To a solution of ether 3.33 (0.109 g, 0.400 mmol) in THF (0.7 mL) was added TBAF (1 
M in THF, 2 mL, 2 mmol).  After stirring for 3 h, the reaction was diluted with EtOAc 
and diluted with saturated aqueous NaHCO3.  The layers were separated and the aqueous 
phase was extracted twice with EtOAc.  The combined organic layers were washed with 
brine and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration 
and volatile materials were removed using a rotary evaporator.  The crude material was 
dissolved in pyridine (2.7 mL) followed by addition of TsCl (229 mg, 1.20 mmol).  The 
reaction was stirred overnight and then poured into water and diluted with EtOAc.  The 
layers were separated and the aqueous layer was extracted three times with EtOAc.  The 
combined organic layers were washed with brine and dried with anhydrous Na2SO4.  The 
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salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatograph 
(10% EtOAc in hexanes) to yield 0.115 g of product as a colorless oil (92% yield over 2 
steps).  1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 
5.87 – 5.72 (m, 1H), 5.12 – 4.88 (m, 2H), 4.08 – 3.82 (m, 2H), 3.31 (s, 3H), 2.98 (dd, J = 
6.8, 4.1 Hz, 1H), 2.45 (s, 3H), 2.30 (q, J = 7.2 Hz, 1H), 2.13 – 1.88 (m, 1H), 0.94 (d, J = 
6.9 Hz, 3H), 0.87 (d, J = 7.0 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 144.8, 141.0, 
133.1, 129.8, 127.9, 114.7, 84.2, 77.3, 77.0, 76.7, 72.7, 60.8, 40.7, 35.6, 10.8. 
 
(3S,4R,5S)-4-Methoxy-3,5-dimethyloct-1-en-7-yne (3.35).  Inside a dry box under a N2 
atmosphere, tosylate 3.26 (1.00 g, 3.20 mmol) was dissolved in dimethylsulfoxide (9.7 
mL).  Lithium acetylide ethylenediamine complex 3.34 (90%, 0.54 g, 5.3 mmol) was 
added to the solution.  The reaction was removed from the dry box and stirred for 1.5 h.  
The reaction was diluted with ether and quenched with saturated aqueous NH4Cl.  The 
layers were separated and the aqueous phase was extracted three times with ether.  The 
combined organic layers were washed with brine and dried with anhydrous Na2SO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatograph 
(2% ether in pentane) to yield 0.414 g of product as a colorless oil (78% yield).  1H NMR 
(400 MHz, CDCl3) δ 5.88 (ddd, J = 17.3, 10.3, 8.0 Hz, 1H), 5.19 – 4.93 (m, 2H), 3.44 (s, 
3H), 3.01 (dd, J = 6.3, 4.9 Hz, 1H), 2.40 (h, J = 7.1 Hz, 1H), 2.22 (qdd, J = 16.8, 6.7, 2.6 
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Hz, 2H), 1.97 (t, J = 2.6 Hz, 1H), 1.88 (qd, J = 6.8, 4.9 Hz, 1H), 1.02 (d, J = 7.0 Hz, 3H), 
1.00 (d, J = 7.0 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 141.2, 114.4, 87.3, 83.3, 69.3, 
61.3, 40.9, 35.3, 23.2, 17.3, 14.3. 
 
(3S,4R,5S)-4-Methoxy-3,5-dimethylnon-1-en-7-yne (3.25).  To a solution of alkyne 
3.35 (0.110 g, 0.662 mmol) in THF (3.9 mL) at 0 °C, was added a solution of n-
butyllithium (2.2 M in hexanes, 0.50 mL, 1.1 mmol).  After stirring for 20 min at 0 °C, 
iodomethane (0.14 mL, 2.2 mmol) was added to the reaction.  The reaction was warmed 
to room temperature and stirred overnight.  The reaction was quenched with saturated 
aqueous NH4Cl and extracted three times with EtOAc.  The combined organic layers 
were washed with brine and dried with anhydrous Na2SO4.  The salts were removed via 
gravity filtration and volatile materials were removed using a rotary evaporator.  The 
crude material was purified via silica gel flash chromatograph (2% ether in pentane) to 
yield 0.106 g of product as a colorless oil (89% yield).  1H NMR (400 MHz, CDCl3) δ 
5.88 (ddd, J = 17.3, 10.3, 8.0 Hz, 1H), 5.15 – 4.92 (m, 2H), 3.44 (s, 3H), 2.98 (dd, J = 
6.3, 5.0 Hz, 1H), 2.40 (dq, J = 7.8, 6.7 Hz, 1H), 2.14 (ddddt, J = 18.9, 14.3, 11.8, 7.2, 2.6 
Hz, 2H), 1.85 – 1.74 (m, 4H), 1.01 (d, J = 6.9 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H). 13C 
NMR (100 MHz, CDCl3) δ 141.4, 114.3, 87.6, 77.8, 76.5, 61.3, 40.9, 35.7, 23.6, 17.3, 
14.4, 3.5. 
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(3S,4R,5S)-4-Methoxy-3,5-dimethylnon-7-yne-1,2-diol (3.36).  Table 3-1, entry 1:  To 
a solution of alkene 3.25 (30. mg, 0.17 mmol) in tert-butanol (0.5 mL), THF (0.5 mL), 
and water (0.1 mL) at 0 °C was added NMO (40. mg, 0.34 mmol) followed by a solution 
of  OsO4 (2.5% in tert-butanol, 0.10 mL, 0.0080 mmol).  The reaction was warmed to 
room temperature and stirred for 5 h.  Additional NMO (15 mg, 0.13 mmol) was added to 
the reaction.  After stirring for an additional 1 h, sodium metabisulfite (250 mg) was 
added to the reaction.  After stirring for an additional 30 min, the salts were removed via 
gravity filtration.  The solid was washed with EtOAc, and the filtrate was concentrated 
using a rotary evaporator.  The crude material was purified via silica gel flash 
chromatograph (4% methanol in DCM) to yield 22.7 mg of product as a colorless oil 
(64% yield).  Major isomer:  1H NMR (400 MHz, CDCl3) δ 3.79 – 3.67 (m, 2H), 3.60 – 
3.51 (m, 4H), 3.31 (dd, J = 8.5, 2.7 Hz, 1H), 2.29 – 2.13 (m, 2H), 2.00 – 1.84 (m, 2H), 
1.81 (t, J = 2.6 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H). 
Table 3-1, entry 2:  To a solution of alkene 3.25 (40. mg, 0.22 mmol) in acetone (0.5 mL) 
and water (1 mL) at 0 °C was added NMO (31 mg, 0.26 mmol) followed by solution of 
OsO4 (4% in water, 0.070 mL, 0.011 mmol).  The reaction was warmed to room 
temperature and stirred for 2.5 h.  Additional NMO (31 mg, 0.26 mmol) was added to the 
reaction.  After stirring for an additional 3 h, the reaction was quenched with saturated 
aqueous sodium sulfite and stirred for 30 min.  The mixture was concentrated using a 
rotary evaporator.  The crude mixture was suspended in saturated aqueous sodium 
thiosulfate and the solution was extracted four times with EtOAc.  The combined organic 
layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
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removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatograph (4% 
methanol in DCM) to yield 21.8 mg of product as a colorless oil (45% yield). 
Table 3-1, entry 3:  A suspension of AD-mix-α (230 mg) was stirred in tert-butanol (0.9 
mL) and water (1 mL) at room temperature before cooling to 0 °C.  A solution of alkene 
3.25 (30. mg, 0.17 mmol) in tert-butanol (0.2 mL) was added to the reaction.  The flask 
containing alkene 3.25 was rinsed with additional tert-butanol (0.2 mL) which was added 
to the reaction and stirred overnight at 0 °C.  After 20 h, an additional portion of AD-
mix-α (480 mg) was added to the reaction and the reaction was stirred at 0 °C overnight.  
The reaction was quenched with saturated aqueous sodium sulfite and warmed to room 
temperature.  After stirring for 30 min, saturated aqueous sodium thiosulfate was added 
to the reaction.  The mixture was extracted four times with EtOAc.  The combined 
organic layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatograph (4% 
methanol in DCM) to yield 27.6 mg of product as a colorless oil (78% yield). 
 
(2R,3R,4S)-3-Methoxy-2,4-dimethyloct-6-ynal (3.24).  A suspension of AD-mix-α (580 
mg) was stirred in tert-butanol (1.7 mL) and water (2 mL) at room temperature before 
cooling to 0 °C.  A solution of alkene 3.25 (75 mg, 0.42 mmol) in tert-butanol (0.3 mL) 
was added to the reaction.  The flask containing alkene 3.25 was rinsed with additional 
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tert-butanol (0.3 mL) which was added to the reaction and stirred overnight at 0 °C.  
After 16 h, an additional portion of AD-mix-α (580 mg) was added to the reaction and the 
reaction was stirred at 0 °C for an additional 24 h.  Sodium sulfite (1.06 g) was added to 
the reaction and warmed to room temperature and stirred for 1.5 h.  The reaction was 
extracted four times with EtOAc.  The combined organic layers were washed with brine 
and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and 
volatile materials were removed using a rotary evaporator.  To a solution of crude diol 
3.36 in DCM (4.2 mL), was added (diacetoxyiodo)benzene (0.16 g, 0.50 mmol).  After 
1.5 h, the reaction was concentrated using a rotary evaporator.  The crude material was 
purified via silica gel flash chromatograph (20% ether in hexanes) to yield 45.2 mg of 
product as a colorless oil (60% yield over 2 steps).  1H NMR (400 MHz, CDCl3) δ 9.81 
(d, J = 2.4 Hz, 1H), 3.48 (dd, J = 7.4, 3.8 Hz, 1H), 3.44 (s, 3H), 2.63 (pd, J = 7.1, 2.4 Hz, 
1H), 2.30 – 2.08 (m, 2H), 1.85 (dtd, J = 7.5, 6.6, 3.8 Hz, 1H), 1.79 (t, J = 2.6 Hz, 3H), 
1.06 (d, J = 7.0 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H). 
Table 3-2, entry 1: To a solution of diol 3.36 (22.7 mg, 0.106 mmol) in THF (0.6 mL) 
and pH 7 phosphate buffer (0.15 mL) was added sodium periodate (34 mg, 0.16 mmol).  
After stirring for 3 h, additional sodium periodate (20. mg, 0.094 mmol) was added to the 
reaction.  After stirring an additional 2.5 h, the suspension was filtered through a cotton 
plug.  The solid was rinsed with EtOAc.  The filtrate was washed with water, brine and 
then dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and 
volatile materials were removed using a rotary evaporator.  The crude material was 
purified via silica gel flash chromatograph (4:1 hexanes:ether) to yield 11.6 mg of 
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product as a colorless oil (60% yield). 
Table 3-2, entry 2:  To a solution of diol 3.36 (21.8 mg, 0.102 mmol) in DCM (1 mL), 
was added (diacetoxyiodo)benzene (39 mg, 0.12 mmol).  After 2 h, the reaction was 
concentrated using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatograph (20% ether in hexanes) to yield 12.5 mg of product as a colorless oil 
(67% yield). 
Table 3-2, entry 3:  To a solution of diol 3.36 (27.6 mg, 0.129 mmol) in DCM (1.3 mL) 
was added lead (IV) acetate (68 mg, 0.15 mmol).  After stirring for 1 h, additional lead 
(IV) acetate (34 mg, 0.077 mmol) was added to the reaction.  After stirring an additional 
1 h, the reaction was quenched with saturated aqueous NaHCO3.  The mixture was 
filtered through Celite® and the filtrate was extracted three times with EtOAc.  The 
combined organic layers were washed with brine and dried with anhydrous Na2SO4.    
The salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatograph 
(4:1 hexanes:ether) to yield 11.2 mg of product as a colorless oil (48% yield). 
 
N-((1S,2S)-1-Hydroxy-1-phenylpropan-2-yl)-N,3-dimethylbut-2-enamide (3.38).  The 
product was synthesized following a previously reported procedure.50  To a solution of 
(1S,2S)-(+)-pseudoephedrine (3.37, 1.0 g, 6.1 mmol) and triethylamine (1.1 mL, 7.9 
mmol) in THF (15 mL) at 0 °C was added 3,3-dimethylacryloyl chloride (0.78 mL, 7.0 
mmol).  After stirring 1 h at 0 °C, the reaction was slowly quenched with water.  The 
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reaction was poured into brine and extracted four times with EtOAc.  The combined 
organic layers were dried with anhydrous Na2SO4.  The salts were removed via gravity 
filtration and volatile materials were removed using a rotary evaporator.  The crude 
material was recrystallized from hot toluene to yield 1.24 g of product as a white solid 
(83% yield).  The resonances in the 1H NMR and 13C spectrum of the product matched 
previously reported chemical shifts.50 
 
(S)-2-Ethyl-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N,3-dimethylbut-3-enamide 
(3.39).  The product was synthesized following a previously reported procedure.50  To a 
suspension of lithium chloride (0.25 g, 5.9 mmol) and diisopropylamine (0.32 mL, 2.3 
mmol) in THF (1.3 mL) at -78 °C was added a solution of n-butyllithium (2.2 M in 
hexanes, 1.0 mL, 2.2 mmol).  The reaction was warmed to room temperature and stirred 
for 10 min and then cooled to -78 °C.  A suspension of amide 3.38 (0.25 g, 1.0 mmol) in 
THF (1.75 mL) was added to the reaction.  The flask containing the suspension of amide 
3.38 was rinsed with additional THF (0.5 mL) which was added to the reaction.  The 
reaction was stirred at -78 °C for 1 h and then warmed to 0 °C and stirred for 15 min.  
The reaction was warmed to room temperature and stirred and additional 15 min before 
cooling to 0 °C.  Iodoethane (0.16 mL, 2.0 mmol) was added dropwise to the reaction and 
stirred for an additional 2 h at 0 °C.  The reaction was quenched with saturated aqueous 
NH4Cl and extracted four times with EtOAc.  The combined organic layers were washed 
with brine and dried with anhydrous Na2SO4.  The salts were removed via gravity 
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filtration and volatile materials were removed using a rotary evaporator.  The crude 
material was purified via silica gel flash chromatograph (25% to 40% EtOAc in hexanes) 
to yield 0.21 g of product as a colorless oil (78% yield). The resonances in the 1H NMR 
and 13C spectrum of the product matched previously reported chemical shifts.50 
 
(R)-3-(((4-Methoxybenzyl)oxy)methyl)pentan-2-one (3.40).  The product was 
synthesized by adapting previously reported procedures.50  To a solution of 
diisopropylamine (0.60 mL, 3.9 mmol) in THF (2.1 mL) at 0 °C was added a solution of 
n-butyllithium (2.2 M in hexanes, 1.7 mL, 3.7 mmol) and stirred at 0 °C for 5 min.  
Borane-ammonia complex (90%, 0.13 g, 3.9 mmol) was added to the reaction and the 
reaction was stirred at 0 °C for an additional 20 min.  The reaction was warmed to room 
temperature and stirred for 30 min before cooling to 0 °C.  A solution of amide 3.39 (0.20 
g, 0.74 mmol) in THF (0.6 mL) was added to the reaction.  The flask containing the 
solution of amide 3.39 was rinsed with additional THF (0.4 mL) which was added to the 
reaction.  The reaction was stirred at 0 °C for 20 min before warming to room 
temperature and stirred for an additional 2 h.  The reaction was cooled to 0 °C, and 3 M 
HCl (8.4 mL) was added dropwise via an addition funnel.  After stirring at 0 °C for 25 
min, the reaction was warmed to room temperature and stirred for an additional 15 min.  
The reaction was extracted three times with 30% ether in pentane.  The combined organic 
layers were concentrated using a rotary evaporator to ~1.2 mL.  The solution of the crude 
alcohol was added dropwise to a suspension of potassium hydride (30% in mineral oil, 
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0.20 g, 0.14 mmol) in THF (1.5 mL) at -20 °C.  The flask containing the alcohol solution 
was rinsed with additional THF (0.5 mL) which was added to the reaction.  After stirring 
at -20 °C for 20 min, PMBCl (0.16 mL, 1.2 mmol) was added to the reaction.  The 
reaction was warmed to room temperature and stirred overnight.  The reaction was 
quenched with ice and diluted with saturated aqueous NH4Cl.  The mixture was extracted 
three times with DCM.  The combined organic layers were washed with brine and dried 
with anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile 
materials were removed using a rotary evaporator. 
 To a solution of the crude material in THF (2.5 mL), tert-butanol (2.5 mL), and 
water (0.5 mL) at 0 °C, was added NMO (0.16 g, 1.4 mmol).  A solution of osmium 
tetraoxide (2.5% in tert-butanol, 0.44 mL, 0.035 mmol) was added to the reaction.  The 
reaction was warmed to room temperature and stirred for 5 h.  Sodium metabisulfite (1 g) 
was added to the reaction and the suspension was stirred for 45 min until the reaction 
became clear.  The suspension was filtered and solids were washed with EtOAc.  The 
filtrate was concentrated via rotary evaporator to yield the crude diol.  To a solution of 
crude diol in THF (3.8 mL) and water (1 mL) was added sodium periodate (0.20 g, 0.91 
mmol).  After stirring at room temperature for 3 h, the reaction was filtered and the solid 
was washed with EtOAc.  The filtrate was dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatograph (15% 
EtOAc in hexanes) to yield 97.9 mg of product as a colorless oil (56% yield over 4 steps).  
The resonances in the 1H NMR and 13C spectrum of the product matched previously 
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reported chemical shifts.50 
 
(R)-((3-(((4-Methoxybenzyl)oxy)methyl)pent-1-en-2-yl)oxy)trimethylsilane (3.20).  
The product was synthesized following a previously reported procedure.50  To solution of 
LiHMDS (1 M in hexanes, 2.1 mL, 2.1 mmol) in THF (13 mL) at -78 °C, was added a 
solution of ketone 3.40 (0.20 g, 0.85 mmol) in THF (0.6 mL).  The flask containing 
ketone 3.40 was rinsed with additional THF (0.4 mL) which was added to the reaction.  
The reaction was stirred at -78 °C and stirred for 15 min.  The reaction was quenched 
with a TEA/TMSCl (1:1 mixture filtered through Celite®, 0.27 mL) and stirred at -78 °C 
for 15 min.  The reaction was warmed to room temperature and diluted with ether (3.5 
mL).  The reaction was concentrated to ~ 1 mL using a rotary evaporator and diluted with 
a 4:1 mixture of hexanes:ether (10 mL).  The suspension was concentrated using a rotary 
evaporator.  The crude material was suspended in a 4:1 mixture of hexanes:ether (10 mL) 
and concentrated under rotary evaporator twice.  The crude material was suspended in a 
4:1 mixture of hexanes:ether (10 mL) and filtered through a plug of Celite®.  The filtrate 
was concentrated using a rotary evaporator to yield 0.20 g of crude silyl enol ether.  The 
silyl enol ether was used without further purification.  The resonances in the 1H NMR and 
13C spectrum of the product matched previously reported chemical shifts.50 
 
(3R,6R,7S,8R,9S)-6-Hydroxy-8-methoxy-3-(((4-methoxybenzyl)oxy)methyl)-7,9-
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dimethyltridec-11-yn-4-one (3.23).  To a solution of aldehyde 3.24 (78.7 mg, 0.432 
mmol) and silyl enol ether (0.20 g crude, 0.65 mmol) in DCM (3.9 mL) at -90 °C 
(methanol:lq N2 bath) was added BF3•Et2O solution (1 M in DCM, 0.7 mL, 0.7 mmol).  
The reaction was stirred at -90 °C for 2 h before quenching with saturated aqueous 
NaHCO3.  The mixture was warmed to room temperature and extracted three times with 
EtOAc and once with DCM.  The combined organic layers were washed with brine and 
dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile 
materials were removed using a rotary evaporator.  The crude material was purified via 
silica gel flash chromatograph to yield 0.115 g of product as a colorless oil (64% yield).  
1H NMR (400 MHz, CDCl3) δ 7.25 – 7.17 (m, 2H), 6.89 – 6.82 (m, 2H), 4.46 – 4.36 (m, 
3H), 3.80 (s, 3H), 3.59 (t, J = 8.8 Hz, 1H), 3.52 – 3.44 (m, 4H), 3.28 (dd, J = 7.8, 4.0 Hz, 
1H), 2.87 – 2.67 (m, 2H), 2.47 (dd, J = 17.0, 3.3 Hz, 1H), 2.35 – 2.09 (m, 2H), 1.89 (qd, J 
= 6.8, 4.0 Hz, 1H), 1.79 (t, J = 2.6 Hz, 3H), 1.74 – 1.50 (m, 2H), 1.50 – 1.35 (m, 1H), 
0.93 (d, J = 6.8 Hz, 3H), 0.87 (t, J = 7.3 Hz, 6H).  13C NMR (100 MHz, CDCl3) δ 214.6, 
159.2, 129.9, 129.3, 113.8, 85.7, 77.8, 76.6, 73.0, 70.6, 66.5, 61.8, 55.2, 54.3, 48.2, 39.8, 
35.4, 23.9, 21.6, 13.6, 11.7, 10.3, 3.5. 
Samarium Iodide 
The product was synthesized following a previously reported procedure.122  Inside a dry 
box under a N2 atmosphere, samarium powder (90. mg, 0.60 mmol) and THF (3 mL) 
were added to a round bottom flask.  Iodine (76 mg, 0.30 mmol) was added to the flask.  
The reaction was sealed with a glass stopper and covered with aluminum foil.  The flask 
was removed from the glovebox and stirred at 60 °C overnight.  The flask was cooled to 
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room temperature and the solution was stored in the dry box.  The solution was titrated 
with 2-heptanone to calculate the concentration.123 
 
(3R,4R,6R,7S,8R,9S)-4-Hydroxy-8-methoxy-3-(((4-methoxybenzyl)oxy)methyl)-7,9-
dimethyltridec-11-yn-6-yl Acetate (3.41).  To a solution of ketone 3.23 (60.7 mg, 0.145 
mmol) and acetaldehyde (0.070 mL, 1.2 mmol) in THF (0.6 mL) at -15 °C was added 
dropwise a solution of SmI2 (0.075 M in THF, 0.78 mL, 0.059 mmol) dropwise.  The 
reaction was stirred at -15 °C for 1 h before quenching with saturated aqueous NaHCO3.  
The mixture was warmed to room temperature and extracted four times with EtOAc.  The 
combined organic layers were washed with brine and dried with anhydrous Na2SO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatograph 
(4:1 hexanes:EtOAc) to yield 58.7 mg of product as a colorless oil (87% yield).  1H NMR 
(400 MHz, CDCl3) δ 7.23 (d, J = 8.5 Hz, 2H), 6.92 – 6.82 (m, 2H), 5.38 (ddd, J = 9.6, 
3.9, 1.8 Hz, 1H), 4.51 – 4.36 (ABq, 2H), 3.80 (s, 3H), 3.68 (dt, J = 10.5, 3.0 Hz, 1H), 
3.57 – 3.44 (m, 3H), 3.41 (s, 3H), 3.05 (dd, J = 9.4, 2.3 Hz, 1H), 2.28 – 2.10 (m, 2H), 
2.08 (s, 3H), 1.92 – 1.76 (m, 4H), 1.76 – 1.64 (m, 2H), 1.64 – 1.51 (m, 2H), 1.53 – 1.28 
(m, 3H), 0.94 – 0.83 (m, 9H).  13C NMR (100 MHz, CDCl3) δ 172.0, 159.1, 130.4, 129.2, 
113.7, 83.9, 78.2, 76.6, 72.9, 71.8, 70.7, 68.8, 61.5, 55.2, 45.5, 40.2, 37.6, 35.7, 24.5, 
21.1, 19.1, 12.8, 12.3, 10.4, 3.4. 
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(4R,6R)-4-((2S,3R,4S)-3-Methoxy-4-methyloct-6-yn-2-yl)-6-((R)-1-((4-
methoxybenzyl)oxy)butan-2-yl)-2,2-dimethyl-1,3-dioxane (3.42).  To a solution of 
alcohol 3.41 (16 mg, 0.035 mmol) in methanol (0.5 mL) was added potassium hydroxide 
(3 mg, 0.05 mmol) and stirred at room temperature.  After 4 h, additional potassium 
hydroxide (10. mg, 0.18 mmol) was added to the reaction and the reaction was stirred for 
an additional 1 h.  The reaction was quenched with saturated aqueous NH4Cl, and 
extracted four times with DCM.  The combined organic layers were washed with brine 
and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and 
volatile materials were removed using a rotary evaporator.  The crude diol was stirred 
overnight in 1,3-dimethoxypropane (1 mL) and PPTS (1 mg).  The reaction was diluted 
with DCM (2 mL) and quench with saturated aqueous NaHCO3.  The layers were 
separated and the aqueous layer was extracted twice with DCM.  The combined organic 
layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatograph (9:1 
hexanes:EtOAc) to yield 9.2 mg of product as a colorless oil (58% yield over 2 steps).  
1H NMR (400 MHz, CDCl3) δ 7.26 – 7.22 (m, 2H), 6.92 – 6.83 (m, 2H), 4.49 – 4.32 (m, 
2H), 4.08 (td, J = 8.0, 2.4 Hz, 1H), 3.88 – 3.75 (m, 4H), 3.47 (s, 3H), 3.46 – 3.36 (m, 
2H), 3.24 (dd, J = 9.3, 2.0 Hz, 1H), 2.26 – 2.07 (m, 2H), 1.84 (td, J = 7.1, 2.0 Hz, 1H), 
1.80 (t, J = 2.5 Hz, 3H), 1.67 – 1.59 (m, 3H), 1.55 – 1.44 (m, 2H), 1.35 (s, 4H), 1.30 (s, 
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4H), 0.95 – 0.85 (m, 6H), 0.82 (d, J = 7.0 Hz, 4H).  13C NMR (100 MHz, CDCl3) δ 
159.1, 130.7, 129.3, 113.7, 100.0, 83.9, 78.5, 76.3, 72.8, 68.5, 67.3, 65.4, 61.3, 55.3, 45.0, 
41.1, 35.7, 34.0, 30.3, 29.7, 25.0, 24.9, 24.7, 20.0, 12.7, 11.7, 10.0, 3.5. 
 
(3R,4R,6R,7S,8R,9S)-6-Acetoxy-8-methoxy-3-(((4-methoxybenzyl)oxy)methyl)-7,9-
dimethyltridec-11-yn-4-yl 2-Cyanoacetate (3.43).  To a solution of alcohol 3.41 (42 
mg, 0.091 mmol) and DCC (21 mg, 0.10 mmol) dissolved in a 400:1 mixture of 
DCM:pyridine (3.6 mL) were added cyanoacetic acid (8.5 mg, 0.10 mmol).  After 4 h, 
additional DCC (11 mg, 0.053 mmol) and cyanoacetic acid (4.0 mg, 0.047 mmol) was 
added to the reaction.  After 2 h, the reaction was filtered through a plug of Celite®.  The 
filtrate was diluted with water and extracted three times with DCM.  The combined 
organic layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material showed unreacted starting material and was resubjected 
to the original reaction conditions and stirred overnight.  Following the workup from the 
first reaction cycle, the crude material showed unreacted starting material and resubjected 
to the original reaction conditions but with additional DCC (42 mg, 0.20 mmol) and 
cyanoacetic acid (17 mg, 0.20 mmol) and stirred overnight. Following the reaction 
workup from the first reaction cycle, the crude material showed full conversion of the 
starting material.  The crude material was purified via silica gel flash chromatograph (4:1 
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hexanes:EtOAc) to yield 34.0 mg of product as a colorless oil (71% yield). 1H NMR (400 
MHz, CDCl3) δ 7.23 – 7.12 (m, 2H), 6.86 – 6.76 (m, 2H), 5.18 (td, J = 6.9, 1.9 Hz, 1H), 
5.13 – 5.00 (m, 1H), 4.31 (s, 2H), 3.73 (s, 3H), 3.42 – 3.30 (m, 5H), 3.27 (s, 2H), 2.96 
(dd, J = 9.3, 2.3 Hz, 1H), 2.23 – 2.00 (m, 2H), 1.97 (s, 3H), 1.81 (dd, J = 8.3, 5.8 Hz, 
2H), 1.77 – 1.62 (m, 6H), 1.54 (dtt, J = 9.2, 7.1, 3.5 Hz, 1H), 1.36 (p, J = 7.3 Hz, 2H), 
0.87 (t, J = 7.4 Hz, 3H), 0.80 (d, J = 6.8 Hz, 3H), 0.77 (d, J = 7.0 Hz, 3H).  13C NMR 
(100 MHz, CDCl3) δ 170.9, 162.8, 159.1, 130.4, 129.3, 113.7, 113.2, 83.8, 78.0, 74.6, 
72.8, 69.7, 68.9, 61.5, 55.2, 43.8, 40.4, 35.6, 34.4, 24.8, 24.5, 21.0, 19.6, 12.8, 12.0, 10.5, 
3.4. 
 
(2S,3S,4S)-5-((tert-Butyldimethylsilyl)oxy)-3-methoxy-2,4-dimethylpentan-1-ol 
(3.48).  To a solution of olefin 3.33 (2.23 g, 8.18 mmol) in DCM (41 mL) and methanol 
(41 mL) at -78 °C was bubbled ozone until the reaction turned blue.  After bubbling 
oxygen thru the reaction for 15 min, sodium borohydride (0.93 g, 25 mmol) was added 
the reaction.  The reaction was warmed to room temperature and stirred for 3 h.  The 
reaction was diluted with EtOAc and quenched with saturated aqueous NH4Cl.  The 
layers were separated and the aqueous layer was extracted three times with EtOAc.  The 
combined organic layers were washed with brine and dried with anhydrous MgSO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatograph 
(20% EtOAc in hexanes) to yield 1.95 g of product as a colorless oil (86% yield). 1H 
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NMR (400 MHz, CDCl3) δ 3.71 – 3.59 (m, 2H), 3.55 – 3.43 (m, 5H), 1.98 – 1.78 (m, 
2H), 0.90 (s, 9H), 0.88 (d, J = 7.0 Hz, 3H), 0.85 (d, J = 6.9 Hz, 3H), 0.05 (s, 6H).  13C 
NMR (100 MHz, CDCl3) δ 86.5, 67.2, 65.5, 61.1, 38.5, 37.6, 25.9, 18.2, 14.7, 10.5, -5.4, 
-5.4.  HRMS calc m/z [C14H32O3Si + Na]+: 299.2019, found: 299.2019. 
 
(((2S,3S,4S)-5-(Benzyloxy)-3-methoxy-2,4-dimethylpentyl)oxy)(tert-
butyl)dimethylsilane (3.49).  To a solution of alcohol 3.48 (0.85 g, 3.1 mmol) in DMF 
(8.7 mL) at 0 °C was added sodium hydride (60% in mineral oil, 0.23 g, 5.8 mmol).  The 
suspension was stirred at 0 °C for 15 min before addition of benzyl bromide (0.69 mL, 
5.8 mmol).  The reaction was stirred an addition 2.5 h at 0 °C.  The reaction was 
quenched with saturated aqueous NH4Cl and extracted four times with EtOAc.  The 
combined organic layers were washed with brine and dried with anhydrous MgSO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via Combiflash silica gel flash 
chromatograph (0% to 2.5% EtOAc in hexanes) to yield 1.02 g of product as a colorless 
oil (92% yield).  1H NMR (400 MHz, CDCl3) δ 7.40 – 7.27 (m, 5H), 4.63 – 4.47 (ABq, 
2H), 3.62 – 3.45 (m, 4H), 3.39 (s, 3H), 3.28 (dd, J = 9.0, 2.8 Hz, 1H), 1.93 (ddt, J = 12.9, 
6.7, 3.4 Hz, 1H), 1.89 – 1.74 (m, 1H), 0.97 (d, J = 6.9 Hz, 3H), 0.91 (s, 9H), 0.81 (d, J = 
6.9 Hz, 3H), 0.06 (s, 6H).  13C NMR (100 MHz, CDCl3) δ 138.9, 128.3, 127.4, 127.3, 
82.0, 73.0, 72.9, 65.6, 60.9, 37.8, 36.8, 25.9, 18.2, 14.8, 9.9, -5.3, -5.4.  HRMS calc m/z 
[C21H38O3Si + Na]+: 389.2482, found: 389.2481. 
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(2S,3S,4S)-5-(Benzyloxy)-3-methoxy-2,4-dimethylpentyl 4-Methylbenzenesulfonate 
(3.47).  The product was synthesized using the procedure for the synthesis of tosylate 
3.26.  Reaction with ether 3.49 (2.42 g, 6.60 mmol) resulted in 2.52 g of product as a 
colorless oil (94% yield) following purification via silica gel flash chromatography (15% 
EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.83 – 7.76 (m, 2H), 7.39 – 7.27 (m, 
7H), 4.48 (s, 2H), 4.01 (dd, J = 9.3, 8.1 Hz, 1H), 3.91 (dd, J = 9.3, 6.0 Hz, 1H), 3.46 (h, J 
= 5.1 Hz, 2H), 3.27 (s, 3H), 3.16 (dd, J = 8.9, 2.8 Hz, 1H), 2.44 (s, 3H), 2.11 – 1.97 (m, 
1H), 1.93 – 1.76 (m, 1H), 0.89 (d, J = 6.9 Hz, 3H), 0.80 (d, J = 6.9 Hz, 3H).  13C NMR 
(100 MHz, CDCl3) δ 144.7, 138.6, 133.1, 129.8, 128.3, 127.9, 127.5, 127.5, 81.3, 73.1, 
72.8, 72.2, 60.9, 36.6, 35.0, 21.6, 14.5, 9.6.  HRMS calc m/z [C22H30O5S + Na]+: 
429.1706, found: 429.1619. 
 
((((2S,3R,4S)-3-Methoxy-2,4-dimethylhept-6-yn-1-yl)oxy)methyl)benzene (3.50).  The 
product was synthesized using the procedure for the synthesis of alkyne 3.35.  Reaction 
with tosylate 3.47 (2.53 g, 6.22 mmol) resulted in 1.39 g of product as a colorless oil 
(86% yield) following purification via silica gel flash chromatography (4% to 6% ether in 
hexanes).  1H NMR (400 MHz, CDCl3) δ 7.38 – 7.31 (m, 4H), 7.31 – 7.26 (m, 1H), 4.52 
(s, 2H), 3.60 – 3.46 (m, 2H), 3.43 (s, 3H), 3.21 (dd, J = 8.6, 3.2 Hz, 1H), 2.25 (qdd, J = 
16.7, 7.2, 2.6 Hz, 2H), 1.99 (t, J = 2.6 Hz, 1H), 1.97 – 1.82 (m, 2H), 0.98 (d, J = 6.9 Hz, 
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3H), 0.94 (d, J = 6.9 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 138.7, 128.3, 127.5, 127.4, 
84.4, 83.6, 73.1, 72.5, 69.3, 61.3, 37.0, 35.1, 23.7, 14.8, 13.2.  HRMS calc m/z [C17H24O2 
+ Na]+: 283.1669, found: 283.1645. 
 
((((2S,3R,4S)-3-Methoxy-2,4-dimethyloct-6-yn-1-yl)oxy)methyl)benzene (3.46).  To 
solution of alkyne 3.50 (0.927 g, 3.56 mmol) in THF (36 mL) at -78 °C, was added a 
solution of LiHMDS (1 M in hexanes, 17.8 mL, 17.8 mmol).  After stirring for 2 h at -78 
°C, iodomethane (3.3 mL, 53 mmol) was added to the reaction.  The reaction was 
warmed to room temperature and stirred for an additional 2 h.  The reaction was 
quenched with water and extracted four times with EtOAc.  The combined organic layers 
were washed with brine and dried with anhydrous MgSO4.  The salts were removed via 
gravity filtration and volatile materials were removed using a rotary evaporator.  The 
crude material was purified via silica gel flash chromatograph (5% ether in pentane) to 
yield 0.945 g of product as a colorless oil (97% yield).  The resonances in the 1H NMR 
and 13C spectrum of the product matched previously reported chemical shifts.50 
 
(2S,3R,4S,E)-3-Methoxy-2,4-dimethyloct-6-en-1-ol (3.51).  The product was 
synthesized following a previously reported procedure.50  To a solution of ammonia (16 
mL) and THF (8 mL) at -78 °C was added alkyne 3.46 (0.87 g, 3.2 mmol) dissolved in 
THF (2 mL).  The flask containing the alkyne with rinsed with additional THF (2 mL) 
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which was added to the reaction; this was repeated two more times.  A few pieces of 
lithium wire were added to the reaction and the reaction was stirred at -78 °C for 20 min 
before warming to -40 °C.  After 1 h, additional lithium wire was added to the reaction.  
After stirring an additional 2 h at -40 °C, additional lithium wire was added to the 
reaction.  After stirring an additional 3 h at -40 °C, the reaction was warmed to room 
temperature to evaporate the ammonia.  The reaction was quenched with the slow 
addition of solid NH4Cl followed by saturated aqueous NH4Cl.  The reaction was 
extracted four times with EtOAc.  The combined organic layers were washed with brine 
and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and 
volatile materials were removed using a rotary evaporator.  The crude material was 
purified via silica gel flash chromatograph (24% EtOAc in hexanes) to yield 0.569 g of 
product as a colorless oil (96% yield).  The resonances in the 1H NMR and 13C spectrum 
of the product matched previously reported chemical shifts.50 
 
(3R,6R,7S,8R,9S,E)-6-Hydroxy-8-methoxy-3-(((4-methoxybenzyl)oxy)methyl)-7,9-
dimethyltridec-11-en-4-one (3.18).  The synthesis was adapted from previously reported 
procedures.50  A suspension of alcohol 3.51 (105 mg, 0.564 mmol), NMO (78 mg, 0.67 
mmol), and powdered 4Å molecular sieves (150 mg) was stirred in DCM (4.5 mL) at 0 
°C for 15 min.  A solution of TPAP (20. mg, 0.056 mmol) in DCM (0.5 mL) was added 
to the reaction.  After stirring at 0 °C for 40 min, the reaction was diluted with 20% 
EtOAc in hexanes and filtered through a plug of silica gel.  The silica gel plug was rinsed 
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with 20% acetate in hexanes.  The crude aldehyde solution was concentrated using a 
rotary evaporator and the crude aldehyde was used without further purification. 
 The crude aldehyde was combined with crude silyl enol ethers 3.20 (~1.9 mmol) 
and dissolved in DCM (5.1 mL) and cooled in a MeOH/lq N2 bath.  BF3•Et2O (0.53 mL, 
4.2 mmol) was added dropwise to the reaction and the reaction was stirred in the 
MeOH/lq N2 bath for 1.5 h.  The reaction was quenched with saturated NaHCO3 solution 
and warmed to room temperature.  The layers were separated and the aqueous phase was 
extracted three times with DCM and once with EtOAc.  The combined organic extracts 
were washed with brine and dry with Na2SO4.  The salts were removed via gravity 
filtration and volatile materials were removed by rotary evaporator.  The crude material 
was initially purified via silica gel flash chromatography (15% EtOAc in hexanes) and 
subsequently purified via Combiflash® silica gel column (5% to 15% EtOAc in hexanes) 
to yield 141.4 mg of product as a colorless oil (60% yield over 2 steps).  The resonances 
in the 1H NMR and 13C spectrum of the product matched previously reported chemical 
shifts.50 
 
(3R,4R,6R,7S,8R,9S,E)-4-Hydroxy-8-methoxy-3-(((4-methoxybenzyl)oxy)methyl)-
7,9-dimethyltridec-11-en-6-yl Acetate (3.52).  The product was synthesized using the 
procedure for the synthesis of alcohol 3.41.  Reaction with ketone 3.18 (40.6 mg, 0.0965 
mmol) resulted in 39.5 mg of product as a colorless oil (88% yield) following purification 
via silica gel flash chromatography (25% EtOAc in hexanes).  1H NMR (400 MHz, 
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CDCl3) δ 7.24 (d, J = 6.3 Hz, 1H), 6.88 (d, J = 8.5 Hz, 2H), 5.54 – 5.33 (m, 3H), 4.53 – 
4.37 (m, 2H), 3.82 (s, 3H), 3.74 (d, J = 7.0 Hz, 1H), 3.69 (d, J = 10.9 Hz, 1H), 3.59 – 
3.46 (m, 2H), 3.40 (s, 3H), 3.31 (s, 1H), 2.85 (d, J = 10.3 Hz, 1H), 2.23 – 1.90 (m, 5H), 
1.79 – 1.63 (m, 5H), 1.64 – 1.50 (m, 3H), 1.51 – 1.31 (m, 2H), 1.31 – 1.19 (m, 2H), 0.92 
(t, J = 7.5 Hz, 3H), 0.87 (d, J = 7.0 Hz, 3H), 0.83 (d, J = 6.8 Hz, 3H).  13C NMR (100 
MHz, CDCl3) δ 172.0, 159.1, 130.5, 130.2, 129.2, 126.4, 113.8, 85.4, 72.9, 71.8, 70.7, 
68.7, 65.8, 61.3, 60.4, 55.3, 45.5, 40.3, 38.4, 37.7, 35.8, 31.6, 22.6, 21.2, 19.1, 18.0, 15.3, 
14.2, 14.1, 12.4, 12.3, 10.6. 
 
(3R,4R,6R,7S,8R,9S,E)-8-Methoxy-3-(((4-methoxybenzyl)oxy)methyl)-7,9-
dimethyltridec-11-ene-4,6-diol (3.54).  To a solution of alcohol 3.52 (5.6 mg, 0.012 
mmol) in methanol (0.5 mL) was added potassium hydroxide (2.2 mg, 0.039 mmol) and 
the reaction was stirred at room temperature.  After 5 h, the reaction was quenched with 
saturated aqueous NH4Cl, and extracted four times with DCM.  The combined organic 
layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatograph (40% 
EtOAc in hexanes) to yield 4.7 mg of product as a colorless oil (92% yield).  The 
resonances in the 1H NMR and 13C spectrum of the product matched previously reported 
chemical shifts.50 
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(3R,4R,6R,7S,8R,9S,E)-6-Acetoxy-8-methoxy-3-(((4-methoxybenzyl)oxy)methyl)-7,9-
dimethyltridec-11-en-4-yl 2-Cyanoacetate (3.53).  To a solution of alcohol 3.54 (83 
mg, 0.18 mmol) and DCC (221 mg, 1.07 mmol) dissolved in a 300:2 mixture of 
DCM:pyridine (7.1 mL) was added cyanoacetic acid (91 mg, 1.1 mmol).  After stirring 
overnight at room temperature, the reaction was filtered through a plug of Celite®.  The 
filtrate was diluted with water and extracted three times with DCM.  The combined 
organic layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified initially via silica gel flash chromatograph 
(35% ether in hexanes).  Impure material was further purified via silica gel flash 
chromatograph (40% ether in hexanes).  The products from the two columns were 
combined to yield 77.2 mg of product as a colorless oil (81% yield).  1H NMR (400 MHz, 
CD2Cl2) δ 7.25 (d, J = 8.6 Hz, 2H), 6.92 – 6.80 (m, 2H), 5.57 – 5.34 (m, 2H), 5.20 (ddd, J 
= 8.1, 5.8, 2.0 Hz, 1H), 5.11 (ddt, J = 8.2, 6.8, 3.4 Hz, 1H), 4.37 (s, 2H), 3.79 (s, 3H), 
3.49 – 3.35 (m, 7H), 2.81 (dd, J = 9.2, 2.3 Hz, 1H), 2.20 – 2.06 (m, 1H), 2.01 (s, 3H), 
2.00 – 1.92 (m, 1H), 1.88 – 1.82 (m, 2H), 1.77 (tdd, J = 10.4, 8.7, 5.5 Hz, 2H), 1.69 – 
1.53 (m, 6H), 1.49 – 1.37 (m, 3H), 0.94 (t, J = 7.5 Hz, 3H), 0.83 (d, J = 7.1 Hz, 3H), 0.79 
(d, J = 6.8 Hz, 3H).  13C NMR (100 MHz, CD2Cl2) δ 171.3, 163.7, 159.8, 131.2, 130.7, 
129.8, 128.9, 126.9, 114.2, 85.8, 75.3, 73.3, 70.4, 69.5, 61.6, 55.8, 44.4, 41.0, 38.9, 36.4, 
35.1, 25.4, 21.4, 20.3, 18.3, 12.8, 12.3, 10.9. 
  132 
 
(3R,4R,6R,7S,8R,9S,E)-6-Acetoxy-3-(hydroxymethyl)-8-methoxy-7,9-dimethyltridec-
11-en-4-yl 2-Cyanoacetate (3.44).  To a solution of ester 3.53 (31.3 mg, 0.0589 mmol) 
in DCM (1 mL) and water (0.09 mL) was added DDQ (33 mg, 0.15 mmol).  After stirring 
20 min, the reaction was diluted with DCM and quenched with saturated aqueous 
NaHCO3.  The layers were separated and the aqueous layer was extracted three times 
with DCM and once with EtOAc.  The combined organic layers were washed with brine 
and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and 
volatile materials were removed using a rotary evaporator.  The crude material was 
purified via silica gel flash chromatograph (40% EtOAc in hexanes) to yield 17.9 mg of 
product as a colorless oil (74% yield).  1H NMR (400 MHz, CD2Cl2) δ 5.52 – 5.35 (m, 
2H), 5.26 (ddd, J = 9.4, 4.1, 1.9 Hz, 1H), 5.13 (dt, J = 11.0, 3.2 Hz, 1H), 3.71 – 3.57 (m, 
1H), 3.52 (d, J = 1.8 Hz, 2H), 3.48 – 3.34 (m, 4H), 2.81 (dd, J = 9.3, 2.3 Hz, 1H), 2.22 – 
2.06 (m, 2H), 2.06 – 1.89 (m, 5H), 1.89 – 1.80 (m, 1H), 1.74 – 1.59 (m, 7H), 1.51 – 1.40 
(m, 1H), 1.35 – 1.16 (m, 3H), 0.95 (t, J = 7.5 Hz, 3H), 0.85 (d, J = 7.1 Hz, 3H), 0.80 (d, J 
= 6.8 Hz, 3H).  13C NMR (100 MHz, CD2Cl2) δ 171.5, 164.8, 130.7, 126.9, 113.9, 85.8, 
74.6, 70.2, 62.1, 61.6, 46.6, 41.1, 38.9, 36.4, 35.6, 25.5, 21.4, 19.4, 18.3, 12.8, 12.5, 10.9. 
 
5-Phenylpent-1-en-3-ol (3.61).  To a solution of hydrocinnamaldehyde (3.60, 3.0 mL, 23 
mmol) in ether (27 mL) at 0 °C was added a solution of vinyl magnesium bromide (1 M 
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in THF, 27 mL, 27 mmol).  After stirring at 0 °C for 1 h, the reaction was quenched with 
saturated aqueous NH4Cl.  The reaction was extracted three times with EtOAc.  The 
combined organic layers were washed with brine and dried with anhydrous MgSO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatograph 
(20% EtOAc in hexanes) to yield 2.10 g of product as a colorless oil (56% yield).  The 
resonances in the 1H NMR and 13C spectrum of the product matched previously reported 
chemical shifts.124 
 
5-Phenylpent-1-en-3-yl 2-Cyanoacetate (3.62).  To a solution of alcohol 3.61 (1.03 g, 
6.35 mmol) and DCC (1.40 g, 6.79 mmol) dissolved in a 400:1 mixture of DCM:pyridine 
(250 mL) was added cyanoacetic acid (0.58 g, 6.8 mmol).  After stirring overnight at 
room temperature, the reaction was filtered through a plug of Celite®.  The filtrate was 
diluted with water and extracted three times with DCM.  The combined organic layers 
were washed with brine and dried with anhydrous MgSO4.  The salts were removed via 
gravity filtration and volatile materials were removed using a rotary evaporator.  The 
crude material was purified via silica gel flash chromatograph (20% EtOAc in hexanes) 
to yield 1.31 g of product as a colorless oil (92% yield). 1H NMR (400 MHz, CDCl3) δ 
7.34 – 7.27 (m, 2H), 7.24 – 7.13 (m, 3H), 5.81 (ddd, J = 17.3, 10.5, 6.7 Hz, 1H), 5.43 – 
5.21 (m, 3H), 3.42 – 3.29 (m, 2H), 2.68 (t, J = 7.8 Hz, 2H), 2.17 – 1.92 (m, 2H).  13C 
NMR (100 MHz, CDCl3) δ 162.1, 140.7, 134.8, 128.5, 128.3, 126.2, 118.7, 112.9, 35.3, 
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31.3, 24.8. 
 
1-Hydroxy-5-phenylpentan-3-yl 2-Cyanoacetate (3.59).  To a solution of ester 3.62 
(0.15 g, 0.65 mmol) in THF (6.5 mL) at 0 °C was added a solution of 9-BBN (0.5 M in 
THF, 4 mL, 2 mmol).  The reaction was warmed to room temperature and stirred 
overnight.  The reaction was cooled to 0 °C and a solution of NaOH (3 M, 0.54 mL) and 
solution of hydrogen peroxide (30%, 0.54 mL) was added to the reaction.  The reaction 
was warmed to room temperature.  The reaction was poured into a solution of Rochelle 
salt (10%, 17.5 mL) and glycerine (0.13 mL).  The mixture was extracted three times 
with EtOAc.  The combined organic layers were washed with brine and dried with 
anhydrous MgSO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was initially purified via 
silica gel flash chromatograph (10% to 20% EtOAc in DCM).  Subsequent purifications 
via silica gel flash chromatograph 2% methanol in chloroform followed by 40% in 
hexanes) to yield 0.532 g of product as a colorless oil (33% yield). 1H NMR (400 MHz, 
CD2Cl2) δ 7.35 – 7.24 (m, 2H), 7.24 – 7.15 (m, 3H), 4.51 – 4.23 (m, 2H), 3.82 – 3.65 (m, 
1H), 3.46 (s, 1H), 2.86 – 2.60 (m, 2H), 1.99 – 1.84 (m, 1H), 1.84 – 1.65 (m, 3H).  13C 
NMR (100 MHz, CD2Cl2) δ 163.9, 142.5, 129.0, 128.9, 126.4, 68.4, 64.7, 39.9, 36.5, 
32.4, 25.4. 
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1-Phenylhex-5-en-3-ol (3.65).  The product was synthesized following a previously 
reported procedure.125  To a solution of hydrocinnamaldehyde (3.60, 2.0 mL, 15 mmol) in 
ether (40 mL) at 0 °C was added a solution of allyl magnesium bromide (1 M in ether, 23 
mL, 23 mmol).  The reaction was warmed to room temperature over 1 h and then 
quenched with saturated aqueous NH4Cl.  The reaction was extracted three times with 
ether.  The combined organic layers were washed with brine and dried with anhydrous 
MgSO4.  The salts were removed via gravity filtration and volatile materials were 
removed using a rotary evaporator.  The crude material was purified via silica gel flash 
chromatograph (20% EtOAc in hexanes) to yield 1.58 g of product as a colorless oil 
(59% yield).  The resonances in the 1H NMR and 13C spectrum of the product matched 
previously reported chemical shifts.125 
 
1-Phenylhex-5-en-3-yl 2-Cyanoacetate (3.66).  To a solution of alcohol 3.65 (0.40 g, 
2.3 mmol) and DCC (0.52 g, 2.5 mmol) dissolved in a 400:1 mixture of DCM:pyridine 
(91 mL) at 0 °C was added cyanoacetic acid (0.21 g, 2.5 mmol).  The reaction was 
warmed to room temperature and stirred for 4 h.  The reaction was filtered through a plug 
of Celite®.  The filtrate was diluted with water and extracted three times with DCM.  The 
combined organic layers were washed twice with water and once with brine and dried 
with anhydrous MgSO4.  The salts were removed via gravity filtration and volatile 
materials were removed using a rotary evaporator.  The crude material was purified via 
silica gel flash chromatograph (5:1 hexanes:EtOAc) to yield 0.41 g of product as a 
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colorless oil (74% yield).  1H NMR (400 MHz, CDCl3) δ 7.34 – 7.27 (m, 2H), 7.24 – 7.13 
(m, 3H), 5.73 (ddt, J = 17.2, 9.4, 7.1 Hz, 1H), 5.18 – 5.08 (m, 2H), 5.05 (p, J = 6.2 Hz, 
1H), 3.44 – 3.21 (ABq, 2H), 2.67 (t, J = 7.8 Hz, 2H), 2.48 – 2.31 (m, 2H), 2.05 – 1.85 (m, 
2H).  13C NMR (100 MHz, CDCl3) δ 162.5, 140.9, 132.6, 128.5, 128.3, 126.1, 118.7, 
113.0, 76.2, 38.6, 34.8, 31.7, 24.7. 
 
2-Oxo-6-phenethyl-5,6-dihydro-2H-pyran-3-carbonitrile (3.64).  To a solution of ester 
3.66 (100. mg, 0.411 mmol) in DCM (1.9 mL) and methanol (0.4 mL) at -78 °C, was 
bubbled ozone until the reaction turned blue.  After the reaction was purged with 
nitrogen, dimethyl sulfide (0.12 mL, 1.6 mmol) was added to the reaction.  After stirring 
at -78 °C for 10 min, pH 7 phosphate buffer (3 mL) was added to the reaction.  The 
reaction was warmed to room temperature and stirred for 5 h.  The mixture was extracted 
three times with DCM.  The combined organic layers were washed with brine and dried 
with anhydrous MgSO4.  The salts were removed via gravity filtration and volatile 
materials were removed using a rotary evaporator.  The crude material was purified via 
silica gel flash chromatograph (3% methanol in chloroform) to yield 70.8 mg of product 
as a beige solid (76% yield).  1H NMR (400 MHz, CDCl3) δ 7.61 (t, J = 4.5 Hz, 1H), 7.34 
– 7.27 (m, 2H), 7.25 – 7.15 (m, 3H), 4.58 – 4.38 (m, 1H), 2.89 (ddd, J = 14.3, 9.0, 5.5 
Hz, 1H), 2.79 (dt, J = 14.0, 8.0 Hz, 1H), 2.62 – 2.52 (m, 2H), 2.18 (dtd, J = 14.1, 8.5, 5.5 
Hz, 1H), 1.99 (dddd, J = 14.1, 12.2, 7.6, 4.2 Hz, 1H).  13C NMR (100 MHz, CDCl3) δ 
158.8, 157.4, 140.0, 128.7, 128.4, 126.4, 113.2, 110.6, 77.0, 36.1, 30.6, 30.2.  mp: 98.7 – 
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99.8 °C. 
 
But-1-en-2-ylmagnesium Bromide (3.67).  To a suspension of magnesium turnings 
(0.48 g, 20 mmol) in THF (9.2 mL) was added 2-bromo-1-butene (1.35 g, 10.0 mmol) 
followed by 1,2-dibromobutane (0.04 mL, 0.5 mmol).  The reaction exotherms to reflux, 
and was stirred at room temperature overnight.  The Grignard solution was titrated with 
2-((2-phenylhydrazono)methyl)phenol.126 
 
4-Methylene-1-phenylhexan-3-ol (3.68).  To a solution of hydrocinnamaldehyde (3.60, 
0.70 mL, 5.4 mmol) in ether (6.4 mL) at 0 °C was added a solution of Grignard 3.67 
(0.74 M in THF, 8.0 mL, 5.9 mmol).  After stirring at 0 °C for 1 h, the reaction was 
quenched with saturated aqueous NH4Cl.  The reaction was extracted three times with 
EtOAc.  The combined organic layers were washed with brine and dried with anhydrous 
MgSO4.  The salts were removed via gravity filtration and volatile materials were 
removed using a rotary evaporator.  The crude material was purified via silica gel flash 
chromatograph (8:1 hexanes:EtOAc) to yield 0.526 g of product as a colorless oil (52% 
yield).  1H NMR (400 MHz, CDCl3) δ 7.32 – 7.26 (m, 2H), 7.24 – 7.15 (m, 3H), 5.08 – 
5.02 (m, 1H), 4.88 (d, J = 1.5 Hz, 1H), 4.12 (dd, J = 7.6, 5.1 Hz, 1H), 2.70 (dddd, J = 
41.4, 13.9, 9.8, 6.4 Hz, 2H), 2.20 – 1.96 (m, 2H), 1.96 – 1.78 (m, 2H), 1.07 (t, J = 7.4 Hz, 
3H).  13C NMR (100 MHz, CDCl3) δ 153.4, 142.0, 128.4, 128.4, 125.8, 108.7, 74.9, 37.1, 
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32.0, 24.0, 12.3. 
 
4-Methylene-1-phenylhexan-3-yl 2-Cyanoacetate (3.69).  The product was synthesized 
using the procedure for the synthesis of ester 3.62.  Reaction with alcohol 3.68 (0.40 g, 
2.1 mmol) resulted in 0.53 g of product as a colorless oil (98% yield) following 
purification via silica gel flash chromatography (8:1 hexanes:EtOAc). 1H NMR (400 
MHz, CDCl3) δ 7.34 – 7.27 (m, 2H), 7.25 – 7.11 (m, 3H), 5.30 (dd, J = 7.8, 5.3 Hz, 1H), 
5.08 (q, J = 1.1 Hz, 1H), 4.98 (q, J = 1.5 Hz, 1H), 3.43 – 3.27 (m, 2H), 2.70 – 2.57 (m, 
2H), 2.14 – 1.93 (m, 4H), 1.08 (t, J = 7.4 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 162.1, 
147.6, 140.8, 128.5, 128.3, 126.1, 111.7, 79.8, 34.4, 31.8, 24.8, 24.3, 11.9. 
 
4-(Hydroxymethyl)-1-phenylhexan-3-yl 2-Cyanoacetate (3.70).  The product was 
synthesized using the procedure for the synthesis of alcohol 3.59.  Reaction with ester 
3.69 (0.585 g, 2.27 mmol) resulted in 0.404 g of product as a colorless oil (64% yield) 
following purification via silica gel flash chromatography (7:3 hexanes:EtOAc).  Main 
isomer:  1H NMR (400 MHz, CDCl3) δ 7.30 (t, J = 7.5 Hz, 2H), 7.19 (dd, J = 12.3, 7.1 
Hz, 3H), 5.22 – 5.11 (m, 1H), 3.78 – 3.59 (m, 2H), 3.51 – 3.37 (m, 1H), 3.37 – 3.09 (m, 
2H), 2.68 (t, J = 7.8 Hz, 2H), 2.11 – 1.98 (m, 2H), 1.77 – 1.56 (m, 3H), 1.52 – 1.34 (m, 
2H), 0.95 (td, J = 7.4, 5.4 Hz, 3H). 
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5-Ethyl-2-oxo-6-phenethyl-5,6-dihydro-2H-pyran-3-carbonitrile (3.71).  To a solution 
of alcohol 3.65 (59 mg, 0.21 mmol) and 1,3,5-trimethoxybenene (12.0 mg, 0.713 mmol) 
in DCM (0.9 mL) was added a solution of Dess-Martin Periodinane (0.3 M in DCM, 1.4 
mL, 0.42 mmol).  After stirring at room temperature for 30 min, the reaction was washed 
with a 1:1 mixture of saturated aqueous NaHCO3 and saturated aqueous Na2S2O3.  The 
mixture was extracted three times with DCM.  The combined organic layers were washed 
twice with a 1:1 mixture of saturated aqueous NaHCO3 and saturated aqueous Na2S2O3, 
twice with saturated aqueous NaHCO3, and once with brine.  The combined organic 
layers were dried with anhydrous Na2SO4.  The salts were removed via gravity filtration 
and volatile materials were removed using a rotary evaporator.  The 1H NMR spectra of 
the crude material showed traces of Dess-Martin Periodinane byproducts.  The crude 
material was dissolved in DCM and wash twice with a 1:1 mixture of saturated aqueous 
NaHCO3, and once with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  One third of the crude material was dissolved in 0.5 mL DCM and stirred 
overnight with 30 mg basic Al2O3.  The suspension was filtered and volatile materials 
were removed using a rotary evaporator.  The 1H NMR spectra of the crude material 
showed 40% cyclization product based on the 1,3,5-trimethoxybenzene standard.  1H 
NMR (400 MHz, CDCl3) δ 7.52 (d, J = 3.4 Hz, 1H), 7.35 – 7.28 (m, 2H), 7.25 – 7.16 (m, 
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3H), 4.30 (td, J = 8.4, 3.7 Hz, 1H), 3.00 – 2.88 (m, 1H), 2.86 – 2.70 (m, 1H), 2.51 (tdd, J 
= 8.2, 4.9, 3.4 Hz, 1H), 2.19 – 1.93 (m, 2H), 1.81 – 1.63 (m, 1H), 1.54 – 1.44 (m, 1H), 
0.98 (t, J = 7.5 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 161.3, 158.2, 140.2, 128.7, 
128.4, 126.4, 113.2, 110.0, 80.6, 40.5, 34.7, 30.8, 23.3, 10.5. 
 
Methyl (2,3-syn)-3-Hydroxy-2-methyl-5-phenylpentanoate (3.75).  To a solution of 
methyl propionate (3.74, 0.51 mL, 5.3 mmol) in DCM (42 mL) at 0 °C was added DIPEA 
(5.3 mL, 30.4 mmol) followed by the dropwise addition of a solution of Bu2BOTf (1 M 
in DCM, 10.5 mL, 10.5 mmol).  After stirring at 0 °C for 30 min, the reaction was cooled 
to -78 °C followed by the dropwise addition of hydrocinnemaldehyde (3.60, 1.0 mL, 7.6 
mmol).  The reaction was stirred at -78 °C for 1 h, followed by stirring at 0 °C for an 
additional 1 h.  The reaction was quenched with pH 7 phosphate buffer (20 mL) and 
warmed to room temperature.  The mixture was poured into a mixture of methanol (210 
mL) and 30% hydrogen peroxide (10 mL) and stirred overnight.  The mixture was 
concentrated via rotary evaporator and the residual mixture was extracted three times 
with DCM.  The combined organic layers were washed with brine and dried with 
anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatograph (4:1 hexanes:EtOAc).  The impure product for further purified via 
silica gel flash chromatograph (4:1 hexanes:EtOAc) to yield 0.984 g of product as a 
colorless oil (84% yield).  The resonances in the 1H NMR and 13C spectrum of the 
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product matched previously reported chemical shifts for the scalemic product.127 
 
(2,3-syn)-2-Methyl-5-phenylpentane-1,3-diol (3.76).  To a suspension of lithium 
aluminum hydride (0.88 g, 23 mmol) in ether (50 mL) at 0 °C was cannula transferred 
dropwise a solution of ester 3.75 (1.29 g, 5.80 mmol) in ether (17 mL).  The reaction was 
warmed to room temperature stirred for 2.5 h before cooling to 0 °C.  The reaction was 
quenched with the addition of water (0.9 mL), 15% sodium hydroxide (0.9 mL), followed 
by water (2.7 mL).  The reaction was allowed to warm to room temperature and was 
stirred for 20 min.  The suspension was filtered through Celite®, and the filtrate was 
concentrated using a rotary evaporator.  The residue was diluted with DCM and dried 
with anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile 
materials were removed using a rotary evaporator.  The crude material was purified via 
Combiflash® silica gel flash chromatograph (30% to 50% EtOAc in hexanes) to yield 
1.03 g of product as a colorless oil (92% yield).  The resonances in the 1H NMR and 13C 
spectrum of the product matched previously reported chemical shifts.128 
 
(2,3-syn)-1-((4-Methoxybenzyl)oxy)-2-methyl-5-phenylpentan-3-ol (3.77).  To a 
suspension of sodium hydride (60% in mineral oil, 220 mg, 5.5 mmol) in DMF (18 mL) 
was added a solution of diol 3.76 (0.267 g, 1.4 mmol) in DMF (12 mL).  The reaction 
was stirred at room temperature for 45 min before cooling to 0 °C. PMBCl (0.19 mL, 1.4 
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mmol) was added dropwise and the reaction was stirred at 0 °C for 5 h.  The reaction was 
quenched with saturated aqueous NH4Cl, and diluted with EtOAc.  The layers were 
separated and the aqueous layer was extracted three times with EtOAc.  The combined 
organic layers were washed twice with brine and dried with anhydrous MgSO4.  The salts 
were removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material contained residual DMF.  The crude material was 
dissolved in ether and washed 5 times with brine and dried with anhydrous MgSO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatograph 
(25% EtOAc in hexanes) to yield 0.293 g of product as a colorless oil (68% yield).  1H 
NMR (400 MHz, DMSO-d6) δ 7.35 – 7.10 (m, 6H), 6.96 – 6.81 (m, 2H), 4.48 – 4.24 (m, 
2H), 3.74 (s, 3H), 3.49 (td, J = 6.4, 3.6 Hz, 1H), 3.43 – 3.36 (m, 1H), 3.20 (dd, J = 9.1, 
6.6 Hz, 1H), 2.70 (dt, J = 14.7, 7.7 Hz, 1H), 2.60 – 2.51 (m, 1H), 1.70 (qd, J = 6.7, 3.7 
Hz, 1H), 1.65 – 1.53 (m, 2H), 1.09 (t, J = 7.0 Hz, 1H), 0.82 (d, J = 6.9 Hz, 3H).  13C 
NMR (100 MHz, DMSO-d6) δ 158.6, 142.5, 130.6, 129.0, 128.3, 128.2, 125.5, 113.6, 
72.5, 71.7, 69.5, 55.0, 38.3, 36.5, 32.0, 11.3. 
 
(2,3-syn)-1-((4-Methoxybenzyl)oxy)-2-methyl-5-phenylpentan-3-yl 2-Cyanoacetate 
(3.78).  To a solution of alcohol 3.77 (0.159 g, 0.506 mmol) and DCC (0.42 g, 2.0 mmol) 
dissolved in a 100:1 mixture of DCM:pyridine (20 mL) at 0 °C was added cyanoacetic 
acid (0.172 g, 2.02 mmol).  The reaction was warmed to room temperature and stirred 
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overnight.  The reaction was filtered through a plug of Celite®.  The filtrate was diluted 
with water and extracted four times with DCM.  The combined organic layers were 
washed twice with brine and dried with anhydrous Na2SO4.  The salts were removed via 
gravity filtration and volatile materials were removed using a rotary evaporator.  The 
crude material was purified via silica gel flash chromatograph (25% EtOAc in hexanes) 
to yield 0.167 g of product as a colorless oil (87% yield). 1H NMR (400 MHz, CDCl3) δ 
7.32 – 7.19 (m, 5H), 7.18 – 7.11 (m, 2H), 6.93 – 6.85 (m, 2H), 5.24 (dt, J = 8.4, 4.1 Hz, 
1H), 4.45 – 4.30 (m, 2H), 3.81 (s, 3H), 3.38 – 3.25 (m, 2H), 3.24 – 3.10 (m, 2H), 2.63 
(ddd, J = 8.9, 6.8, 1.9 Hz, 2H), 2.12 – 1.96 (m, 2H), 1.86 (dddd, J = 14.0, 8.9, 7.1, 4.5 Hz, 
1H), 0.97 (d, J = 7.0 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 162.6, 159.2, 141.1, 130.2, 
129.5, 128.5, 128.3, 126.1, 113.8, 113.1, 77.7, 72.9, 71.8, 55.3, 37.0, 33.2, 32.2, 24.6, 
11.3. 
 
(2,3-syn)-1-Hydroxy-2-methyl-5-phenylpentan-3-yl 2-Cyanoacetate (3.73).  To a 
solution of ester 3.78 (0.167 g, 0.437 mmol) in DCM (2.3 mL) and water (0.23 mL) was 
added DDQ (0.25 g, 1.1 mmol).  After stirring for 1 h, the reaction was diluted with 
DCM and quenched with saturated aqueous NaHCO3.  The layers were separated and the 
aqueous layer was extracted three times with DCM and once with EtOAc.  The combined 
organic layers were washed with brine and the resulting emulsion was filtered through a 
plug of Celite®.  The layers were separated and the organic layer was dried with 
anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
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were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatograph (40% EtOAc in hexanes) to yield 0.0805 mg of product as a 
colorless oil (70% yield).  1H NMR (400 MHz, CD2Cl2) δ 7.36 – 7.26 (m, 2H), 7.25 – 
7.15 (m, 3H), 5.22 (dt, J = 9.2, 3.6 Hz, 1H), 3.52 – 3.28 (m, 4H), 2.66 (t, J = 7.8 Hz, 2H), 
2.18 – 1.99 (m, 1H), 2.01 – 1.75 (m, 3H), 1.15 (t, J = 7.0 Hz, 1H), 0.90 (d, J = 7.0 Hz, 
3H). 
 
(5,6-syn)-5-Methyl-2-oxo-6-phenethyl-5,6-dihydro-2H-pyran-3-carbonitrile (3.79).  
To a solution of alcohol 3.73 (23.6 mg, 0.0903 mmol) in DCM (0.45 mL) was added a 
solution of Dess-Martin Periodinane (0.3 M in DCM, 0.60 mL, 0.18 mmol).  After 
stirring at room temperature for 2 h, the reaction was quenched with a 1:1 mixture of 
saturated aqueous NaHCO3 and saturated aqueous Na2S2O3 and stirred at room 
temperature for 15 min.  The mixture was extracted three times with DCM.  The 
combined organic layers were washed with brine and dried with anhydrous Na2SO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator to yield 21 mg of crude aldehyde product. 
 To a suspension of sodium hydride (60% in  mineral oil, 3.4 mg, 0.085 mmol) in 
THF (0.4 mL) at -20 °C, was added dropwise a solution of the crude aldehyde in THF 
(0.2 mL).  The vial containing the crude aldehyde was rinsed with additional THF (0.2 
mL) which was added to the reaction.  The reaction was stirred at -20 °C for 30 min 
before quenching with saturated aqueous NH4Cl.  The mixture was extract four times 
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with EtOAc.  The combined organic layers were washed with brine and dried with 
anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The 1H NMR spectra of the crude material 
showed a 30:1 mixture of lactone 3.39 to α,β-unsaturated aldehyde 3.80.  The crude 
material was purified via silica gel flash chromatograph (30% EtOAc in hexanes) to yield 
7.7 mg of product as a colorless oil (35% yield). 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J 
= 6.3 Hz, 1H), 7.35 – 7.27 (m, 2H), 7.25 – 7.13 (m, 3H), 4.44 (dt, J = 9.4, 3.7 Hz, 1H), 
2.92 (ddd, J = 14.2, 9.0, 5.3 Hz, 1H), 2.74 (dt, J = 13.8, 8.1 Hz, 1H), 2.58 (pd, J = 7.0, 3.3 
Hz, 1H), 2.18 (ddt, J = 14.3, 9.1, 4.4 Hz, 1H), 1.83 (dddd, J = 13.9, 8.8, 7.6, 4.0 Hz, 1H), 
1.15 (d, J = 7.1 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 163.0, 158.8, 140.1, 128.7, 
128.4, 126.5, 113.2, 109.6, 79.1, 33.2, 32.8, 31.0, 10.8. 
 
(2R,3S,4R,5S,E)-1-((2R)-5-Cyano-3-ethyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)-4-
methoxy-3,5-dimethylnon-7-en-2-yl Acetate (3.55)...  To a solution of alcohol 3.44 
(11.2 mg, 0.0272 mmol) in DCM (0.4 mL) was added a solution of Dess-Martin 
Periodinane (0.3 M in DCM, 0.18 mL, 0.054 mmol).  After stirring at room temperature 
for 1.5 h, the reaction was quenched with a 1:1 mixture of saturated aqueous NaHCO3 
and saturated aqueous Na2S2O3 and stirred at room temperature for 15 min.  The mixture 
was extracted 5 times with DCM.  The combined organic layers were washed with brine 
and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and 
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volatile materials were removed using a rotary evaporator to yield crude aldehyde 
product. 
 To a suspension of sodium hydride (60% in mineral oil, 1.3 mg, 0.033 mmol) in 
THF (0.4 mL) at -20 °C, was added dropwise a solution of crude aldehyde in THF (0.2 
mL).  The vial containing the crude aldehyde was rinsed with additional THF (0.2 mL) 
which was added to the reaction.  The reaction was stirred at -20 °C for 45 min before 
quenching with saturated aqueous NH4Cl.  The mixture was extracted four times with 
EtOAc.  The combined organic layers were washed with brine and dried with anhydrous 
Na2SO4.  The salts were removed via gravity filtration and volatile materials were 
removed using a rotary evaporator.  The 1H NMR spectra of the crude material showed 
lactone product 3.55 as a single isomer.  The crude material was purified via silica gel 
flash chromatograph (10% to 30% EtOAc in hexanes) to yield 5.3 mg of product as a 
mixture of isomers (50% yield). 
Major Isomer: 1H NMR (400 MHz, CD2Cl2) δ 7.76 (d, J = 6.3 Hz, 1H), 5.57 – 5.35 (m, 
2H), 5.31 – 5.23 (m, 1H), 4.60 – 4.48 (m, 1H), 3.37 (d, J = 1.0 Hz, 3H), 2.87 (dd, J = 9.3, 
2.3 Hz, 1H), 2.55 – 2.47 (m, 1H), 2.20 – 2.09 (m, 1H), 2.07 – 1.93 (m, 5H), 1.93 – 1.76 
(m, 2H), 1.76 – 1.45 (m, 6H), 0.99 (t, J = 7.5 Hz, 3H), 0.91 – 0.85 (m, 3H), 0.81 (d, J = 
6.8 Hz, 3H).   13C NMR (100 MHz, CD2Cl2) δ 171.0, 163.6, 159.1, 130.5, 126.8, 113.9, 
110.2, 85.5, 78.2, 70.4, 61.4, 61.4, 40.7, 40.3, 39.8, 38.6, 36.2, 35.1, 21.3, 20.8, 18.1, 
12.6, 11.1, 10.6. 
Minor Isomer:1H NMR (400 MHz, CD2Cl2) δ 7.56 (d, J = 3.5 Hz, 1H), 5.57 – 5.35 (m, 
2H), 5.31 – 5.23 (m, 1H), 4.41 (td, J = 8.2, 3.5 Hz, 1H), 3.37 (d, J = 1.0 Hz, 3H), 2.87 
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(dd, J = 9.3, 2.3 Hz, 1H), 2.58 (dd, J = 7.7, 3.6 Hz, 1H), 2.20 – 2.09 (m, 1H), 2.07 – 1.93 
(m, 5H), 1.93 – 1.76 (m, 2H), 1.76 – 1.45 (m, 6H), 0.99 (t, J = 7.5 Hz, 3H), 0.91 – 0.85 
(m, 3H), 0.81 (d, J = 6.8 Hz, 3H). 
 
(R)-1-(4-(tert-Butyl)-2-thioxothiazolidin-3-yl)ethan-1-one (3.97).  The product was 
synthesized following a previously reported procedure for the corresponding (S)-
enantiomer.71  To a suspension of sodium borohydride (1.04 g, 27.4 mmol) in THF (24 
mL) was added D-tert-leucine (1.2 g, 9.2 mmol); the suspension was cooled to 0 °C.  A 
solution of iodine (2.8 g, 11 mmol) in THF (7.2 mL) was added over 20 min via addition 
funnel.  After the evolution of gas stopped, the reaction was heated to reflux overnight.  
The reaction was cooled to room temperature and methanol was slowly added until the 
reaction became clear.  After stirring for 40 min at room temperature, volatile materials 
were removed using a rotary evaporator.  The crude material was dissolved in 20% 
aqueous KOH (19 mL) and stirred for 4 h.  Carbon disulfide (4.4 mL, 73 mmol) was 
added to the solution and the reaction was heated to reflux for 2.5 days.  The reaction was 
cooled to room temperature and the mixture was extracted four times with DCM.  The 
combined organic layers were washed with brine and dried with anhydrous MgSO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatography 
(20% to 25% EtOAc in hexanes) to yield 0.822 g of (R)-4-(tert-butyl)thiazolidine-2-
thione as a white solid (51% yield over 2 steps).  1H NMR (400 MHz, CDCl3) δ 7.96 (s, 
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1H), 4.02 (t, J = 8.7 Hz, 1H), 3.39 (qd, J = 11.2, 8.7 Hz, 2H), 0.99 (s, 9H).  13C NMR 
(100 MHz, CDCl3) δ 201.3, 73.5, 34.5, 34.3, 25.8.  HRMS calc m/z [C7H13NS2 + Na]+: 
198.0382, found: 198.0395.  mp: 138.9 – 140.0 °C. 
 To a solution of (R)-4-(tert-butyl)thiazolidine-2-thione (0.50 g, 2.9 mmol) in THF 
(12.5 mL) at -78 °C was added dropwise a solution of n-butyllithium (2.5 M in hexanes, 
1.3 mL, 3.1 mmol).  After stirring at -78 °C for 30 min, acetyl chloride (0.22 mL, 3.1 
mmol) was added dropwise to the reaction.  The reaction was stirred at -78 °C for 1 h 
before warming to room temperature and stirred an additional 30 min.  The reaction was 
quenched with saturated aqueous NH4Cl, and the mixture was extracted four times the 
DCM.  The combined organic layers were washed with brine and dried with anhydrous 
MgSO4.  The salts were removed via gravity filtration and volatile materials were 
removed using a rotary evaporator.  The crude material was purified via silica gel flash 
chromatography (10% EtOAc in hexanes) to yield 0.495 g of product as a yellow solid 
(80% yield).  1H NMR (400 MHz, CDCl3) δ 5.32 (d, J = 8.4 Hz, 1H), 3.53 (dd, J = 11.8, 
8.4 Hz, 1H), 3.10 (d, J = 11.7 Hz, 1H), 2.78 (s, 3H), 1.04 (s, 9H).  13C NMR (100 MHz, 
CDCl3) δ 205.3, 170.3, 72.0, 38.0, 30.4, 26.8, 26.7.  [α]D = -556.52 (c = 0.229, CHCl3).  
HRMS calc m/z [C9H15NOS2 + Na]+: 240.0487, found: 240.0474.  mp: 33.9-35.7 °C. 
 
(3R,4S,5R,6S,E)-1-((R)-4-(tert-Butyl)-2-thioxothiazolidin-3-yl)-3-hydroxy-5-
methoxy-4,6-dimethyldec-8-en-1-one (3.98).  A suspension of alcohol 3.51 (162 mg, 
0.870 mmol), NMO (122 mg, 1.04 mmol), and powdered 4Å molecular sieves (243 mg) 
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was stirred in DCM (6 mL) at 0 °C for 15 min.  A solution of TPAP (31 mg, 0.087 mmol) 
in DCM (2 mL) was added to the reaction.  After stirring 20 min at 0 °C, the reaction was 
diluted with 40% ethyl acetate in hexanes and filtered through a plug of silica gel.  The 
silica gel plug was rinsed with 40% acetate in hexanes.  The crude aldehyde solution was 
concentrated using a rotary evaporator and the crude aldehyde was used without further 
purification. 
 To a solution of thiazolidinethione 3.97 (246 mg, 1.13 mmol) in DCM (3.6 mL) at 
room temperature was added dichlorophenylborane (0.15 mL, 1.1 mmol).  After stirring 
for 20 min, (+)-sparteine (0.52 mL, 2.3 mmol) was added to the reaction and the reaction 
was stirred for 30 min before cooling to -78 °C.  The crude aldehyde was dissolved in 
DCM (0.2 mL) and added to the reaction dropwise.  The vial containing the aldehyde was 
rinsed with additional DCM (0.2 mL) which was added to the reaction dropwise.  The 
reaction was stirred at -78 °C for 5 h before warming to room temperature over 2 h and 
stirred at room temperature for 30 min.   The reaction was diluted with hexanes (6 mL) 
and quenched with 30% hydrogen peroxide (3 mL) and stirred vigorously for 3 min.  The 
reaction was diluted with 4:1 hexanes:DCM (200 mL).  The layers were separated and 
the organic layer was washed with water followed by brine and dried with anhydrous 
MgSO4.  The salts were removed via gravity filtration and volatile materials were 
removed using a rotary evaporator.  The crude material was purified via silica gel flash 
chromatography (15% ethyl acetate in hexanes) to yield 244 mg of product as a yellow 
oil (70% over 2 steps).  1H NMR (400 MHz, C6D6) δ 5.56 – 5.34 (m, 2H), 5.02 (d, J = 8.2 
Hz, 1H), 4.70 (ddd, J = 8.9, 2.9 Hz, 1H), 3.81 (dd, J = 16.9, 9.8 Hz, 1H), 3.39 (s, 3H), 
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3.37 (d, J = 3.8 Hz, 1H), 3.25 – 3.12 (m, 2H), 2.55 (dd, J = 11.9, 8.3 Hz, 1H), 2.30 – 2.16 
(m, 1H), 2.06 (d, J = 11.6 Hz, 2H), 1.83 – 1.65 (m, 2H), 1.62 (d, J = 4.3 Hz, 3H), 0.95 (d, 
J = 6.8 Hz, 3H), 0.92 (d, J = 7.0 Hz, 3H), 0.76 (s, 9H).  13C NMR (100 MHz, C6D6) δ 
205.4, 173.2, 130.7, 126.5, 86.8, 72.3, 67.8, 61.3, 44.0, 40.7, 38.4, 37.9, 36.3, 29.9, 26.8, 
18.2, 13.4, 10.9.  HRMS calc m/z [C20H35NO3S2 + Na]+: 424.1951, found: 424.1928. 
 
(3R,4R,5R,6S,E)-1-((R)-4-(tert-Butyl)-2-thioxothiazolidin-3-yl)-3-((tert-
butyldimethylsilyl)oxy)-5-methoxy-4,6-dimethyldec-8-en-1-one (3.99).  To a solution 
of alcohol 3.98 (0.68 g, 1.7 mmol) and 2,6-lutidine (0.40 mL, 3.4 mmol) in DCM (17 
mL) at 0 °C was added TBSOTf (0.58 mL, 2.5 mmol) dropwise.  The reaction was 
warmed to room temperature and stirred for 45 min before quenching with saturated 
NaHCO3.  The layers were separated and the aqueous phase was extracted four times 
with DCM.  The combined organic layers were washed with brine and dried with 
Na2SO4.  The suspension was filter and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatography (7% 
ethyl acetate in hexanes) to yield 0.78 g of product as a yellow oil (89% yield).   1H NMR 
(400 MHz, C6D6) δ 5.54 – 5.31 (m, 2H), 5.09 – 5.01 (m, 1H), 4.99 (d, J = 8.1 Hz, 1H), 
3.82 (dd, J = 16.3, 5.0 Hz, 1H), 3.64 (dd, J = 16.3, 7.6 Hz, 1H), 3.49 (s, 3H), 3.31 (dd, J = 
9.6, 1.8 Hz, 1H), 2.52 (dd, J = 11.8, 8.2 Hz, 1H), 2.37 – 2.18 (m, 1H), 2.17 – 2.09 (m, 
1H), 2.05 (d, J = 11.8 Hz, 1H), 1.94 – 1.80 (m, 1H), 1.80 – 1.68 (m, 1H), 1.64 (d, J = 3.8 
Hz, 3H), 1.02 (s, 9H), 0.98 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 6.9 Hz, 3H), 0.80 (s, 9H), 
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0.27 (s, 3H), 0.25 (s, 3H).  13C NMR (100 MHz, C6D6) δ 205.5, 170.6, 131.1, 126.4, 84.2, 
72.2, 69.5, 61.0, 44.3, 42.2, 38.8, 37.8, 36.2, 30.1, 26.9, 26.3, 18.7, 18.2, 13.2, 10.5, -3.0, 
-4.1.  HRMS calc m/z [C26H49NO3S2Si + Na]+: 538.2815, found: 538.2816. 
 
(3R,4R,5R,6S,E)-3-((tert-Butyldimethylsilyl)oxy)-5-methoxy-4,6-dimethyldec-8-enal 
(3.100).  To a solution of amide 3.99 (280 mg, 0.55 mmol) in DCM (6.1 mL) at -78 °C 
was added DIBAL-H (1 M in hexanes, 1.1 mL, 1.1 mmol) dropwise.  The reaction was 
determined to be complete after the reaction turned from yellow to clean upon addition of 
DIBAL-H.  The reaction was quenched with saturated aqueous Rochelle salt and diluted 
with DCM and warmed to room temperature.  The slurry was stirred at room temperature 
for 1.5 h.  The layers were separated and the aqueous phase was extracted three times 
with DCM.  The combined organic layers were washed with brine and dried with 
anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatography (5% acetone in hexanes) to yield 161 mg of product as a colorless 
oil (85% yield).  1H NMR (400 MHz, C6D6) δ 9.47 – 9.40 (m, 1H), 5.53 – 5.31 (m, 2H), 
4.67 (td, J = 6.1, 1.9 Hz, 1H), 3.38 (s, 3H), 3.17 (dd, J = 9.3, 1.9 Hz, 1H), 2.35 (ddd, J = 
16.4, 6.6, 2.2 Hz, 1H), 2.22 (dt, J = 13.1, 6.7 Hz, 1H), 2.16 – 1.95 (m, 2H), 1.74 – 1.55 
(m, 4H), 1.51 (ddd, J = 9.1, 7.0, 2.0 Hz, 1H), 1.00 – 0.89 (m, 12H), 0.72 (d, J = 7.0 Hz, 
3H), 0.13 (s, 3H), 0.03 (s, 3H).  13C NMR (100 MHz, C6D6) δ 199.6, 130.9, 126.6, 84.0, 
  152 
67.2, 60.6, 51.2, 42.9, 38.8, 36.1, 26.2, 18.5, 18.2, 13.3, 10.5, -3.6, -4.3.  HRMS calc m/z 
[C19H38O3Si + Na]+: 365.2482, found: 365.2446. 
 
(S)-1-(4-Benzyl-2-thioxothiazolidin-3-yl)butan-1-one (3.93).  The product was 
synthesized following a previously reported procedure.99  To a solution of (S)-4-
benzylthiazolidine-2-thione (0.15 g, 0.72 mmol) and triethylamine (0.11 mL, 0.79 mmol) 
in DCM (1.1 mL) at 0 °C was added dropwise a solution of butyryl chloride (0.078 mL, 
0.75 mmol) dissolved in DCM (0.3 mL) over 2 min.  The vial containing the butyryl 
chloride solution was rinsed with additional DCM (0.3 mL) which was added to the 
reaction.  The reaction was warmed to room temperature and stirred for 4.5 h.  The 
reaction was then quenched with water and the organic layer was separated from the 
aqueous phase.  The aqueous phase was extracted three times with DCM.  The combined 
organic layers was washed with brine and dried with anhydrous Na2SO4.  The suspension 
was filter and volatile materials were removed using a rotary evaporator.  The crude 
material was purified via silica gel flash chromatography (7% acetone in hexanes) to 
yield 0.169 g of product as a yellow solid (84% yield).  The resonances in the 1H NMR 
and 13C spectrum of the product matched previously reported chemical shifts.99 
 
(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
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butyldimethylsilyl)oxy)-2-ethyl-3-hydroxy-7-methoxy-6,8-dimethyldodec-10-en-1-
one (3.101).  Thiazolidinethione 3.93 (48.4 mg, 0.173 mmol) was dissolved in DCM (0.7 
mL) and cooled to 0 °C.  Titanium chloride (0.17 mL, 0.17 mmol) was added to the 
reaction dropwise and the reaction was stirred for 20 min at 0 °C.  Diisopropylethylamine 
(30 µL, 0.17 mmol) was added to the reaction dropwise and the reaction was stirred for 
an additional 20 min at 0 °C before adding NMP (17 µL, 0.17 mmol) dropwise to the 
reaction.  The reaction was stirred for an additional 20 min at 0 °C before cooling to -78 
°C.  Aldehyde 3.100 (17.2 mg, 0.0502 mmol) was dissolved in DCM (0.2 mL) and added 
dropwise to the reaction at -78 °C.  The vial containing the aldehyde solution was rinsed 
with additional DCM (0.2 mL) which was added to the reaction dropwise.  The reaction 
was stirred at -78 °C for 3 h before warmed to -50 °C and stirred overnight.  The reaction 
was quenched with saturated aqueous NH4Cl and warmed to room temperature.  The 
layers were separated and the aqueous phase was extracted three times with DCM.  The 
combined organic layers were washed with brine and dried with anhydrous Na2SO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatography 
(7:1 hexanes:EtOAc) to yield 23.7 mg of product as a yellow oil (76% yield).  1H NMR 
(400 MHz, C6D6) δ 7.10 – 7.02 (m, 3H), 7.02 – 6.94 (m, 2H), 5.54 – 5.37 (m, 2H), 5.17 
(dd, J = 8.9, 4.5 Hz, 1H), 5.11 (ddt, J = 10.6, 6.9, 3.4 Hz, 1H), 4.34 (td, J = 5.6, 2.8 Hz, 
1H), 4.26 (dd, J = 8.7, 4.2 Hz, 1H), 3.44 (s, 3H), 3.25 (dd, J = 8.6, 2.1 Hz, 1H), 3.10 (dd, 
J = 13.2, 3.7 Hz, 1H), 2.71 (dd, J = 13.2, 10.7 Hz, 1H), 2.62 (d, J = 3.5 Hz, 1H), 2.55 – 
2.45 (m, 1H), 2.36 – 2.21 (m, 1H), 2.22 – 1.99 (m, 4H), 1.98 – 1.82 (m, 2H), 1.82 – 1.68 
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(m, 2H), 1.65 (d, J = 4.1 Hz, 3H), 1.10 (t, J = 7.4 Hz, 3H), 1.02 (s, 9H), 1.02 (d, J = 6.7 
Hz, 3H), 0.96 (d, J = 7.0 Hz, 3H), 0.23 (s, 3H), 0.18 (s, 3H).  13C NMR (100 MHz, C6D6) 
δ 202.0, 176.4, 137.0, 130.9, 129.6, 128.9, 127.2, 126.6, 84.6, 71.7, 70.6, 69.4, 60.4, 50.9, 
41.7, 40.8, 39.0, 36.9, 36.1, 31.4, 26.3, 20.7, 18.6, 18.2, 13.7, 12.1, 11.4, -3.5, -3.9.  
HRMS calc m/z [C33H55NO4S2Si + Na]+: 644.3234, found: 644.3013. 
 
(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-3,5-bis((tert-
butyldimethylsilyl)oxy)-2-ethyl-7-methoxy-6,8-dimethyldodec-10-en-1-one (3.102). 
To a solution of alcohol 3.101 (0.67 g, 1.1 mmol) and 2,6-lutidine (0.25 mL, 2.2 mmol) 
in DCM (22 mL) at 0 °C was added TBSOTf (0.37 mL, 1.6 mmol) dropwise.  The 
reaction was removed from the ice bath and stirred at room temperature.  After 45 min, 
TLC analysis of the reactions showed incomplete conversion.  The reaction was cooled to 
0 °C, and 2,6-lutidine (0.25 mL, 2.2 mmol) followed by TBSOTf (0.37 mL, 1.6 mmol) 
was added to the reaction.  The reaction was removed from the ice bath and stirred at 
room temperature.  After stirring for 20 min, the reaction was quenched with saturated 
NaHCO3.  The layers were separated and the aqueous phase was extracted three times 
with DCM.  The combined organic layers were washed with brine and dried with 
anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatography (4% EtOAc in hexanes) to yield 0.751 g of product as a yellow oil 
(95% yield).  1H NMR (400 MHz, C6D6) δ 7.13 – 6.98 (m, 5H), 5.44 (dt, J = 5.2, 3.5 Hz, 
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2H), 5.15 (dtd, J = 19.7, 7.0, 3.6 Hz, 2H), 4.39 (dd, J = 9.3, 4.3 Hz, 1H), 4.22 (dt, J = 7.4, 
4.5 Hz, 1H), 3.53 (s, 3H), 3.33 (dd, J = 9.7, 1.6 Hz, 1H), 3.21 (dd, J = 13.1, 3.5 Hz, 1H), 
2.88 – 2.73 (m, 2H), 2.40 – 2.21 (m, 3H), 2.22 – 2.06 (m, 2H), 1.95 (dp, J = 14.0, 7.1 Hz, 
1H), 1.89 – 1.69 (m, 2H), 1.73 – 1.55 (m, 3H), 1.23 (t, J = 7.4 Hz, 3H), 1.04 (s, 9H), 1.03 
(s, 9H), 1.00 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H), 0.30 (s, 3H), 0.28 (s, 3H), 0.21 
(s, 6H), 0.06 (s, 3H).  13C NMR (100 MHz, C6D6) δ 201.3, 176.0, 137.2, 131.1, 129.7, 
129.0, 128.5, 127.2, 126.4, 84.1, 71.5, 69.9, 69.7, 61.1, 51.3, 42.9, 41.4, 38.9, 36.7, 36.2, 
31.5, 26.3, 26.1, 22.0, 18.7, 18.3, 18.2, 13.2, 12.4, 10.1, -2.5, -2.8, -3.8, -4.1.  HRMS calc 
m/z [C38H72NO4S2Si2 + Na]+: 758.4157, found: 758.4145. 
 
(2S,3R,5R,6R,7R,8S,E)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-ethyl-7-methoxy-6,8-
dimethyldodec-10-enal (3.103).  To a solution of thiazolidinethione 3.102 (0.215 g, 
0.292 mmol) in DCM (7.3 mL) at -78 °C was added DIBAL-H (1 M in toluene, 0.58 mL, 
0.58 mmol) dropwise.  The reaction was determined to be complete after the reaction 
turned from yellow to clear upon addition of DIBAL-H.  The reaction was quenched with 
saturated aqueous Rochelle salt and diluted with DCM and warmed to room temperature.  
The slurry was stirred at room temperature for 1.5 h.  The layers were separated and the 
aqueous phase was extracted four times with DCM.  The combined organic layers were 
washed with brine and dried the Na2SO4.  The salts were removed via gravity filtration 
and volatile materials were removed using a rotary evaporator.  The crude material was 
purified via silica gel flash chromatography (4% EtOAc in hexanes) to yield 0.143 g of 
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product as a colorless oil (93% yield).  1H NMR (400 MHz, C6D6) δ 9.71 (d, J = 1.3 Hz, 
1H), 5.54 – 5.33 (m, 2H), 4.28 (td, J = 7.2, 2.6 Hz, 1H), 4.16 (t, J = 7.2 Hz, 1H), 3.41 (s, 
3H), 3.26 (dd, J = 9.7, 1.7 Hz, 1H), 2.38 – 2.16 (m, 2H), 2.17 – 2.04 (m, 1H), 1.97 (h, J = 
6.8 Hz, 3H), 1.79 – 1.52 (m, 6H), 1.04 – 0.95 (m, 15H), 0.93 (s, 9H), 0.88 (d, J = 6.9 Hz, 
3H), 0.16 (s, 3H), 0.15 (s, 3H), 0.12 (s, 3H), 0.05 (s, 3H).  13C NMR (100 MHz, C6D6) δ 
203.3, 130.9, 126.5, 83.9, 69.8, 69.5, 61.0, 57.9, 41.2, 40.7, 38.8, 36.1, 26.2, 25.9, 18.5, 
18.2, 18.2, 16.6, 13.0, 12.9, 9.6, -2.9, -4.1, -4.2, -4.5.  HRMS calc m/z [C29H60O4Si2 + 
Na]+: 551.3928, found: 551.3922. 
 
Ethyl 2-(Bis(o-tolyloxy)phosphoryl)propanoate (3.106a) and Ethyl 2-(Bis(o-
tolyloxy)phosphoryl)-2-methylpropanoate (3.108a).  The product was synthesized 
following a previously reported procedure.66  To a solution of phosphonate ester 3.107 
(0.50 g, 1.4 mmol) in DMSO (5.3 mL) was added sodium hydride (60% in mineral oil, 
0.057 g, 1.4 mmol).  After stirring at room temperature for 20 min, iodomethane (0.10 
mL, 1.6 mmol) was added to the reaction.  After stirring for 1 h, the reaction was 
quenched with saturated aqueous NH4Cl.  The mixture was extracted four times with 
EtOAc.  The combined organic layers were washed with brine and dried with anhydrous 
MgSO4.  The salts were removed via gravity filtration and volatile materials were 
removed using a rotary evaporator.  The 31P NMR spectra showed a 1.4:4.3:1 ratio of 
3.107:3.106a:3.108a.  The crude material was purified via silica gel flash 
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chromatography (10% to 30% EtOAc in hexanes) to yield 0.284 g of product 3.106a 
(55% yield) and 0.063 g of product 3.108a (12% yield). 
Ethyl 2-(bis(o-tolyloxy)phosphoryl)propanoate (3.106a):  1H NMR (400 MHz, CDCl3) δ 
7.33 – 7.25 (m, 2H), 7.21 – 7.14 (m, 2H), 7.14 – 6.98 (m, 4H), 4.22 (qd, J = 7.1, 1.3 Hz, 
2H), 3.43 (dq, J = 24.0, 7.3 Hz, 1H), 2.25 (s, 3H), 2.22 (s, 3H), 1.69 (dd, J = 19.2, 7.3 Hz, 
3H), 1.25 (t, J = 7.1 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 168.8, 168.8, 149.1, 149.0, 
149.0, 131.4, 131.4, 129.3, 129.3, 129.2, 127.0, 127.0, 125.1, 125.1, 120.3, 120.2, 120.2, 
120.2, 61.8, 40.08 (d, J = 136.5 Hz), 16.4, 14.0, 11.95 (d, J = 6.4 Hz).  31P NMR (162 
MHz, CDCl3) δ 16.4.  HRMS calc m/z [C19H23O5P + Na]+: 385.1175, found: 385.1211. 
Ethyl 2-(Bis(o-tolyloxy)phosphoryl)-2-methylpropanoate (3.108a):  1H NMR (400 MHz, 
CDCl3) δ 7.40 – 7.31 (m, 2H), 7.19 – 7.11 (m, 2H), 7.12 – 6.96 (m, 4H), 4.16 (q, J = 7.1 
Hz, 2H), 2.24 (s, 6H), 1.72 (d, J = 17.7 Hz, 6H), 1.18 (t, J = 7.1 Hz, 3H).  13C NMR (100 
MHz, CDCl3) δ 171.6, 171.5, 149.6, 149.5, 131.2, 128.8, 128.8, 127.0, 126.9, 124.7, 
120.0, 120.0, 61.9, 44.99 (d, J = 139.7 Hz), 21.40 (d, J = 4.6 Hz), 16.4, 13.9.  31P NMR 
(162 MHz, CDCl3) δ 19.8.  HRMS calc m/z [C20H25O5P + Na]+: 399.1332, found: 
399.1335. 
 
Ethyl 2-(Bis(o-tolyloxy)phosphoryl)-2-chloroacetate (3.106b) and Ethyl 2-(Bis(o-
tolyloxy)phosphoryl)-2,2-dichloroacetate (3.108b).  The synthesis was adapted from a 
previously reported procedure.69  To a solution of phosphonate ester 3.107 (0.50 g, 1.4 
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mmol) in THF (7.2 mL) at 0 °C was added sodium hydride (60% in mineral oil, 0.069 g, 
1.7 mmol) in two portions.  After stirring at room temperature for 10 min, NCS (0.23 g, 
1.7 mmol) was added to the reaction.  After stirring for 10 min, the reaction was diluted 
with water.  The mixture was extracted four times with EtOAc.  The combined organic 
layers were washed with brine and dried with anhydrous MgSO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The 31P NMR spectra showed a 1:2.3:2.1 ratio of 3.107:3.106b:3.108b.  The 
crude material was purified via silica gel flash chromatography (5% to 30% EtOAc in 
hexanes) to yield 0.163 g of product 3.106b (30% yield) and 0.196 g of product 3.108b 
(33% yield). 
Ethyl 2-(bis(o-tolyloxy)phosphoryl)-2-chloroacetate (3.106b):  1H NMR (400 MHz, 
CDCl3) δ 7.41 – 7.29 (m, 2H), 7.22 – 7.17 (m, 2H), 7.17 – 7.04 (m, 4H), 4.86 (d, J = 16.1 
Hz, 1H), 4.29 (qd, J = 7.2, 1.7 Hz, 2H), 2.27 (s, 6H), 1.27 (t, J = 7.1 Hz, 3H).  13C NMR 
(100 MHz, CDCl3) δ 164.0, 148.9, 148.8, 148.8, 131.6, 131.5, 129.4, 129.4, 127.2, 127.1, 
127.1, 127.1, 125.6, 125.6, 125.6, 120.2, 120.1, 120.1, 120.0, 63.5, 50.07 (d, J = 150.9 
Hz), 16.3, 13.8.  31P NMR (162 MHz, CDCl3) δ 4.6.  HRMS calc m/z [C18H20ClO5P + 
Na]+: 405.0629, found: 405.0617. 
Ethyl 2-(bis(o-tolyloxy)phosphoryl)-2,2-dichloroacetate (3.108b):  1H NMR (400 MHz, 
CDCl3) δ 7.49 – 7.40 (m, 2H), 7.24 – 7.18 (m, 2H), 7.18 – 7.05 (m, 4H), 4.29 (q, J = 7.1 
Hz, 2H), 2.31 (s, 6H), 1.22 (t, J = 7.2 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 162.7, 
162.7, 149.6, 149.5, 131.5, 129.1, 129.0, 127.1, 127.1, 125.5, 119.9, 119.9, 74.35 (d, J = 
177.0 Hz), 65.0, 16.4, 13.6.  31P NMR (162 MHz, CDCl3) δ -1.2.  HRMS calc m/z 
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[C18H19Cl2O5P + Na]+: 439.0239, found: 439.0231. 
 
Ethyl 2-(Bis(o-tolyloxy)phosphoryl)-2-bromoacetate (3.106c) and Ethyl 2-(Bis(o-
tolyloxy)phosphoryl)-2,2-dibromoacetate (3.108c).  The product was synthesized using 
the procedure for the synthesis of phosphonate ester 3.106b.  The reaction was performed 
with phosphonate ester 3.107 (1.2 g, 3.5 mmol) and 1,2-dibromotetrachloroethane (1.3 g, 
4.1 mmol) instead of NCS.  The 31P NMR spectra showed a 1.7:10:1 ratio of 
3.107:3.106c:3.108c.  The crude material was purified via silica gel flash 
chromatography (12% EtOAc in hexanes) to yield 0.811 g of product 3.106c (55% yield). 
Ethyl 2-(bis(o-tolyloxy)phosphoryl)-2-bromoacetate (3.106c):  1H NMR (400 MHz, 
CDCl3) δ 7.41 – 7.32 (m, 2H), 7.22 – 7.17 (m, 2H), 7.17 – 7.04 (m, 4H), 4.71 (d, J = 14.0 
Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 2.30 (s, 3H), 2.28 (s, 3H), 1.25 (t, J = 7.2 Hz, 3H).  13C 
NMR (100 MHz, CDCl3) δ 164.2, 149.1, 149.0, 149.0, 148.9, 131.6, 131.5, 129.4, 129.4, 
129.3, 129.3, 127.1, 127.1, 127.1, 127.0, 125.6, 125.5, 125.5, 120.1, 120.1, 120.1, 120.0, 
63.5, 35.23 (d, J = 151.2 Hz), 16.4, 13.8.  31P NMR (162 MHz, CDCl3) δ 4.7.  HRMS 
calc m/z [C18H20BrO5P + Na]+: 449.0124, found: 449.0229. 
Ethyl 2-(bis(o-tolyloxy)phosphoryl)-2,2-dibromoacetate (3.108c):  1H NMR (400 MHz, 
CDCl3) δ 7.51 – 7.43 (m, 2H), 7.23 – 7.17 (m, 2H), 7.17 – 7.05 (m, 4H), 4.28 (q, J = 7.1 
Hz, 2H), 2.34 (s, 6H), 1.21 (t, J = 7.2 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 163.1, 
163.1, 149.8, 149.7, 131.4, 129.1, 129.0, 127.0, 127.0, 125.4, 119.9, 119.9, 65.0, 45.87 
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(d, J = 168.8 Hz), 16.6, 13.5.  31P NMR (162 MHz, CDCl3) δ -1.3.  HRMS calc m/z 
[C18H19Br2O5P + Na]+: 526.9229, found: 526.9223. 
 
Ethyl 2-(Bis(o-tolyloxy)phosphoryl)-2-fluoroacetate (3.106d).  To a solution of o-
cresol (0.70 mL, 6.8 mmol) and triethylamine (1.0 mL, 7.2 mol) in toluene (5.2 mL) at 0 
°C was cannula transferred a solution of ethyl dichlorophosphite (3.109, 0.40 mL, 3.5 
mmol) in ether (2.1 mL).  The reaction was warmed to room temperature and stirred 
overnight.  The reaction was filtered through a fritted funnel and washed with toluene.  
The filtrate was filtered through a plug of basic alumina.  Volatile materials were 
removed using a rotary evaporator.  To the crude phosphite at 130 °C was added ethyl 
bromofluoroacetate (0.72 mL, 6.1 mmol) dropwise.  After heating at 130 °C, overnight, 
the 31P NMR spectra of the crude reaction showed no product.  Additional 
bromofluoroacetate (0.36 mL, 3.0 mmol) was added to the reaction, and the reaction was 
heated to 180 °C overnight.  The crude material was purified via silica gel flash 
chromatograph (20% EtOAc in hexanes) to yield 0.42 g of product as a colorless oil 
(41% yield).  1H NMR (400 MHz, CDCl3) δ 7.39 – 7.27 (m, 2H), 7.24 – 7.05 (m, 6H), 
5.52 (dd, J = 46.7, 11.9 Hz, 1H), 4.31 (qq, J = 7.7, 3.5 Hz, 2H), 2.28 (s, 3H), 2.24 (s, 4H), 
1.28 (t, J = 7.2 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 163.9 (dd, J = 22.1, 1.3 Hz), 
148.6, 148.5, 148.5, 148.4, 131.6, 131.6, 129.6, 129.5, 129.4, 127.2, 127.2, 127.1, 127.1, 
125.8, 125.7, 120.3, 120.3, 120.2, 120.2, 84.1 (dd, J = 200.6, 162.8 Hz). 62.9, 16.2, 16.2, 
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13.9. 31P NMR (162 MHz, CDCl3) δ 2.30 (d, J = 73.3 Hz).  19F NMR (376 MHz, CDCl3) 
δ -208.07 (d, J = 73.4 Hz).  HRMS calc m/z [C18H20FO5P + Na]+: 389.0925, found: 
389.0938. 
 
Ethyl (2Z,4R,5R,7R,8R,9R,10S,12E)-5,7-Bis((tert-butyldimethylsilyl)oxy)-4-ethyl-9-
methoxy-2,8,10-trimethyltetradeca-2,12-dienoate (3.111a).  To a solution of 
phosphonate ester 3.106a (144 mg, 0.397 mmol) in THF (4.8 mL) at 0 °C was added 
sodium hydride (60% in mineral oil, 16 mg, 0.40 mmol).  The reaction was stirred at 0 °C 
for 15 min before cooling to -78 °C.  Aldehyde 3.103 (20.4 mg, 0.0386 mmol) was 
dissolved in THF (0.2 mL) and added to the reaction dropwise.  The vial containing the 
aldehyde solution was rinsed with additional THF (0.2 mL) which was added to the 
reaction.  The reaction was slowly warmed from -78 °C to ~0 °C over 2 h.  The reaction 
was quenched with saturated aqueous NH4Cl.  The layers were separated and the aqueous 
phase was extracted four times with EtOAc.  The combined organic layers were washed 
with brine and dried with anhydrous Na2SO4.  The salts were removed via gravity 
filtration and volatile materials were removed using a rotary evaporator.  The crude 
material was purified via silica gel flash chromatography (6% ether in hexanes).  The 
impure material was purified via silica gel flash chromatography (3%EtOAc in hexanes) 
to yield 20.7 mg of product as a colorless oil (87%).  1H NMR (400 MHz, C6D6) δ 5.95 
(dd, J = 10.0, 1.6 Hz, 1H), 5.62 – 5.35 (m, 2H), 4.37 (dd, J = 10.0, 4.6 Hz, 1H), 4.17 – 
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3.93 (m, 3H), 3.53 (s, 3H), 3.49 – 3.30 (m, 2H), 2.32 (dt, J = 15.0, 6.2 Hz, 1H), 2.15 
(ddd, J = 13.6, 9.2, 4.7 Hz, 2H), 2.09 – 1.87 (m, 6H), 1.87 – 1.74 (m, 1H), 1.72 – 1.49 
(m, 4H), 1.11 (d, J = 6.8 Hz, 3H), 1.07 (t, J = 7.5 Hz, 3H), 1.04 – 1.00 (m, 21H), 0.98 (d, 
J = 6.9 Hz, 3H), 0.26 (s, 3H), 0.23 (s, 3H), 0.17 (s, 3H), 0.10 (s, 3H).  13C NMR (100 
MHz, C6D6) δ 167.4, 145.6, 131.3, 126.3, 84.1, 73.1, 69.4, 61.0, 60.0, 44.6, 42.1, 40.4, 
39.0, 36.3, 26.3, 26.1, 21.7, 21.2, 18.6, 18.3, 18.2, 14.3, 13.2, 12.3, 9.7, -2.6, -4.0, -4.1, -
4.4.  HRMS calc m/z [C34H68O5Si2 + Na]+: 635.4503, found: 635.4459. 
 
Ethyl (2E,4R,5R,7R,8R,9R,10S,12E)-5,7-Bis((tert-butyldimethylsilyl)oxy)-2-chloro-4-
ethyl-9-methoxy-8,10-dimethyltetradeca-2,12-dienoate (3.111b).  To a solution of 
phosphonate ester 3.106b (66.2 mg, 0.173 mmol) in THF (5 mL) at 0 °C was added 
sodium hydride (60% in mineral oil, 5.8 mg, 0.14 mmol).  After stirring at 0 °C for 15 
min, a solution of aldehyde 3.103 (30.5 mg, 0.0577 mmol) in THF (0.2 mL) was added to 
the reaction dropwise.  The vial containing the aldehyde solution was rinsed with 
additional THF (0.2 mL) and subsequently added to the reaction.  The reaction was 
slowly warmed to room temperature over 2 h.  The reaction was quenched with saturated 
aqueous NH4Cl.  The layers were separated and the aqueous phase was extracted four 
times with EtOAc.  The combined organic layers were washed with brine and dried with 
anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
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flash chromatography (6% ether in hexanes).  The impure material was purified via silica 
gel flash chromatography (6%EtOAc in hexanes) to yield 6.8 mg of product 3.111b as a 
colorless oil (19%) and 17.5 mg of unreacted aldehyde 3.103 (57%).  1H NMR (400 
MHz, C6D6) δ 6.56 (d, J = 10.5 Hz, 1H), 5.60 – 5.39 (m, 2H), 4.30 (dd, J = 10.1, 4.6 Hz, 
1H), 4.11 – 3.88 (m, 3H), 3.50 (s, 3H), 3.43 (ddd, J = 10.5, 7.4, 2.6 Hz, 1H), 3.35 (dd, J = 
9.6, 1.7 Hz, 1H), 2.37 – 2.23 (m, 1H), 2.23 – 1.98 (m, 3H), 1.98 – 1.89 (m, 1H), 1.89 – 
1.73 (m, 2H), 1.66 (dt, J = 3.3, 1.3 Hz, 3H), 1.62 – 1.48 (m, 1H), 1.08 (d, J = 6.8 Hz, 3H), 
1.01 (s, 9H), 1.00 – 0.92 (m, 18H), 0.22 (s, 3H), 0.20 (s, 3H), 0.13 (s, 3H), 0.13 (s, 3H).  
13C NMR (100 MHz, C6D6) δ 162.6, 147.4, 131.2, 126.4, 122.9, 84.0, 72.5, 69.1, 61.8, 
61.1, 45.6, 41.8, 40.4, 39.0, 36.2, 26.3, 26.1, 21.3, 18.6, 18.2, 18.2, 13.9, 13.2, 12.1, 9.6, -
2.7, -4.1, -4.5.  HRMS calc m/z [C33H65ClO5Si2 + Na]+: 655.3951, found: 655.4024. 
 
Ethyl (2E,4R,5R,7R,8R,9R,10S,12E)-2-Bromo-5,7-bis((tert-butyldimethylsilyl)oxy)-4-
ethyl-9-methoxy-8,10-dimethyltetradeca-2,12-dienoate (3.111c).  To a suspension of 
sodium hydride (60% in mineral oil, 15 mg, 0.61 mmol) in THF (2 mL) at 0 °C was 
added a solution of phosphonate ester 3.106c (283 mg, 0.662 mmol) in THF (1 mL).  The 
vial containing the phosphonate ester was rinsed with additional THF (1 mL) and 
subsequently added to the reaction.  After stirring at 0 °C for 20 min, a solution of 
aldehyde 3.103 (117 mg, 0.221 mmol) in THF (0.4 mL) was added to the reaction 
dropwise.  The vial containing the aldehyde solution was rinsed with additional THF (0.4 
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mL) which was added to the reaction.  The reaction was slowly warmed to room 
temperature over 2 h.  The reaction was quenched with saturated NH4Cl.  The layers were 
separated and the aqueous phase was extracted four times with EtOAc.  The combined 
organic layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatography (5% 
ether in hexanes) to yield 38.9 mg of product 3.111c as a colorless oil (25%) and 72.3 mg 
of unreacted aldehyde 3.103 (62%).  1H NMR (400 MHz, C6D6) δ 6.76 (d, J = 10.5 Hz, 
1H), 5.60 – 5.35 (m, 2H), 4.27 (dd, J = 9.9, 4.7 Hz, 1H), 4.10 – 3.93 (m, 3H), 3.49 (s, 
3H), 3.43 – 3.23 (m, 2H), 2.38 – 2.24 (m, 1H), 2.21 – 1.94 (m, 3H), 1.94 – 1.87 (m, 1H), 
1.87 – 1.72 (m, 2H), 1.66 (dt, J = 4.6, 1.4 Hz, 3H), 1.63 – 1.48 (m, 1H), 1.08 (d, J = 6.8 
Hz, 3H), 1.01 (s, 9H), 1.00 – 0.92 (m, 18H), 0.21 (s, 3H), 0.19 (s, 3H), 0.14 (s, 3H), 0.13 
(s, 3H).  13C NMR (100 MHz, C6D6) δ 162.9, 150.7, 131.2, 126.4, 111.6, 84.0, 72.4, 69.0, 
61.9, 61.1, 47.0, 41.7, 40.4, 39.0, 36.2, 26.3, 26.1, 21.0, 18.6, 18.2, 18.2, 13.9, 13.2, 12.2, 
9.6, -2.7, -4.1, -4.1, -4.5.  HRMS calc m/z [C33H65BrO5Si2 + Na]+: 699.3452, found: 
699.3496. 
 
Ethyl (2E,4R,5R,7R,8R,9R,10S,12E)-5,7-Bis((tert-butyldimethylsilyl)oxy)-4-ethyl-2-
fluoro-9-methoxy-8,10-dimethyltetradeca-2,12-dienoate (3.105).  To a solution of 
phosphonate ester 3.106d (105 mg, 0.287 mmol) in THF (2.5 mL) at 0 °C was added 
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sodium hydride (60% in mineral oil, 11 mg, 0.27 mmol).  After stirring at 0 °C for 15 
min, a solution of aldehyde 3.103 (15.2 mg, 0.0287 mmol) in THF (0.2 mL) was added to 
the reaction dropwise.  The vial containing the aldehyde solution was rinsed with 
additional THF (0.2 mL) and subsequently added to the reaction.  The reaction was 
slowly warmed to room temperature over 2 h.  The reaction was quenched with saturated 
aqueous NH4Cl.  The layers were separated and the aqueous phase was extracted four 
times with EtOAc.  The combined organic layers were washed with brine and dried with 
Na2SO4.  The salts were removed via gravity filtration and volatile materials were 
removed using a rotary evaporator.  The crude material was purified via silica gel flash 
chromatography (4% ether in hexanes) to yield 11.1 mg of product as a colorless oil 
(63%).  1H NMR (400 MHz, C6D6) δ 6.03 (dd, J = 22.5, 10.8 Hz, 1H), 5.59 – 5.36 (m, 
2H), 4.34 (dd, J = 9.8, 4.5 Hz, 1H), 4.08 – 3.89 (m, 3H), 3.62 – 3.47 (m, 4H), 3.35 (dd, J 
= 9.6, 1.7 Hz, 1H), 2.38 – 2.24 (m, 1H), 2.22 – 2.12 (m, 1H), 2.11 – 2.03 (m, 1H), 2.03 – 
1.84 (m, 3H), 1.84 – 1.74 (m, 1H), 1.73 – 1.58 (m, 3H), 1.48 (ddd, J = 13.7, 10.5, 7.2 Hz, 
1H), 1.07 (d, J = 6.9 Hz, 3H), 1.02 (s, 9H), 0.99 – 0.89 (m, 18H), 0.23 (s, 3H), 0.21 (s, 
3H), 0.14 (s, 3H), 0.10 (s, 3H).  13C NMR (100 MHz, C6D6) δ 161.0 (d, J = 35.2 Hz), 
148.0 (d, J = 256.8 Hz), 131.2, 126.5, 126.2 (d, J = 16.6 Hz), 84.1, (d, J = 2.6 Hz), 69.4, 
61.2, 61.1, 42.2 (d, J = 4.1 Hz), 41.9, 40.8, 39.0, 36.3, 26.3, 26.1, 21.9, 21.9, 18.7, 18.3, 
18.3, 14.0, 13.2, 12.1, 9.8, -2.7, -4.0, -4.0, -4.4.  19F NMR (376 MHz, C6D6) δ -119.4.  
HRMS calc m/z [C33H65FO5Si2 + Na]+: 639.4539, found: 639.4198. 
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(5R,6R)-5-Ethyl-6-((2R,3S,4R,5S,E)-2-hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-
yl)-3-methyl-5,6-dihydro-2H-pyran-2-one (3.112a).  A solution of ester 3.111a (20.7 
mg, 0.0338 mmol) in 1% HCl in ethanol (0.85 mL) was stirred overnight.  The reaction 
was quenched with saturated aqueous NaHCO3 and extracted four times with DCM.  The 
combined organic layers were washed with brine and dried with Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatography (30% 
EtOAc in hexanes) to yield 8.5 mg of product 3.112a as c colorless oil (74%).  1H NMR 
(400 MHz, C6D6) δ 6.04 (dd, J = 6.0, 1.6 Hz, 1H), 5.56 – 5.27 (m, 2H), 4.68 (dt, J = 8.1, 
3.9 Hz, 1H), 4.51 – 4.34 (m, 1H), 3.15 (d, J = 2.6 Hz, 1H), 3.11 (s, 3H), 2.76 (dd, J = 6.3, 
4.2 Hz, 1H), 2.15 – 1.97 (m, 1H), 1.90 – 1.75 (m, 5H), 1.76 – 1.53 (m, 7H), 1.43 – 1.26 
(m, 2H), 1.21 (ddd, J = 13.3, 9.8, 7.1 Hz, 1H), 0.96 (d, J = 7.0 Hz, 3H), 0.93 (d, J = 6.2 
Hz, 3H), 0.66 (t, J = 7.5 Hz, 3H).  13C NMR (100 MHz, C6D6) δ 165.1, 143.5, 129.5, 
128.2, 126.9, 91.2, 77.6, 67.3, 61.4, 39.6, 39.6, 37.7, 37.6, 36.6, 21.1, 18.2, 17.4, 15.6, 
11.9, 11.2.  HRMS calc m/z [C20H34O4 + Na]+: 361.2349, found: 361.2331.  >98% pure 
by UPLC analysis 
 
(5R,6R)-3-Chloro-5-ethyl-6-((2R,3S,4R,5S,E)-2-hydroxy-4-methoxy-3,5-
dimethylnon-7-en-1-yl)-5,6-dihydro-2H-pyran-2-one (3.112b).  The product was 
synthesized using the procedure for the synthesis of lactone 3.112a.  Reaction with ester 
3.111b (23.7 mg, 0.0374 mmol) resulted in 9.27 mg of product as a colorless oil (69% 
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yield) stirring 48 h at room temperature and purification via silica gel flash 
chromatography (25% EtOAc in hexanes).  1H NMR (400 MHz, C6D6) δ 6.34 (d, J = 6.4 
Hz, 1H), 5.59 – 5.28 (m, 2H), 4.62 – 4.46 (m, 1H), 4.27 (ddt, J = 8.9, 4.4, 2.0 Hz, 1H), 
3.13 (d, J = 2.5 Hz, 1H), 3.09 (s, 3H), 2.73 (dd, J = 6.4, 4.1 Hz, 1H), 2.14 – 1.95 (m, 1H), 
1.94 – 1.72 (m, 2H), 1.69 – 1.55 (m, 5H), 1.52 – 1.44 (m, 2H), 1.24 – 1.09 (m, 1H), 1.09 
– 0.95 (m, 1H), 0.96 – 0.86 (m, 6H), 0.48 (t, J = 7.5 Hz, 3H).  13C NMR (100 MHz, 
C6D6) δ 159.6, 145.1, 129.4, 127.1, 124.6, 91.2, 78.4, 67.2, 61.4, 41.0, 39.5, 37.5, 37.1, 
36.6, 20.8, 18.2, 15.6, 11.9, 10.9.  HRMS calc m/z [C19H31ClO4 + Na]+: 381.1803, found: 
381.1799.  >95% pure by UPLC analysis 
 
(5R,6R)-3-bromo-5-ethyl-6-((2R,3S,4R,5S,E)-2-hydroxy-4-methoxy-3,5-dimethylnon-
7-en-1-yl)-5,6-dihydro-2H-pyran-2-one (3.112c).  The product was synthesized using 
the procedure for the synthesis of lactone 3.112a.  Reaction with ester 3.111c (10.5 mg, 
0.0155 mmol) resulted in 5.36 mg of product as a white solid (86% yield) after stirring 
for 44 h at room temperature and purification via silica gel flash chromatography (25% 
EtOAc in hexanes).  1H NMR (400 MHz, C6D6) δ 6.72 (d, J = 6.4 Hz, 1H), 5.67 – 5.36 
(m, 2H), 4.68 – 4.56 (m, 1H), 4.44 – 4.28 (m, 1H), 3.23 (s, 1H), 3.20 (s, 3H), 2.83 (dd, J 
= 6.4, 4.2 Hz, 1H), 2.24 – 2.05 (m, 1H), 1.98 – 1.80 (m, 2H), 1.80 – 1.63 (m, 5H), 1.63 – 
1.50 (m, 2H), 1.32 – 1.20 (m, 1H), 1.20 – 1.09 (m, 1H), 1.03 (d, J = 6.3 Hz, 3H), 1.00 (d, 
J = 7.1 Hz, 3H), 0.59 (t, J = 7.5 Hz, 3H).  13C NMR (100 MHz, C6D6) δ 159.4, 150.1, 
129.4, 127.0, 114.6, 91.1, 78.4, 67.2, 61.4, 42.2, 39.5, 37.5, 37.1, 36.6, 20.7, 18.2, 15.6, 
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11.9, 10.9.  HRMS calc m/z [C19H31BrO4 + Na]+: 425.1298, found: 425.1323.  >98% pure 
by UPLC analysis. 
 
(5R,6R)-5-ethyl-3-fluoro-6-((2R,3S,4R,5S,E)-2-hydroxy-4-methoxy-3,5-dimethylnon-
7-en-1-yl)-5,6-dihydro-2H-pyran-2-one (3.112d).  The product was synthesized using 
the procedure for the synthesis of lactone 3.112a.  Reaction with ester 3.105 (22.3 mg, 
0.0361 mmol) resulted in 5.71 mg of product as a colorless oil (46% yield) after stirring 
for 42 h at room temperature and purification via silica gel flash chromatography (5% to 
20% EtOAc in hexanes).  1H NMR (400 MHz, C6D6) δ 5.66 (dd, J = 11.1, 6.5 Hz, 1H), 
5.53 – 5.29 (m, 2H), 4.57 (td, J = 6.8, 6.3, 3.7 Hz, 1H), 4.29 (t, J = 6.4 Hz, 1H), 3.18 (d, J 
= 2.4 Hz, 1H), 3.11 (s, 3H), 2.75 (dd, J = 6.4, 4.2 Hz, 1H), 2.12 – 1.95 (m, 1H), 1.87 – 
1.72 (m, 2H), 1.68 – 1.57 (m, 5H), 1.54 – 1.45 (m, 2H), 1.25 – 1.12 (m, 1H), 1.10 – 0.96 
(m, 1H), 0.93 (d, J = 4.9 Hz, 3H), 0.92 (d, J = 5.8 Hz, 3H), 0.50 (t, J = 7.5 Hz, 3H).  13C 
NMR (100 MHz, C6D6) δ 158.70 (d, J = 31.1 Hz), 147.36 (d, J = 259.4 Hz), 129.5, 127.0, 
122.55 (d, J = 10.2 Hz), 91.1, 78.6, 67.2, 61.4, 39.5, 38.70 (d, J = 3.7 Hz), 37.5, 37.2, 
36.6, 21.05 (d, J = 3.2 Hz), 18.2, 15.6, 11.9, 10.8.  19F NMR (376 MHz, C6D6) δ -127.1.  
HRMS calc m/z [C19H31FO4 + Na]+: 365.2099, found: 365.2078. >95% pure by UPLC 
analysis. 
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Methyl (2,3-syn)-3-((tert-Butyldimethylsilyl)oxy)-2-methyl-5-phenylpentanoate 
(3.114).  To a solution of alcohol 3.75 (0.52 g, 2.3 mmol) in DMF (1.6 mL) was added 
imidazole (0.24 g, 3.5 mmol) followed by TBSCl (0.53 g, 3.5 mmol).  The reaction was 
stirred overnight, and then diluted with water.  The mixture was extracted four times with 
ether.  The combined organic layers were washed with brine and dried with MgSO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatography 
(5% ether in hexanes) to yield 0.61 g of product as a colorless oil (78%).  1H NMR (400 
MHz, CDCl3) δ 7.33 – 7.27 (m, 2H), 7.24 – 7.11 (m, 3H), 4.07 (q, J = 5.5 Hz, 1H), 3.68 
(s, 3H), 2.77 – 2.50 (m, 3H), 1.92 – 1.68 (m, 2H), 1.17 (d, J = 6.9 Hz, 3H), 0.89 (s, 9H), 
0.07 (s, 3H), 0.02 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 175.4, 142.2, 128.4, 128.3, 
125.8, 73.0, 51.5, 44.5, 37.2, 31.5, 25.8, 18.1, 11.4, -4.2, -4.7. 
 
(2,3-syn)-3-((tert-Butyldimethylsilyl)oxy)-2-methyl-5-phenylpentanal (3.115).  To a 
solution of ester 3.114 (0.275 g, 0.817 mmol) in DCM (5.8 mL) at -78 °C, was added a 
solution of DIBAL-H (1 M in toluene, 1.6 mL, 1.6 mmol).  After stirring at -78 °C for 15 
min, the reaction was quenched with saturated aqueous Rochelle salt (8 mL).  The 
mixture was warmed to room temperature and stirred for 1 h.  The layers were separated 
and the aqueous layer was extracted three times with DCM.  The combined organic 
layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
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evaporator.  The crude material was purified via silica gel flash chromatograph (5% ether 
in hexanes) to yield 0.13 g of product as a colorless oil (52% yield).  1H NMR (400 MHz, 
CDCl3) δ 9.79 (d, J = 1.0 Hz, 1H), 7.34 – 7.27 (m, 2H), 7.24 – 7.10 (m, 3H), 4.16 (td, J = 
6.4, 3.7 Hz, 1H), 2.80 – 2.63 (m, 1H), 2.63 – 2.49 (m, 2H), 1.83 (dtdd, J = 20.1, 13.6, 
10.9, 6.1 Hz, 2H), 1.10 (d, J = 7.0 Hz, 3H), 0.89 (s, 9H), 0.09 (s, 3H), 0.04 (s, 3H).  13C 
NMR (100 MHz, CDCl3) δ 205.1, 141.6, 128.5, 128.2, 126.0, 71.8, 51.3, 36.4, 32.2, 25.8, 
25.7, 18.0, 7.9, -4.2, -4.6. 
 
Ethyl (4,5-syn,E)-2-Bromo-5-((tert-butyldimethylsilyl)oxy)-4-methyl-7-phenylhept-2-
enoate (3.116).  To a solution of phosphonate ester 3.106c (0.92 g, 2.2 mmol) in THF (8 
mL) at 0 °C was added sodium hydride (60% in mineral oil, 0.075 mg, 1.9 mmol).  After 
stirring at 0 °C for 10 min, a solution of aldehyde 3.115 (0.33 g, 1.1 mmol) in THF (1 
mL) was added to the reaction dropwise.  The vial containing the aldehyde solution was 
rinsed with additional THF (1 mL) which was added to the reaction.  The reaction was 
stirred at 0 °C for 2 h and quenched with saturated aqueous NH4Cl.  The mixture was 
extracted four times with EtOAc.  The combined organic layers were washed with brine 
and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and 
volatile materials were removed using a rotary evaporator.  The crude material was 
purified via silica gel flash chromatography (2% ether in hexanes) to yield 0.37 g of 
product as a white solid (75%).  1H NMR (400 MHz, CDCl3) δ 7.32 – 7.28 (m, 2H), 7.21 
– 7.12 (m, 3H), 6.61 (d, J = 10.5 Hz, 1H), 4.28 (q, J = 7.1 Hz, 2H), 3.71 (td, J = 5.9, 4.5 
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Hz, 1H), 3.42 – 3.29 (m, 1H), 2.72 – 2.51 (m, 2H), 1.91 – 1.67 (m, 2H), 1.34 (t, J = 7.1 
Hz, 3H), 1.04 (d, J = 6.7 Hz, 3H), 0.91 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H).  13C NMR (100 
MHz, CDCl3) δ 162.9, 151.5, 142.2, 128.4, 128.3, 125.8, 110.4, 74.5, 62.1, 40.2, 36.9, 
31.5, 25.9, 25.9, 18.1, 14.1, 13.9, -4.2, -4.6.  mp: 61.4-63.4 °C. 
 
(5,6-syn)-3-Bromo-5-methyl-6-phenethyl-5,6-dihydro-2H-pyran-2-one (3.113).  A 
solution of ester 3.116 (167 mg, 0.367 mmol) in 1% HCl in ethanol (3.5 mL) was stirred 
at room temperature for 48 h.  The reaction was quenched with saturated aqueous 
NaHCO3 and extracted four times with DCM.  The combined organic layers were washed 
with brine and dried with anhydrous Na2SO4.  The salts were removed via gravity 
filtration and volatile materials were removed using a rotary evaporator.  The crude 
material was purified via silica gel flash chromatography (20% ether in hexanes) to yield 
83.5 mg of product as a white solid (77%).  1H NMR (400 MHz, CDCl3) δ 7.36 – 7.27 
(m, 2H), 7.24 – 7.15 (m, 3H), 4.48 (dt, J = 9.4, 3.8 Hz, 1H), 2.90 (ddd, J = 14.3, 9.1, 5.3 
Hz, 1H), 2.72 (ddd, J = 13.9, 8.9, 7.3 Hz, 1H), 2.45 (pd, J = 7.0, 3.4 Hz, 1H), 2.16 (dtd, J 
= 14.4, 9.2, 5.4 Hz, 1H), 1.80 (dddd, J = 13.7, 9.1, 7.3, 4.1 Hz, 1H), 1.10 (d, J = 7.0 Hz, 
3H).  13C NMR (100 MHz, CDCl3) δ 160.1, 151.2, 140.5, 128.6, 128.5, 126.3, 113.7, 
79.6, 35.5, 33.0, 31.2, 11.2. 
 
  172 
Ethyl (4,5-syn,Z)-5-((tert-Butyldimethylsilyl)oxy)-2-cyano-4-methyl-7-phenylhept-2-
enoate (3.117).  Inside a glovebox under a nitrogen atmosphere, [(tBu)3PPdBr]2 (1.3 mg, 
0.0017 mmol), zinc cyanide (7.1 mg, 0.060 mmol), acid washed Zn0 (0.3 mg, 0.004 
mmol) were added to a vial containing ester 3.116 (15.2 mg, 0.0334 mmol).  After 
addition of DMF (0.33 mL) to the vial, the vial was sealed with a cap containing a 
PTFE/silicone septum and removed from the glovebox.  The reaction was stirred 
overnight at room temperature.  The reaction was diluted with water and the mixture was 
extracted four times with EtOAc.  The combined organic layers were washed twice with 
brine and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration 
through a plug of Celite® and volatile materials were removed using a rotary evaporator.  
The crude material was purified via silica gel flash chromatography (5% EtOAc in 
hexanes) to yield 11.7 mg of product as a white solid (87%).  1H NMR (400 MHz, 
CDCl3) δ 7.62 (d, J = 10.8 Hz, 1H), 7.36 – 7.27 (m, 2H), 7.23 – 7.14 (m, 4H), 4.32 (qd, J 
= 7.2, 2.9 Hz, 2H), 3.74 (td, J = 5.9, 4.3 Hz, 1H), 3.06 (dqd, J = 11.0, 6.8, 4.3 Hz, 1H), 
2.66 (qdd, J = 13.7, 10.7, 5.7 Hz, 3H), 1.89 (ddt, J = 13.8, 11.1, 5.7 Hz, 1H), 1.75 (ddt, J 
= 13.7, 10.7, 6.1 Hz, 1H), 1.35 (t, J = 7.1 Hz, 3H), 1.14 (d, J = 6.7 Hz, 3H), 0.92 (s, 9H), 
0.07 (s, 3H), 0.05 (s, 4H).  13C NMR (100 MHz, CDCl3) δ 166.3, 161.3, 141.6, 128.5, 
128.3, 126.0, 113.7, 108.8, 73.9, 62.5, 41.7, 36.5, 31.6, 25.8, 18.1, 14.1, 13.7, -4.2, -4.7. 
 
(6R)-5-Ethyl-6-((2R,3S,4R,5S,E)-2-hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-yl)-
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2-oxo-5,6-dihydro-2H-pyran-3-carbonitrile (3.15).  Inside a glovebox under a nitrogen 
atmosphere, [(tBu)3PPdBr]2 (1.7 mg, 0.0022 mmol), zinc cyanide (4.5 mg, 0.039 mmol), 
acid washed Zn0 (1.2 mg, 0.018 mmol) were added to a vial containing ester 3.112c (8.7 
mg, 0.022 mmol).  After addition of DMF (0.3 mL) to the vial, the vial was sealed with a 
cap containing a PTFE/silicone septum and removed from the glovebox.  The reaction 
was stirred overnight at room temperature.  The reaction was diluted with water and the 
mixture was extracted 5 times with EtOAc.  The combined organic layers were washed 
twice with brine and dried with anhydrous Na2SO4.  The salts were removed via gravity 
filtration through a plug of Celite® and volatile materials were removed using a rotary 
evaporator.  To the crude material was added 4 mg TMT129 and dissolved in 0.5 mL 
toluene.  The suspension was stirred overnight and filtered through a plug of Celite®.  
Volatile materials were removed using a rotary evaporator.  The crude material was 
purified via silica gel flash chromatography to yield 5.1 mg of impure product as a 
colorless oil (66%) and 2.3 mg recovered starting material 3.112c.  HRMS calc m/z 
[C20H31NO4 + Na]+: 372.2151, found: 372.2089. 
Mixture of Isomers: 1H NMR (400 MHz, CD2Cl2) δ 7.78 (d, J = 6.2 Hz, 0.5H), 7.58 (d, J 
= 3.7 Hz, 0.5H), 5.59 – 5.35 (m, 2H), 4.89 – 4.73 (m, 0.5H), 4.65 (ddd, J = 9.7, 7.1, 3.1 
Hz, 0.5H), 4.29 – 4.08 (m, 1H), 3.55 – 3.39 (m, 3H), 3.31 (t, J = 9.7 Hz, 1H), 3.09 – 2.91 
(m, 1H), 2.57 (tt, J = 7.8, 4.6 Hz, 1H), 2.11 (d, J = 11.8 Hz, 1H), 2.05 – 1.94 (m, 1H), 
1.93 – 1.40 (m, 10H), 1.17 – 0.75 (m, 9H). 
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(5R,6R)-3-Bromo-6-((2R,3R,4R,5S,E)-2-((tert-butyldimethylsilyl)oxy)-4-methoxy-3,5-
dimethylnon-7-en-1-yl)-5-ethyl-5,6-dihydro-2H-pyran-2-one (3.119).  To a solution of 
alcohol 3.112c (37.8 mg, 0.0937 mmol) and 2,6-lutidine (0.055 mL, 0.47 mmol) in DCM 
(3 mL) at -78 °C was added TBSOTf (0.043 mL, 0.19 mmol) dropwise.  After stirring at -
78 °C for 45 min, the reaction was quenched with saturated NaHCO3.  The layers were 
separated and the aqueous phase was extract three times with DCM.  The combined 
organic layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatography (10% 
EtOAc in hexanes) to yield 44.8 mg of product as a colorless oil (92% yield).  1H NMR 
(400 MHz, C6D6) δ 6.55 (d, J = 6.4 Hz, 1H), 5.50 – 5.35 (m, 2H), 4.38 – 4.22 (m, 2H), 
3.38 (s, 3H), 3.19 (dd, J = 9.4, 1.9 Hz, 1H), 2.31 – 2.15 (m, 1H), 2.15 – 1.97 (m, 1H), 
1.83 (ddd, J = 14.0, 9.2, 6.2 Hz, 1H), 1.70 (qd, J = 7.0, 1.7 Hz, 1H), 1.65 (d, J = 4.4 Hz, 
3H), 1.62 – 1.43 (m, 3H), 1.12 (ddd, J = 13.5, 7.6, 4.7 Hz, 1H), 1.06 – 0.99 (m, 1H), 0.99 
– 0.95 (m, 12H), 0.80 (d, J = 7.0 Hz, 3H), 0.48 (t, J = 7.5 Hz, 3H), 0.13 (s, 6H).  13C 
NMR (100 MHz, C6D6) δ 159.1, 149.9, 130.9, 126.6, 114.6, 84.2, 77.4, 68.7, 60.8, 42.0, 
41.5, 38.8, 37.7, 36.2, 26.3, 20.7, 18.7, 18.3, 13.3, 10.9, 10.6, -3.5, -3.5.  HRMS calc m/z 
[C25H45BrO4Si + Na]+: 539.2163, found: 539.2085. 
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(5,6-syn)-5-Methyl-6-phenethyl-3-phenyl-5,6-dihydro-2H-pyran-2-one (3.121).  Table 
3-5, entry 3:  Inside a glovebox under a nitrogen atmosphere, phenylboronic acid (5.9 mg, 
0.048 mmol), potassium phosphate (11.3 mg, 0.0532 mmol) and [(tBu)3PPdBr]2 (1.3 mg, 
0.0016 mmol) were added to a vial containing lactone 3.113 (9.54 mg, 0.0323 mmol).  
The mixture was suspended in THF (0.3 mL) and acetonitrile (0.2 mL).  The vial was 
sealed with a cap containing a PTFE/silicone septum and removed from the glovebox.  
Degassed water (0.1 mL) was added to the reaction and the suspension was stirred at 
room temperature for 3 h.  The reaction was diluted with water and EtOAc.   The layers 
were separated and the aqueous layer was extracted three times with EtOAc.  The 
combined organic layers were washed with brine and dry with anhydrous Na2SO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  1,3,5-Trimethoxybenzene (1.54 mg) was added to the crude material 
for calculating the yield via 1H NMR spectroscopy (74% NMR yield).  The crude 
material was purified via silica gel flash chromatography (12% EtOAc in hexanes) to 
yield 8.98 mg of product as a colorless oil (95% yield). 1H NMR (400 MHz, CDCl3) δ 
7.53 – 7.42 (m, 2H), 7.41 – 7.27 (m, 5H), 7.27 – 7.17 (m, 3H), 6.99 (d, J = 6.4 Hz, 1H), 
4.51 (dt, J = 9.4, 3.9 Hz, 1H), 2.95 (ddd, J = 14.5, 9.6, 5.4 Hz, 1H), 2.76 (ddd, J = 13.9, 
9.2, 7.0 Hz, 1H), 2.53 (pd, J = 7.0, 3.4 Hz, 1H), 2.30 – 2.12 (m, 1H), 1.84 (dddd, J = 
13.9, 9.6, 7.0, 4.3 Hz, 1H), 1.13 (d, J = 7.1 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 
164.5, 147.2, 141.0, 135.3, 131.8, 129.6, 128.6, 128.5, 128.3, 128.2, 128.2, 126.2, 78.9, 
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33.2, 32.9, 31.4, 11.4. 
Table 3-5, entry 2:  Inside a glovebox under a nitrogen atmosphere, phenylboronic acid 
(5.8 mg, 0.048 mmol), potassium fluoride (8.3 mg, 0.14 mmol) and [(tBu)3PPdBr]2 (1.2 
mg, 0.0016 mmol) were added to a vial containing lactone 3.113 (9.36 mg, 0.0317 
mmol).  The mixture was suspended in THF (0.4 mL).  The vial was sealed with a cap 
containing a PTFE/silicone septum and removed from the glovebox.  Degassed water (1.1 
µL, 0.063 mmol) was added to the reaction and the suspension was stirred at room 
temperature for 5.5 h.  The reaction was diluted with water and EtOAc.   The layers were 
separated and the aqueous layer was extracted three times with EtOAc.  The combined 
organic layers were washed with brine and dry with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  1,3,5-Trimethoxybenzene (1.47 mg) was added to the crude material for 
calculating the yield via 1H NMR spectroscopy (94% NMR yield) 
Table 3-5, entry 4:  Inside a glovebox under a nitrogen atmosphere, phenylboronic acid 
(5.9 mg, 0.048 mmol), potassium phosphate (13.8 mg, 0.0650 mmol) and Xphos Pd G2 
(2.63 mg, 0.00334 mmol) were added to a vial containing lactone 3.113 (9.58 mg, 0.0325 
mmol).  The mixture was suspended in THF (0.2 mL).  The vial was sealed with a cap 
containing a PTFE/silicone septum and removed from the glovebox.  Degassed water (0.4 
mL) was added to the reaction and the reaction was stirred at room temperature for 3 h.  
The reaction was diluted with water and EtOAc.  The layers were separated and the 
aqueous layer was extracted three times with EtOAc.  The combined organic layers were 
washed with brine and dry with anhydrous Na2SO4.  The salts were removed via gravity 
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filtration and volatile materials were removed using a rotary evaporator.  1,3,5-
Trimethoxybenzene (1.39 mg) was added to the crude material for calculating the yield 
via 1H NMR spectroscopy (76% NMR yield). 
 
(5R,6R)-6-((2R,3R,4R,5S,E)-2-((tert-Butyldimethylsilyl)oxy)-4-methoxy-3,5-
dimethylnon-7-en-1-yl)-5-ethyl-3-phenyl-5,6-dihydro-2H-pyran-2-one (3.123).  Inside 
a glovebox under a nitrogen atmosphere, phenyl boronic acid (7.4 mg, 0.060 mmol), 
potassium phosphate (14.1 mg, 0.0664 mmol) and [(tBu)3PPdBr]2 (1.6 mg, 0.0020 mmol) 
were added to a vial containing lactone 3.119 (20.8 mg, 0.0402 mmol).  The mixture was 
suspended in THF (0.3 mL) and acetonitrile (0.2 mL).  The vial was sealed with cap 
containing a PTFE/silicone septum and removed from the glovebox.  Degassed water (0.1 
mL) was added to reaction and the suspension was stirred at room temperature for 6 h.  
The reaction was diluted with water and EtOAc.   The layers were separated and the 
aqueous layer was extracted four times with EtOAc.  The combined organic layers were 
washed with brine and dry with anhydrous Na2SO4.  The salts were removed via gravity 
filtration and volatile materials were removed using a rotary evaporator.  The crude 
material was purified via silica gel flash chromatography (17% ether in hexanes).  Impure 
material was further purified via silica gel flash chromatography (15% ether in hexanes).  
To the combined product was added 8 mg TMT129 and suspended in toluene (1 mL) and 
stirred overnight.  The suspension was filtered through a plug of Celite® and the filtrate 
was concentrated using a rotary evaporator to yield 11.18 mg product as a colorless oil 
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(54% yield).  1H NMR (400 MHz, C6D6) δ 7.62 – 7.54 (m, 2H), 7.24 – 7.09 (m, 3H), 6.52 
(d, J = 6.3 Hz, 1H), 5.55 – 5.35 (m, 2H), 4.54 (dt, J = 8.8, 4.1 Hz, 1H), 4.46 (ddd, J = 7.7, 
5.9, 1.6 Hz, 1H), 3.43 (s, 3H), 3.26 (dd, J = 9.3, 1.9 Hz, 1H), 2.32 – 2.19 (m, 1H), 2.15 – 
2.04 (m, 1H), 1.99 (ddd, J = 14.8, 9.3, 5.8 Hz, 1H), 1.85 (dq, J = 9.8, 4.8 Hz, 1H), 1.79 – 
1.61 (m, 6H), 1.41 – 1.20 (m, 2H), 1.10 – 0.93 (m, 12H), 0.87 (d, J = 7.1 Hz, 3H), 0.68 (t, 
J = 7.5 Hz, 3H), 0.23 (s, 3H), 0.20 (s, 3H).  13C NMR (100 MHz, C6D6) δ 163.3, 145.4, 
136.5, 133.2, 131.0, 128.9, 126.6, 84.3, 76.5, 69.0, 60.8, 42.2, 39.3, 38.8, 38.0, 36.2, 26.3, 
21.1, 18.7, 18.2, 13.3, 11.2, 10.7, -3.5.  HRMS calc m/z [C31H50O4Si + Na]+: 537.3371, 
found: 537.3301. 
 
(5R,6R)-5-Ethyl-6-((2R,3S,4R,5S,E)-2-hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-
yl)-3-phenyl-5,6-dihydro-2H-pyran-2-one (3.122).  To a solution of lactone 3.123 
(10.21 mg, 0.01983 mmol) in CHCl3 (0.8 mL) at 0 °C was added dropwise BF3•Et2O 
(0.020 mL, 0.16 mmol).  The reaction was stirred at 0 °C for 40 min and then quenched 
with saturated aqueous NaHCO3 and diluted with DCM.  The layers were separated and 
the aqueous phase was extracted three times with DCM.  The combined organic layers 
were washed with brine and dry with anhydrous Na2SO4.  The salts were removed via 
gravity filtration and volatile materials were removed using a rotary evaporator.  The 
crude material was purified via silica gel flash chromatography (20% EtOAc in hexanes) 
to yield 6.93 mg of product as a colorless oil (87% yield).  1H NMR (400 MHz, C6D6) δ 
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7.60 – 7.53 (m, 2H), 7.22 – 7.10 (m, 3H), 6.56 (d, J = 6.2 Hz, 1H), 5.56 – 5.27 (m, 2H), 
4.78 (dt, J = 8.1, 3.9 Hz, 1H), 4.51 – 4.40 (m, 1H), 3.19 (d, J = 2.1 Hz, 1H), 3.12 (s, 3H), 
2.78 (dd, J = 6.3, 4.3 Hz, 1H), 2.15 – 1.99 (m, 1H), 1.93 – 1.77 (m, 3H), 1.77 – 1.58 (m, 
6H), 1.47 – 1.18 (m, 2H), 0.98 (d, J = 7.1 Hz, 3H), 0.94 (d, J = 6.3 Hz, 3H), 0.69 (t, J = 
7.5 Hz, 3H).  13C NMR (100 MHz, C6D6) δ 163.6, 145.7, 136.6, 133.0, 129.5, 129.0, 
127.0, 91.2, 77.5, 67.4, 61.4, 39.9, 39.7, 37.6, 37.5, 36.6, 21.1, 18.2, 15.6, 12.0, 11.3.  
HRMS calc m/z [C25H36O4 + Na]+: 423.2506, found: 423.2459. >96% pure by UPLC 
analysis. 
 
(5,6-syn)-3-((Diphenylmethylene)amino)-5-methyl-6-phenethyl-5,6-dihydro-2H-
pyran-2-one (3.126).  Inside a glovebox under a nitrogen atmosphere, benzophenone 
imine (6.7 mg, 0.037 mmol), potassium phosphate (16.4 mg, 0.0773 mmol), 1,3,5-
trimethoxybenzene (3.4 mg, 0.030 mmol), Pd2(dba)3 (5.7 mg, 0.0062 mmol), and tBu-
Xphos (7.9 mg, 0.018 mmol) were added to a vial containing lactone 3.113 (6.7 mg, 
0.031 mmol).  The mixture was suspended in DME (0.3 mL).  The vial was sealed with a 
cap containing a PTFE/silicone septum and removed from the glovebox and stirred at 30 
°C for 18 h.  The reaction was diluted with water and extracted four times with EtOAc.  
The combined organic layers were washed with brine and dried with anhydrous Na2SO4.  
1H NMR analysis of the crude material showed the product was synthesized in 50% 
yield.  1H NMR (400 MHz, CDCl3) δ 7.78 – 7.67 (m, 2H), 7.49 – 7.43 (m, 1H), 7.42 – 
7.27 (m, 7H), 7.26 – 7.09 (m, 5H), 5.86 (d, J = 6.5 Hz, 1H), 4.19 (dt, J = 9.5, 3.8 Hz, 1H), 
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2.81 (ddd, J = 14.1, 9.0, 5.3 Hz, 1H), 2.63 (dt, J = 14.0, 8.1 Hz, 1H), 2.24 (td, J = 6.9, 3.3 
Hz, 1H), 2.11 – 1.94 (m, 1H), 1.66 (dddd, J = 13.4, 9.2, 7.7, 4.1 Hz, 1H), 0.80 (d, J = 7.0 
Hz, 3H). 
 
(5,6-syn)-3-Imino-5-methyl-6-phenethyltetrahydro-2H-pyran-2-one (3.127).  Imine 
3.126 (9.4 mg, 0.024 mmol) and hydroxylamine hydrochloride (6.6 mg, 0.095 mmol) 
were dissolved in THF (0.4 mL) and water (0.4 mL) and stirred at room temperature for 
16 h.  The mixture was then extracted four times with EtOAc.  The combined organic 
layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatography (40% 
EtOAc in hexanes) to yield 3.12 mg of product as a colorless oil (57% yield).  1H NMR 
(400 MHz, CDCl3) δ 7.34 – 7.27 (m, 2H), 7.25 – 7.13 (m, 3H), 4.34 (dt, J = 10.1, 3.1 Hz, 
1H), 2.92 (ddd, J = 14.3, 9.3, 5.1 Hz, 1H), 2.85 – 2.58 (m, 3H), 2.31 – 2.17 (m, 1H), 2.06 
(dtd, J = 14.0, 9.4, 5.1 Hz, 1H), 1.83 (dddd, J = 13.6, 9.9, 7.9, 3.7 Hz, 1H), 1.02 (d, J = 
7.0 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 161.3, 146.8, 140.7, 128.6, 128.5, 126.3, 
81.3, 33.4, 31.5, 29.9, 29.1, 13.4.  HRMS calc m/z [C14H17NO2 + K]+: 270.0891, found: 
270.1168. 
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(5R,6R)-6-((2R,3R,4R,5S,E)-2-((tert-Butyldimethylsilyl)oxy)-4-methoxy-3,5-
dimethylnon-7-en-1-yl)-3-((diphenylmethylene)amino)-5-ethyl-5,6-dihydro-2H-
pyran-2-one (3.128).  Inside a glovebox under a nitrogen atmosphere, benzophenone 
imine (6.4 mg, 0.035 mmol), potassium phosphate (15.6 mg, 0.0735 mmol), Pd2(dba)3 
(13.5 mg, 0.0147 mmol), and tBu-Xphos (15.0 mg, 0.0353 mmol) were added to a vial 
containing lactone 3.119 (15.2 mg, 0.0294 mmol).  The mixture was suspended in DME 
(0.4 mL).  The vial was sealed with a cap containing a PTFE/silicone septum and 
removed from the glovebox and stirred at 30 °C for 10 h.  The reaction was diluted with 
water and extracted four times with EtOAc.  The combined organic layers were washed 
with brine and dried with anhydrous Na2SO4.  The crude material was initially purified 
via silica gel column chromatography (5% to 40% ether in hexanes).  The impure 
material was further purified via silica gel column chromatography (10% EtOAc in 
hexanes) to yield 1.65 mg of product as a colorless oil (9% yield).  1H NMR (400 MHz, 
C6D6) δ 7.99 – 7.90 (m, 2H), 7.23 – 7.13 (m, 2H), 7.14 – 7.00 (m, 6H), 5.50 (d, J = 6.5 
Hz, 1H), 5.48 – 5.37 (m, 2H), 4.42 (dt, J = 8.6, 4.3 Hz, 1H), 4.34 (t, J = 6.7 Hz, 1H), 3.40 
(s, 3H), 3.23 (dd, J = 9.3, 1.8 Hz, 1H), 2.31 – 2.18 (m, 1H), 2.16 – 2.04 (m, 1H), 1.88 
(ddd, J = 14.7, 8.9, 6.2 Hz, 1H), 1.74 (qt, J = 7.9, 4.6 Hz, 2H), 1.69 – 1.56 (m, 5H), 1.33 
– 1.20 (m, 1H), 1.11 – 0.94 (m, 13H), 0.82 (d, J = 6.9 Hz, 3H), 0.40 (t, J = 7.4 Hz, 3H), 
0.15 (s, 6H).  13C NMR (100 MHz, C6D6) δ 171.3, 161.3, 140.8, 139.0, 136.8, 131.2, 
131.0, 129.9, 128.7, 128.6, 128.4, 127.2, 126.5, 84.1, 77.2, 68.9, 60.8, 41.9, 38.8, 38.3, 
38.2, 36.2, 26.3, 21.4, 18.7, 18.2, 13.3, 10.8, 10.4, -3.4, -3.5.  HRMS calc m/z 
[C38H55NO4Si + Na]+: 640.3793, found: 640.3756. 
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6.4 Chapter 4 experimental procedures. 
6.4.1 Synthetic procedures and compound characterization data 
 
4-((4-Methoxybenzyl)oxy)butan-2-one (4.11a).  4-Hydroxy-2-butanone (0.20 mL, 2.3 
mmol), diisopropylethylamine (0.80 mL, 4.6 mmol) and 4-methoxybenzyl chloride (0.35 
mL, 2.6 mmol) were stirred in a sealed vial at 150 °C.  After 2.5 h, the reaction was 
cooled to room temperature and dilutes with EtOAc and 10% aqueous sodium bisulfate.  
The layers were separated and the aqueous phase was extract three times with EtOAc.  
The combined organic layers were washed with brine and dried with anhydrous MgSO4.  
The suspension was filtered and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatography (5:1 
hexanes:EtOAc) to yield 0.16 g of product as a colorless oil (34% yield).  The resonances 
in the 1H NMR and 13C spectrum of the product matched previously reported chemical 
shifts.130 
 
4-((4-Methoxybenzyl)oxy)-3,3-dimethylbutan-2-one (4.11b).  4-Hydroxy-3,3-
dimethylbutan-2-one was synthesized following previously reported procedure.  A 
solution of 3-methyl-2-butanone (2.0 mL, 19 mmol) and paraformaldehyde (0.56 g) in 
trifluoroacetic acid (2.8 mL) was heated overnight at 90 °C in a round bottom flask 
equipped with a reflux condenser.  The reaction was cooled to room temperature and 
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quenched with saturated aqueous NaHCO3.  The mixture was extracted three times with 
DCM and the combined organic layers were washed with brine and dried with anhydrous 
MgSO4.  The suspension was filtered and volatile materials were removed using a rotary 
evaporator.  The impure material was purified via silica gel flash chromatography (35% 
EtOAc in hexanes) to yield 0.40 g of product as a colorless oil (18% yield).  The 
resonances in the 1H NMR spectrum of the intermediate ketone matched previously 
reported chemical shifts.131 
Ketone 4.11b was synthesized following the procedure for the synthesis of ketone 
4.11a.  Reaction with 4-hydroxy-3,3-dimethylbutan-2-one (0.40 g, 3.4 mmol) yielded 
0.54 g of product as a colorless oil (67% yield) following purification via Combiflash® 
silica gel flash chromatography (1% to 10% EtOAc in hexanes).  1H NMR (400 MHz, 
CDCl3) δ 7.25 – 7.19 (m, 2H), 6.91 – 6.83 (m, 2H), 4.43 (s, 2H), 3.81 (s, 3H), 3.41 (s, 
2H), 2.13 (s, 3H), 1.13 (s, 6H).  13C NMR (100 MHz, CDCl3) δ 212.7, 159.1, 130.3, 
129.1, 113.7, 77.2, 73.0, 55.3, 48.6, 25.8, 22.0.  HRMS calc m/z [C14H20O3 + Na]+: 
259.1305, found: 259.1284. 
 
((4-((4-Methoxybenzyl)oxy)but-1-en-2-yl)oxy)trimethylsilane (4.10a) and ((4-((4-
Methoxybenzyl)oxy)but-2-en-2-yl)oxy)trimethylsilane (4.12).  To diisopropylamine 
(0.16 mL, 1.1 mmol) in THF (1.4 mL) at 0 °C was added a solution of n-butyllithium (2.5 
M in hexanes, 0.48 mL, 1.2 mmol) dropwise.  After 25 min, the reaction was cooled to -
78 °C.  A solution of ketone 4.11a (0.16 g, 0.75 mmol) in THF (0.6 mL) was added 
dropwise.  After 15 min, chlorotrimethylsilane (0.14 mL, 1.1 mmol) was added and the 
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reaction was warmed to room temperature over 2 h.  The reaction was diluted with 
pentane and washed with saturated aqueous NaHCO3 solution and dried with anhydrous 
Na2SO4.  The salts were removed via gravity filtration and volatile materials were 
removed by rotary evaporator. 1H NMR analysis of the crude material showed a 1.1:1 
mixture of 4.10a and 4.12.  The crude mixture was used without further purification. 
 
((4-((4-Methoxybenzyl)oxy)-3,3-dimethylbut-1-en-2-yl)oxy)trimethylsilane (4.10b).  
The procedure was adapted from a previously report procedure.50  To THF (11.4 mL) was 
added a solution of lithium bis(trimethylsilyl)amide (1 M in hexanes, 1.9 mL, 1.9 mmol) 
and the solution was cooled to -78 °C.  Ketone 4.11b (0.18 g, 0.75 mmol) was dissolved 
in a separate vial in THF (0.6 mL) and added to the reaction dropwise.  The vial 
containing the solution of with ketone 4.11b was rinsed with additional THF (0.3 mL) 
which was added to the reaction.  The reaction was stirred at -78 °C for 40 min.  Then a 
mixture of TEA/TMSCl (1:1 v/v, filter through Celite(R), 0.24 mL) was added to the 
reaction and stirred at -78 °C for 20 min.  The reaction was warmed to room temperature 
and concentrated to ~ 1 mL.  The reaction was diluted with a 4:1 hexanes:diethyl ether 
solution (12 mL) and concentrated using a rotary evaporator.  The crude material was 
resuspended in a 4:1 hexanes:diethyl ether solution (12 mL) and concentrated using a 
rotary evaporator and repeated once.  The crude material was resuspended in a 4:1 
hexanes:diethyl ether (12 mL) solution and filter through Celite®.  Volatile materials 
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were removed by rotary evaporator.  The crude silyl enol ether was used without further 
purification. 
 
(5R,6S,7R,8S,E)-5-Hydroxy-7-methoxy-1-((4-methoxybenzyl)oxy)-6,8-
dimethyldodec-10-en-3-one (4.8a) and (4S,5S,6R,7S,E)-4-Hydroxy-6-methoxy-3-(((4-
methoxybenzyl)oxy)methyl)-5,7-dimethylundec-9-en-2-one (4.14).  A suspension of 
alcohol 4.13 (35 mg, 0.19 mmol), NMO (26 mg, 0.23 mmol), and powdered 4Å 
molecular sieves (50 mg) was stirred in DCM (1 mL) at 0 °C for 15 min.  A solution of 
TPAP (6.6 mg, 0.019 mmol) in DCM (0.3 mL) was added to the reaction.  After stirring 
at 35 min at 0 °C, the reaction was diluted with 40% EtOAc in hexanes and filtered 
through a plug of silica gel.  The silica gel plug was rinsed with 40% acetate in hexanes.  
The crude aldehyde solution was concentrated using a rotary evaporator the crude 
aldehyde was used without further purification. 
The crude aldehyde was combined with crude silyl enol ethers 4.10a/4.12 (~0.75 
mmol) and dissolved in DCM (1.7 mL) and cooled in a MeOH/lq N2 bath.  BF3•Et2O 
(0.47 mL, 0.94 mmol) was added dropwise and the reaction was stirred in the MeOH/lq 
N2 bath for 2.25 h.  The reaction was quenched with saturated aqueous NaHCO3 and 
warmed to room temperature.  The layers were separated and the aqueous phase was 
extracted three times with DCM and once with EtOAc.  The combined organic extracts 
were washed with brine and dried with anhydrous Na2SO4.  The salts were removed via 
gravity filtration and volatile materials were removed by rotary evaporator.  The crude 
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material was initially purified via Combiflash® silica gel flash chromatography (5% to 
30% EtOAc in hexanes) and subsequently purified silica gel column (25% EtOAc in 
hexanes and 30% EtOAc in hexanes) to yield 24.7 mg of 4.8a (35% yield) and 9.0 mg of 
4.14 (12% yield).  4.8a. 1H NMR (400 MHz, CDCl3) δ 7.25 – 7.20 (m, 1H), 6.96 – 6.82 
(m, 2H), 5.53 – 5.30 (m, 2H), 4.43 (s, 3H), 3.80 (s, 3H), 3.71 (t, J = 6.3 Hz, 2H), 3.48 (s, 
3H), 3.34 (d, J = 2.6 Hz, 1H), 3.08 (dd, J = 7.1, 4.5 Hz, 1H), 2.80 – 2.64 (m, 3H), 2.46 
(dd, J = 16.7, 3.5 Hz, 1H), 2.22 – 2.09 (m, 1H), 2.01 – 1.88 (m, 1H), 1.75 (ddd, J = 12.8, 
7.8, 5.6 Hz, 1H), 1.70 – 1.63 (m, 3H), 1.63 – 1.55 (m, 1H), 0.88 (d, J = 2.6 Hz, 3H), 0.86 
(d, J = 2.3 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 210.0, 159.2, 130.0, 129.6, 129.4, 
126.6, 113.8, 87.8, 72.9, 66.8, 64.9, 61.6, 55.3, 48.2, 43.6, 39.4, 37.5, 35.9, 18.0, 13.7, 
10.9.  HRMS calc m/z [C23H36O5 + Na]+: 415.2455, found: 415.2490 .  4.14. 1H NMR 
(400 MHz, CDCl3) δ 7.24 – 7.15 (m, 2H), 6.91 – 6.81 (m, 2H), 5.51 – 5.26 (m, 2H), 4.50 
– 4.34 (ABq, 2H), 4.18 (dd, J = 9.9, 1.5 Hz, 1H), 3.86 (dd, J = 9.0, 4.8 Hz, 1H), 3.80 (s, 
3H), 3.71 (t, J = 8.9 Hz, 1H), 3.55 (s, 1H), 3.46 (s, 3H), 3.08 (ddd, J = 9.9, 8.8, 4.8 Hz, 
1H), 2.91 (dd, J = 7.1, 3.6 Hz, 1H), 2.17 (s, 3H), 2.12 – 1.99 (m, 1H), 1.86 – 1.74 (m, 
2H), 1.71 – 1.54 (m, 4H), 1.02 (d, J = 7.1 Hz, 3H), 0.93 (d, J = 6.3 Hz, 3H).  13C NMR 
(100 MHz, CDCl3) δ 210.3, 159.1, 130.1, 129.2, 128.5, 126.9, 113.7, 91.0, 73.0, 70.2, 
69.4, 61.9, 56.6, 55.2, 36.5, 36.3, 36.0, 31.4, 18.0, 15.3, 11.6.  .  HRMS calc m/z 
[C23H36O5 + Na]+: 415.2455, found: 415.2538. 
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(5R,6S,7R,8S,E)-5-Hydroxy-7-methoxy-1-((4-methoxybenzyl)oxy)-2,2,6,8-
tetramethyldodec-10-en-3-one (4.8b).  A suspension of alcohol 4.13 (40. mg, 0.22 
mmol), NMO (30. mg, 0.25 mmol), and powdered 4Å molecular sieves (50 mg) was 
stirred in DCM (1.5 mL) at 0 °C for 20 min.  A solution of TPAP (6.5 mg, 0.021 mmol) 
in DCM (0.5 mL) was added to the reaction.  After stirring at 1 h at 0 °C, the reaction 
was diluted with 40% EtOAc in hexanes and filtered through a plug of silica gel.  The 
silica gel plug was rinsed with 40% acetate in hexanes.  The crude aldehyde solution was 
concentrated using a rotary evaporator the crude aldehyde was used without further 
purification. 
 The crude aldehyde was combined with crude silyl enol ethers 4.10b (~0.75 
mmol) and dissolved in DCM (2 mL) and cooled in a MeOH/lq N2 bath.  BF3•Et2O (0.20 
mL, 1.6 mmol) was added dropwise and the reaction was stirred in the MeOH/lq N2 bath 
for 2 h.  The reaction was quenched with saturated aqueous NaHCO3 and warmed to 
room temperature.  The layers were separated and the aqueous phase was extracted three 
times with DCM and once with EtOAc.  The combined organic extracts were washed 
with brine and dried with anhydrous Na2SO4.  The salts were removed via gravity 
filtration and volatile materials were removed by rotary evaporator.  The crude material 
was initially purified via Combiflash® silica gel flash chromatography (5% to 10% 
EtOAc in hexanes) and subsequently purified via silica gel column (2% diethyl ether in 
DCM) to yield 46.6 mg of product as a colorless oil (52% yield).  1H NMR (400 MHz, 
CDCl3) δ 7.25 – 7.17 (m, 2H), 6.98 – 6.81 (m, 2H), 5.58 – 5.35 (m, 2H), 4.48 – 4.36 (m, 
3H), 3.80 (s, 3H), 3.50 (s, 3H), 3.40 (s, 2H), 3.38 (d, J = 2.0 Hz, 1H), 3.12 (dd, J = 7.7, 
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4.0 Hz, 1H), 2.67 (dd, J = 17.8, 8.7 Hz, 1H), 2.56 (dd, J = 17.7, 3.7 Hz, 1H), 2.17 (dt, J = 
12.2, 5.4 Hz, 1H), 1.97 (dt, J = 13.2, 7.1 Hz, 1H), 1.84 – 1.70 (m, 1H), 1.66 (d, J = 5.1 
Hz, 3H), 1.57 – 1.51 (m, 1H), 1.13 (s, 3H), 1.12 (s, 3H), 0.86 (d, J = 7.4 Hz, 3H), 0.84 (d, 
J = 7.4 Hz, 3H).  HRMS calc m/z [C25H40O5 + Na]+: 443.2768, found:  443.2775. 
 
(3S,5R,6S,7R,8S,E)-3-Hydroxy-7-methoxy-1-((4-methoxybenzyl)oxy)-6,8-
dimethyldodec-10-en-5-yl Acetate (4.15a).  To a solution of ketone 4.8a (68 mg, 0.17 
mmol) in THF (0.7 mL) in a MeOH/ice bath was added acetaldehyde (0.078 mL, 1.4 
mmol) followed by a solution of SmI2 (0.06 M in THF, 1.2 mL, 0.069 mmol).  The 
reaction was stirred in a MeOH/ice bath for 2 h.  The reaction was quenched with 
saturated aqueous NaHCO3 and warmed to room temperature.  The layers were separated 
and the aqueous phased was extracted four times with EtOAc.  The combined organic 
layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatography (25% 
EtOAc in hexanes) to yield 61.1 mg of product as a colorless oil (81% yield). 1H NMR 
(400 MHz, CDCl3) δ 7.25 (d, J = 10.7 Hz, 3H), 6.87 (d, J = 8.6 Hz, 2H), 5.56 – 5.32 (m, 
3H), 4.43 (s, 2H), 3.80 (s, 3H), 3.73 – 3.52 (m, 3H), 3.37 (s, 3H), 2.82 (dd, J = 9.4, 2.2 
Hz, 1H), 2.21 – 2.06 (m, 4H), 2.08 – 1.90 (m, 1H), 1.84 – 1.70 (m, 3H), 1.70 – 1.55 (m, 
5H), 1.46 (ddd, J = 13.8, 10.3, 3.2 Hz, 1H), 0.86 (d, J = 7.0 Hz, 3H), 0.81 (d, J = 6.8 Hz, 
3H).  13C NMR (100 MHz, CDCl3) δ 172.4, 159.1, 130.4, 130.1, 129.2, 126.4, 113.7, 
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85.3, 72.7, 71.1, 67.4, 65.4, 61.3, 55.2, 41.4, 40.2, 38.3, 36.7, 35.7, 21.1, 17.9, 12.3, 10.5.  
HRMS calc m/z [C25H40O6 + Na]+: 459.2717, found: 459.2736. 
 
(3R,5R,6S,7R,8S,E)-3-Hydroxy-7-methoxy-1-((4-methoxybenzyl)oxy)-2,2,6,8-
tetramethyldodec-10-en-5-yl Acetate (4.15b).  The product was synthesized following 
the procedure for the synthesis of intermediate 4.15a.  Reaction with ketone 4.8b (46.9, 
0.112 mmol) yielded 49.8 mg of product as a colorless oil (96% yield) following 
purification via silica gel flash chromatography (15% EtOAc in hexanes).  1H NMR (400 
MHz, CDCl3) δ 7.26 – 7.19 (m, 2H), 6.96 – 6.80 (m, 2H), 5.56 – 5.28 (m, 3H), 4.42 (s, 
2H), 3.80 (s, 3H), 3.44 – 3.34 (m, 2H), 3.39 (s, 3H), 3.34 – 3.19 (ABq, 2H), 2.84 (dd, J = 
9.4, 2.1 Hz, 1H), 2.19 – 2.09 (m, 1H), 2.08 (s, 3H), 2.05 – 1.91 (m, 1H), 1.82 – 1.70 (m, 
2H), 1.71 – 1.63 (m, 4H), 1.42 (ddd, J = 14.1, 10.6, 3.5 Hz, 1H), 0.90 (s, 3H), 0.88 (s, 
3H), 0.86 (d, J = 7.0 Hz, 3H), 0.82 (d, J = 6.8 Hz, 3H).  HRMS calc m/z [C27H44O6 + 
Na]+: 487.3030, found: 487.3016. 
 
(4R,6S)-4-((2S,3R,4S,E)-3-Methoxy-4-methyloct-6-en-2-yl)-6-(2-((4-
methoxybenzyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxane (4.16a).  To a solution of ester 
4.15a (7.0 mg, 0.016 mmol) in methanol (0.6 mL) was added potassium hydroxide (4.5 
mg, 0.080 mmol).  After stirring at room temperature for 3.5 h, the reaction was poured 
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into saturated aqueous NH4Cl.  The mixture was extracted four times with DCM.  The 
combined organic layers were washed with brine and dried with anhydrous Na2SO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was dissolved in 2,2-dimethoxypropane (1 mL) 
and PPTS (1 mg, 0.004 mmol) was added to the reaction.  After stirring overnight at 
room temperature, the reaction was diluted with DCM and saturated aqueous NaHCO3.  
The layers were separated and the aqueous layer was extracted three times with DCM.  
The combined organic layers were washed with brine and dried with anhydrous Na2SO4.  
The salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  Crude material was purified via silica gel flash chromatography (10% 
EtOAc in hexanes) to yield 4.0 mg of product as a colorless oil (58% yield).  1H NMR 
(400 MHz, CDCl3) δ 7.27 – 7.21 (m, 2H), 6.96 – 6.82 (m, 2H), 5.56 – 5.33 (m, 2H), 4.43 
(s, 2H), 4.13 (ddd, J = 9.2, 6.9, 2.4 Hz, 1H), 3.93 (dd, J = 11.3, 5.4 Hz, 1H), 3.80 (s, 3H), 
3.59 – 3.50 (m, 2H), 3.46 (s, 3H), 3.08 (dd, J = 9.3, 2.0 Hz, 1H), 2.17 – 2.11 (m, 1H), 
2.08 – 1.92 (m, 1H), 1.82 – 1.61 (m, 7H), 1.54 – 1.44 (m, 2H), 1.36 (s, 3H), 1.30 (s, 3H), 
0.82 (d, J = 4.9 Hz, 3H), 0.80 (d, J = 4.8 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 159.1, 
130.6, 130.4, 129.3, 126.2, 113.8, 100.0, 85.1, 72.8, 66.4, 65.2, 64.1, 61.2, 55.3, 41.0, 
38.6, 36.2, 36.0, 35.9, 25.2, 25.0, 18.0, 12.3, 10.0.  HRMS calc m/z [C26H42O5 + Na]+: 
457.2924, found: 457.2897 and 417.2601 (hydrolyzed acetonide). 
 
(4R,6R)-4-((2S,3R,4S,E)-3-Methoxy-4-methyloct-6-en-2-yl)-6-(1-((4-
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methoxybenzyl)oxy)-2-methylpropan-2-yl)-2,2-dimethyl-1,3-dioxane (4.16b).  To a 
solution of ester 4.15b (8.8 mg, 0.019 mmol) in methanol (0.8 mL) was added potassium 
hydroxide (3.5 mg, 0.063 mmol).  After stirring at room temperature for 8 h, additional 
potassium hydroxide (3.5 mg, 0.063 mmol) was added to the reaction.  After stirring at 
room temperature overnight, the reaction was poured into saturated aqueous NH4Cl.  The 
mixture was extracted four times with DCM.  The combined organic layers were washed 
with brine and dried with anhydrous Na2SO4.  The salts were removed via gravity 
filtration and volatile materials were removed using a rotary evaporator.  The crude 
material was dissolved in 2,2-dimethoxypropane (1 mL) and PPTS (1 mg, 0.004 mmol) 
was added to the reaction.  After stirring overnight at room temperature, the reaction was 
diluted with DCM and saturated aqueous NaHCO3.  The layers were separated and the 
aqueous layer was extracted three times with DCM.  The combined organic layers were 
washed with brine and dried with anhydrous Na2SO4.  The salts were removed via gravity 
filtration and volatile materials were removed using a rotary evaporator.  The crude 
material was purified via silica gel flash chromatography (5% EtOAc in hexanes) to yield 
5.1 mg of product as a colorless oil (58% yield).  1H NMR (400 MHz, CDCl3) δ 7.26 – 
7.22 (m, 2H), 6.92 – 6.84 (m, 2H), 5.51 – 5.36 (m, 2H), 4.50 – 4.35 (m, 2H), 4.03 (ddd, J 
= 9.2, 6.7, 2.4 Hz, 1H), 3.80 (s, 3H), 3.71 (dd, J = 10.6, 5.9 Hz, 1H), 3.46 (s, 3H), 3.30 – 
3.10 (m, 2H), 3.08 (dd, J = 9.2, 1.9 Hz, 1H), 2.24 – 2.09 (m, 1H), 2.08 – 1.91 (m, 1H), 
1.73 – 1.59 (m, 5H), 1.55 – 1.43 (m, 2H), 1.32 (s, 3H), 1.28 (s, 3H), 0.89 (s, 3H), 0.85 (s, 
3H), 0.81 (d, J = 6.8 Hz, 3H).  HRMS calc m/z [C28H46O5 + Na]+: 485.3237, found: 
485.3220. 
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(3S,5R,6S,7R,8S,E)-7-Methoxy-1-((4-methoxybenzyl)oxy)-6,8-dimethyldodec-10-ene-
3,5-diyl Diacetate (4.17a).  To solution of alcohol 4.15a (53 mg, 0.12 mmol) in DCM 
(0.9 mL) was added TEA (0.30 mL, 2.2 mmol), Ac2O (0.2 mL, 2.2 mmol) followed by 
DMAP (1 mg).  The reaction was stirred overnight.  The reaction was diluted with DCM 
and quenched with saturated aqueous NaHCO3.  The biphasic mixture was stirred for 2.5 
h.  The layers were separated and the aqueous phase was extracted three times with 
DCM.  The combined organic layers were washed with brine and dried with anhydrous 
Na2SO4.  The salts were removed via gravity filtration and volatile materials were 
removed using a rotary evaporator.  The crude material was purified via silica gel flash 
chromatography (20% EtOAc in hexanes) to yield 46.1 mg of product as a colorless oil 
(79% yield).  1H NMR (400 MHz, CDCl3) δ 7.26 – 7.20 (m, 4H), 6.94 – 6.79 (m, 2H), 
5.55 – 5.34 (m, 2H), 5.30 (ddd, J = 9.2, 4.3, 2.1 Hz, 1H), 4.99 (dd, J = 10.0, 5.8 Hz, 1H), 
4.40 (s, 2H), 3.80 (s, 3H), 3.54 – 3.45 (m, 2H), 3.43 (s, 3H), 2.84 (dd, J = 9.3, 2.3 Hz, 
1H), 2.18 – 2.06 (m, 1H), 2.03 (s, 3H), 2.07 – 1.95 (m, 1H , 2.00 (s, 3H), 1.97 – 1.81 (m, 
3H), 1.75 (ddd, J = 14.2, 9.7, 4.3 Hz, 1H), 1.70 – 1.58 (m, 5H), 0.83 (d, J = 7.1 Hz, 3H), 
0.80 (d, J = 6.8 Hz, 2H).  13C NMR (100 MHz, CDCl3) δ 170.7, 170.6, 159.1, 130.5, 
130.1, 129.3, 126.4, 113.7, 85.3, 72.6, 69.9, 68.7, 66.3, 61.2, 55.2, 40.3, 38.4, 37.9, 35.8, 
34.7, 21.1, 21.1, 18.0, 12.4, 10.6.  HRMS calc m/z [C27H42O7 + Na]+: 501.2823, found: 
501.2834. 
  193 
 
(3R,5R,6S,7R,8S,E)-7-Methoxy-1-((4-methoxybenzyl)oxy)-2,2,6,8-tetramethyldodec-
10-ene-3,5-diyl Diacetate (4.17b).  The product was synthesized following the procedure 
for the synthesis of intermediate 4.17a.  Reaction with alcohol 4.15b (49.8 mg, 0.107 
mmol) yielded 53.8 mg of product as a colorless oil (99% yield) following purification 
via silica gel flash chromatography (12% EtOAc in hexanes).   1H NMR (400 MHz, 
CDCl3) δ 7.27 – 7.23 (m, 3H), 6.93 – 6.82 (m, 2H), 5.53 – 5.31 (m, 2H), 5.15 (dt, J = 
10.1, 3.0 Hz, 1H), 5.01 (dd, J = 11.2, 2.4 Hz, 1H), 4.49 – 4.32 (ABq, 2H), 3.80 (s, 3H), 
3.47 (s, 3H), 3.27 – 3.04 (ABq, 2H), 2.91 (dd, J = 9.3, 2.1 Hz, 1H), 2.21 – 2.07 (m, 1H), 
2.04 (s, 3H), 2.00 (s, 3H), 1.99 – 1.85 (m, 2H), 1.77 – 1.59 (m, 6H), 0.93 (s, 3H), 0.88 (s, 
3H), 0.81 (d, J = 6.5 Hz, 3H), 0.78 (d, J = 6.5 Hz, 3H).  HRMS calc m/z [C29H46O7 + 
Na]+: 529.3136, found: 529.3120. 
 
(3S,5R,6S,7R,8S,E)-1-Hydroxy-7-methoxy-6,8-dimethyldodec-10-ene-3,5-diyl 
Diacetate (4.18a). To a solution of ester 4.17a (46.1 mg, 0.0963 mmol) in DCM (1 mL) 
and water (0.09 mL) was added DDQ (55 mg, 0.24 mmol).  After stirring at room 
temperature for 30 min, the reaction was diluted with DCM and quenched with saturated 
NaHCO3.  The layers were separated and the aqueous phase was extracted three times 
with DCM.  The combined organic phase was washed with brine.  The resulting emulsion 
was filtered through Celite® and the organic layer was separated and dried with 
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anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatography (20% EtOAc in hexanes and then 40% EtOAc in hexanes) to yield 
21.5 mg of product as a colorless oil (62% yield).  1H NMR (400 MHz, C6D6) δ 5.61 
(ddd, J = 9.9, 4.0, 2.1 Hz, 1H), 5.52 – 5.35 (m, 2H), 5.18 (tt, J = 9.9, 3.5 Hz, 1H), 3.61 – 
3.49 (m, 1H), 3.49 – 3.40 (m, 1H),  3.46 (s, 3H), 2.88 (dd, J = 9.1, 2.4 Hz, 1H), 2.51 (bs, 
1H), 2.25 – 2.11 (m, 1H), 2.12 – 1.96 (m, 1H), 1.87 (s, 3H), 1.75 (s, 3H), 1.72 – 1.52 (m, 
8H), 1.45 (ddt, J = 13.7, 9.4, 4.0 Hz, 1H), 0.95 (d, J = 6.8 Hz, 3H), 0.78 (d, J = 7.0 Hz, 
3H).  13C NMR (100 MHz, C6D6) δ 171.9, 170.2, 130.7, 126.7, 85.6, 69.6, 68.0, 61.2, 
58.3, 40.8, 38.9, 38.9, 38.5, 36.4, 20.9, 20.7, 18.2, 12.9, 10.9.  HRMS calc m/z [C19H34O6 
+ Na]+: 381.2248, found: 381.2266. 
 
(3R,5R,6S,7R,8S,E)-1-Hydroxy-7-methoxy-2,2,6,8-tetramethyldodec-10-ene-3,5-diyl 
Diacetate (4.18b).  The product was synthesized following the procedure for 
intermediate 4.18a.  Reaction with ether 4.17b (20.1 mg, 0.0397 mmol) in DCM (1 mL) 
and water (0.09 mL) yielded 10.4 mg of product as a colorless oil (68% yield) following 
purification via silica gel flash chromatography (25% EtOAc in hexanes).  1H NMR (400 
MHz, CD2Cl2) δ 5.54 – 5.33 (m, 2H), 5.20 (dt, J = 9.5, 2.9 Hz, 1H), 4.80 (dd, J = 11.1, 
2.5 Hz, 1H), 3.41 (s, 3H), 3.22 (dd, J = 11.8, 4.3 Hz, 1H), 3.02 (t, J = 11.0 Hz, 1H), 2.90 
(dd, J = 10.2, 4.4 Hz, 1H), 2.84 (dd, J = 9.1, 2.3 Hz, 1H), 2.20 – 2.03 (m, 1H), 2.08 (s, 
3H), 2.05 – 1.92 (m, 1H), 2.00 (s, 3H), 1.92 – 1.82 (m, 1H), 1.80 – 1.70 (m, 1H), 1.69 – 
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1.59 (m, 5H), 0.94 (s, 3H), 0.83 (d, J = 7.1 Hz, 3H), 0.80 (d, J = 6.8 Hz, 3H), 0.76 (s, 
3H).  HRMS calc m/z [C21H38O6 + Na]+: 409.2561, found: 409.2544. 
 
(2R,3S,4R,5S,E)-4-Methoxy-3,5-dimethyl-1-((S)-6-oxo-3,6-dihydro-2H-pyran-2-
yl)non-7-en-2-yl Acetate (4.19a).  A suspension of alcohol 4.18a (21 mg, 0.059 mmol), 
NMO (10. mg, 0.088 mmol) and powdered 4Å molecular sieves (30 mg) was stirred in 
DCM (1 mL) at 0 °C for 15 min.  A solution of TPAP (2 mg, 0.006 mmol) in DCM (0.2 
mL) was added to the reaction.  After stirring 40 min at 0 °C, the reaction was diluted 
with 40% EtOAc in hexanes and filtered through a plug of silica gel.  The silica gel was 
rinsed with 40% EtOAc in hexanes.  The crude aldehyde solution was concentrated using 
a rotary evaporator and the crude aldehyde was used without further purification. 
 To as solution of diisopropylamine (9.3 µL, 0.065 mmol) in THF (0.7 mL) at 0 °C 
was added n-butyllithium (2.4 M in hexanes, 25 µL, 0.060 mmol); the reaction was 
stirred at 0 °C for 20 min before cooling to -78 °C.  Methyl acetate (5.2 µL, 0.065 mmol) 
was then added to reaction and the reaction was stirred at -78 °C for 40 min.  A solution 
of the crude aldehyde dissolved in THF (0.24 mL) was added dropwise to the reaction.  
The vial containing the aldehyde solution was rinsed with additional THF (0.1 mL) and 
added dropwise to the reaction.  The reaction was stirred at -78 °C for 1.5 h before 
warming to 0 °C and stirring for 30 min followed by warming to room temperature and 
stirring for an additional 15 min.  The reaction was poured into DCM and pH 7 phosphate 
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buffer.  The layers were separated and the aqueous phase was extracted three times with 
DCM and once with EtOAc.  The combined organic layers were washed with brine and 
dried with Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatography (4% acetone in DCM) to yield 4.7 mg of product as a colorless oil 
(24% yield).  1H NMR (400 MHz, C6D6) δ 5.79 (ddd, J = 9.8, 6.0, 2.3 Hz, 1H), 5.68 (ddd, 
J = 9.8, 2.7, 0.9 Hz, 1H), 5.50 (td, J = 6.7, 2.1 Hz, 1H), 5.49 – 5.35 (m, 2H), 4.14 – 3.95 
(m, 1H), 3.38 (s, 3H), 2.91 (dd, J = 9.3, 2.3 Hz, 1H), 2.22 – 2.11 (m, 1H), 2.13 – 1.99 (m, 
1H), 1.89 – 1.62 (m, 5H), 1.73 (s, 3H), 1.62 (d, J = 4.3 Hz, 3H), 1.43 (dddd, J = 18.1, 6.0, 
4.0, 0.7 Hz, 1H), 0.97 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 7.0 Hz, 3H).  13C NMR (100 MHz, 
C6D6) δ 170.0, 162.7, 143.7, 130.6, 126.6, 121.5, 85.5, 74.8, 70.6, 61.3, 39.7, 38.8, 38.2, 
36.3, 29.1, 20.8, 18.1, 12.8, 10.6.  HRMS calc m/z [C19H30O5 + Na]+: 361.1991, found: 
361.1995. 
 
(2R,3S,4R,5S,E)-1-((R)-3,3-Dimethyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)-4-methoxy-
3,5-dimethylnon-7-en-2-yl Acetate (4.19b).  To a solution of alcohol 4.18b (26.5 mg, 
0.0686 mmol) in DCM (1 mL) was added Dess-Martin periodinane (0.3 M in DCM, 0.47 
mL, 0.14 mmol) at room temperature.  After 2 h, the reaction was quenched with a 1:1 
mixture of saturated aqueous solutions of NaHCO3 and Na2S2O3 and stirred at room 
temperature for 30 min.  The layers were separated and the aqueous phase was extracted 
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three times with DCM.  The combined organic layers were washed with brine and dried 
with Na2SO4.  The salts were removed via gravity filtration and volatile materials were 
removed using a rotary evaporator.  The crude aldehyde was used without further 
purification. 
 Lithium bis(trimethylsilyl)amide (1 M in hexanes, 72 µL, 0.072 mmol) was added 
to THF (0.7 mL) at room temperature and the solution was cooled to -78 °C.  Methyl 
acetate (0.75 M in THF, 0.10 mL, 0.075 mmol) was then added to the reaction and the 
reaction was stirred at -78 °C for 20 min.  A solution of the crude aldehyde dissolved in 
THF (0.2 mL) was then added dropwise to the reaction.  The vial containing the aldehyde 
solution was rinsed with additional THF (0.1 mL) and added dropwise to the reaction.  
The reaction was stirred at -78 °C for 20 min before warming to 0 °C and stirring for 30 
min followed by warming to room temperature and stirring for an additional 30 min.  The 
reaction was poured into DCM and pH 7 phosphate buffer.  The layers were separated 
and the aqueous phase was extracted three times with DCM and once with EtOAc.  The 
combined organic layers were washed with brine and filtered through a plug of Celite®.  
The organic layer was dried with anhydrous Na2SO4.  The salts were removed via gravity 
filtration and volatile materials were removed using a rotary evaporator.  The crude 
material was purified via silica gel flash chromatography (30% EtOAc in hexanes) to 
yield 13.1 mg of product as a colorless oil (52% yield).  1H NMR (400 MHz, CD2Cl2) δ 
6.60 (d, J = 9.7 Hz, 1H), 5.82 (d, J = 9.7 Hz, 1H), 5.55 – 5.39 (m, 2H), 5.37 (ddd, J = 7.3, 
4.7, 2.4 Hz, 1H), 4.13 (dd, J = 9.2, 2.5 Hz, 1H), 3.38 (s, 3H), 2.89 (dd, J = 9.2, 2.3 Hz, 
1H), 2.22 – 2.09 (m, 1H), 2.03 (s, 3H), 2.03 – 1.93 (m, 1H), 1.91 – 1.72 (m, 3H), 1.73 – 
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1.62 (m, 4H), 1.07 (s, 3H), 1.00 (s, 3H), 0.89 (d, J = 7.0 Hz, 3H), 0.82 (d, J = 6.8 Hz, 
3H).  HRMS calc m/z [C21H34O5 + Na]+: 389.2298, found: 389.2298. 
 
(S)-6-((2R,3S,4R,5S,E)-2-Hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-yl)-5,6-
dihydro-2H-pyran-2-one (4.6a).  To a solution of lactone 4.19a (4.0 mg, 12 µmol) in 
MeOH (0.27 mL) was added HCl (3 M in MeOH, 50 µL, 150 µmol).  The reaction was 
heated to 60 °C and stirred overnight.  The reaction was cooled to room temperature and 
quenched with saturated aqueous NaHCO3 and extracted four times with DCM and once 
with EtOAc.  The combined organic layers were washed with brine and dried with 
anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude mixture was purified via silica gel 
flash chromatography (5% to 15% EtOAc in DCM) to yield 0.80 mg of product as a 
colorless oil (23% yield).  1H NMR (400 MHz, C6D6) δ 5.87 (ddd, J = 9.8, 5.8, 2.6 Hz, 
1H), 5.82 – 5.62 (m, 1H), 5.58 – 5.26 (m, 2H), 4.43 (ddt, J = 11.3, 8.4, 4.1 Hz, 1H), 4.35 
(dq, J = 9.6, 2.5 Hz, 1H), 3.10 (s, 3H), 3.04 (dd, J = 2.8, 1.1 Hz, 1H), 2.75 (dd, J = 6.4, 
4.5 Hz, 1H), 2.12 – 1.97 (m, 1H), 1.87 – 1.69 (m, 2H), 1.69 – 1.50 (m, 5H), 1.50 – 1.40 
(m, 1H), 0.93 (d, J = 6.5 Hz, 3H), 0.90 (d, J = 7.0 Hz, 3H).  13C NMR (226 MHz, C6D6) δ 
163.2, 144.1, 129.5, 128.0, 126.9, 121.7, 90.9, 75.1, 67.2, 61.1, 41.0, 39.4, 37.6, 36.6, 
30.1, 18.2, 15.4, 11.9.  HRMS calc m/z [C17H28O4 + Na]+: 319.1880, found: 319.1858.  
96% pure by HPLC analysis. 
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(R)-6-((2R,3S,4R,5S,E)-2-Hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-yl)-5,5-
dimethyl-5,6-dihydro-2H-pyran-2-one (4.6b).  To a solution of lactone 4.19b (12.8 mg, 
34.9 µmol) in MeOH (0.3 mL) was added HCl (3 M in MeOH, 60 µL, 180 µmol).  The 
reaction was heated to 60 °C and stirred overnight to dryness.  The reaction was cooled to 
room temperature and diluted with MeOH and quenched with saturated aqueous NaHCO3 
and extracted four times with DCM and once with EtOAc.  The combined organic layers 
were washed with brine and dried with anhydrous Na2SO4.  The crude 1H NMR spectrum 
showed ~50% conversion, and the crude material was resubmitted to the reaction 
conditions and heated for an additional 26 h.  The reaction was cooled to room 
temperature and quenched with saturated aqueous NaHCO3 and extracted four times with 
DCM and once with EtOAc.  The combined organic layers were washed with brine and 
dried with anhydrous Na2SO4.    The salts were removed via gravity filtration and volatile 
materials were removed using a rotary evaporator.  The crude mixture was purified via 
silica gel flash chromatography (5% to 15% EtOAc in hexanes) to yield 6.69 mg of 
product as a white solid (59% yield).  1H NMR (400 MHz, CD2Cl2) δ 6.63 (d, J = 9.7 Hz, 
1H), 5.82 (d, J = 9.7 Hz, 1H), 5.56 – 5.35 (m, 2H), 4.40 (dd, J = 10.6, 1.7 Hz, 1H), 4.17 
(dd, J = 9.9, 2.4 Hz, 1H), 3.47 (s, 3H), 3.18 (d, J = 3.4 Hz, 1H), 3.01 (t, J = 5.4 Hz, 1H), 
2.20 – 2.07 (m, 1H), 1.97 – 1.75 (m, 3H), 1.73 – 1.59 (m, 5H), 1.53 (ddd, J = 13.9, 10.6, 
2.5 Hz, 1H), 1.10 (s, 3H), 1.02 (s, 3H), 0.98 (d, J = 7.1 Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H).  
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13C NMR (100 MHz, CD2Cl2) δ 164.7, 157.6, 129.7, 127.3, 119.0, 91.2, 82.3, 67.5, 61.9, 
39.7, 37.8, 36.8, 35.3, 35.0, 24.9, 19.9, 18.3, 15.3, 12.4.  HRMS calc m/z [C19H32O4 + 
Na]+: 347.2193, found: 347.2199.  97% pure by HPLC analysis. 
 
(1R,2S)-2-((N-Benzyl-2,4,6-trimethylphenyl)sulfonamido)-1-phenylpropyl Butyrate 
(4.26).  To a solution of (1R,2S)-2-[N-Benzyl-N-(mesitylenesulfonyl)amino]-1-phenyl-1-
propanol (0.35 g, 0.83 mmol) and pyridine (0.087 mL, 1.1 mmol) in DCM (4.7 mL) at 0 
°C was added butyryl chloride (0.10 mL, 0.99 mmol) dropwise.  The reaction was 
warmed to room temperature and stirred overnight.  The reaction was diluted with ether 
and washed with water, 1 M HCl, saturated aqueous NaHCO3, and brine before drying 
with anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile 
materials were removed using a rotary evaporator.  The crude material was purified via 
silica gel flash chromatography (70% DCM in hexanes) to yield 0.64 g of product as a 
white solid (77% yield).  1H NMR (400 MHz, CDCl3) δ 7.37 – 7.29 (m, 2H), 7.29 – 7.14 
(m, 4H), 6.95 – 6.83 (m, 4H), 5.82 (d, J = 4.1 Hz, 1H), 4.84 – 4.50 (m, 2H), 4.05 (qd, J = 
6.9, 4.1 Hz, 1H), 2.51 (s, 6H), 2.28 (s, 3H), 2.22 – 2.01 (m, 2H), 1.54 (h, J = 7.8 Hz, 4H), 
1.12 (d, J = 7.0 Hz, 3H), 0.87 (t, J = 7.4 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 171.9, 
142.5, 140.2, 138.7, 138.6, 133.4, 132.1, 128.4, 128.3, 127.8, 127.4, 127.1, 126.0, 77.9, 
56.7, 48.1, 36.1, 23.0, 20.9, 18.1, 13.6, 12.9.  [α]D = +17.5 (c 0.189, CHCl3). HRMS calc 
m/z [C29H35NO4S + Na]+: 516.2179, found: 516.2132.  mp: 79.2 – 80.4 °C. 
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(1R,2S)-2-((N-Benzyl-2,4,6-trimethylphenyl)sulfonamido)-1-phenylpropyl 
(2R,3R,5R,6R,7R,8S,E)-5-((tert-Butyldimethylsilyl)oxy)-2-ethyl-3-hydroxy-7-
methoxy-6,8-dimethyldodec-10-enoate (4.27).  Ester 4.26 (74 mg, 0.15 mmol) was 
dissolved in DCM (2 mL) and cooled to -78 °C.  A solution of TEA (84 µL, 0.60 mmol) 
and dicyclohexylboron trifluoromethanesulfonate (98 mg, 0.30 mmol) in DCM (0.4 mL) 
cooled to -78 °C was transferred dropwise via cannula to the reaction and the reaction 
was stirred at -78 °C for 2 h.  A solution of aldehyde 4.25 (42.9 mg, 0.125 mmol) in 
DCM (0.2 mL) was added dropwise to the reaction.  The vial containing the aldehyde 
solution was rinsed with additional DCM (0.2 mL) which was added to the reaction.  The 
reaction was stirred at -78 °C for 2 h before warming to -40 °C and stirring overnight.  
The reaction was warmed to 0 °C and stirred for 1 h.  The reaction was quenched with 
MeOH (0.7 mL), pH 7 phosphate buffer (0.7 mL), and 30% hydrogen peroxide (0.7 mL) 
and vigorously stirred at room temperature for 8 h.  The layers were separated and the 
aqueous phase was extracted three times with DCM.  The combined organic layers were 
washed with brine and dried with anhydrous Na2SO4.  The salts were removed via gravity 
filtration and the volatile materials were removed using a rotary evaporator.  The crude 
material was purified via silica gel flash chromatography (10% EtOAc in hexanes 
followed by 100:1 to 100:1.5 DCM:acetone) to yield 58.2 mg of product as a colorless oil 
(56% yield).  1H NMR (400 MHz, C6D6) δ 7.61 – 7.46 (m, 2H), 7.10 (t, J = 7.4 Hz, 2H), 
7.06 – 6.94 (m, 6H), 6.51 (s, 2H), 6.20 (d, J = 5.3 Hz, 1H), 5.58 – 5.34 (ABq, 2H), 4.85 
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(dd, J = 138.9, 16.4 Hz, 2H), 4.51 – 4.32 (m, 2H), 4.10 (dtd, J = 9.2, 6.4, 2.4 Hz, 1H), 
3.37 (s, 3H), 3.19 (dd, J = 8.7, 2.0 Hz, 1H), 2.90 (d, J = 6.2 Hz, 1H), 2.53 (s, 6H), 2.38 
(dt, J = 8.7, 6.0 Hz, 1H), 2.30 – 2.17 (m, 1H), 2.14 – 2.00 (m, 1H), 1.94 – 1.84 (m, 1H), 
1.88 (s, 3H), 1.78 (ddd, J = 14.1, 6.5, 2.6 Hz, 1H), 1.69 (qd, J = 6.6, 1.6 Hz, 1H), 1.64 (d, 
J = 4.5 Hz, 3H), 1.62 – 1.44 (m, 3H), 1.37 (d, J = 6.9 Hz, 3H), 1.03 – 0.96 (m, 12H), 0.89 
(d, J = 7.0 Hz, 3H), 0.72 (t, J = 7.4 Hz, 3H), 0.19 (s, 3H), 0.16 (s, 3H).  13C NMR (100 
MHz, C6D6) δ 174.0, 142.1, 140.6, 139.5, 139.0, 134.5, 132.3, 130.9, 128.6, 128.5, 127.4, 
127.1, 126.6, 84.6, 78.5, 70.9, 69.8, 60.4, 57.1, 54.3, 48.7, 42.2, 42.1, 39.0, 36.1, 26.3, 
23.2, 22.9, 20.6, 18.6, 18.2, 14.7, 13.6, 11.9, 11.4, -3.6, -3.8.  HRMS calc m/z 
[C48H73NO7SSi + Na]+: 858.4775, found: 858.4855. 
 
(1R,2S)-2-((N-Benzyl-2,4,6-trimethylphenyl)sulfonamido)-1-phenylpropyl 
(2R,3R,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-2-ethyl-7-methoxy-6,8-
dimethyldodec-10-enoate (4.28).  To a solution of alcohol 4.27 (51.6 mg, 0.0617 mmol) 
in DCM (1 mL) was added 2,6-lutidine (30 µL, 0.26 mmol) followed by TBSOTf (25 µL, 
0.11 mmol) dropwise.  The reaction was warmed to room temperature and stirred for 1 h 
and then quenched with saturated aqueous NaHCO3.   The layers were separated and the 
aqueous phase was extracted three times with DCM.  The combined organic phases were 
washed with brine and dried with anhydrous Na2SO4.  The salts were removed via gravity 
filtration and volatile materials were removed using a rotary evaporator.  The crude 
material was purified via silica gel flash chromatography (5% EtOAc in hexanes) to yield 
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52.7 mg of product as a colorless oil (90% yield).  1H NMR (400 MHz, C6D6) δ 7.56 – 
7.43 (m, 2H), 7.24 – 7.13 (m, 3H), 7.13 – 6.93 (m, 6H), 6.51 (s, 2H), 6.18 (d, J = 5.5 Hz, 
1H), 5.56 – 5.34 (m, 2H), 5.11 – 4.52 (m, 2H), 4.51 – 4.35 (m, 2H), 4.07 – 3.91 (m, 1H), 
3.49 (s, 3H), 3.30 (dd, J = 9.7, 1.6 Hz, 1H), 2.61 (td, J = 7.2, 2.5 Hz, 1H), 2.50 (s, 6H), 
2.33 – 2.18 (m, 1H), 2.18 – 2.02 (m, 1H), 1.92 (s, 3H), 1.99 – 1.86 (m, 2H), 1.86 – 1.77 
(m, 1H), 1.78 – 1.54 (m, 6H), 1.40 (d, J = 6.9 Hz, 3H), 1.03 – 0.95 (m, 22H), 0.89 (d, J = 
6.9 Hz, 3H), 0.83 (t, J = 7.4 Hz, 3H), 0.15 (s, 3H), 0.13 (s, 3H), 0.11 (s, 3H), 0.01 (s, 3H).  
13C NMR (100 MHz, C6D6) δ 171.5, 142.0, 140.5, 139.5, 139.2, 134.4, 132.3, 131.0, 
128.6, 128.4, 128.4, 127.9, 127.4, 127.2, 126.5, 83.8, 79.1, 70.5, 69.2, 61.4, 57.5, 52.7, 
48.7, 41.1, 40.2, 38.7, 36.1, 26.3, 26.1, 23.2, 21.4, 20.6, 18.5, 18.4, 18.2, 15.2, 12.9, 12.3, 
9.4, -2.8, -3.9, -4.5, -4.5.  HRMS calc m/z [C54H87NO7SSi2 + Na]+: 972.5639, found: 
972.5743. 
 
(2S,3R,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-2-ethyl-7-methoxy-6,8-
dimethyldodec-10-en-1-ol (4.29).  To a solution of ester 4.28 (52.4 mg, 0.0551 mmol) 
dissolved in DCM (1 mL) at -78 °C was added DIBAL-H (1 M in hexanes, 0.17 mL, 0.17 
mmol).  The reaction was stirred at -78 °C for 2.5 h before additional DIBAL-H (1 M in 
hexanes, 0.17 mL, 0.17 mmol) was added to the reaction.  The reaction was quenched 
with MeOH (20 µL) followed by saturated aqueous Rochelle salt and warmed to room 
temperature.  After stirring for 2 h, the layers were separated and the aqueous phase was 
extracted three times with DCM.  The combined organic phase was washed with brine 
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and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and 
purified via silica gel flash chromatography (11:1 hexanes:EtOAc) to yield 21.2 mg of 
product as a colorless oil (72% yield).  1H NMR (400 MHz, C6D6) δ 5.57 – 5.34 (m, 2H), 
4.24 (dd, J = 10.5, 4.5 Hz, 1H), 4.21 – 4.05 (m, 1H), 4.07 – 3.94 (m, 1H), 3.81 (ddd, J = 
11.5, 8.1, 4.5 Hz, 1H), 3.40 (s, 3H), 3.27 (dd, J = 9.8, 1.7 Hz, 1H), 2.55 (d, J = 8.0 Hz, 
1H), 2.23 (ddd, J = 13.4, 10.1, 4.9 Hz, 2H), 2.15 – 2.06 (m, 1H), 2.01 (ddd, J = 13.4, 
10.6, 4.7 Hz, 1H), 1.80 – 1.53 (m, 8H), 1.05 – 0.99 (m, 12H), 0.97 (d, J = 6.8 Hz, 3H), 
0.94 (s, 9H), 0.92 (d, J = 6.9 Hz, 3H), 0.21 (s, 3H), 0.17 (s, 3H), 0.13 (s, 3H), 0.08 (s, 
3H).  13C NMR (100 MHz, C6D6) δ 130.9, 126.5, 84.0, 72.9, 69.0, 62.4, 61.1, 44.6, 41.4, 
40.0, 38.8, 36.1, 26.2, 26.0, 22.2, 18.5, 18.2, 18.1, 12.8, 12.4, 9.5, -2.8, -4.1, -4.3, -4.7.  
HRMS calc m/z [C29H62O4Si2 + Na]+: 553.4079, found: 553.4098. 
 
(2R,3R,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-2-ethyl-7-methoxy-6,8-
dimethyldodec-10-enal (4.30).  A suspension of alcohol 4.29 (21.2 mg, 0.0399 mmol), 
NMO (6.1 mg, 0.052 mmol), and powdered 4Å molecular sieves (20 mg) was stirred in 
DCM (0.6 mL) at 0 °C for 15 min.  A solution of TPAP (1.4 mg, 0.0040 mmol) in DCM 
(0.2 mL) was added to the reaction.  After stirring 20 min at 0 °C, the reaction was 
warmed to room temperature and stirred for 30 min.  Silica gel was added to the reaction 
and volatile materials were removed using a rotary evaporator.  Purification via silica gel 
flash chromatography yielded 17.9 mg of product as a colorless oil (85% yield).  1H 
NMR (400 MHz, C6D6) δ 9.83 (d, J = 3.6 Hz, 1H), 5.55 – 5.28 (m, 2H), 4.40 (dd, J = 9.4, 
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5.6 Hz, 1H), 3.95 (ddd, J = 8.6, 5.9, 1.8 Hz, 1H), 3.47 (s, 3H), 3.28 (dd, J = 9.8, 1.7 Hz, 
1H), 2.29 (dddd, J = 8.1, 6.1, 3.7, 1.9 Hz, 1H), 2.26 – 2.16 (m, 1H), 2.15 – 2.06 (m, 1H), 
2.06 – 1.97 (m, 2H), 1.83 – 1.68 (m, 2H), 1.68 – 1.62 (m, 3H), 1.62 – 1.46 (m, 2H), 1.00 
(s, 9H), 0.96 (d, J = 6.8 Hz, 3H), 0.92 (s, 9H), 0.89 (d, J = 6.9 Hz, 3H), 0.83 (t, J = 7.5 
Hz, 3H), 0.26 (s, 3H), 0.24 (s, 3H), 0.09 (s, 3H), 0.03 (s, 3H).  13C NMR (100 MHz, 
C6D6) δ 204.3, 130.9, 126.6, 83.9, 71.2, 68.6, 61.3, 56.9, 42.2, 40.4, 38.7, 36.1, 26.2, 
25.9, 20.1, 18.5, 18.2, 12.9, 11.9, 9.4, -2.9, -4.1, -4.4, -4.7.  HRMS calc m/z [C29H60O4Si2 
+ K]+: 567.3662, found: 567.3780. 
 
(2Z,4S,5R,7R,8R,9R,10S,12E)-Ethyl 5,7-Bis((tert-butyldimethylsilyl)oxy)-4-ethyl-9-
methoxy-8,10-dimethyltetradeca-2,12-dienoate (4.32).  To a solution of phosphonate 
ester 4.31 (121 mg, 0.347 mmol) in THF (4.3 mL) at 0 °C was added sodium hydride 
(60% in mineral oil, 14 mg, 0.35 mmol).  The reaction was stirred at 0 °C for 15 min 
before cooling to -78 °C.  Aldehyde 4.30 (17.9 mg, 0.0338 mmol) was dissolved in THF 
(0.3 mL) and added to the reaction dropwise.  The vial containing the aldehyde solution 
was rinsed with additional THF (0.3 mL) which was added to the reaction.  The reaction 
was slowly warmed from -78 °C to ~0 °C over 2 h.  The reaction was quenched with 
saturated aqueous NH4Cl.  The layers were separated and the aqueous phase was 
extracted three times with EtOAc.  The combined organic layers were washed with brine 
and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and 
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volatile materials were removed using a rotary evaporator.  The crude material was 
purified via silica gel flash chromatography (4% ether in hexanes and 5% ether in 
hexanes) to yield 11.5 mg of product as a colorless oil (57% yield).  1H NMR (400 MHz, 
C6D6) δ 6.47 (dd, J = 11.7, 10.2 Hz, 1H), 6.04 (d, J = 11.6 Hz, 1H), 5.52 – 5.37 (m, 2H), 
4.38 (dd, J = 9.2, 5.2 Hz, 1H), 4.14 – 3.95 (m, 3H), 3.96 – 3.84 (m, 1H), 3.62 (s, 3H), 
3.33 (dd, J = 9.6, 1.8 Hz, 1H), 2.39 – 2.24 (m, 1H), 2.17 – 2.06 (m, 1H), 2.00 – 1.84 (m, 
2H), 1.84 – 1.72 (m, 2H), 1.73 – 1.62 (m, 4H), 1.63 – 1.45 (m, 2H), 1.07 – 0.98 (m, 9H), 
1.02, (s, 9H), 0.99 (s, 9H), 0.95 (d, J = 7.0 Hz, 4H), 0.20 (s, 6H), 0.19 (s, 3H), 0.15 (s, 
3H).  13C NMR (100 MHz, C6D6) δ 166.0, 150.6, 131.1, 126.4, 121.7, 83.9, 71.3, 69.1, 
61.3, 59.7, 44.0, 42.7, 40.8, 38.9, 36.2, 26.3, 26.1, 25.2, 18.6, 18.3, 18.2, 14.3, 13.0, 12.1, 
9.6, -2.8, -3.9, -4.2, -4.4.  HRMS calc m/z [C33H66O5Si2 + Na]+: 621.4347, found: 
621.4364. 
 
(5S,6R)-5-Ethyl-6-((2R,3S,4R,5S,E)-2-hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-
yl)-5,6-dihydro-2H-pyran-2-one (4.20).  Ester 4.32 (11.5 mg, 0.0192 mmol) was 
dissolved in a hydrochloric acid/ethanol solution (1% HCl in ethanol, 0.48 mL) and 
stirred at room temperature overnight.  The reaction was diluted with DCM and quenched 
with saturated aqueous NaHCO3.  The layers were separated and the aqueous phase was 
extracted three times with DCM.  The combined organic phase was washed with brine 
and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and 
volatile materials were removed using a rotary evaporator.  The crude material was 
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purified via silica gel flash chromatography (5% EtOAc in DCM and 35% EtOAc in 
hexanes twice) to yield 8.48 mg of product as a colorless oil (44% yield). )  1H NMR 
(400 MHz, CDCl3) δ 6.79 (dd, J = 9.9, 3.5 Hz, 1H), 6.00 (dd, J = 9.8, 2.0 Hz, 1H), 5.56 – 
5.29 (m, 2H), 4.54 (ddd, J = 9.9, 7.5, 2.9 Hz, 1H), 4.24 (dq, J = 10.0, 2.6 Hz, 1H), 3.47 
(s, 3H), 3.38 (dd, J = 3.2, 1.1 Hz, 1H), 2.98 (dd, J = 6.1, 4.6 Hz, 1H), 2.31 (tdt, J = 7.7, 
5.2, 2.0 Hz, 1H), 2.19 – 2.01 (m, 1H), 1.94 – 1.72 (m, 4H), 1.72 – 1.61 (m, 4H), 1.50 (dt, 
J = 13.8, 7.4 Hz, 1H), 1.01 (t, J = 7.5 Hz, 3H), 0.98 (d, J = 7.1 Hz, 3H), 0.95 (d, J = 6.5 
Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 163.7, 149.1, 128.8, 126.9, 120.6, 90.8, 78.9, 
67.4, 61.5, 39.8, 39.0, 38.7, 37.3, 36.1, 24.3, 18.0, 15.1, 12.2, 10.6.  HRMS calc m/z 
[C19H32O4 + Na]+: 347.2193, found: 347.2201.  97% pure by HPLC analysis. 
 
(1S,2R)-2-((N-Benzyl-2,4,6-trimethylphenyl)sulfonamido)-1-phenylpropyl Butyrate 
(4.33).  The product was synthesized following the procedure for the synthesis of ester 
4.26.  Reaction with (1S,2R)-2-[N-benzyl-N-(mesitylenesulfonyl)amino]-1-phenyl-1-
propanol (0.35 g, 0.83 mmol) resulted in 0.32 g of product as a white solid (77% yield) 
after purification via silica gel flash chromatography (70% DCM in hexanes and 0.5% 
ether in CHCl3).  1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 7.1 Hz, 2H), 7.29 – 7.12 (m, 
4H), 6.96 – 6.81 (m, 4H), 5.82 (d, J = 4.0 Hz, 1H), 4.85 – 4.51 (ABq, 2H), 4.05 (qd, J = 
7.0, 4.0 Hz, 1H), 2.51 (s, 6H), 2.28 (s, 3H), 2.26 – 1.97 (m, 2H), 1.54 (d, J = 7.6 Hz, 2H), 
1.12 (d, J = 7.0 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 171.9, 
142.5, 140.2, 138.7, 138.6, 133.4, 132.1, 128.4, 128.3, 127.8, 127.4, 127.1, 126.0, 77.9, 
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56.7, 48.2, 36.1, 23.0, 20.9, 18.1, 13.6, 12.9.  [α]D = -17.5 (c 0.188, CHCl3).  HRMS calc 
m/z [C29H35NO4S + Na]+: 516.2179, found: 516.2146.  mp: 80.8 – 81.5 °C. 
 
(1S,2R)-2-((N-Benzyl-2,4,6-trimethylphenyl)sulfonamido)-1-phenylpropyl 
(2S,3S,5R,6R,7R,8S,E)-5-((tert-butyldimethylsilyl)oxy)-2-ethyl-3-hydroxy-7-
methoxy-6,8-dimethyldodec-10-enoate (4.34).  The product was synthesized following 
the procedure for the synthesis of intermediate 4.27.  Reaction with ester 4.33 (0.16 g, 
0.33 mmol), TEA (0.18 mL, 1.3 mmol), dicyclohexylboron trifluoromethanesulfonate 
(0.22 g, 0.66 mmol) and aldehyde 4.25 (47.2 mg, 0.138 mmol) resulted in 76 mg of 
product as a colorless oil (66% yield) after purification via silica gel flash 
chromatography (25% ether in hexanes).  1H NMR (400 MHz, C6D6) δ 7.63 – 7.54 (m, 
2H), 7.16 – 7.10 (m, 2H), 7.09 – 7.00 (m, 1H), 7.01 – 6.91 (m, 5H), 6.53 (s, 2H), 6.21 (d, 
J = 5.0 Hz, 1H), 5.55 – 5.35 (ABq, 2H), 5.13 – 4.68 (m, 2H), 4.49 (dd, J = 9.6, 4.3 Hz, 
1H), 4.38 (td, J = 7.0, 5.1 Hz, 1H), 3.92 (s, 1H), 3.39 (s, 3H), 3.26 (dd, J = 9.5, 1.8 Hz, 
1H), 2.97 (d, J = 5.4 Hz, 1H), 2.54 (s, 6H), 2.42 (ddd, J = 9.5, 7.3, 4.6 Hz, 1H), 2.30 – 
2.16 (m, 1H), 2.15 – 2.02 (m, 1H), 1.89 (s, 3H), 1.88 – 1.68 (m, 4H), 1.65 (d, J = 4.2 Hz, 
3H), 1.61 – 1.48 (m, 1H), 1.50 – 1.39 (m, 1H), 1.36 (d, J = 6.9 Hz, 3H), 1.03 (s, 9H), 0.93 
(d, J = 6.8 Hz, 3H), 0.84 (d, J = 7.0 Hz, 3H), 0.64 (t, J = 7.4 Hz, 3H), 0.23 (s, 3H), 0.19 
(s, 3H).  13C NMR (100 MHz, C6D6) δ 174.1, 142.1, 140.6, 139.8, 139.1, 134.6, 132.3, 
130.9, 128.6, 128.5, 128.4, 127.4, 127.0, 126.5, 84.8, 78.4, 70.0, 69.7, 60.9, 57.2, 54.5, 
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48.6, 41.5, 40.1, 38.8, 36.1, 26.2, 23.2, 22.6, 20.6, 18.5, 18.2, 14.6, 13.1, 11.8, 10.1, -3.1, 
-4.1.  HRMS calc m/z [C48H73NO7SSi + Na]+: 858.4775, found: 858.4813. 
 
(1S,2R)-2-((N-Benzyl-2,4,6-trimethylphenyl)sulfonamido)-1-phenylpropyl 
(2S,3S,5R,6R,7R,8S,E)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-ethyl-7-methoxy-6,8-
dimethyldodec-10-enoate (4.35).  The product was synthesized following the procedure 
for the synthesis of intermediate 4.28.  Reaction with alcohol 4.34 (0.103 g, 0.123 mmol) 
resulted in 99 mg of product as a colorless oil (85% yield) after purification via silica gel 
flash chromatography (5% EtOAc in hexanes).  1H NMR (400 MHz, C6D6) δ 7.55 – 7.46 
(m, 2H), 7.14 – 7.06 (m, 2H), 7.05 – 7.00 (m, 1H), 7.00 – 6.90 (m, 5H), 6.47 (s, 2H), 6.13 
(d, J = 6.7 Hz, 1H), 5.44 (dq, J = 4.7, 2.0 Hz, 2H), 5.01 – 4.41 (ABq, 2H), 4.51 – 4.30 
(m, 2H), 4.19 (dt, J = 9.9, 2.7 Hz, 1H), 3.46 (s, 3H), 3.32 (dd, J = 9.7, 1.6 Hz, 1H), 2.64 
(dt, J = 8.6, 4.5 Hz, 1H), 2.45 (s, 6H), 2.33 – 2.21 (m, 1H), 2.17 – 2.04 (m, 1H), 1.97 – 
1.80 (m, 4H), 1.89 (s, 3H), 1.80 – 1.69 (m, 2H), 1.69 – 1.59 (m, 3H), 1.43 (d, J = 6.8 Hz, 
3H), 1.01 (s, 18H), 0.94 (d, J = 6.8 Hz, 3H), 0.84 (t, J = 7.3 Hz, 4H), 0.71 (d, J = 6.8 Hz, 
3H), 0.27 (s, 3H), 0.20 (s, 3H), 0.19 (s, 3H), 0.16 (s, 3H).  13C NMR (100 MHz, C6D6) δ 
172.0, 142.0, 140.6, 139.0, 138.8, 134.1, 132.3, 131.2, 128.7, 128.5, 128.1, 127.6, 127.3, 
126.3, 83.9, 78.1, 70.0, 69.1, 60.9, 56.9, 54.8, 48.7, 39.4, 38.9, 38.9, 36.2, 26.3, 26.2, 
23.1, 20.6, 18.6, 18.5, 18.5, 18.2, 15.8, 13.3, 12.9, 9.4, -2.6, -4.0, -4.1, -4.6.  HRMS calc 
m/z [C54H87NO7SSi2 + Na]+: 972.5634, found: 972.5703. 
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(2R,3S,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-2-ethyl-7-methoxy-6,8-
dimethyldodec-10-en-1-ol (4.36).  The product was synthesized following the procedure 
for the synthesis of intermediate 4.29.  Reaction with ester 4.35 (97.9 mg, 0.103 mmol) 
resulted in 48.2 mg of product as a colorless oil (88% yield) after purification via silica 
gel flash chromatography (11:1 hexanes:EtOAc).  1H NMR (400 MHz, C6D6) δ 5.53 – 
5.38 (m, 2H), 4.41 (dd, J = 8.9, 5.4 Hz, 1H), 4.06 (dt, J = 7.5, 3.7 Hz, 1H), 3.59 (dt, J = 
10.9, 3.8 Hz, 1H), 3.47 (s, 3H), 3.39 – 3.28 (m, 2H), 2.36 – 2.21 (m, 1H), 2.21 – 2.03 (m, 
1H), 1.91 – 1.75 (m, 4H), 1.75 – 1.60 (m, 4H), 1.55 (ddq, J = 11.5, 7.5, 3.8 Hz, 1H), 1.32 
(ddt, J = 16.5, 14.4, 7.3 Hz, 1H), 1.22 (dd, J = 6.3, 3.6 Hz, 1H), 1.04 (s, 18H), 1.01 (d, J 
= 6.8 Hz, 3H), 0.96 (t, J = 7.5 Hz, 3H), 0.87 (d, J = 6.8 Hz, 3H), 0.26 (s, 3H), 0.23 (s, 
3H), 0.22 (s, 3H), 0.15 (s, 3H).  13C NMR (100 MHz, C6D6) δ 131.1, 126.4, 84.1, 71.4, 
69.7, 62.6, 60.9, 48.3, 40.0, 39.5, 38.9, 36.3, 26.4, 26.2, 19.8, 18.6, 18.3, 18.2, 13.0, 12.9, 
9.8, -2.7, -3.9, -4.0, -4.3.  HRMS calc m/z [C29H62O4Si2 + Na]+: 553.4084, found: 
553.4170. 
 
(2S,3S,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-2-ethyl-7-methoxy-6,8-
dimethyldodec-10-enal (4.37).  The product was synthesized following the procedure for 
the synthesis of intermediate 4.30.  Reaction with alcohol 4.36 (42.1 mg, 0.0793 mmol) 
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resulted in 36.0 mg of product as a colorless oil (86% yield) after purification via silica 
gel flash chromatography (5% EtOAc in hexanes)  1H NMR (400 MHz, C6D6) δ 9.53 (d, 
J = 2.0 Hz, 1H), 5.56 – 5.32 (m, 2H), 4.39 (ddd, J = 10.0, 4.3, 1.2 Hz, 1H), 4.10 (dt, J = 
8.6, 3.3 Hz, 1H), 3.45 (s, 3H), 3.30 (dd, J = 9.6, 1.7 Hz, 1H), 2.34 – 2.18 (m, 2H), 2.19 – 
2.02 (m, 1H), 1.92 – 1.79 (m, 2H), 1.79 – 1.55 (m, 7H), 1.05 – 0.96 (m, 21H), 0.87 (t, J = 
7.4 Hz, 3H), 0.83 (d, J = 6.9 Hz, 3H), 0.20 (s, 3H), 0.18 (s, 6H), 0.05 (s, 3H).  13C NMR 
(100 MHz, C6D6) δ 202.7, 131.1, 126.4, 84.0, 69.5, 69.2, 60.8, 60.0, 40.6, 39.8, 38.9, 
36.2, 26.3, 26.1, 18.6, 18.2, 18.2, 17.8, 13.0, 12.8, 9.6, -2.7, -4.0, -4.2, -4.4.  HRMS calc 
m/z [C29H60O4Si2 + Na]+: 551.3928, found: 551.3856. 
 
(2Z,4R,5S,7R,8R,9R,10S,12E)-Ethyl 5,7-Bis((tert-butyldimethylsilyl)oxy)-4-ethyl-9-
methoxy-8,10-dimethyltetradeca-2,12-dienoate (4.38).  The product was synthesized 
following the procedure for the synthesis of intermediate 4.32.  Reaction with aldehyde 
4.37 (35.5 mg, 0.0671 mmol) resulted in 29.6 mg of product as a colorless oil (74% 
yield) after purification via silica gel flash chromatography (3% ether in hexanes).  1H 
NMR (400 MHz, C6D6) δ 5.96 – 5.84 (m, 2H), 5.53 – 5.38 (m, 2H), 4.47 (ddd, J = 9.2, 
5.2, 1.4 Hz, 1H), 4.06 (dt, J = 8.5, 3.4 Hz, 1H), 4.02 – 3.83 (m, 3H), 3.49 (s, 3H), 3.33 
(dd, J = 9.5, 1.7 Hz, 1H), 2.37 – 2.21 (m, 1H), 2.19 – 2.05 (m, 1H), 2.02 – 1.85 (m, 2H), 
1.86 – 1.68 (m, 3H), 1.68 – 1.60 (m, 3H), 1.43 – 1.29 (m, 1H), 1.10 (s, 9H), 1.05 (s, 9H), 
1.00 – 0.91 (m, 10H), 0.83 (d, J = 7.0 Hz, 3H), 0.38 (s, 3H), 0.36 (s, 3H), 0.28 (s, 3H), 
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0.24 (s, 3H).  13C NMR (100 MHz, C6D6) δ 165.9, 151.5, 131.1, 126.4, 122.0, 83.8, 72.0, 
69.7, 60.8, 59.8, 46.0, 40.4, 39.9, 38.9, 36.3, 26.4, 26.4, 22.9, 18.6, 18.4, 18.2, 14.2, 12.9, 
12.6, 9.8, -2.7, -3.7, -3.8, -4.5.  HRMS calc m/z [C33H66O5Si2 + Na]+: 621.4341, found: 
621.4409. 
 
(5R,6S)-5-Ethyl-6-((2R,3S,4R,5S,E)-2-hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-
yl)-5,6-dihydro-2H-pyran-2-one (4.21).  The product was synthesized following the 
procedure for the synthesis of analog 4.20.  Reaction with ester 4.38 (29.5 mg, 0.0492 
mmol) resulted in 4.05 mg of product as a colorless oil (25% yield) after purification via 
silica gel flash chromatography (30% EtOAc in hexanes).  1H NMR (400 MHz, CDCl3) δ 
6.80 (dd, J = 9.9, 3.5 Hz, 1H), 6.00 (dd, J = 9.9, 2.0 Hz, 1H), 5.53 – 5.29 (m, 2H), 4.45 
(td, J = 7.4, 5.0 Hz, 1H), 4.25 – 4.13 (m, 1H), 3.49 (s, 3H), 3.23 (d, J = 2.7 Hz, 1H), 3.06 
(t, J = 5.7 Hz, 1H), 2.45 (ddt, J = 9.8, 7.7, 4.0 Hz, 1H), 2.19 – 2.09 (m, 1H), 2.01 (ddd, J 
= 14.5, 8.8, 7.4 Hz, 1H), 1.96 – 1.83 (m, 1H), 1.84 – 1.62 (m, 7H), 1.48 (dt, J = 14.3, 7.4 
Hz, 1H), 1.01 (t, J = 7.5 Hz, 3H), 0.94 (d, J = 7.1 Hz, 3H), 0.91 (d, J = 6.7 Hz, 3H).  13C 
NMR (100 MHz, CDCl3) δ 163.4, 149.2, 129.2, 126.8, 120.4, 89.2, 80.6, 68.1, 61.6, 39.4, 
39.0, 38.0, 37.4, 36.0, 24.0, 18.0, 14.3, 11.3, 10.6.  HRMS calc m/z [C19H32O4 + Na]+: 
347.2193, found: 347.2170.  97% pure by HPLC analysis. 
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(R)-1-(4-Benzyl-2-thioxothiazolidin-3-yl)butan-1-one (4.39).  To a solution of (R)-4-
benzylthiazolidine-2-thione (0.25 g, 1.2 mmol) and triethylamine (0.18 mL, 1.3 mmol) in 
DCM (2 mL) at 0 °C was added dropwise a solution of butyryl chloride (0.13 mL, 1.25 
mmol) dissolved in DMM (0.5 mL) over 7 min.  The vial containing the butyryl chloride 
solution was rinsed with additional DCM (0.5 mL) which was added to the reaction.  The 
reaction was warmed to room temperature and stirred for 2 h.  The reaction was then 
quenched with saturated aqueous NH4Cl.  The layers were separated and the aqueous 
layer was extracted three times with DCM.  The combined organic layers were washed 
with brine and dried with anhydrous Na2SO4.  The suspension was filter and volatile 
materials were removed using a rotary evaporator.  The crude material was purified via 
silica gel flash chromatography (1:1 DCM:hexanes) to yield 0.25 g of product as a yellow 
solid (75% yield).  The resonances in the 1H NMR and 13C spectrum of the product 
matched previously reported chemical shifts.132 
 
(2R,3S,5R,6R,7R,8S,E)-1-((R)-4-Benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-2-ethyl-3-hydroxy-7-methoxy-6,8-dimethyldodec-10-en-1-
one (4.40).  The procedure was adapted from a previously reported reaction.50  
Thiazolidinethione 4.39 (115 mg, 0.412 mmol) was dissolved in DCM (1.7 mL) and 
cooled to 0 °C.  Titanium chloride (45 µL, 0.41 mmol) was added to the reaction 
dropwise and the reaction was stirred for 20 min at 0 °C.  Diisopropylethylamine (72 µL, 
0.41 mmol) was added to the reaction dropwise and the reaction was stirred for an 
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additional 20 min at 0 °C before adding NMP (40 µL, 0.41 mmol) dropwise to the 
reaction.  The reaction was stirred for an additional 20 min at 0 °C before cooling to -78 
°C.  Aldehyde 4.25 (41 mg, 0.12 mmol) was dissolved in DCM (0.5 mL) and added 
dropwise to the reaction at -78 °C.  The vial containing the aldehyde solution was rinsed 
with additional DCM (0.5 mL) which was added to the reaction dropwise.  The reaction 
was stirred at -78 °C for 4 h before warmed to -50 °C and stirring overnight.  The 
reaction was quenched with saturated aqueous NH4Cl and warmed to room temperature.  
The layers were separated and the aqueous phase was extracted three times with DCM.  
The combined organic layers were washed with brine and dried with anhydrous Na2SO4.  
The salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was purified via silica gel flash chromatography 
(4:1 hexanes:EtOAc) to yield 55.8 mg of product as a yellow oil (75% yield).  1H NMR 
(400 MHz, C6D6) δ 7.11 – 7.01 (m, 3H), 7.01 – 6.94 (m, 2H), 5.54 – 5.36 (m, 2H), 5.20 – 
5.04 (m, 2H), 4.50 (ddd, J = 9.8, 4.1, 1.3 Hz, 1H), 3.97 (ddd, J = 10.5, 5.0, 2.3 Hz, 1H), 
3.45 (s, 3H), 3.31 (dd, J = 9.5, 1.7 Hz, 1H), 3.08 (dd, J = 13.2, 3.7 Hz, 1H), 2.70 (dd, J = 
13.2, 10.6 Hz, 1H), 2.49 (dd, J = 11.5, 7.1 Hz, 1H), 2.33 – 2.17 (m, 1H), 2.17 – 1.94 (m, 
4H), 1.94 – 1.81 (m, 2H), 1.80 – 1.67 (m, 2H), 1.67 – 1.59 (m, 3H), 1.08 – 0.97 (m, 15H), 
0.89 (d, J = 6.9 Hz, 3H), 0.26 (s, 3H), 0.20 (s, 3H).  13C NMR (100 MHz, C6D6) δ 202.2, 
176.5, 137.0, 131.0, 129.6, 129.0, 127.2, 126.5, 84.5, 70.5, 69.9, 69.4, 61.0, 51.0, 40.4, 
40.2, 38.9, 37.0, 36.2, 31.4, 26.3, 21.2, 18.6, 18.2, 13.2, 12.2, 10.0, -2.9, -4.2.  HRMS 
calc m/z [C33H55NO4S2Si + Na]+: 644.3234, found: 644.3206. 
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(2R,3S,5R,6R,7R,8S,E)-1-((R)-4-Benzyl-2-thioxothiazolidin-3-yl)-3,5-bis((tert-
butyldimethylsilyl)oxy)-2-ethyl-7-methoxy-6,8-dimethyldodec-10-en-1-one (4.41).  
To a solution of alcohol 4.40 (55.8 mg, 0.0897 mmol) and 2,6-lutidine (21 µL, 0.18 
mmol) in DCM (0.8 mL) at 0 °C was added TBSOTf (31 µL, 0.14 mmol) dropwise.  The 
reaction was removed from the ice bath and stirred at room temperature.  After 35 min, 
the reaction was quenched with saturated aqueous NaHCO3.  The layers were separated 
and the aqueous phase was extract three times with DCM.  Wash combined organic 
layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatography (4% 
EtOAc in hexanes) to yield 49.9 mg of product as a yellow oil (76% yield).  1H NMR 
(400 MHz, C6D6) δ 7.13 – 6.98 (m, 5H), 5.57 – 5.38 (m, 2H), 5.18 (ddd, J = 10.5, 6.9, 3.6 
Hz, 1H), 4.92 (td, J = 7.0, 3.8 Hz, 1H), 4.50 (dd, J = 9.9, 4.6 Hz, 1H), 4.07 (dt, J = 7.2, 
3.2 Hz, 1H), 3.49 (s, 3H), 3.37 (dd, J = 9.8, 1.6 Hz, 1H), 3.20 (dd, J = 13.1, 3.6 Hz, 1H), 
2.86 – 2.69 (m, 2H), 2.36 – 2.22 (m, 3H), 2.21 – 2.09 (m, 3H), 1.92 – 1.76 (m, 2H), 1.76 
– 1.56 (m, 4H), 1.13 – 0.98 (m, 24H), 0.92 (d, J = 6.8 Hz, 3H), 0.35 (s, 3H), 0.29 (s, 3H), 
0.25 (s, 3H), 0.20 (s, 3H).  13C NMR (100 MHz, C6D6) δ 201.4, 175.4, 137.1, 131.1, 
129.7, 129.0, 127.2, 126.4, 84.1, 71.1, 69.6, 69.2, 60.9, 52.3, 41.0, 39.5, 38.9, 36.8, 36.2, 
31.6, 26.4, 26.3, 22.0, 18.7, 18.3, 18.2, 12.9, 11.9, 9.5, -2.3, -3.8, -3.9, -4.2.  HRMS calc 
m/z [C39H69NO4S2Si2 + Na]+: 758.4104, found: 758.4091. 
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(2R,3S,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-2-ethyl-7-methoxy-6,8-
dimethyldodec-10-enal (4.42).  To a solution of amide 4.41 (49.9 mg, 0.0678 mmol) in 
DCM (1.6 mL) at -78 °C was added DIBAL-H (1 M in hexanes, 0.14 mL, 0.14 mmol) 
dropwise.  The yellow color persisted after 5 min and additional DIBAL-H (1 M in 
hexanes, 0.07 mL, 0.07 mmol) was added dropwise to the reaction.  After stirring an 
additional couple min, the reaction was quenched with saturated aqueous Rochelle salt 
and diluted with DCM and warmed to room temperature.  The slurry was stirred at room 
temperature for 1.5 h.  The layers were separated and the aqueous phase was extracted 
three times with DCM.  The combined organic layers were washed with brine and dried 
with anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile 
materials were removed using a rotary evaporator.  The crude material was purified via 
silica gel flash chromatography (4% EtOAc in hexanes) to yield 28.6 mg of product as a 
white solid (80% yield). 1H NMR (400 MHz, C6D6) δ 9.93 (d, J = 1.8 Hz, 1H), 5.54 – 
5.35 (m, 2H), 4.39 (dd, J = 8.7, 5.1 Hz, 1H), 3.96 (dt, J = 8.2, 4.2 Hz, 1H), 3.44 (s, 3H), 
3.31 (dd, J = 9.7, 1.6 Hz, 1H), 2.32 (dtd, J = 9.1, 4.8, 1.8 Hz, 1H), 2.29 – 2.20 (m, 1H), 
2.19 – 2.03 (m, 1H), 1.90 – 1.80 (m, 2H), 1.80 – 1.67 (m, 3H), 1.68 – 1.61 (m, 3H), 1.27 
– 1.12 (m, 1H), 1.04 – 0.93 (m, 21H), 0.81 (t, J = 7.4 Hz, 3H), 0.79 (d, J = 6.9 Hz, 3H), 
0.21 (s, 3H), 0.19 (s, 3H), 0.17 (s, 3H), 0.09 (s, 3H).  13C NMR (100 MHz, C6D6) δ 203.3, 
131.0, 126.5, 83.9, 70.4, 68.8, 60.9, 59.8, 40.1, 39.7, 38.9, 36.2, 26.3, 26.1, 18.6, 18.5, 
18.2, 18.2, 12.9, 12.5, 9.4, -2.7, -4.0, -4.0, -4.5.  HRMS calc m/z [C29H60O4Si2 + Na]+: 
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551.3928, found: 551.3913. 
 
(2Z,4S,5S,7R,8R,9R,10S,12E)-Ethyl 5,7-Bis((tert-butyldimethylsilyl)oxy)-4-ethyl-9-
methoxy-8,10-dimethyltetradeca-2,12-dienoate (4.43).  The product was synthesized 
following the procedure for the synthesis of intermediate 4.32.  Reaction with aldehyde 
4.42 (28.2 mg, 0.0533 mmol) resulted in 23.0 mg of product as a colorless oil (72% 
yield) after purification via silica gel flash chromatography (3% ether in hexanes).  1H 
NMR (400 MHz, C6D6) δ 6.11 (dd, J = 11.7, 10.0 Hz, 1H), 5.96 (d, J = 11.6 Hz, 1H), 
5.57 – 5.34 (m, 2H), 4.49 (dd, J = 9.9, 4.3 Hz, 1H), 4.10 – 3.93 (m, 2H), 3.93 – 3.82 (m, 
2H), 3.51 (s, 3H), 3.37 (dd, J = 9.6, 1.7 Hz, 1H), 2.38 – 2.24 (m, 1H), 2.22 – 2.09 (m, 
1H), 2.07 – 1.74 (m, 4H), 1.71 – 1.64 (m, 3H), 1.64 – 1.54 (m, 1H), 1.45 – 1.27 (m, 2H), 
1.05 (s, 9H), 1.04 (s, 9H), 1.03 (d, J = 7.1 Hz, 3H), 0.99 (t, J = 7.1 Hz, 3H), 0.97 (t, J = 
7.6 Hz, 3H), 0.92 (d, J = 6.9 Hz, 3H), 0.27 (s, 3H), 0.25 (s, 3H), 0.24 (s, 3H), 0.20 (s, 
3H).  13C NMR (100 MHz, C6D6) δ 166.0, 151.9, 131.2, 126.4, 121.7, 84.1, 72.8, 69.6, 
61.0, 59.7, 46.1, 40.7, 40.1, 39.0, 36.3, 26.4, 26.4, 23.5, 18.7, 18.4, 18.2, 14.3, 13.0, 12.3, 
9.6, -2.5, -3.9, -3.9, -4.0.  HRMS calc m/z [C33H66O5Si2 + Na]+: 621.4347, found: 
621.4255. 
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(5S,6S)-5-Ethyl-6-((2R,3S,4R,5S,E)-2-hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-
yl)-5,6-dihydro-2H-pyran-2-one (4.22).  The product was synthesized following the 
procedure for the synthesis of analog 4.20.  Reaction with ester 4.43 (23.0 mg, 0.0384 
mmol) resulted in 2.18 mg of product as a colorless oil (18% yield) after purification via 
silica gel flash chromatography (30% EtOAc in hexanes).  1H NMR (400 MHz, CDCl3) δ 
7.02 (dd, J = 9.8, 6.1 Hz, 1H), 6.04 (dd, J = 9.7, 0.9 Hz, 1H), 5.55 – 5.29 (m, 2H), 4.70 
(td, J = 7.4, 3.5 Hz, 1H), 4.03 (dd, J = 7.6, 3.0 Hz, 1H), 3.49 (s, 3H), 3.25 (d, J = 3.4 Hz, 
1H), 3.09 (t, J = 5.7 Hz, 1H), 2.37 (dq, J = 9.9, 4.6 Hz, 1H), 2.19 – 2.03 (m, 2H), 1.96 – 
1.84 (m, 1H), 1.83 – 1.71 (m, 2H), 1.70 – 1.61 (m, 5H), 1.56 – 1.43 (m, 1H), 0.97 (t, J = 
7.4 Hz, 3H), 0.95 (d, J = 7.1 Hz, 3H), 0.92 (d, J = 6.7 Hz, 3H).  13C NMR (100 MHz, 
CDCl3) δ 164.4, 150.5, 129.2, 126.8, 120.8, 89.2, 79.1, 68.5, 61.5, 39.3, 37.4, 37.4, 36.1, 
35.6, 20.6, 18.0, 14.4, 11.7, 10.9.  HRMS calc m/z [C19H32O4+ Na]+: 347.2193, found: 
347.2193.  98% pure by HPLC analysis. 
 
(S)-1-(4-Benzyl-2-thioxothiazolidin-3-yl)propan-1-one (4.45a).  The product was 
synthesized following the procedure for the synthesis of thiazolidinethione 4.39.  
Reaction with (S)-4-benzylthiazolidine-2-thione (0.20 g, 0.96 mmol) and propionyl 
chloride (0.09 mL, 1.00 mmol) resulted in 0.190 g of product as a yellow solid (75% 
yield) after purification via silica gel flash chromatography.  The resonances in the 1H 
NMR and 13C spectrum of the product matched previously reported chemical shifts.133 
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(S)-1-(4-Benzyl-2-thioxothiazolidin-3-yl)pentan-1-one (4.45b).  The product was 
synthesized following the procedure for the synthesis of thiazolidinethione 4.39.  
Reaction with (S)-4-benzylthiazolidine-2-thione (0.20 g, 0.96 mmol) and pentanoyl 
chloride (0.12 mL, 1.0 mmol) resulted in 0.225 g of product as a yellow oil (80% yield) 
after purification via silica gel flash chromatography (50% DCM in hexanes).  1H NMR 
(400 MHz, CDCl3) δ 7.40 – 7.27 (m, 5H), 5.37 (ddd, J = 10.7, 7.1, 3.9 Hz, 1H), 3.45 – 
3.27 (m, 2H), 3.27 – 3.09 (m, 2H), 3.04 (dd, J = 13.2, 10.5 Hz, 1H), 2.88 (d, J = 11.5 Hz, 
1H), 1.68 (ddddd, J = 15.9, 14.8, 13.4, 8.4, 6.3 Hz, 2H), 1.39 (h, J = 7.4 Hz, 2H), 0.94 (t, 
J = 7.4 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 201.1, 174.2, 136.6, 129.4, 128.9, 127.2, 
68.6, 38.2, 36.8, 31.9, 26.8, 22.2, 13.9.  [α]D = +204 (c 0.232, CHCl3). HRMS calc m/z 
[C15H19NOS2 + Na]+: 316.0800, found: 316.0770. 
 
(S)-1-(4-Benzyl-2-thioxothiazolidin-3-yl)-4,4,4-trifluorobutan-1-one (4.45c).  To a 
solution of (S)-4-benzylthiazolidine-2-thione (0.20 g, 0.96 mmol), 4,4,4-trifluorobutyric 
acid (0.18 g, 1.2 mmol), and DMAP (15 mg, 0.012 mmol) in DCM (1.3 mL) at 0 °C was 
added DCC (0.26 g, 1.2 mmol).  The reaction was stirred at 0 °C for 10 min before 
warming to room temperature and stirring an additional 3.5 h.  Solid precipitates were 
removed via filtration through a cotton plug.  The filtrate was washed with saturated 
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aqueous NaHCO3 and brine before drying with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatography (10% 
EtOAc in hexanes) to yield 0.238 g of product as a yellow solid (75% yield).  1H NMR 
(400 MHz, CDCl3) δ 7.39 – 7.27 (m, 5H), 5.39 (ddd, J = 10.8, 7.1, 4.1 Hz, 1H), 3.71 
(ddd, J = 18.4, 9.6, 5.6 Hz, 1H), 3.50 – 3.31 (m, 2H), 3.21 (dd, J = 13.2, 4.1 Hz, 1H), 
3.05 (dd, J = 13.2, 10.4 Hz, 1H), 2.92 (d, J = 11.6 Hz, 1H), 2.68 – 2.38 (m, 2H).  13C 
NMR (100 MHz, CDCl3) δ 201.2, 171.0, 136.2, 129.4, 128.9, 127.3, 126.6 (q, J = 276.1 
Hz), 68.5, 36.7, 32.1, 32.0 (q, J = 3.1 Hz), 29.1 (q, J = 29.8 Hz).  19F NMR (376 MHz, 
CDCl3) δ -66.4.  [α]D = +160 (c 0.176, CHCl3).  HRMS calc m/z [C14H14F3NOS2 + Na]+: 
356.0361, found: 356.0373.  mp: 72.9 – 73.6 °C. 
 
(S)-1-(4-Benzyl-2-thioxothiazolidin-3-yl)-2-cyclopropylethanone (4.45d).  The product 
was synthesized following the procedure for the synthesis of thiazolidinethione 4.45c.  
Reaction with (S)-4-benzylthiazolidine-2-thione (0.20 g, 0.96 mmol) and 
cyclopropylacetic acid (0.124 g, 1.24 mmol) resulted in 0.237 g of product as a yellow 
solid (85% yield) after purification via silica gel flash chromatography (10% EtOAc in 
hexanes).  1H NMR (400 MHz, CDCl3) δ 7.41 – 7.27 (m, 5H), 5.40 (ddd, J = 10.8, 7.1, 
3.8 Hz, 1H), 3.48 – 3.30 (m, 2H), 3.25 (dd, J = 13.2, 3.8 Hz, 1H), 3.16 – 2.99 (m, 2H), 
2.89 (d, J = 11.6 Hz, 1H), 1.15 (tdd, J = 7.9, 6.2, 3.5 Hz, 1H), 0.60 (dqd, J = 10.0, 5.6, 3.0 
Hz, 2H), 0.20 (dtt, J = 16.5, 9.5, 4.7 Hz, 2H).  13C NMR (100 MHz, CDCl3) δ 201.2, 
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173.9, 136.6, 129.5, 128.9, 127.2, 68.7, 43.8, 36.8, 32.0, 6.6, 4.4, 4.2.  [α]D = +208 (c 
0.202, CHCl3).  HRMS calc m/z [C15H17NOS2 + Na]+: 314.0644, found: 314.0671.  mp: 
88.1 – 88.8 °C. 
 
(S)-1-(4-Benzyl-2-thioxothiazolidin-3-yl)-4-methylpentan-1-one (4.45e).  The product 
was synthesized following the procedure for the synthesis of thiazolidinethione 4.45c.  
Reaction with (S)-4-benzylthiazolidine-2-thione (0.20 g, 0.96 mmol) and 4-
methylpentanoic acid (0.144 g, 1.24 mmol) resulted in 0.268 g of product as a yellow 
solid (91% yield) after purification via silica gel flash chromatography (10% EtOAc in 
hexanes).  The resonances in the 1H NMR and 13C spectrum of the product matched 
previously reported chemical shifts.99 
 
(S)-1-(4-Benzyl-2-thioxothiazolidin-3-yl)-3-phenylpropan-1-one (4.45f).  The product 
was synthesized following the procedure for the synthesis of thiazolidinethione 4.39.  
Reaction with (S)-4-benzylthiazolidine-2-thione (0.20 g, 0.96 mmol) and 3-
phenylpropanoyl chloride (0.15 mL, 1.0 mmol) resulted in 0.296 g of product as a yellow 
solid (91% yield) after purification via silica gel flash chromatography (40% to 50% 
DCM in hexanes).  The resonances in the 1H NMR and 13C spectrum of the product 
matched previously reported chemical shifts.99 
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(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxy-7-methoxy-2,6,8-trimethyldodec-10-en-1-one 
(4.48a).  The product was synthesized following the procedure for the synthesis of 
intermediate 4.40.  Reaction with thiazolidinethione 4.45a (131 mg, 0.493 mmol) and 
aldehyde 4.25 (49 mg, 0.14 mmol) resulted in 73.9.8 mg of product as a yellow oil (85% 
yield) after purification via silica gel flash chromatography (7:1 hexanes:EtOAc and 
subsequently 10% acetones in hexanes).  1H NMR (400 MHz, C6D6) δ 7.12 – 7.00 (m, 
3H), 7.01 – 6.90 (m, 2H), 5.57 – 5.34 (m, 2H), 4.99 (ddd, J = 10.6, 7.0, 3.7 Hz, 1H), 4.76 
(dd, J = 6.9, 3.2 Hz, 1H), 4.42 – 4.28 (m, 2H), 3.47 (s, 3H), 3.27 (dd, J = 8.8, 1.9 Hz, 
1H), 3.13 (bs, 1H), 3.02 (dd, J = 13.2, 3.7 Hz, 1H), 2.65 (dd, J = 13.2, 10.6 Hz, 1H), 2.42 
(dd, J = 11.6, 7.1 Hz, 1H), 2.27 (dt, J = 12.7, 5.9 Hz, 1H), 2.15 – 2.04 (m, 1H), 2.05 – 
1.96 (m, 2H), 1.98 – 1.85 (m, 1H), 1.82 – 1.68 (m, 2H), 1.66 (d, J = 4.3 Hz, 3H), 1.40 (d, 
J = 6.8 Hz, 3H), 1.07 – 0.98 (m, 26H), 0.94 (d, J = 6.8 Hz, 3H), 0.24 (s, 3H), 0.19 (s, 
3H).  13C NMR (100 MHz, C6D6) δ 201.4, 178.0, 136.9, 131.0, 129.7, 129.0, 128.6, 
127.2, 126.6, 84.3, 71.1, 70.1, 69.1, 60.5, 44.6, 41.7, 40.7, 39.0, 36.7, 36.1, 31.6, 26.3, 
18.6, 18.3, 13.6, 11.1, 11.1, -3.4, -3.9.  HMRS calc m/z [C32H53NO4S2Si + Na]+: 
630.3077, found: 630.3072. 
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(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxy-7-methoxy-6,8-dimethyl-2-propyldodec-10-en-1-
one (4.48b).  The product was synthesized following the procedure for the synthesis of 
intermediate 4.40.  Reaction with thiazolidinethione 4.45b (0.123 g, 0.419 mmol) and 
aldehyde 4.25 (41.5 mg, 0.121 mmol) resulted in 59.4 mg of product as a yellow oil (77% 
yield) after purification via silica gel flash chromatography (7:1 hexanes:acetone 
followed by 7:1 hexanes:EtOAc followed by 30% ether in hexanes).  1H NMR (400 
MHz, C6D6) δ 7.11 – 7.01 (m, 3H), 7.01 – 6.93 (m, 2H), 5.54 – 5.38 (m, 2H), 5.28 (dt, J 
= 8.9, 4.3 Hz, 1H), 5.12 (ddd, J = 10.7, 7.0, 3.7 Hz, 1H), 4.35 (td, J = 5.7, 2.6 Hz, 1H), 
4.25 (dt, J = 8.4, 3.9 Hz, 1H), 3.45 (s, 3H), 3.26 (dd, J = 8.8, 2.0 Hz, 1H), 3.12 (dd, J = 
13.1, 3.7 Hz, 1H), 2.72 (dd, J = 13.1, 10.6 Hz, 1H), 2.60 – 2.39 (m, 1H), 2.35 – 2.20 (m, 
1H), 2.21 – 2.00 (m, 4H), 1.98 – 1.84 (m, 2H), 1.80 – 1.62 (m, 5H), 1.62 – 1.49 (m, 2H), 
1.08 – 0.99 (m, 12H), 0.95 (t, J = 7.2 Hz, 3H), 0.95 (d, J = 7.0 Hz, 3H), 0.24 (s, 3H), 0.19 
(s, 3H).  13C NMR (100 MHz, C6D6) δ 202.2, 176.5, 137.0, 130.9, 129.7, 129.0, 127.2, 
126.6, 84.6, 71.7, 70.9, 69.5, 60.5, 49.6, 41.8, 40.8, 39.0, 36.9, 36.1, 31.4, 29.7, 26.3, 
21.2, 18.6, 18.2, 14.7, 13.6, 11.3, -3.4, -3.9.  HRMS calc m/z [C34H57NO4S2Si + Na]+: 
658.3390, found: 658.3372. 
 
(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxy-7-methoxy-6,8-dimethyl-2-(2,2,2-
trifluoroethyl)dodec-10-en-1-one (4.48c).  The product was synthesized following the 
  224 
procedure for the synthesis of intermediate 4.40.  Reaction with thiazolidinethione 4.45c 
(0.171 g, 0.513 mmol) and aldehyde 4.25 (51 mg, 0.15 mmol) resulted in 70.8 mg of 
product as a yellow oil (70% yield) after purification via silica gel flash chromatography 
(15% EtOAc in hexanes).  1H NMR (400 MHz, C6D6) δ 7.11 – 6.98 (m, 3H), 6.99 – 6.90 
(m, 2H), 5.88 (dt, J = 10.0, 2.7 Hz, 1H), 5.55 – 5.35 (m, 2H), 5.11 (ddd, J = 10.5, 7.1, 3.3 
Hz, 1H), 4.47 – 4.32 (m, 1H), 4.23 (q, J = 4.8 Hz, 1H), 3.41 (s, 3H), 3.36 – 3.16 (m, 2H), 
3.07 (dd, J = 13.3, 3.3 Hz, 1H), 2.91 (s, 1H), 2.62 (dd, J = 13.3, 10.8 Hz, 1H), 2.52 – 2.33 
(m, 2H), 2.32 – 2.16 (m, 1H), 2.15 – 2.02 (m, 2H), 1.98 (dd, J = 11.6, 2.4 Hz, 1H), 1.92 – 
1.80 (m, 2H), 1.76 – 1.63 (m, 4H), 1.01 (d, J = 6.6 Hz, 3H), 0.97 (s, 9H), 0.94 (d, J = 7.0 
Hz, 3H), 0.16 (s, 3H), 0.13 (s, 3H).  13C NMR (100 MHz, C6D6) δ 202.3, 173.3, 136.9, 
130.7, 129.7, 129.0, 127.3, 126.9, 84.7, 71.9, 70.3, 69.7, 60.3, 44.6 (d, J = 1.6 Hz), 41.4, 
40.5, 39.1, 36.5, 36.1, 30.9 (q, J = 29.1 Hz), 30.8, 26.2, 18.5, 18.3, 13.9, 11.8, -3.6, -4.1.  
Quaternary -CF3 13C resonance not observed in spectrum.  19F NMR (376 MHz, C6D6) δ -
64.0  HRMS calc m/z [C33H52F3NO4S2Si + Na]+: 698.2951, found: 698.2948. 
 
(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-2-cyclopropyl-3-hydroxy-7-methoxy-6,8-dimethyldodec-10-
en-1-one (4.48d).  The product was synthesized following the procedure for the synthesis 
of intermediate 4.40.  Reaction with thiazolidinethione 4.45d (0.153 g, 0.525 mmol) and 
aldehyde 4.25 (52.1 mg, 0.152 mmol) resulted in 69.2 mg of product as a yellow oil (72% 
yield) after purification via silica gel flash chromatography (15% EtOAc in hexanes 
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followed by three times with 10% acetone in hexanes).  1H NMR (400 MHz, C6D6) δ 
7.13 – 6.99 (m, 3H), 7.01 – 6.94 (m, 2H), 5.57 – 5.38 (m, 2H), 5.10 (ddd, J = 10.7, 7.0, 
3.6 Hz, 1H), 4.74 (dd, J = 9.8, 4.0 Hz, 1H), 4.45 (dt, J = 10.5, 3.0 Hz, 1H), 4.38 (tt, J = 
6.2, 3.2 Hz, 1H), 3.47 (s, 3H), 3.30 (dd, J = 8.3, 2.0 Hz, 1H), 3.18 (dd, J = 13.2, 3.6 Hz, 
1H), 3.05 (bs, 1H), 2.72 (dd, J = 13.1, 10.8 Hz, 1H), 2.49 (dd, J = 11.6, 7.2 Hz, 1H), 2.38 
– 2.24 (m, 1H), 2.24 – 1.92 (m, 5H), 1.77 – 1.69 (m, 1H), 1.66 (d, J = 4.3 Hz, 3H), 1.49 – 
1.30 (m, 1H), 1.12 – 0.97 (m, 15H), 0.63 (dd, J = 9.4, 4.6 Hz, 1H), 0.58 – 0.44 (m, 2H), 
0.41 – 0.31 (m, 1H), 0.25 (s, 3H), 0.20 (s, 3H).  13C NMR (100 MHz, C6D6) δ 202.3, 
176.3, 137.0, 130.9, 129.6, 129.0, 128.6, 127.2, 126.6, 84.2, 72.0, 71.2, 69.7, 60.2, 53.9, 
41.6, 40.5, 39.2, 37.0, 36.0, 31.4, 26.3, 18.6, 18.3, 13.9, 11.5, 9.1, 5.6, 2.8, -3.4, -3.9.  
HRMS calc m/z [C34H55NO4S2Si + Na]+: 656.3240, found: 656.3242. 
 
(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxy-2-isobutyl-7-methoxy-6,8-dimethyldodec-10-en-
1-one (4.48e).  The product was synthesized following the procedure for the synthesis of 
intermediate 4.40.  Reaction with thiazolidinethione 4.45e (0.141 g, 0.459 mmol) and 
aldehyde 4.25 (45.5 mg, 0.133 mmol) resulted in 53.0 mg of product as a yellow oil (61% 
yield) after purification via silica gel flash chromatography (30% ether in hexanes 
followed by 7:1 hexanes:acetone).  1H NMR (400 MHz, C6D6) δ 7.12 – 6.91 (m, 5H), 
5.56 – 5.48 (m, 1H), 5.45 (t, J = 4.8 Hz, 2H), 5.13 (ddd, J = 10.7, 7.0, 3.7 Hz, 1H), 4.36 
(td, J = 5.8, 2.7 Hz, 1H), 4.23 (tt, J = 7.1, 4.1 Hz, 1H), 3.46 (s, 3H), 3.27 (dd, J = 8.7, 2.1 
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Hz, 1H), 3.15 (dd, J = 13.1, 3.6 Hz, 1H), 2.73 (dd, J = 13.2, 10.7 Hz, 1H), 2.49 (dd, J = 
11.2, 7.0 Hz, 1H), 2.43 (d, J = 3.8 Hz, 1H), 2.34 – 2.17 (m, 2H), 2.17 – 2.05 (m, 2H), 
2.01 (d, J = 11.6 Hz, 1H), 1.94 (t, J = 5.6 Hz, 2H), 1.89 – 1.79 (m, 1H), 1.73 (ddd, J = 
13.7, 6.9, 1.8 Hz, 1H), 1.66 (d, J = 4.0 Hz, 3H), 1.44 (ddd, J = 13.7, 8.0, 3.5 Hz, 1H), 
1.10 – 1.00 (m, 18H), 0.97 (d, J = 6.9 Hz, 4H), 0.25 (s, 3H), 0.20 (s, 3H).  13C NMR (100 
MHz, C6D6) δ 202.5, 176.0, 137.0, 130.9, 129.7, 128.9, 128.5, 127.2, 126.6, 84.6, 71.7, 
71.3, 69.8, 60.5, 48.0, 41.7, 40.6, 39.1, 36.9, 36.1, 36.0, 31.2, 26.9, 26.3, 23.7, 22.9, 18.6, 
18.2, 13.7, 11.3, -3.4, -3.9.  HRMS calc m/z [C35H59NO4S2Si + Na]+: 672.3553, found: 
672.3518. 
 
(2S,3R,5R,6R,7R,8S,E)-2-Benzyl-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxy-7-methoxy-6,8-dimethyldodec-10-en-1-one 
(4.48f).  The product was synthesized following the procedure for the synthesis of 
intermediate 4.40.  Reaction with thiazolidinethione 4.45f (0.140 g, 0.410 mmol) and 
aldehyde 4.25 (40.8 mg, 0.119 mmol) resulted in 51.6 mg of product as a yellow oil (63% 
yield) after purification via silica gel flash chromatography (7:1 hexanes:EtOAc).  1H 
NMR (400 MHz, C6D6) δ 7.42 (d, J = 7.5 Hz, 2H), 7.14 – 7.09 (m, 2H), 7.10 – 6.95 (m, 
4H), 6.93 – 6.83 (m, 2H), 5.85 (ddd, J = 9.3, 5.8, 4.0 Hz, 1H), 5.54 – 5.38 (m, 2H), 5.07 
(ddd, J = 10.6, 7.1, 3.5 Hz, 1H), 4.43 – 4.28 (m, 2H), 3.52 – 3.39 (m, 1H), 3.43 (s, 3H), 
3.24 (dd, J = 8.5, 2.0 Hz, 1H), 3.09 (dd, J = 13.9, 6.0 Hz, 1H), 2.81 (s, 1H), 2.73 (dd, J = 
13.3, 3.4 Hz, 1H), 2.49 (dd, J = 13.3, 10.6 Hz, 1H), 2.41 (dd, J = 11.6, 7.3 Hz, 1H), 2.35 
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– 2.16 (m, 1H), 2.17 – 2.04 (m, 2H), 2.04 – 1.89 (m, 3H), 1.73 (dd, J = 8.2, 6.2 Hz, 1H), 
1.66 (d, J = 4.2 Hz, 3H), 1.07 – 1.00 (m, 12H), 0.97 (d, J = 7.0 Hz, 4H), 0.23 (s, 3H), 
0.19 (s, 3H).  13C NMR (100 MHz, C6D6) δ 202.1, 175.6, 130.9, 129.8, 129.6, 128.9, 
128.7, 128.5, 127.1, 126.6, 126.6, 84.6, 71.9, 70.6, 69.2, 60.4, 50.9, 41.6, 40.5, 39.1, 36.7, 
36.1, 33.4, 31.0, 26.3, 18.6, 18.2, 13.7, 11.4, -3.4, -3.9.  HRMS calc m/z [C38H57NO4S2Si 
+ Na]+: 706.3396, found: 706.3363. 
 
(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-3,5-bis((tert-
butyldimethylsilyl)oxy)-7-methoxy-2,6,8-trimethyldodec-10-en-1-one (4.49a).  The 
product was synthesized following the procedure for the synthesis of intermediate 4.41.  
Reaction with alcohol 4.48a (70.9 mg, 0.117 mmol) resulted in 109 mg of product as a 
yellow oil (94% yield) after purification via silica gel flash chromatography (100:3 
hexanes:EtOAc).  1H NMR (400 MHz, C6D6) δ 7.13 – 6.97 (m, 5H), 5.57 – 5.37 (m, 2H), 
5.16 (ddd, J = 10.6, 6.9, 3.5 Hz, 1H), 5.00 (qd, J = 6.8, 4.2 Hz, 1H), 4.36 (dd, J = 9.0, 4.6 
Hz, 1H), 4.25 (dt, J = 7.6, 4.7 Hz, 1H), 3.51 (s, 3H), 3.37 – 3.28 (m, 1H), 3.16 (dd, J = 
13.1, 3.5 Hz, 1H), 2.82 – 2.65 (m, 2H), 2.36 – 2.05 (m, 5H), 1.95 – 1.81 (m, 1H), 1.75 (q, 
J = 7.1 Hz, 1H), 1.65 (d, J = 3.9 Hz, 3H), 1.52 (d, J = 6.9 Hz, 3H), 1.09 – 0.99 (m, 21H), 
0.95 (d, J = 6.8 Hz, 3H), 0.26 (s, 3H), 0.24 (s, 3H), 0.21 (s, 3H), 0.18 (s, 3H).  13C NMR 
(100 MHz, C6D6) δ 200.9, 176.6, 137.2, 131.2, 129.7, 129.0, 128.6, 127.2, 126.5, 84.1, 
72.1, 69.8, 69.5, 61.2, 45.1, 42.7, 41.4, 39.0, 36.7, 36.2, 31.6, 26.4, 26.2, 18.7, 18.3, 18.3, 
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13.3, 10.1, -2.4, -3.8, -4.0, -4.1.  HRMS calc m/z [C38H67NO4S2Si2 + Na]+: 744.3942, 
found: 744.3884. 
 
(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-3,5-bis((tert-
butyldimethylsilyl)oxy)-7-methoxy-6,8-dimethyl-2-propyldodec-10-en-1-one (4.49b).  
To a solution of alcohol 4.48b (59.4 mg, 0.0934 mmol) and 2,6-lutidine (22 µL, 0.19 
mmol) in DCM (0.85 mL) at 0 °C was added TBSOTf (32 µL, 0.14 mmol) dropwise.  
The reaction was removed from the ice bath and stirred at room temperature.  The 
reaction was incomplete by TLC analysis after 30 min and cooled to 0 °C.  Additional 
2,6-lutidine (16 µL, 0.14 mmol) was added to the reaction followed by the addition 
TBSOTf (21 µL, 0.093 mmol) dropwise.  The reaction was removed from the ice bath 
and stirred at room temperature.  After 30 min, the reaction was quenched with saturated 
aqueous NaHCO3.  The layers were separated and the aqueous phase was extract three 
times with DCM.  The combined organic layers were washed with brine and dried with 
anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatography (100:3 hexanes:EtOAc) to yield 60.7 mg of product as a yellow oil 
(87% yield).  1H NMR (400 MHz, C6D6) δ 7.14 – 6.98 (m, 5H), 5.53 – 5.36 (m, 2H), 5.27 
– 5.10 (m, 2H), 4.40 (dd, J = 9.4, 4.2 Hz, 1H), 4.21 (dt, J = 8.0, 4.4 Hz, 1H), 3.54 (s, 3H), 
3.34 (dd, J = 9.7, 1.7 Hz, 1H), 3.24 (dd, J = 13.1, 3.4 Hz, 1H), 2.88 – 2.69 (m, 2H), 2.40 
– 2.22 (m, 3H), 2.23 – 2.05 (m, 3H), 1.94 – 1.81 (m, 2H), 1.81 – 1.56 (m, 6H), 1.09 – 
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0.98 (m, 25H), 0.95 (d, J = 6.9 Hz, 3H), 0.31 (s, 3H), 0.29 (s, 3H), 0.21 (s, 3H), 0.21 (s, 
3H).  13C NMR (100 MHz, C6D6) δ 201.2, 176.0, 137.2, 131.1, 129.7, 129.0, 127.2, 
126.4, 84.0, 71.8, 69.9, 69.8, 61.1, 50.1, 42.7, 41.3, 38.9, 36.7, 36.2, 31.5, 30.9, 26.3, 
26.2, 21.3, 18.7, 18.3, 18.2, 14.8, 13.2, 10.1, -2.5, -3.8, -4.1, -4.1.  HRMS calc m/z 
[C40H71NO4S2Si2 + Na]+: 772.4261, found: 772.4137. 
 
(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-3,5-bis((tert-
butyldimethylsilyl)oxy)-7-methoxy-6,8-dimethyl-2-(2,2,2-trifluoroethyl)dodec-10-en-
1-one (4.49c).  The product was synthesized following the procedure for the synthesis of 
intermediate 4.49b.  Reaction with alcohol 4.48c (70.2 mg, 0.104 mmol) resulted in 66.5 
mg of product as a yellow oil (81% yield) after purification via silica gel flash 
chromatography (100:3 hexanes:EtOAc followed by 100:3 hexanes:acetone, and 4% 
ether in hexanes twice).  1H NMR (400 MHz, C6D6) δ 7.11 – 6.92 (m, 5H), 5.88 (d, J = 
9.9 Hz, 1H), 5.56 – 5.35 (m, 2H), 5.10 (ddd, J = 10.3, 6.7, 3.2 Hz, 1H), 4.38 (dd, J = 9.0, 
5.1 Hz, 1H), 4.16 (s, 1H), 3.58 (d, J = 0.9 Hz, 3H), 3.55 – 3.37 (m, 1H), 3.30 (d, J = 9.5 
Hz, 1H), 3.18 (dd, J = 13.2, 3.2 Hz, 1H), 2.77 – 2.52 (m, 3H), 2.36 – 2.22 (m, 1H), 2.21 – 
2.07 (m, 2H), 2.07 – 1.94 (m, 2H), 1.88 – 1.70 (m, 2H), 1.65 (d, J = 3.9 Hz, 3H), 1.05 (d, 
J = 6.7 Hz, 3H), 1.02 (s, 8H), 0.98 (s, 7H), 0.91 (d, J = 6.8 Hz, 3H), 0.27 (s, 6H), 0.11 (s, 
3H), 0.05 (s, 3H).  13C NMR (100 MHz, C6D6) δ 201.0, 173.1, 137.1, 131.0, 129.7, 129.1, 
127.3, 126.6, 83.8, 70.9, 70.2, 68.7, 61.2, 45.1, 43.5, 41.2, 38.9, 36.3, 36.2, 31.3, 30.7 (q, 
J = 29.1 Hz), 26.3, 26.1, 18.6, 18.3, 18.3, 13.4, 10.2, -2.8, -3.9, -3.9, -4.7.  Quaternary -
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CF3 13C resonance not observed in spectrum.  19F NMR (376 MHz, C6D6) δ -63.6.  
HRMS calc m/z [C39H66F3NO4S2Si2 + Na]+: 812.3822, found: 812.3812. 
 
(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-3,5-bis((tert-
butyldimethylsilyl)oxy)-2-cyclopropyl-7-methoxy-6,8-dimethyldodec-10-en-1-one 
(4.49d).  The product was synthesized following the procedure for the synthesis of 
intermediate 4.49b.  Reaction with alcohol 4.48d (67.8 mg, 0.107 mmol) resulted in 75.4 
mg of product as a yellow oil (93% yield) after purification via silica gel flash 
chromatography (100:3 hexanes:EtOAc followed by 4% ether in hexanes).  1H NMR 
(400 MHz, C6D6) δ 7.14 – 6.97 (m, 5H), 5.60 – 5.37 (m, 2H), 5.15 (ddd, J = 10.6, 6.9, 3.3 
Hz, 1H), 4.86 (dd, J = 10.2, 3.6 Hz, 1H), 4.66 (dd, J = 9.4, 4.7 Hz, 1H), 4.28 (dt, J = 8.3, 
4.4 Hz, 1H), 3.49 (s, 3H), 3.38 (dd, J = 9.8, 1.5 Hz, 1H), 3.28 (dd, J = 13.0, 3.3 Hz, 1H), 
2.79 (dd, J = 13.1, 10.8 Hz, 1H), 2.67 (dd, J = 11.5, 7.0 Hz, 1H), 2.43 (ddd, J = 13.3, 7.9, 
4.6 Hz, 1H), 2.34 – 2.21 (m, 1H), 2.20 – 2.06 (m, 3H), 1.96 (p, J = 7.1 Hz, 1H), 1.77 (q, J 
= 7.1 Hz, 1H), 1.72 – 1.62 (m, 3H), 1.62 – 1.48 (m, 1H), 1.11 – 1.00 (m, 22H), 0.98 (d, J 
= 6.8 Hz, 3H), 0.76 (dp, J = 9.0, 4.7 Hz, 1H), 0.56 (ddp, J = 24.2, 9.6, 5.0 Hz, 2H), 0.35 
(s, 3H), 0.35 (s, 3H), 0.21 (s, 3H), 0.20 (s, 3H)  13C NMR (100 MHz, C6D6) δ 201.7, 
175.9, 137.4, 131.2, 129.8, 129.0, 128.6, 127.2, 126.5, 84.0, 73.0, 70.2, 69.6, 61.2, 54.1, 
43.0, 41.0, 38.9, 36.8, 36.2, 31.5, 26.4, 26.3, 18.8, 18.3, 18.3, 13.3, 11.1, 10.1, 5.6, 3.9, -
2.0, -3.7, -4.1, -4.3.  HRMS calc m/z [C40H69NO4S2Si2 + Na]+: 770.4068, found: 
770.4068. 
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(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-3,5-bis((tert-
butyldimethylsilyl)oxy)-2-isobutyl-7-methoxy-6,8-dimethyldodec-10-en-1-one 
(4.49e).  The product was synthesized following the procedure for the synthesis of 
intermediate 4.49b.  Reaction with alcohol 4.48e (51.6 mg, 0.0794 mmol) resulted in 49.2 
mg of product as a yellow oil (81% yield) after purification via silica gel flash 
chromatography (100:3 hexanes:ether).  1H NMR (400 MHz, C6D6) δ 7.11 – 6.97 (m, 
5H), 5.60 – 5.39 (m, 2H), 5.34 (dt, J = 9.6, 4.0 Hz, 1H), 5.16 (ddd, J = 10.5, 6.8, 3.5 Hz, 
1H), 4.41 (dd, J = 9.7, 4.4 Hz, 1H), 4.20 (ddd, J = 7.8, 4.8, 3.1 Hz, 1H), 3.55 (s, 3H), 3.36 
(dd, J = 9.6, 1.6 Hz, 1H), 3.27 (dd, J = 13.1, 3.4 Hz, 1H), 2.88 – 2.69 (m, 2H), 2.41 (ddd, 
J = 13.6, 9.6, 6.3 Hz, 1H), 2.34 – 2.07 (m, 5H), 2.03 – 1.94 (m, 1H), 1.94 – 1.86 (m, 1H), 
1.86 – 1.72 (m, 1H), 1.74 – 1.59 (m, 4H), 1.13 (d, J = 5.3 Hz, 4H), 1.08 (d, J = 6.8 Hz, 
3H), 1.04 (s, 9H), 1.02 (s, 9H), 0.95 (d, J = 6.9 Hz, 3H), 0.31 (s, 3H), 0.29 (s, 3H), 0.19 
(s, 3H), 0.16 (s, 3H).  13C NMR (100 MHz, C6D6) δ 201.0, 175.7, 137.3, 131.2, 129.8, 
129.1, 127.2, 126.5, 84.0, 71.8, 70.1, 69.7, 61.1, 48.6, 42.4, 41.2, 39.0, 36.7, 36.4, 36.3, 
31.5, 26.8, 26.4, 26.2, 23.7, 23.3, 18.7, 18.3, 18.3, 13.5, 10.2, -2.4, -3.6, -3.8, -4.2.  
HRMS calc m/z [C41H73NO4S2Si2 + Na]+: 786.4417, found: 786.4306. 
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(2S,3R,5R,6R,7R,8S,E)-2-Benzyl-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-3,5-
bis((tert-butyldimethylsilyl)oxy)-7-methoxy-6,8-dimethyldodec-10-en-1-one (4.49f).  
The product was synthesized following the procedure for the synthesis of intermediate 
4.41.  Reaction with alcohol 4.48f (51.6 mg, 0.0754 mmol) resulted in 47.1 mg of product 
as a yellow oil (78% yield) after purification via silica gel flash chromatography (100:3 
hexanes:EtOAc).  1H NMR (400 MHz, C6D6) δ 7.66 – 7.58 (m, 2H), 7.24 – 7.18 (m, 2H), 
7.10 – 6.99 (m, 4H), 6.98 – 6.91 (m, 2H), 5.83 (ddd, J = 9.1, 6.1, 3.3 Hz, 1H), 5.60 – 5.35 
(m, 2H), 5.14 (ddd, J = 10.5, 6.9, 3.4 Hz, 1H), 4.49 (dd, J = 9.7, 4.4 Hz, 1H), 4.29 (dt, J = 
7.9, 4.4 Hz, 1H), 3.63 (dd, J = 13.9, 8.9 Hz, 1H), 3.56 (s, 3H), 3.37 (dd, J = 9.6, 1.6 Hz, 
1H), 3.28 (dd, J = 14.0, 6.1 Hz, 1H), 2.90 (dd, J = 13.2, 3.3 Hz, 1H), 2.69 (dd, J = 11.5, 
7.0 Hz, 1H), 2.58 (dd, J = 13.3, 10.7 Hz, 1H), 2.36 – 2.22 (m, 2H), 2.22 – 2.06 (m, 3H), 
1.92 (dt, J = 13.7, 6.9 Hz, 1H), 1.78 (q, J = 7.1 Hz, 1H), 1.70 – 1.60 (m, 3H), 1.10 – 1.04 
(m, 13H), 1.03 (s, 10H), 0.96 (d, J = 6.9 Hz, 3H), 0.26 (s, 6H), 0.19 (s, 3H), 0.18 (s, 3H).  
13C NMR (100 MHz, C6D6) δ 201.1, 175.0, 139.8, 137.2, 131.2, 130.1, 129.7, 129.0, 
128.7, 128.6, 127.2, 126.7, 126.5, 84.1, 71.3, 69.7, 69.6, 61.2, 51.5, 43.0, 41.2, 39.0, 36.5, 
36.3, 33.6, 31.2, 26.4, 26.3, 18.7, 18.4, 18.3, 13.5, 10.1, -2.4, -3.8, -3.9, -4.1.  HRMS calc 
m/z [C44H71NO4S2Si2 + Na]+: 820.4261, found: 820.4097. 
 
(2S,3R,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-7-methoxy-2,6,8-
trimethyldodec-10-enal (4.46a).  To a solution of amide 4.49a (77.9 mg, 0.108 mmol) in 
DCM (2.6 mL) at -78 °C was added DIBAL-H (1 M in hexanes, 0.22 mL, 0.22 mmol) 
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dropwise.  The reaction was determined to be complete after the reaction turned from 
yellow to clear upon addition of DIBAL-H.  The reaction was quenched with saturated 
aqueous Rochelle salt and diluted with DCM and warmed to room temperature.  The 
slurry was stirred at room temperature for 1.5 h.  The layers were separated and the 
aqueous phase was extracted three times with DCM.  The combined organic layers were 
washed with brine and dried with anhydrous Na2SO4.  The salts were removed via gravity 
filtration and volatile materials were removed using a rotary evaporator.  The crude 
material was purified via silica gel flash chromatography (4% EtOAc in hexanes) to yield 
50.0 mg of product as a colorless oil (90% yield).  1H NMR (400 MHz, C6D6) δ 9.53 (s, 
1H), 5.56 – 5.33 (m, 2H), 4.34 (ddd, J = 8.4, 5.6, 2.0 Hz, 1H), 4.15 (dd, J = 9.4, 5.3 Hz, 
1H), 3.39 (s, 2H), 3.27 (dd, J = 9.9, 1.6 Hz, 1H), 2.39 (qd, J = 6.9, 2.2 Hz, 1H), 2.32 – 
2.16 (m, 1H), 2.16 – 2.02 (m, 1H), 2.03 – 1.85 (m, 2H), 1.79 – 1.60 (m, 5H), 1.20 (d, J = 
7.0 Hz, 2H), 0.99 (s, 9H), 0.97 (d, J = 6.8 Hz, 3H), 0.91 (s, 8H), 0.90 (d, J = 6.9 Hz, 3H), 
0.15 (s, 3H), 0.13 (s, 3H), 0.12 (s, 3H), 0.04 (s, 3H).  13C NMR (100 MHz, C6D6) δ 202.8, 
130.9, 126.6, 83.8, 69.1, 68.9, 61.1, 50.1, 40.9, 40.7, 38.8, 36.0, 26.2, 25.9, 18.5, 18.2, 
18.2, 13.0, 9.5, 6.8, -2.8, -4.0, -4.2, -4.6.  HRMS calc m/z [C28H58O4Si2 + Na]+: 537.3771, 
found: 537.3771. 
 
(2S,3R,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-7-methoxy-6,8-dimethyl-
2-propyldodec-10-enal (4.46b)  The product was synthesized following the procedure 
for the synthesis of intermediate 4.46a.  Reaction with amide 4.49b (59.2 mg, 0.0789 
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mmol) resulted in 31.4 mg of product as a colorless oil (73% yield) after purification via 
silica gel flash chromatography (4% EtOAc in hexanes).  1H NMR (400 MHz, C6D6) δ 
9.72 (d, J = 1.3 Hz, 1H), 5.54 – 5.32 (m, 2H), 4.31 (td, J = 8.2, 2.5 Hz, 1H), 4.25 – 4.14 
(m, 2H), 3.41 (s, 3H), 3.27 (dd, J = 9.7, 1.7 Hz, 1H), 2.41 (d, J = 9.8 Hz, 1H), 2.32 – 2.17 
(m, 1H), 2.18 – 2.05 (m, 1H), 2.06 – 1.91 (m, 3H), 1.81 – 1.68 (m, 2H), 1.68 – 1.60 (m, 
3H), 1.63 – 1.44 (m, 2H), 1.40 – 1.23 (m, 1H), 1.01 – 0.92 (m, 23H), 0.90 (d, J = 6.9 Hz, 
3H), 0.18 (s, 3H), 0.15 (s, 3H), 0.13 (s, 3H), 0.06 (s, 3H).  13C NMR (100 MHz, C6D6) δ 
203.4, 130.9, 126.5, 83.9, 69.9, 69.3, 61.0, 55.7, 41.1, 40.6, 38.8, 36.1, 26.2, 26.0, 25.5, 
21.7, 18.5, 18.2, 18.2, 14.4, 12.9, 9.5, -2.8, -4.1, -4.2, -4.5.  HRMS calc m/z [C30H62O4Si2 
+ Na]+: 565.4084, found: 565.4067. 
 
(2S,3R,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-7-methoxy-6,8-dimethyl-
2-(2,2,2-trifluoroethyl)dodec-10-enal (4.46c).  The product was synthesized following 
the procedure for the synthesis of intermediate 4.42.  Reaction with amide 4.49c (63.2 
mg, 0.0800 mmol) resulted in 24.6 mg of product as a colorless oil (53% yield) after 
purification via silica gel flash chromatography (100:1 DCM:ether followed by 40% 
DCM in hexanes to 1% ether in DCM).   1H NMR (400 MHz, C6D6) δ 9.41 (s, 1H), 5.55 
– 5.30 (m, 2H), 4.33 (dd, J = 9.4, 5.1 Hz, 1H), 4.21 (dd, J = 10.3, 4.9 Hz, 1H), 3.39 (s, 
3H), 3.25 (d, J = 9.2 Hz, 1H), 3.08 – 2.89 (m, 1H), 2.85 (d, J = 8.5 Hz, 1H), 2.44 – 2.29 
(m, 1H), 2.28 – 2.16 (m, 1H), 2.16 – 2.03 (m, 1H), 1.97 (ddd, J = 15.1, 10.3, 5.3 Hz, 1H), 
1.86 (ddd, J = 14.0, 9.5, 5.0 Hz, 1H), 1.77 – 1.58 (m, 5H), 1.01 – 0.93 (m, 12H), 0.87 (d, 
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J = 6.9 Hz, 3H), 0.84 (s, 9H), 0.13 (s, 6H), 0.03 (s, 3H), -0.05 (s, 3H).  13C NMR (100 
MHz, C6D6) δ 198.9, 130.9, 126.7, 83.7, 68.5, 68.1, 61.1, 49.8 (d, J = 1.8 Hz), 40.8, 40.4, 
38.8, 36.1, 26.9 (q, J = 29.3 Hz), 26.1, 25.8, 18.5, 18.3, 18.1, 12.9, 9.4, -3.1, -4.2, -4.3, -
4.8.  Quaternary -CF3 13C resonance not observed in spectrum.  19F NMR (376 MHz, 
C6D6) δ -64.3.  HRMS calc m/z [C29H57F3O4Si2 + Na]+: 605.3640, found: 605.3620. 
 
(2S,3R,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-2-cyclopropyl-7-
methoxy-6,8-dimethyldodec-10-enal (4.46d).  The product was synthesized following 
the procedure for the synthesis of intermediate 4.46a.  Reaction with amide 4.49d (75.4 
mg, 0.101 mmol) resulted in 49.2 mg of product as a colorless oil (90% yield) after 
purification via silica gel flash chromatography (4% EtOAc in hexanes).  1H NMR (400 
MHz, C6D6) δ 9.82 (d, J = 1.5 Hz, 1H), 5.56 – 5.32 (m, 2H), 4.42 (ddd, J = 8.4, 5.6, 2.3 
Hz, 1H), 4.25 (ddd, J = 9.4, 5.4, 1.2 Hz, 1H), 3.39 (s, 3H), 3.28 (dd, J = 9.7, 1.6 Hz, 1H), 
2.34 – 2.15 (m, 2H), 2.13 – 2.03 (m, 1H), 1.98 (ddd, J = 13.4, 9.4, 5.7 Hz, 1H), 1.76 – 
1.66 (m, 2H), 1.66 – 1.62 (m, 3H), 1.57 (dt, J = 10.0, 1.9 Hz, 1H), 1.27 – 1.13 (m, 1H), 
1.01 (s, 9H), 0.98 – 0.93 (m, 12H), 0.90 (d, J = 6.9 Hz, 3H), 0.61 – 0.43 (m, 2H), 0.27 
(dq, J = 9.3, 4.9 Hz, 1H), 0.21 (s, 3H), 0.18 (s, 6H), 0.11 (s, 3H), 0.01 (dq, J = 9.9, 5.1, 
4.7 Hz, 1H).  13C NMR (100 MHz, C6D6) δ 203.9, 131.0, 126.5, 83.8, 70.5, 69.5, 60.9, 
60.4, 41.3, 40.5, 38.9, 36.0, 26.3, 26.1, 18.6, 18.3, 18.2, 13.0, 9.5, 5.7, 5.2, 2.6, -2.4, -3.9, 
-4.0, -4.5.  HRMS calc m/z [C30H60O4Si2 + Na]+: 563.3922, found: 563.3929. 
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(2S,3R,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-2-isobutyl-7-methoxy-
6,8-dimethyldodec-10-enal (4.46e).  The product was synthesized following the 
procedure for the synthesis of intermediate 4.42.  Reaction with amide 4.49e (49.2 mg, 
0.0644 mmol) resulted in 29.2 mg of product as a colorless oil (81% yield) after 
purification via silica gel flash chromatography (4% EtOAc in hexanes).  1H NMR (400 
MHz, C6D6) δ 9.76 (d, J = 1.6 Hz, 1H), 5.51 – 5.37 (m, 2H), 4.32 (ddd, J = 8.6, 6.0, 2.5 
Hz, 1H), 4.22 (dd, J = 9.5, 5.3 Hz, 1H), 3.41 (s, 3H), 3.29 (dd, J = 9.7, 1.7 Hz, 1H), 2.52 
(dd, J = 10.2, 2.2 Hz, 1H), 2.32 – 2.19 (m, 1H), 2.17 – 1.90 (m, 4H), 1.80 – 1.67 (m, 3H), 
1.65 (d, J = 4.0 Hz, 3H), 1.40 (ddd, J = 14.0, 9.1, 3.0 Hz, 1H), 1.02 – 0.93 (m, 27H), 0.91 
(d, J = 6.9 Hz, 3H), 0.19 (s, 3H), 0.16 (s, 3H), 0.13 (s, 3H), 0.07 (s, 3H).  13C NMR (100 
MHz, C6D6) δ 203.9, 131.0, 126.5, 83.7, 70.2, 69.1, 60.9, 53.7, 40.8, 40.3, 38.8, 36.1, 
32.2, 26.6, 26.2, 26.0, 23.8, 22.1, 18.5, 18.2, 12.9, 9.4, -2.7, -4.1, -4.5.  HRMS calc m/z 
[C31H64O4Si2 + Na]+: 579.4235, found: 579.4234. 
 
(2S,3R,5R,6R,7R,8S,E)-2-Benzyl-3,5-bis((tert-butyldimethylsilyl)oxy)-7-methoxy-6,8-
dimethyldodec-10-enal (4.46f).  The product was synthesized following the procedure 
for the synthesis of intermediate 4.46a.  Reaction with 4.49f (47.1 mg, 0.0590 mmol) 
resulted in 28.2 mg of product as a colorless oil (81% yield) after purification via silica 
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gel flash chromatography (4% EtOAc in hexanes).  1H NMR (400 MHz, C6D6) δ 9.69 (d, 
J = 1.0 Hz, 1H), 7.30 (d, J = 7.4 Hz, 2H), 7.20 – 7.12 (m, 2H), 7.05 (td, J = 7.1, 1.3 Hz, 
1H), 5.55 – 5.33 (m, 2H), 4.40 (ddd, J = 8.4, 6.0, 2.2 Hz, 1H), 4.28 (dd, J = 9.5, 5.4 Hz, 
1H), 3.42 (s, 3H), 3.36 (dd, J = 14.5, 9.4 Hz, 1H), 3.29 (dd, J = 9.7, 1.6 Hz, 1H), 2.98 
(dd, J = 14.5, 4.2 Hz, 1H), 2.91 – 2.80 (m, 1H), 2.31 – 2.16 (m, 1H), 2.17 – 1.96 (m, 3H), 
1.81 – 1.68 (m, 2H), 1.65 (d, J = 4.3 Hz, 3H), 1.02 – 0.93 (m, 22H), 0.90 (d, J = 6.9 Hz, 
3H), 0.15 (s, 3H), 0.13 (s, 3H), 0.12 (s, 3H), 0.05 (s, 3H).  13C NMR (100 MHz, C6D6) δ 
202.5, 140.5, 130.9, 129.4, 128.9, 126.5, 83.8, 69.4, 69.2, 61.0, 57.5, 41.0, 40.4, 38.8, 
36.0, 29.3, 26.2, 26.0, 18.5, 18.2, 13.0, 9.5, -2.7, -4.1, -4.1, -4.6.  HRMS calc m/z 
[C34H62O4Si2 + Na]+: 613.4079, found: 613.4087. 
 
(2Z,4R,5R,7R,8R,9R,10S,12E)-Ethyl 5,7-Bis((tert-butyldimethylsilyl)oxy)-9-methoxy-
4,8,10-trimethyltetradeca-2,12-dienoate (4.47a).  The product was synthesized 
following the procedure for the synthesis of intermediate 4.32.  Reaction with aldehyde 
4.46a (49.2 mg, 0.0955 mmol) resulted in 39.6 mg of product as a colorless oil (71% 
yield) after purification via silica gel flash chromatography (4% EtOAc in hexanes).  1H 
NMR (400 MHz, C6D6) δ 6.22 (dd, J = 11.6, 9.5 Hz, 1H), 5.84 (dd, J = 11.5, 0.9 Hz, 1H), 
5.53 – 5.37 (m, 2H), 4.38 (ddd, J = 9.5, 4.8, 1.2 Hz, 1H), 4.10 – 3.90 (m, 4H), 3.54 (d, J = 
1.5 Hz, 3H), 3.36 (dd, J = 9.6, 1.7 Hz, 1H), 2.42 – 2.27 (m, 1H), 2.23 – 2.11 (m, 1H), 
2.11 – 1.91 (m, 3H), 1.81 (qd, J = 7.2, 1.7 Hz, 1H), 1.73 – 1.56 (m, 3H), 1.21 (d, J = 6.5 
Hz, 3H), 1.11 (d, J = 6.9 Hz, 3H), 1.03 (s, 9H), 1.01 – 0.94 (m, 16H), 0.24 (s, 3H), 0.23 
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(s, 3H), 0.15 (s, 3H), 0.08 (s, 3H).  13C NMR (100 MHz, C6D6) δ 165.7, 153.8, 131.3, 
126.3, 119.1, 84.1, 72.8, 69.5, 61.0, 59.7, 41.9, 40.7, 39.0, 37.1, 36.3, 26.3, 26.1, 18.6, 
18.3, 18.2, 14.3, 13.7, 13.2, 9.8, -2.7, -3.9, -4.0, -4.3.  HRMS calc m/z [C32H64O5Si2 + 
Na]+: 607.4184, found: 607.4182. 
 
(2Z,4R,5R,7R,8R,9R,10S,12E)-Ethyl 5,7-Bis((tert-butyldimethylsilyl)oxy)-9-methoxy-
8,10-dimethyl-4-propyltetradeca-2,12-dienoate (4.47b).  The product was synthesized 
following the procedure for the synthesis of intermediate 4.32.  Reaction with aldehyde 
4.46b (31.4 mg, 0.0578 mmol) resulted in 29.8 mg of product as a colorless oil (84% 
yield) after purification via silica gel flash chromatography (3% ether in hexanes).  1H 
NMR (400 MHz, C6D6) δ 6.17 (dd, J = 11.7, 10.0 Hz, 1H), 5.94 (d, J = 11.7 Hz, 1H), 
5.56 – 5.41 (m, 2H), 4.40 (dd, J = 9.8, 4.7 Hz, 1H), 4.11 – 3.88 (m, 4H), 3.54 (s, 3H), 
3.39 (dd, J = 9.6, 1.7 Hz, 1H), 2.41 – 2.29 (m, 1H), 2.26 – 2.09 (m, 2H), 2.09 – 1.95 (m, 
2H), 1.92 – 1.75 (m, 2H), 1.73 – 1.65 (m, 3H), 1.65 – 1.55 (m, 1H), 1.45 (tq, J = 13.5, 7.4 
Hz, 2H), 1.14 (d, J = 6.8 Hz, 3H), 1.07 – 0.94 (m, 27H), 0.26 (s, 3H), 0.25 (s, 3H), 0.17 
(s, 3H), 0.10 (s, 3H).  13C NMR (100 MHz, C6D6) δ 165.8, 153.5, 131.3, 126.3, 120.6, 
84.1, 73.1, 69.5, 61.0, 59.7, 42.1, 41.9, 40.5, 39.0, 36.3, 30.9, 26.3, 26.2, 20.9, 18.6, 18.3, 
18.2, 14.5, 14.2, 13.2, 9.8, -2.6, -3.9, -4.0, -4.3.  HRMS calc m/z [C34H68O5Si2 + Na]+: 
635.4497, found: 635.4536. 
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(2Z,4R,5R,7R,8R,9R,10S,12E)-Ethyl 5,7-Bis((tert-butyldimethylsilyl)oxy)-9-methoxy-
8,10-dimethyl-4-(2,2,2-trifluoroethyl)tetradeca-2,12-dienoate (4.47c).  The product 
was synthesized following the procedure for the synthesis of intermediate 4.32.  Reaction 
with aldehyde 4.46c (24.6 mg, 0.0422 mmol) resulted in 26.3 mg of product as a 
colorless oil (95% yield) after purification via silica gel flash chromatography (4% 
EtOAc in hexanes).  1H NMR (400 MHz, C6D6) δ 6.17 – 6.03 (m, 1H), 5.86 (dd, J = 11.5, 
1.0 Hz, 1H), 5.53 – 5.41 (m, 2H), 4.43 – 4.35 (m, 1H), 4.31 (t, J = 10.2 Hz, 1H), 4.05 – 
3.88 (m, 3H), 3.53 (s, 3H), 3.35 (dd, J = 9.6, 1.7 Hz, 1H), 2.75 – 2.54 (m, 1H), 2.41 – 
2.24 (m, 2H), 2.24 – 2.11 (m, 1H), 2.08 – 1.88 (m, 3H), 1.80 (qd, J = 7.1, 1.7 Hz, 1H), 
1.70 – 1.62 (m, 3H), 1.11 (d, J = 6.9 Hz, 3H), 1.01 (s, 9H), 0.98 – 0.87 (m, 15H), 0.23 (d, 
J = 0.7 Hz, 6H), 0.08 (s, 3H), -0.01 (s, 3H).  13C NMR (100 MHz, C6D6) δ 165.4, 150.7, 
131.3, 126.4, 121.0, 84.0, 73.0, 68.8, 61.1, 60.0, 42.5, 40.5, 39.0, 37.1 (d, J = 2.6 Hz), 
36.4, 33.8 (q, J = 27.6 Hz), 26.3, 26.1, 18.6, 18.3, 18.3, 14.1, 13.3, 9.7, -2.9, -4.0, -4.1, -
4.5.  Quaternary -CF3 13C resonance not observed in spectrum.  19F NMR (376 MHz, 
C6D6) δ -63.0.  HRMS calc m/z [C33H63F3O5Si2 + Na]+: 675.4064, found: 675.4087. 
 
(2Z,4R,5R,7R,8R,9R,10S,12E)-Ethyl 5,7-Bis((tert-butyldimethylsilyl)oxy)-4-
cyclopropyl-9-methoxy-8,10-dimethyltetradeca-2,12-dienoate (4.47d).  The product 
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was synthesized following the procedure for the synthesis of 4.32.  Reaction with 
aldehyde 4.46d (48.2 mg, 0.0891 mmol) resulted in 48.9 mg of product as a colorless oil 
(90% yield) after purification via silica gel flash chromatography (100:4 
hexanes:EtOAc).  1H NMR (400 MHz, C6D6) δ 6.38 (dd, J = 11.6, 10.2 Hz, 1H), 5.89 
(dd, J = 11.7, 0.9 Hz, 1H), 5.54 – 5.38 (m, 2H), 4.50 (ddd, J = 9.4, 5.1, 1.3 Hz, 1H), 4.15 
(ddd, J = 8.4, 5.5, 2.8 Hz, 1H), 4.09 – 3.87 (m, 2H), 3.51 (d, J = 0.9 Hz, 3H), 3.40 (dd, J 
= 9.8, 1.5 Hz, 1H), 3.29 (td, J = 9.8, 2.7 Hz, 1H), 2.46 – 2.27 (m, 2H), 2.24 – 2.11 (m, 
1H), 2.09 – 1.94 (m, 2H), 1.82 (qd, J = 7.1, 1.5 Hz, 1H), 1.71 – 1.61 (m, 3H), 1.17 – 1.07 
(m, 1H), 1.12 (d, J = 6.8 Hz, 3H), 1.05 (s, 9H), 1.01 (s, 9H), 0.99 (d, J = 6.9 Hz, 3H), 
0.96 (t, J = 7.1 Hz, 3H), 0.70 – 0.55 (m, 2H), 0.44 – 0.32 (m, 2H), 0.27 (s, 3H), 0.24 (s, 
3H), 0.20 (s, 3H), 0.12 (s, 3H).  13C NMR (100 MHz, C6D6) δ 165.9, 152.2, 131.4, 126.4, 
119.2, 84.0, 73.3, 69.9, 61.0, 59.8, 46.9, 41.9, 40.6, 39.1, 36.3, 26.4, 26.2, 18.8, 18.4, 
18.3, 14.3, 13.3, 10.8, 9.8, 6.6, 2.5, -2.2, -3.8, -3.9, -4.2  HRMS calc m/z [C34H66O5Si2 + 
Na]+: 633.4341, found: 633.4298. 
 
(2Z,4R,5R,7R,8R,9R,10S,12E)-Ethyl 5,7-Bis((tert-butyldimethylsilyl)oxy)-4-isobutyl-
9-methoxy-8,10-dimethyltetradeca-2,12-dienoate (4.47e).  The product was 
synthesized following the procedure for the synthesis of intermediate 4.32.  Reaction with 
aldehyde 4.46e (29.2 mg, 0.0524 mmol) resulted in 23.0 mg of product as a colorless oil 
(70% yield) after purification via silica gel flash chromatography (3% ether in hexanes).  
1H NMR (400 MHz, C6D6) δ 6.17 (dd, J = 11.7, 9.9 Hz, 1H), 5.94 (d, J = 11.9 Hz, 1H), 
  241 
5.57 – 5.40 (m, 2H), 4.41 (dd, J = 10.5, 4.5 Hz, 1H), 4.07 (ddd, J = 8.8, 5.2, 3.0 Hz, 1H), 
4.04 – 3.91 (m, 3H), 3.54 (s, 3H), 3.42 (dd, J = 9.7, 1.7 Hz, 1H), 2.42 – 2.31 (m, 1H), 
2.27 – 2.09 (m, 3H), 2.03 (ddd, J = 13.5, 10.3, 5.2 Hz, 1H), 1.85 (dq, J = 6.9, 1.2 Hz, 
1H), 1.75 – 1.51 (m, 6H), 1.19 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 5.7 Hz, 3H), 1.06 – 0.95 
(m, 27H), 0.27 (s, 3H), 0.25 (s, 3H), 0.16 (s, 3H), 0.09 (s, 3H).  13C NMR (100 MHz, 
C6D6) δ 165.8, 154.3, 131.4, 126.3, 120.4, 84.0, 73.3, 69.3, 61.1, 59.8, 41.8, 40.2, 40.1, 
39.1, 37.8, 36.4, 26.4, 26.3, 26.2, 24.8, 21.9, 18.7, 18.4, 18.3, 14.3, 13.3, 9.7, -2.4, -3.9, -
3.9, -4.3.  HRMS calc m/z [C35H70O5Si2 + Na]+: 649.4654, found: 649.4662. 
 
(2Z,4R,5R,7R,8R,9R,10S,12E)-Ethyl 4-Benzyl-5,7-bis((tert-butyldimethylsilyl)oxy)-9-
methoxy-8,10-dimethyltetradeca-2,12-dienoate (4.47f).  The product was synthesized 
following the procedure for the synthesis of intermediate 4.32.  Reaction with aldehyde 
4.46f (28.2 mg, 0.0477 mmol) resulted in 27.4 mg of product as a colorless oil (87% 
yield) after purification via silica gel flash chromatography (4% EtOAc in hexanes).  1H 
NMR (400 MHz, C6D6) δ 7.43 – 7.30 (m, 2H), 7.23 – 7.12 (m, 2H), 7.04 (t, J = 7.4 Hz, 
1H), 6.21 (dd, J = 11.6, 9.7 Hz, 1H), 5.76 (d, J = 11.6 Hz, 1H), 5.49 (q, J = 2.9, 1.6 Hz, 
2H), 4.55 (dd, J = 10.1, 4.8 Hz, 1H), 4.33 (td, J = 10.1, 8.2, 4.8 Hz, 1H), 4.16 (ddd, J = 
8.6, 5.3, 3.0 Hz, 1H), 3.98 – 3.77 (m, 2H), 3.58 (s, 3H), 3.43 (dd, J = 9.6, 1.7 Hz, 1H), 
3.30 (dd, J = 13.8, 4.2 Hz, 1H), 2.89 (dd, J = 13.8, 10.5 Hz, 1H), 2.45 – 2.31 (m, 1H), 
2.29 – 2.13 (m, 3H), 2.09 (ddd, J = 13.6, 10.1, 5.3 Hz, 1H), 1.85 (q, J = 7.0 Hz, 1H), 1.73 
– 1.61 (m, 3H), 1.17 (d, J = 6.8 Hz, 3H), 1.10 – 0.97 (m, 21H), 0.88 (t, J = 7.1 Hz, 4H), 
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0.24 (s, 3H), 0.21 (s, 4H), 0.17 (s, 3H), 0.09 (s, 3H).  13C NMR (100 MHz, C6D6) δ 165.6, 
152.8, 140.4, 131.3, 129.5, 128.6, 126.3, 126.3, 120.7, 84.2, 72.7, 69.4, 61.1, 59.6, 43.8, 
42.1, 40.3, 39.1, 36.4, 35.2, 26.3, 26.2, 18.6, 18.4, 18.2, 14.1, 13.3, 9.8, -2.5, -3.9, -4.0, -
4.3.  HRMS calc m/z [C38H68O5Si2 + Na]+: 683.4497, found: 683.4513. 
 
(5R,6R)-6-((2R,3S,4R,5S,E)-2-Hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-yl)-5-
methyl-5,6-dihydro-2H-pyran-2-one (4.44a).  The product was synthesized following 
the procedure for the synthesis of analog 4.20.  Reaction with ester 4.47a (35.9 mg, 
0.0614 mmol) resulted in 14.7 mg of product as a white solid (77% yield) after 
purification via silica gel flash chromatography (25% acetone in hexanes followed by 1:1 
hexanes:EtOAc).  1H NMR (400 MHz, C6D6) δ 6.05 (dd, J = 9.6, 6.1 Hz, 1H), 5.73 (dd, J 
= 9.7, 0.8 Hz, 1H), 5.61 – 5.23 (m, 2H), 4.59 (ddd, J = 9.8, 5.4, 3.4 Hz, 1H), 4.38 (ddd, J 
= 6.7, 4.6, 2.3 Hz, 1H), 3.17 (d, J = 2.6 Hz, 1H), 3.12 (s, 3H), 2.77 (dd, J = 6.4, 4.4 Hz, 
1H), 2.18 – 1.94 (m, 1H), 1.89 – 1.75 (m, 2H), 1.75 – 1.65 (m, 2H), 1.62 (dt, J = 6.2, 1.3 
Hz, 3H), 1.59 – 1.52 (m, 2H), 0.94 (d, J = 7.1 Hz, 3H), 0.93 (d, J = 6.5 Hz, 3H), 0.64 (d, 
J = 7.1 Hz, 3H).  13C NMR (100 MHz, C6D6) δ 163.5, 150.8, 129.5, 126.9, 120.3, 91.0, 
77.3, 67.2, 61.4, 39.6, 37.8, 37.5, 36.5, 32.8, 18.1, 15.5, 11.8, 11.4.  HRMS calc m/z 
[C18H30O4 + Na]+: 333.2036, found: 333.2023.  97% pure by HPLC analysis. 
 
  243 
(5R,6R)-6-((2R,3S,4R,5S,E)-2-Hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-yl)-5-
propyl-5,6-dihydro-2H-pyran-2-one (4.44b).  The product was synthesized following 
the procedure for the synthesis of analog 4.20.  Reaction with ester 4.47b (29.8 mg, 
0.0486 mmol) resulted in 11.4 mg of product as a white solid (69% yield) after 
purification via silica gel flash chromatography (40% EtOAc in hexanes).  1H NMR (400 
MHz, C6D6) δ 6.18 (dd, J = 9.8, 5.9 Hz, 1H), 5.80 (dd, J = 9.8, 0.9 Hz, 1H), 5.56 – 5.29 
(m, 2H), 4.66 (dt, J = 8.1, 3.8 Hz, 1H), 4.42 (dd, J = 9.5, 3.5 Hz, 1H), 3.19 (d, J = 2.6 Hz, 
1H), 3.12 (s, 3H), 2.78 (dd, J = 6.4, 4.3 Hz, 1H), 2.16 – 1.94 (m, 1H), 1.89 – 1.77 (m, 
2H), 1.77 – 1.66 (m, 2H), 1.66 – 1.55 (m, 5H), 1.32 – 1.16 (m, 2H), 1.16 – 1.01 (m, 1H), 
0.99 – 0.88 (m, 1H), 0.95 (d, J = 7.2 Hz, 3H), 0.94 (d, J = 6.5 Hz, 3H), 0.69 (t, J = 7.2 
Hz, 3H).  13C NMR (100 MHz, C6D6) δ 163.6, 149.9, 129.5, 126.9, 121.0, 91.0, 77.7, 
67.2, 61.4, 39.6, 37.5, 37.5, 37.5, 36.5, 30.0, 19.9, 18.1, 15.5, 14.2, 11.8.  HRMS calc m/z 
[C20H34O4 + Na]+: 361.2349, found: 361.2328.  98% pure by HPLC analysis. 
 
(5R,6R)-6-((2R,3S,4R,5S,E)-2-Hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-yl)-5-
(2,2,2-trifluoroethyl)-5,6-dihydro-2H-pyran-2-one (4.44c).  Ester 4.47c (20.8 mg, 
0.0319 mmol) was dissolved in a hydrochloric acid/ethanol solution (1% HCl in ethanol, 
0.8 mL) and stirred at room temperature overnight.  The reaction was diluted with DCM 
and quenched with saturated aqueous NaHCO3.  The layers were separated and the 
aqueous phase was extracted three times with DCM.  The combined organic phase was 
washed with brine and dried with anhydrous Na2SO4.  The salts were removed via gravity 
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filtration and volatile materials were removed using a rotary evaporator.  19F NMR 
spectroscopy of the crude material showed unreacted starting material.  The crude 
material was resubmitted to the reaction conditions and stirred overnight.  The reaction 
was diluted with DCM and quenched with saturated aqueous NaHCO3.  The layers were 
separated and the aqueous phase was extracted three times with DCM.  The combined 
organic phase was washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatography (5% to 
15% EtOAc in DCM) to yield 6.52 mg of product as a white solid (54% yield).  1H NMR 
(400 MHz, C6D6) δ 6.24 (ddt, J = 9.9, 6.3, 2.0 Hz, 1H), 5.70 (d, J = 9.8 Hz, 1H), 5.52 – 
5.39 (m, 1H), 5.39 – 5.28 (m, 1H), 4.37 (dd, J = 8.2, 4.1 Hz, 1H), 4.17 (dd, J = 10.2, 2.2 
Hz, 1H), 3.17 (s, 1H), 3.06 (s, 3H), 2.69 (dd, J = 6.7, 3.9 Hz, 1H), 2.20 – 1.92 (m, 3H), 
1.88 – 1.68 (m, 2H), 1.69 – 1.50 (m, 5H), 1.41 (ddd, J = 14.4, 10.1, 4.7 Hz, 1H), 1.26 (dd, 
J = 13.4, 9.5 Hz, 1H), 0.92 (d, J = 6.3 Hz, 3H), 0.87 (d, J = 7.1 Hz, 3H).  13C NMR (100 
MHz, C6D6) δ 162.7, 147.5, 129.3, 127.1, 121.6, 91.2, 77.2, 67.2, 61.5, 39.4, 37.4, 37.3, 
36.6, 32.3 (q, J = 28.1 Hz), 32.1 (d, J = 2.3 Hz), 18.2, 15.6, 11.9.  Quaternary -CF3 13C 
resonance not observed in spectrum.  19F NMR (376 MHz, C6D6) δ -62.9.  HRMS calc 
m/z [C19H29F3O4 + Na]+: 401.1910, found: 401.1906.  95% pure by HPLC analysis. 
 
(5R,6R)-5-Cyclopropyl-6-((2R,3S,4R,5S,E)-2-hydroxy-4-methoxy-3,5-dimethylnon-7-
en-1-yl)-5,6-dihydro-2H-pyran-2-one (4.44d).  The product was synthesized following 
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the procedure for the synthesis of analog 4.20.  Reaction with ester 4.47d (44.7 mg, 
0.0732 mmol) resulted in 18.0 mg of product as a white solid (73% yield) after 
purification via silica gel flash chromatography (45% to 50% EtOAc in hexanes).  1H 
NMR (400 MHz, C6D6) δ 6.09 (dd, J = 9.7, 5.9 Hz, 1H), 5.80 (dd, J = 9.7, 0.9 Hz, 1H), 
5.54 – 5.30 (m, 2H), 4.67 (dt, J = 9.5, 3.3 Hz, 1H), 4.51 (dq, J = 9.6, 2.5 Hz, 1H), 3.17 
(dd, J = 2.6, 1.3 Hz, 1H), 3.14 (s, 3H), 2.80 (dd, J = 6.3, 4.2 Hz, 1H), 2.18 – 2.03 (m, 
1H), 1.94 – 1.71 (m, 5H), 1.68 – 1.58 (m, 3H), 1.02 (d, J = 7.1 Hz, 3H), 0.95 (d, J = 6.3 
Hz, 3H), 0.89 – 0.81 (m, 1H), 0.46 – 0.34 (m, 1H), 0.22 (dddd, J = 9.2, 7.9, 5.8, 4.4 Hz, 
1H), 0.10 (dddd, J = 9.2, 8.1, 5.5, 4.4 Hz, 1H), -0.10 (dq, J = 9.8, 5.0 Hz, 1H), -0.29 (dq, 
J = 9.8, 5.0 Hz, 1H).  13C NMR (100 MHz, C6D6) δ 162.4, 147.1, 128.3, 125.7, 119.5, 
89.9, 76.7, 65.9, 60.2, 41.1, 38.4, 36.8, 36.3, 35.3, 16.9, 14.3, 10.7, 7.4, 3.8, 0.0.  HRMS 
calc m/z [C20H32O4 + Na]+: 359.2193, found: 359.2167.  97% pure by HPLC analysis. 
 
(5R,6R)-6-((2R,3S,4R,5S,E)-2-Hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-yl)-5-
isobutyl-5,6-dihydro-2H-pyran-2-one (4.44e).  The product was synthesized following 
the procedure for the synthesis of analog 4.20.  Reaction with ester 4.47e (23.0 mg, 
0.0367 mmol) resulted in 7.57 mg of product as a white solid (59% yield) after 
purification via silica gel flash chromatography (35% EtOAc in hexanes).  1H NMR (400 
MHz, C6D6) δ 6.19 (dd, J = 9.8, 6.0 Hz, 1H), 5.81 (dd, J = 9.8, 0.8 Hz, 1H), 5.54 – 5.29 
(m, 2H), 4.68 (dt, J = 7.9, 3.8 Hz, 1H), 4.42 (d, J = 8.7 Hz, 1H), 3.18 (d, J = 1.9 Hz, 1H), 
3.12 (s, 3H), 2.77 (dd, J = 6.4, 4.3 Hz, 1H), 2.16 – 1.99 (m, 1H), 1.93 – 1.76 (m, 3H), 
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1.75 – 1.67 (m, 1H), 1.67 – 1.56 (m, 5H), 1.32 – 1.21 (m, 2H), 1.14 (ddd, J = 13.6, 11.3, 
4.8 Hz, 1H), 0.95 (d, J = 7.1 Hz, 3H), 0.93 (d, J = 6.4 Hz, 3H), 0.70 (d, J = 6.2 Hz, 3H), 
0.65 (d, J = 6.3 Hz, 3H).  13C NMR (100 MHz, C6D6) δ 163.6, 150.1, 129.5, 126.9, 120.9, 
91.1, 77.9, 67.3, 61.4, 39.6, 37.5, 37.5, 36.8, 36.5, 35.6, 25.1, 24.0, 21.3, 18.1, 15.5, 11.8.  
HRMS calc m/z [C21H36O4 + Na]+: 375.2506, found: 375.2489.  93% pure by HPLC 
analysis. 
 
(5R,6R)-5-Benzyl-6-((2R,3S,4R,5S,E)-2-hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-
yl)-5,6-dihydro-2H-pyran-2-one (4.44f).  The product was synthesized following the 
procedure for the synthesis of analog 4.20.  Reaction with ester 4.47f (25.8 mg, 0.0390 
mmol) resulted in 6.52 mg of product as a colorless oil (43% yield) after purification via 
silica gel flash chromatography (20% acetone in hexanes followed by 4% EtOAc in 
DCM to 9% EtOAc in hexanes twice).  1H NMR (400 MHz, C6D6) δ 7.13 – 7.00 (m, 3H), 
6.93 – 6.76 (m, 2H), 5.96 (dd, J = 9.7, 5.9 Hz, 1H), 5.75 (d, J = 9.8 Hz, 1H), 5.60 – 5.27 
(m, 2H), 4.61 (dt, J = 8.2, 3.9 Hz, 1H), 4.35 (dq, J = 9.8, 2.3 Hz, 1H), 3.22 (t, J = 1.7 Hz, 
1H), 3.10 (s, 3H), 2.82 (dd, J = 12.9, 5.0 Hz, 1H), 2.75 (dd, J = 6.4, 4.2 Hz, 1H), 2.30 
(dd, J = 12.9, 11.4 Hz, 1H), 2.22 – 1.98 (m, 2H), 1.88 – 1.75 (m, 2H), 1.75 – 1.57 (m, 
6H), 0.95 (d, J = 7.1 Hz, 3H), 0.95 (d, J = 6.3 Hz, 3H). 13C NMR (100 MHz, C6D6) δ 
163.5, 150.1, 138.8, 129.5, 129.3, 128.7, 127.0, 126.6, 121.0, 91.3, 77.9, 67.7, 61.4, 39.6, 
39.5, 37.8, 37.5, 36.6, 34.1, 18.2, 15.6, 12.0.  HRMS calc m/z [C24H34O4 + Na]+: 
409.2349, found: 409.2345.  97% pure by HPLC analysis. 
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(S)-1-(4-Benzyl-2-thioxothiazolidin-3-yl)-3-methylbutan-1-one (4.45g).  The product 
was synthesized following the procedure for the synthesis of thiazolidinethione 4.39.  
Reaction with (S)-4-benzylthiazolidine-2-thione (0.20 g, 0.96 mmol) and 3-methylbutyric 
chloride (0.12 mL, 1.0 mmol) resulted in 0.226 g of product as a yellow solid (81% yield) 
after purification via silica gel flash chromatography (40% to 50% DCM in hexanes).    
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.27 (m, 5H), 5.38 (ddd, J = 10.8, 7.1, 3.9 Hz, 1H), 
3.37 (dd, J = 11.5, 7.2 Hz, 1H), 3.28 – 2.99 (m, 4H), 2.87 (d, J = 11.5 Hz, 1H), 2.24 (dp, 
J = 13.4, 6.7 Hz, 1H), 1.01 (d, J = 6.7 Hz, 3H), 0.97 (d, J = 6.6 Hz, 3H).  13C NMR (100 
MHz, CDCl3) δ 201.1, 173.4, 136.6, 129.5, 128.9, 127.2, 68.6, 46.8, 36.8, 31.9, 25.3, 
22.6, 22.3.  [α]D = +234 (c 0.188, CHCl3).  HRMS calc m/z [C15H19NOS2 + Na]+: 
316.0800, found: 316.0844. 
 
(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxy-2-isopropyl-7-methoxy-6,8-dimethyldodec-10-en-
1-one (4.48g).  The product was synthesized following the procedure for the synthesis of 
intermediate 4.40.  Reaction with thiazolidinethione 4.45g (0.137 g, 0.467 mmol) and 
aldehyde 4.25 (46.4 mg, 0.135 mmol) resulted in 65.7 mg of product as a yellow oil (76% 
yield) after purification via silica gel flash chromatography (10% EtOAc in hexanes).  1H 
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NMR (400 MHz, C6D6) δ 7.14 – 6.96 (m, 5H), 5.53 – 5.37 (m, 3H), 5.26 (ddd, J = 10.7, 
7.1, 3.7 Hz, 1H), 4.38 – 4.20 (m, 2H), 3.40 (s, 3H), 3.23 (dd, J = 8.7, 2.0 Hz, 1H), 3.12 
(dd, J = 13.1, 3.7 Hz, 1H), 2.74 (dd, J = 13.1, 10.7 Hz, 1H), 2.56 (dd, J = 11.5, 7.2 Hz, 
1H), 2.44 (bs, 1H), 2.42 – 2.32 (m, 1H), 2.32 – 2.17 (m, 1H), 2.15 – 1.91 (m, 5H), 1.82 – 
1.68 (m, 1H), 1.64 (d, J = 4.2 Hz, 3H), 1.24 (d, J = 6.7 Hz, 3H), 1.10 (d, J = 6.8 Hz, 3H), 
1.04 – 0.98 (m, 12H), 0.96 (d, J = 6.9 Hz, 3H), 0.23 (s, 3H), 0.17 (s, 3H).  13C NMR (100 
MHz, C6D6) δ 202.7, 175.9, 137.1, 130.9, 129.7, 128.9, 128.5, 127.2, 126.5, 84.9, 72.1, 
70.4, 69.4, 60.4, 54.6, 41.7, 39.1, 39.0, 37.0, 36.1, 31.2, 29.3, 26.3, 21.8, 20.1, 18.6, 18.2, 
13.6, 11.5, -3.4, -4.0.  HRMS calc m/z [C34H57NO4S2Si + Na]+: 658.3390, found: 
658.3448. 
 
(2S,3R,5R,6R,7R,8S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-3,5-bis((tert-
butyldimethylsilyl)oxy)-2-isopropyl-7-methoxy-6,8-dimethyldodec-10-en-1-one 
(4.49g).  The product was synthesized following the procedure for the synthesis of 
intermediate 4.49b.  Reaction with alcohol 4.48g (68.7 mg, 0.108 mmol) resulted in 75.4 
mg of product as a yellow oil (93% yield) after purification via silica gel flash 
chromatography (100:3 hexanes:EtOAc followed by 4% ether in hexanes).  1H NMR 
(400 MHz, C6D6) δ 7.14 – 6.99 (m, 5H), 5.52 – 5.40 (m, 2H), 5.36 (dd, J = 9.8, 3.9 Hz, 
1H), 5.23 (ddd, J = 10.6, 6.9, 3.4 Hz, 1H), 4.49 (dd, J = 9.2, 4.4 Hz, 1H), 4.27 (dt, J = 
7.1, 4.5 Hz, 1H), 3.51 (s, 3H), 3.35 (dd, J = 9.7, 1.6 Hz, 1H), 3.25 (dd, J = 13.0, 3.3 Hz, 
1H), 2.79 (dd, J = 13.1, 10.9 Hz, 1H), 2.69 (dd, J = 11.5, 7.0 Hz, 1H), 2.59 – 2.39 (m, 
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2H), 2.35 – 2.20 (m, 1H), 2.18 – 2.04 (m, 3H), 1.90 – 1.79 (m, 1H), 1.76 (q, J = 7.0 Hz, 
1H), 1.69 – 1.62 (m, 3H), 1.32 (d, J = 6.8 Hz, 3H), 1.30 (d, J = 6.6 Hz, 3H), 1.06 (s, 9H), 
1.02 (s, 9H), 0.98 (d, J = 6.9 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H), 0.38 (s, 3H), 0.35 (s, 3H), 
0.29 (s, 3H), 0.23 (s, 3H).  13C NMR (100 MHz, C6D6) δ 201.9, 176.1, 137.3, 131.1, 
129.8, 129.0, 128.6, 127.2, 126.5, 84.2, 71.4, 70.1, 70.0, 61.1, 56.0, 42.8, 41.5, 39.0, 36.7, 
36.3, 31.2, 29.3, 26.4, 26.3, 21.6, 21.3, 18.8, 18.3, 18.2, 13.1, 10.4, -2.3, -3.7, -3.7, -4.3.  
HRMS calc m/z [C40H71NO4S2Si2 + Na]+: 772.4261, found: 772.4287. 
 
(2R,3R,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-2-isopropyl-7-methoxy-
6,8-dimethyldodec-10-en-1-ol (4.50).  To a solution of amide 4.49g (39.4 mg, 0.0525 
mmol) in ether (15 mL) and MeOH (0.03 mL) at 0 °C was added LiBH4 (2 M in THF, 58 
µL, 0.120 mmol).  The reaction was stirred at 0 °C for 3 h before additional LiBH4 (2 M 
in THF, 58 µL, 0.120 mmol) was added to the reaction.  The reaction was stirred at 0 °C 
for an addition 2 h before additional LiBH4 (2 M in THF, 58 µL, 0.120 mmol) was added 
to the reaction.  The reaction was then stored in a 4 °C refrigerator overnight.  The 
reaction was quenched with saturated aqueous NH4Cl.  The mixture was extracted four 
times with EtOAc.  The combined organic layers were washed with brine and dried with 
anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatography (10% EtOAc in hexanes) to yield 17.1 mg of product as a colorless 
oil (60% yield) and 11.9 mg of recovered starting material.  1H NMR (400 MHz, C6D6) δ 
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5.51 – 5.34 (m, 2H), 4.29 (ddd, J = 8.5, 6.1, 2.1 Hz, 1H), 4.22 (dd, J = 9.7, 5.2 Hz, 1H), 
3.67 (d, J = 6.7 Hz, 2H), 3.45 (s, 3H), 3.31 (dd, J = 9.8, 1.6 Hz, 1H), 2.30 – 2.18 (m, 1H), 
2.17 – 1.99 (m, 4H), 1.83 (dq, J = 9.6, 6.9 Hz, 1H), 1.73 (q, J = 7.7, 7.0 Hz, 1H), 1.68 – 
1.62 (m, 3H), 1.62 – 1.54 (m, 1H), 1.42 (bs, 1H), 1.13 (d, J = 7.0 Hz, 3H), 1.05 (d, J = 
6.8 Hz, 3H), 1.01 (s, 9H), 1.01 (s, 9H), 0.99 (d, J = 6.8 Hz, 3H), 0.93 (d, J = 6.9 Hz, 3H), 
0.22 (s, 3H), 0.20 (s, 3H), 0.19 (s, 3H), 0.18 (s, 3H).  13C NMR (100 MHz, C6D6) δ 131.0, 
126.4, 84.3, 70.1, 70.0, 61.0, 60.3, 49.4, 40.6, 40.1, 38.9, 36.1, 26.3, 26.2, 25.7, 23.5, 
19.9, 18.6, 18.3, 18.2, 13.0, 9.7, -2.7, -4.2, -4.2, -4.3.  HRMS calc m/z [C30H64O4Si2 + 
Na]+: 567.4235, found: 567.4224. 
 
(2S,3R,5R,6R,7R,8S,E)-3,5-Bis((tert-butyldimethylsilyl)oxy)-2-isopropyl-7-methoxy-
6,8-dimethyldodec-10-enal (4.46g).  To a suspension of alcohol 4.50 (26.0 mg, 0.0477 
mmol) and powdered 4Å molecular sieves (11 mg) in DCM (0.6 mL) at 0 °C was added a 
solution of TPAP (1.7 mg, 4.8 µmol) in DCM (0.2 mL).  The reaction was stirred for 30 
min at 0 °C followed by addition of NMO (7.3 mg, 0.062 mmol).  After stirring an 
additional 1 h at 0 °C, additional NMO (7.3 mg, 0.062 mmol) was added to the reaction 
followed by a solution of TPAP (1.7 mg, 4.8 µmol) in DCM (0.2 mL).  After the reaction 
was judged to be complete via TLC analysis, silica gel was added to the reaction and 
volatile materials were removed using a rotary evaporator.  Purification via silica gel 
flash chromatography (5% EtOAc in hexanes) yielded 19.2 mg of product as a colorless 
oil (74% yield).  1H NMR (400 MHz, C6D6) δ 9.84 (d, J = 2.6 Hz, 1H), 5.55 – 5.33 (m, 
  251 
2H), 4.35 (td, J = 6.7, 3.6 Hz, 1H), 4.26 – 4.14 (m, 2H), 3.42 (s, 3H), 3.26 (dd, J = 9.7, 
1.7 Hz, 1H), 2.30 (ddd, J = 6.4, 3.7, 2.6 Hz, 1H), 2.28 – 2.14 (m, 2H), 2.15 – 1.92 (m, 
3H), 1.81 – 1.67 (m, 2H), 1.65 (d, J = 3.9 Hz, 3H), 1.07 (dd, J = 6.8, 1.1 Hz, 6H), 1.00 (s, 
9H), 0.99 – 0.94 (m, 12H), 0.88 (d, J = 7.0 Hz, 3H), 0.19 (s, 3H), 0.17 (s, 6H), 0.13 (s, 
3H).  13C NMR (100 MHz, C6D6) δ 203.4, 131.0, 126.5, 84.0, 70.3, 70.0, 62.4, 60.9, 41.1, 
41.1, 38.9, 36.1, 26.2, 26.1, 25.6, 21.9, 20.7, 18.6, 18.2, 13.1, 9.9, -2.8, -4.0, -4.1, -4.2.  
HRMS calc m/z [C30H62O4Si2 + Na]+: 565.4079, found: 565.4053. 
 
(4R,5R,7R,8R,9R,10S,E)-Ethyl 5,7-Bis((tert-butyldimethylsilyl)oxy)-3-hydroxy-4-
isopropyl-9-methoxy-8,10-dimethyltetradec-12-enoate (4.51).  To THF (0.5 mL) at 0 
°C was added lithium bis(trimethylsilyl)amide (1 M in hexanes, 0.062 mL, 0.062 mmol).  
The solution was stirred at 0 °C for 15 min before cooling to -78 °C.  Ethyl acetate (5.6 
µL, 0.057 mmol) was added dropwise to the reaction and the reaction was stirred at -78 
°C for 30 min.  A solution of aldehyde 4.46g (22.3 mg, 0.0411 mmol) dissolved in THF 
(0.5 mL) was slowly cannula transferred to the reaction.  The vial containing the 
aldehyde solution was rinsed with additional THF (0.5 mL) which was cannula 
transferred to the reaction.  After stirring for 15 min at -78 °C, the reaction was quenched 
with saturated aqueous NH4Cl and warmed to room temperature.  The layers were 
separated and the aqueous phase was extracted three times with EtOAc.  The combined 
organic layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
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evaporator.  The crude material was purified via silica gel flash chromatography (10% 
EtOAc in hexanes) to yield 18.9 mg of product as a colorless oil (73% yield).  1H NMR 
(400 MHz, C6D6) δ 5.52 – 5.30 (m, 2H), 4.69 (t, J = 8.2 Hz, 1H), 4.22 (dd, J = 10.7, 4.3 
Hz, 1H), 4.17 (dd, J = 9.6, 5.2 Hz, 1H), 4.02 – 3.83 (m, 2H), 3.40 (s, 3H), 3.28 (dd, J = 
9.8, 1.6 Hz, 1H), 3.13 (bs, 1H), 2.75 (dd, J = 16.0, 2.5 Hz, 1H), 2.65 (dd, J = 16.0, 9.9 
Hz, 1H), 2.35 – 2.12 (m, 3H), 2.12 – 1.98 (m, 2H), 1.87 (dt, J = 9.1, 6.9 Hz, 1H), 1.71 (q, 
J = 6.9 Hz, 1H), 1.68 – 1.59 (m, 4H), 1.39 (d, J = 6.9 Hz, 3H), 1.29 (d, J = 6.8 Hz, 3H), 
1.04 – 0.95 (m, 21H), 0.91 (d, J = 6.9 Hz, 3H), 0.91 (t, J = 7.1 Hz, 3H), 0.22 (s, 3H), 0.18 
(s, 3H), 0.17 (s, 3H), 0.13 (s, 3H).  13C NMR (100 MHz, C6D6) δ 173.1, 131.0, 126.5, 
84.4, 69.8, 69.7, 68.3, 61.1, 60.5, 52.0, 42.0, 39.9, 39.5, 38.8, 36.1, 26.4, 26.2, 26.2, 24.8, 
21.0, 18.5, 18.3, 18.2, 14.1, 13.0, 9.6, -2.8, -3.5, -4.2, -4.3.  HRMS calc m/z [C34H70O6Si2 
+ Na]+: 653.4603, found: 653.4624. 
 
(5R,6R)-6-((2R,3S,4R,5S,E)-2-Hydroxy-4-methoxy-3,5-dimethylnon-7-en-1-yl)-5-
isopropyl-5,6-dihydro-2H-pyran-2-one (4.44g).  To an NMR tube containing p-
toluenesulfonic acid monohydrate (5.7 mg, 0.030 mmol) was added a solution of ester 
4.51 (18.2 mg, 0.0288 mmol) dissolved in d8-toluene (1 mL).  The reaction was heated to 
110 °C in an oil bath and monitored by 1H NMR spectroscopy.   After heating for 1.5 h, 
additional p-toluenesulfonic acid monohydrate (5.7 mg, 0.030 mmol) was added to the 
reaction followed by d8-toluene (50 µL).  The reaction was heated to 110 °C for an 
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additional 2.5 h and judged to be complete by 1H NMR spectroscopy.  The reaction was 
diluted with EtOAc and washed with saturated aqueous NaHCO3 and brine before drying 
with anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile 
materials were removed using a rotary evaporator.  The crude material was purified via 
silica gel flash chromatography (20% acetone in hexanes) to yield 6.6 mg of product as a 
white solid (65% yield).  1H NMR (400 MHz, CD2Cl2) δ 6.88 (dd, J = 9.9, 5.8 Hz, 1H), 
6.07 (dd, J = 9.9, 1.3 Hz, 1H), 5.58 – 5.35 (m, 2H), 4.83 – 4.67 (m, 1H), 4.16 (t, J = 6.7 
Hz, 1H), 3.47 (s, 3H), 3.21 (d, J = 2.5 Hz, 1H), 3.01 (dd, J = 6.0, 4.7 Hz, 1H), 2.34 (dtd, J 
= 5.8, 4.5, 1.3 Hz, 1H), 2.25 – 2.06 (m, 2H), 1.95 – 1.82 (m, 2H), 1.82 – 1.75 (m, 1H), 
1.75 – 1.70 (m, 2H), 1.70 – 1.62 (m, 3H), 0.98 (d, J = 7.1 Hz, 6H), 0.95 (d, J = 6.5 Hz, 
3H), 0.88 (d, J = 6.8 Hz, 3H).  13C NMR (100 MHz, CD2Cl2) δ 164.8, 147.6, 129.6, 
127.3, 122.9, 91.2, 78.2, 67.7, 62.0, 43.8, 39.7, 37.8, 37.0, 36.8, 27.9, 21.6, 18.3, 18.3, 
15.4, 12.3.  HRMS calc m/z [C20H34O4 + Na]+: 361.2349, found: 361.2398.  95% pure by 
HPLC analysis, 
6.4.2 Covalent docking protocol.  Pironetin and related analogs were docked using 
Schrödinger® Maestro software package.  α-Tubulin was selected from previously 
reported pironetin crystal structure (chain C of PDB ID 5FNV).  Following removal of 
the pironetin from the protein, the protein was prepared via Protein Preparation Wizard.  
Poses for each ligand were prepared using the Ligprep module using an OLPS3 force 
field.  Pironetin analogs were docked into the prepared α-tubulin using Glide CovDoc 
module.  The binding site was centered at Cys316 and docking poses were generated for 
covalent adducts resulting from the Michael addition of Cys316 into each analog.  Ten 
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poses were obtained for each analog and each pose was given a separate docking score, 
glide score and Cdcok affinity. 
6.5 Chapter 5 experimental procedures. 
 
(5R,6R)-6-((2R,3S,4R,5S,E)-2,4-Dihydroxy-3,5-dimethylnon-7-en-1-yl)-5-ethyl-5,6-
dihydro-2H-pyran-2-one/ Demethylpironetin/NK10958P (5.2).  Demethyl pironetin 
was isolated from the combination of the three following reactions conditions:  The 
reaction conditions were adapted from previously a published reaction.52 
Reaction 1.  To a solution of pironetin (8.7 mg, 0.027 mmol) in DCM (1.4 mL) at -78 °C 
was added a 15-crown-5 solution (0.3 M in DCM, 0.54 mL, 0.16 mmol) saturated with 
sodium iodide. BBr3 (1 M in DCM, 80 µL, 0.080 mmol) was subsequently added 
dropwise to the reaction at -78 °C.  The reaction was warmed to 0 °C over 3 h and stirred 
at 0 °C for 3 h.  The reaction was diluted with diethyl ether and quenched with saturated 
aqueous NH4Cl and saturated sodium thiosulfate solutions.  The layers were separated 
and the aqueous layer was extract four times with ether.  The combined organic extracts 
were washed with brine and dried with anhydrous Na2SO4.  The salts were removed via 
gravity filtration and volatile materials were removed using a rotary evaporator.  The 
crude material was frozen in benzene prior to purification. 
Reaction 2.  To a solution of pironetin (3.4 mg, 0.010 mmol) in DCM (0.5 mL) at -78 °C 
was added a 15-crown-5 solution (0.3 M in DCM, 0.20 mL, 0.060 mmol) saturated with 
sodium iodide. BBr3 (1 M in DCM, 30 µL, 0.030 mmol) was added dropwise to the 
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reaction at -78 °C.  The reaction was warmed to 0 °C over 3 h and stirred at 0 °C for 3 h.  
The reaction was diluted with diethyl ether and quenched with saturated aqueous NH4Cl 
and saturated sodium thiosulfate solutions.  The layers were separated and aqueous layer 
was extract four times with ether.  The combined organic extracts were washed with 
brine and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration 
and volatile materials were removed using a rotary evaporator.  The crude material was 
frozen in benzene prior to purification. 
Reaction 3.  To a solution of pironetin (5.2 mg, 0.016 mmol) in DCM (0.5 mL) at -30 °C 
(ethanol/ice bath) was added a 15-crown-5 solution (0.3 M in DCM, 0.33 mL, 0.099 
mmol) saturated with sodium iodide.  BBr3 (1 M in DCM, 50 µL, 0.050 mmol) was 
subsequently added dropwise to the reaction at -30 °C.  After 1.5 h at -30 °C, the reaction 
was quenched with saturated aqueous NH4Cl and saturated sodium thiosulfate solutions.  
The layers were separated and aqueous layer was extract four times with ethyl acetate.  
The combined organic extracts were washed with brine and dried with anhydrous 
Na2SO4.  The salts were removed via gravity filtration and volatile materials were 
removed using a rotary evaporator.  The crude material was frozen in benzene prior to 
purification. 
The combined crude material from these three reactions was purified by silica gel flash 
chromatography through the following series of solvent mixtures: 30% to 50% ethyl 
acetate in hexanes, 50% ethyl acetate in hexanes (three times).  2.2 mg of demethyl 
pironetin was isolated as a color oil resulting in 13% yield from the combined amount of 
pironetin used for the three reactions.  The resonances in the 1H NMR and 13C spectrum 
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of the product matched previously reported chemical shifts.52,112  86% pure by HPLC 
analysis. 
 
tert-Butyl(((2S,3S,4S)-3-methoxy-5-((4-methoxybenzyl)oxy)-2,4-
dimethylpentyl)oxy)dimethylsilane (5.16b).  To a solution of alcohol 5.17 (0.61 g, 2.2 
mmol) in DMF (6.3 mL) at 0 °C was added sodium hydride (60% in mineral oil, 0.17 g, 
4.2 mmol).  The suspension was stirred at 0 °C for 20 min before the addition of PMBCl 
(0.57 mL, 4.2 mmol).  The reaction was warmed to room temperature and stirred for 4.5 
h.  The reaction was quenched with saturated aqueous NH4Cl and extracted four times 
with EtOAc.  The combined organic layers were washed with brine and dried with 
anhydrous MgSO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via 
Combiflash® silica gel flash chromatograph (5% to 100% EtOAc in hexanes) to yield 
0.51 g of product as a colorless oil (59% yield).  1H NMR (400 MHz, CDCl3) δ 7.30 – 
7.24 (m, 2H), 6.91 – 6.84 (m, 2H), 4.54 – 4.37 (m, 2H), 3.80 (s, 3H), 3.62 – 3.51 (m, 2H), 
3.45 (ddd, J = 12.9, 9.3, 6.4 Hz, 2H), 3.38 (s, 3H), 3.25 (dd, J = 8.9, 2.8 Hz, 1H), 2.00 – 
1.88 (m, 1H), 1.88 – 1.75 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 0.80 (d, J = 6.9 
Hz, 3H), 0.05 (s, 6H).  13C NMR (100 MHz, CDCl3) δ 159.0, 131.0, 129.0, 113.7, 82.1, 
72.7, 72.6, 65.7, 60.8, 55.2, 37.8, 36.8, 25.9, 25.9, 18.2, 14.8, 9.9, -5.3. 
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(2S,3S,4S)-3-Methoxy-5-((4-methoxybenzyl)oxy)-2,4-dimethylpentyl 4-
methylbenzenesulfonate (5.18).  To a solution of ether 5.16b (0.51 g, 1.3 mmol) in THF 
(2.1 mL) was added TBAF (1 M in THF, 6.4 mL, 6.4 mmol).  After stirring for 2.5 h, the 
reaction was diluted with EtOAc and quenched with saturated aqueous NaHCO3.  The 
layers were separated and the aqueous phase was extracted three times with EtOAc.  The 
combined organic layers were washed with brine and dried with anhydrous MgSO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
rotary evaporator.  The crude material was dissolved in pyridine (8.6 mL) followed by the 
addition of TsCl (0.74 g, 3.9 mmol).  The reaction was stirred overnight and then poured 
into water and diluted with ether.  The layers were separated and the aqueous layer was 
extracted three times with ether.  The combined organic layers were washed with brine 
and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and 
volatile materials were removed using a rotary evaporator.  The crude material was 
purified via Combiflash® silica gel flash chromatograph (5% to 20% EtOAc in hexanes) 
to yield 0.48 g of product as a colorless oil (85% yield over 2 steps).  1H NMR (400 
MHz, CDCl3) δ 7.84 – 7.74 (m, 2H), 7.37 – 7.30 (m, 2H), 7.27 – 7.20 (m, 2H), 6.92 – 
6.84 (m, 2H), 4.41 (s, 2H), 4.00 (dd, J = 9.3, 8.1 Hz, 1H), 3.90 (dd, J = 9.4, 6.0 Hz, 1H), 
3.81 (s, 3H), 3.50 – 3.35 (m, 2H), 3.27 (s, 3H), 3.14 (dd, J = 8.9, 2.8 Hz, 1H), 2.44 (s, 
3H), 2.10 – 1.94 (m, 2H), 1.91 – 1.76 (m, 1H), 0.87 (d, J = 6.9 Hz, 3H), 0.80 (d, J = 6.9 
Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 159.1, 144.7, 133.1, 130.6, 129.8, 129.2, 127.9, 
113.7, 81.3, 72.8, 72.7, 71.9, 60.8, 55.2, 36.6, 35.0, 21.7, 14.5, 9.6. 
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(2S,3R,4S)-5-(Benzyloxy)-3-methoxy-2,4-dimethylpentan-1-ol (5.20a).  To a solution 
of ether 5.16a (0.10 g, 0.27 mmol) in THF (0.45 mL) was added TBAF (1 M in THF, 1.4 
mL, 1.4 mmol).  After stirring for 3.5 h, the reaction was quenched with saturated 
aqueous NaHCO3 and the mixture was extracted four times with EtOAc.  The combined 
organic layers were washed with brine and dried with anhydrous MgSO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatograph (33% 
EtOAc in hexanes) to yield 67.3 mg of product as a colorless oil (98% yield).  1H NMR 
(400 MHz, CDCl3) δ 7.38 – 7.30 (m, 4H), 7.32 – 7.25 (m, 1H), 4.51 (s, 2H), 3.63 (t, J = 
5.5 Hz, 2H), 3.61 – 3.44 (m, 2H), 3.41 (s, 3H), 3.27 (dd, J = 8.4, 3.1 Hz, 1H), 2.06 – 1.92 
(m, 1H), 1.95 – 1.82 (m, 2H), 1.29 – 1.16 (m, 1H), 0.97 (d, J = 7.0 Hz, 3H), 0.90 (d, J = 
7.0 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 138.6, 128.3, 127.6, 127.5, 83.9, 73.1, 72.5, 
66.6, 60.6, 37.4, 36.6, 14.8, 10.5.  HRMS calc m/z [C15H24O3 + Na]+: 275.1618, found: 
275.1632. 
 
(2S,3S,4S)-5-(Benzyloxy)-3-methoxy-2,4-dimethyl-1-phenylpentan-1-ol (5.22a).  A 
suspension of alcohol 5.20a (50. mg, 0.20 mmol), NMO (28 mg, 0.24 mmol), and 
powdered 4Å molecular sieves (55 mg) was stirred in DCM (1.8 mL) at 0 °C for 20 min.  
A solution of TPAP (7 mg, 0.02 mmol) in DCM (0.5 mL) was added to the reaction.  The 
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reaction was warmed to room temperature and stirred for 45 min.  The reaction was 
diluted with 40% EtOAc in hexanes and filtered through a plug of silica gel.  The silica 
gel plug was rinsed with 40% acetate in hexanes.  The solution of crude material was 
concentrated using a rotary evaporator and the crude aldehyde was used without further 
purification. 
 To a solution of the crude aldehyde in THF (2 mL) at -78 °C was added 
phenylmagnesium bromide (2.8 M in ether, 0.10 mL, 0.28 mmol).  After stirring at -78 
°C for 1.5 h, the reaction was quenched with saturated aqueous NH4Cl.  The mixture was 
warmed to room temperature and extracted four times with EtOAc.  The combined 
organic layers were washed with brine and dried with anhydrous MgSO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was purified via silica gel flash chromatograph (12% 
EtOAc in hexanes) to yield 41.9 mg of product as a colorless oil (64% yield over 2 steps).  
1H NMR (400 MHz, CDCl3) δ 7.34 (q, J = 4.1 Hz, 16H), 7.30 – 7.21 (m, 4H), 4.97 (d, J 
= 2.8 Hz, 1H), 4.58 (dd, J = 8.4, 3.8 Hz, 1H), 4.57 – 4.46 (m, 4H), 3.64 – 3.54 (m, 3H), 
3.54 – 3.44 (m, 9H), 2.66 (d, J = 3.9 Hz, 1H), 2.17 – 1.90 (m, 4H), 0.97 (dd, J = 7.0, 4.6 
Hz, 6H), 0.83 (d, J = 7.0 Hz, 3H), 0.72 (d, J = 7.1 Hz, 3H).  13C NMR (100 MHz, CDCl3) 
δ 144.3, 143.6, 138.6, 138.4, 128.4, 128.4, 128.3, 128.1, 127.6, 127.6, 127.5, 127.5, 
127.4, 126.9, 126.6, 126.0, 87.2, 82.0, 77.5, 73.2, 73.1, 72.8, 72.2, 60.1, 60.0, 41.5, 41.4, 
36.7, 36.7, 14.6, 14.5, 10.8, 6.0.  HRMS calc m/z [C21H28O3 + Na]+: 351.1931, found: 
351.1947. 
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(2S,3R,4S)-3-Methoxy-2,4-dimethyl-5-phenylpentan-1-ol (5.15).  To a solution of 
alcohol 5.22a (32 mg, 0.097 mmol) and DMAP (2.4 mg, 0.019 mmol) in DCM (2 mL) at 
0 °C was added trifluoroacetic anhydride (0.035 mL, 0.25 mmol).  After stirring at 0 °C 
for 1 h, the reaction was quenched with saturated aqueous NaHCO3 and warmed to room 
temperature.  The layers were separated and the aqueous layer was extracted three times 
with DCM.  The combined organic layers were washed with brine and dried with 
anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was dissolved in 30% 
EtOAc in hexanes and filtered through a plug of silica gel.  The silica gel plug was rinsed 
with 30% EtOAc in hexanes.  The crude trifluoroacetate ester solution was concentrated 
using a rotary evaporator; the crude material was used without further purification. 
 To a solution of the crude material dissolved in EtOAc (1 mL) was added palladium 
(10% on carbon, 10. mg, 0.0097mmol).  The reaction was placed under a balloon of H2 
and stirred at room temperature overnight.  The reaction was filtered through a Celite® 
plug and the Celite® plug was rinsed with EtOAc.  The solution of the crude material 
was concentrated using a rotary evaporator.  The crude material was purified via silica 
gel flash chromatograph (35% EtOAc in hexanes) to yield 17.2 mg of product as a 
colorless oil (80% yield over 2 steps).  1H NMR (400 MHz, CDCl3) δ 7.30 – 7.20 (m, 
2H), 7.20 – 7.09 (m, 3H), 3.61 (d, J = 5.2 Hz, 2H), 3.49 (s, 3H), 3.00 (dd, J = 7.9, 3.2 Hz, 
1H), 2.76 (dd, J = 13.4, 5.7 Hz, 1H), 2.68 (s, 1H), 2.49 (dd, J = 13.4, 9.2 Hz, 1H), 2.00 
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(tq, J = 9.3, 3.1 Hz, 1H), 1.88 (ddt, J = 9.5, 7.3, 3.6 Hz, 1H), 0.86 (d, J = 6.9 Hz, 3H), 
0.84 (d, J = 6.8 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 141.0, 129.0, 128.3, 125.9, 
90.0, 66.7, 61.2, 40.8, 37.9, 37.8, 15.1, 13.4.  HRMS calc m/z [C14H22O2 + Na]+: 
245.1512, found: 245.1525. 
 
(3R,6R,7S,8R,9S)-6-Hydroxy-8-methoxy-3-(((4-methoxybenzyl)oxy)methyl)-7,9-
dimethyl-10-phenyldecan-4-one (5.28).  A suspension of alcohol 5.15 (64.1 mg, 0.288 
mmol), NMO (44 mg, 0.38 mmol), and powdered 4Å molecular sieves (79 mg) was 
stirred in DCM (2 mL) at 0 °C for 15 min.  A solution of TPAP (10. mg, 0.029 mmol) in 
DCM (0.6 mL) was added to the reaction.  After stirring at 0 °C for 40 min, the reaction 
was diluted with 40% EtOAc in hexanes and filtered through a plug of silica gel.  The 
silica gel plug was rinsed with 40% acetate in hexanes.  The crude aldehyde solution was 
concentrated using a rotary evaporator and the crude aldehyde was used without further 
purification. 
 The crude aldehyde was combined with crude silyl enol ethers 5.27 (~0.57 mmol) 
and dissolved in DCM (2.6 mL) and cooled in a MeOH/lq N2 bath.  A solution of 
BF3•Et2O (2M in DCM, 0.36 mL, 0.72 mmol) was added dropwise and the reaction was 
stirred in the MeOH/lq N2 bath for 1.5 h.  The reaction was quenched with saturated 
aqueous NaHCO3 solution and warmed to room temperature.  The layers were separated 
and the aqueous phase was extracted three times with DCM and once with EtOAc.  The 
combined organic extracts were washed with brine and dry with anhydrous Na2SO4.  The 
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salts were removed via gravity filtration and volatile materials were removed by rotary 
evaporator.  The crude material was purified via silica gel flash chromatography (20% 
EtOAc in hexanes) to yield 76.3 mg of product as a colorless oil (58% yield over 2 steps).  
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.27 (m, 2H), 7.24 – 7.14 (m, 5H), 6.90 – 6.77 (m, 
2H), 4.47 (d, J = 8.4 Hz, 1H), 4.40 (s, 2H), 3.79 (s, 3H), 3.59 (t, J = 8.8 Hz, 1H), 3.52 (s, 
3H), 3.49 (dd, J = 9.1, 5.0 Hz, 1H), 3.35 (d, J = 2.5 Hz, 1H), 3.18 (dd, J = 7.9, 3.6 Hz, 
1H), 2.90 – 2.68 (m, 3H), 2.56 – 2.41 (m, 2H), 2.04 (dq, J = 9.9, 4.5 Hz, 1H), 1.63 (ddt, J 
= 11.0, 7.6, 5.6 Hz, 2H), 1.51 – 1.37 (m, 1H), 0.88 (t, J = 7.5 Hz, 3H), 0.86 (d, J = 7.0 
Hz, 3H), 0.80 (d, J = 6.8 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 214.6, 159.2, 141.2, 
129.9, 129.3, 129.1, 128.2, 125.7, 113.7, 87.1, 72.9, 70.5, 66.5, 61.6, 55.2, 54.3, 48.1, 
40.9, 40.0, 37.5, 21.5, 12.7, 11.7, 10.4.  HRMS calc m/z [C28H40O5 + Na]+: 479.2768, 
found: 479.2854. 
 
(2S,3R,4S,5R,7R,8R)-7-Hydroxy-3-methoxy-8-(((4-methoxybenzyl)oxy)methyl)-2,4-
dimethyl-1-phenyldecan-5-yl Acetate (5.29).  To a solution of ketone 5.28 (76.3 mg, 
0.167 mmol) and acetaldehyde (0.075 mL, 1.3 mmol) in THF (0.7 mL) at -15 °C was 
added dropwise a solution of SmI2 (0.06 M in THF, 1.1 mL, 0.067 mmol).  The reaction 
was stirred at -15 °C for 1 h before quenching with saturated aqueous NaHCO3.  The 
mixture was warmed to room temperature and extracted four times with EtOAc.  The 
combined organic layers were washed with brine and dried with anhydrous Na2SO4.  The 
salts were removed via gravity filtration and volatile materials were removed using a 
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rotary evaporator.  The crude material was initially purified via silica gel flash 
chromatograph (4:1 hexanes:EtOAc).  The impure product was subsequently purified via 
silica gel flash chromatograph (25% EtOAc in hexanes twice) to yield 76.1 mg of product 
as a colorless oil (91% yield).  1H NMR (400 MHz, CDCl3) δ 7.33 – 7.14 (m, 7H), 6.91 – 
6.81 (m, 2H), 5.40 (ddd, J = 9.6, 3.9, 2.0 Hz, 1H), 4.51 – 4.31 (ABq, 2H), 3.80 (s, 3H), 
3.67 (dt, J = 10.5, 3.0 Hz, 1H), 3.56 – 3.45 (m, 2H), 3.44 (s, 3H), 2.89 (dd, J = 9.4, 2.0 
Hz, 1H), 2.78 (dd, J = 13.4, 5.4 Hz, 1H), 2.59 (dd, J = 13.3, 9.5 Hz, 1H), 2.05 (s, 3H), 
2.03 – 1.92 (m, 1H), 1.83 – 1.64 (m, 2H), 1.56 (tdd, J = 14.1, 9.4, 4.0 Hz, 2H), 1.49 – 
1.29 (m, 2H), 0.91 (t, J = 7.5 Hz, 3H), 0.86 (d, J = 7.0 Hz, 3H), 0.80 (d, J = 6.7 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 172.1, 159.1, 141.3, 130.4, 129.2, 129.1, 128.2, 125.8, 
113.7, 85.5, 72.9, 71.8, 70.7, 68.7, 61.4, 55.3, 45.5, 41.6, 40.3, 37.6, 37.4, 21.2, 19.1, 
12.4, 12.1, 10.5.  HRMS calc m/z [C30H44O6 + Na]+: 523.3030, found: 523.3085. 
 
(4R,6R)-4-((2S,3R,4S,E)-3-Methoxy-4-methyloct-6-en-2-yl)-6-((R)-1-((4-
methoxybenzyl)oxy)butan-2-yl)-2,2-dimethyl-1,3-dioxane (5.30).  To a solution of 
alcohol 5.29 (7.0 mg, 0.014 mmol) in methanol (0.55 mL) was added potassium 
hydroxide (4 mg, 0.07 mmol).  The reaction was stirred at room temperature for 3.5 h.  
The reaction was quenched with saturated aqueous NH4Cl and extracted four times with 
DCM.  The combined organic layers were washed with brine and dried with anhydrous 
Na2SO4.  The salts were removed via gravity filtration and volatile materials were 
removed using a rotary evaporator.  The crude diol was stirred overnight in 2,2-
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dimethoxypropane (1 mL) with PPTS (1 mg).  The reaction was diluted with DCM and 
quenched with saturated aqueous NaHCO3.  The layers were separated and the aqueous 
layer was extracted three times with DCM.  The combined organic layers were washed 
with brine and dried with anhydrous Na2SO4.  The salts were removed via gravity 
filtration and volatile materials were removed using a rotary evaporator.  The crude 
material was purified via silica gel flash chromatograph (7% EtOAc in hexanes) to yield 
4.1 mg of product as a colorless oil (59% yield over 2 steps).  1H NMR (400 MHz, 
CDCl3) δ 7.34 – 7.11 (m, 7H), 6.91 – 6.82 (m, 2H), 4.47 – 4.33 (ABq, 2H), 4.06 (ddd, J = 
9.1, 6.9, 2.7 Hz, 1H), 3.80 (s, 3H), 3.83 – 3.74 (m, 1H), 3.52 (s, 3H), 3.47 – 3.29 (m, 2H), 
3.15 (dd, J = 9.1, 1.9 Hz, 1H), 2.82 (dd, J = 13.2, 5.0 Hz, 1H), 2.57 (dd, J = 13.2, 9.7 Hz, 
1H), 1.97 (q, J = 6.1 Hz, 1H), 1.68 – 1.43 (m, 5H), 1.41 (s, 1H), 1.35 (s, 3H), 1.29 (s, 
3H), 0.90 (t, J = 7.4 Hz, 3H), 0.84 (d, J = 6.9 Hz, 3H), 0.79 (d, J = 6.7 Hz, 3H).  13C 
NMR (100 MHz, CDCl3) δ 159.1, 141.5, 130.7, 129.3, 129.2, 129.1, 128.2, 128.2, 125.7, 
113.8, 113.7, 100.0, 85.3, 72.8, 68.4, 67.2, 65.6, 61.0, 55.2, 45.0, 41.9, 41.0, 37.6, 33.9, 
25.0, 24.8, 20.0, 12.1, 11.7, 10.2.  HRMS calc m/z [C31H46O5 + Na]+: 521.3237, found: 
521.3203 + 481.2931 (hydrolyzed acetonide). 
 
(3R,4R,6R,7S,8R,9S)-8-Methoxy-3-(((4-methoxybenzyl)oxy)methyl)-7,9-dimethyl-10-
phenyldecane-4,6-diyl Diacetate (5.31).  To solution of alcohol 5.29 (67.7 mg, 0.135 
mmol) in DCM (1 mL) was added TEA (0.34 mL, 2.4 mmol), Ac2O (0.23 mL, 2.4 mmol) 
followed by DMAP (1 mg, 0.06 mmol).  The reaction was stirred overnight.  The reaction 
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was diluted with DCM and quenched with saturated aqueous NaHCO3 (10 mL).  The 
biphasic mixture was stirred for 2.5 h.  The layers were separated and the aqueous phase 
was extracted three times with DCM.  The combined organic layers were washed with 
brine and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration 
and volatile materials were removed using a rotary evaporator.  The crude material was 
purified via silica gel flash chromatography (20% EtOAc in hexanes) to yield 64.5 mg of 
product as a colorless oil (88% yield).  1H NMR (400 MHz, CDCl3) δ 7.32 – 7.23 (m, 
4H), 7.22 – 7.12 (m, 3H), 6.89 – 6.82 (m, 2H), 5.25 (ddd, J = 9.3, 4.5, 2.1 Hz, 1H), 5.03 
(dt, J = 10.2, 3.9 Hz, 1H), 4.39 (s, 2H), 3.79 (s, 3H), 3.50 (s, 3H), 3.45 – 3.27 (m, 2H), 
2.92 (dd, J = 9.3, 2.0 Hz, 1H), 2.78 (dd, J = 13.3, 5.1 Hz, 1H), 2.56 (dd, J = 13.3, 9.7 Hz, 
1H), 2.01 (s, 3H), 2.00 (s, 3H), 1.99 – 1.89 (m, 1H), 1.85 (ddd, J = 13.4, 9.3, 3.7 Hz, 1H), 
1.80 – 1.63 (m, 3H), 1.41 (p, J = 7.3 Hz, 2H), 0.94 (t, J = 7.5 Hz, 3H), 0.83 (d, J = 7.1 
Hz, 3H), 0.78 (d, J = 6.7 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 170.7, 170.6, 159.0, 
141.2, 130.7, 129.1, 129.1, 129.1, 128.2, 125.8, 113.6, 85.6, 72.7, 71.1, 70.1, 69.1, 61.2, 
55.2, 43.7, 41.6, 40.4, 37.4, 34.4, 21.1, 21.0, 20.2, 12.0, 10.6.  HRMS calc m/z [C32H46O7 
+ Na]+: 565.3136, found: 565.3164. 
 
(3R,4R,6R,7S,8R,9S)-3-(Hydroxymethyl)-8-methoxy-7,9-dimethyl-10-phenyldecane-
4,6-diyl Diacetate (5.32).  To a solution of ester 5.31 (63.9 mg, 0.118 mmol) in DCM (1 
mL) and water (0.09 mL) was added DDQ (67 mg, 0.29 mmol).  After stirring at room 
temperature for 30 min, the reaction was diluted with DCM and quenched with saturated 
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aqueous NaHCO3.  The layers were separated and the aqueous phase was extracted three 
times with DCM.  The combined organic phase was washed with brine and dried with 
anhydrous Na2SO4.  The salts were removed via gravity filtration and volatile materials 
were removed using a rotary evaporator.  The crude material was purified via silica gel 
flash chromatography (30% EtOAc in hexanes) to yield 40.9 mg of product as a colorless 
oil (82% yield).  1H NMR (400 MHz, CD2Cl2) δ 7.32 – 7.24 (m, 2H), 7.22 – 7.13 (m, 
3H), 5.25 (ddd, J = 9.3, 4.2, 2.2 Hz, 1H), 5.03 (dt, J = 10.6, 2.9 Hz, 1H), 3.58 (ddd, J = 
12.6, 8.4, 4.9 Hz, 1H), 3.46 (s, 3H), 3.25 (ddd, J = 12.1, 9.0, 3.9 Hz, 1H), 2.89 (dd, J = 
9.2, 2.2 Hz, 1H), 2.78 (dd, J = 13.3, 5.3 Hz, 1H), 2.66 (dd, J = 8.9, 4.8 Hz, 1H), 2.56 (dd, 
J = 13.3, 9.6 Hz, 1H), 2.05 (s, 3H), 1.98 (s, 3H), 2.01 – 1.93 (m, 1H) 1.88 (ddd, J = 14.7, 
10.6, 4.2 Hz, 1H), 1.75 (ddd, J = 14.5, 9.4, 3.2 Hz, 1H), 1.68 (ddd, J = 9.2, 7.1, 2.2 Hz, 
1H), 1.63 – 1.52 (m, 1H), 1.45 (dtd, J = 15.0, 7.4, 4.3 Hz, 1H), 1.14 (ddt, J = 14.2, 8.6, 
7.2 Hz, 1H), 0.93 (t, J = 7.5 Hz, 3H), 0.85 (d, J = 7.0 Hz, 3H), 0.77 (d, J = 6.8 Hz, 3H).  
13C NMR (100 MHz, CD2Cl2) δ 172.7, 171.1, 142.0, 129.6, 128.7, 126.3, 86.0, 70.9, 
70.6, 62.2, 61.5, 46.9, 42.1, 41.0, 38.0, 35.9, 21.4, 21.4, 19.2, 12.6, 12.5, 10.9.  HRMS 
calc m/z [C24H38O6 + Na]+: 445.2561, found: 445.2596. 
 
(2R,3S,4R,5S)-1-((2R,3R)-3-Ethyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)-4-methoxy-3,5-
dimethyl-6-phenylhexan-2-yl Acetate (5.33).  A suspension of alcohol 5.32 (40.9 mg, 
0.0968 mmol), NMO (17 mg, 0.15 mmol), and powdered 4Å molecular sieves (47 mg) 
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was stirred in DCM (1.6 mL) at 0 °C for 15 min.  A solution of TPAP (3.4 mg, 0.0097 
mmol) in DCM (0.3 mL) was added to the reaction.  After stirring 40 min at 0 °C, the 
reaction was diluted with 40% EtOAc in hexanes and filtered through a plug of silica gel.  
The silica gel was rinsed with 40% EtOAc in hexanes.  The crude aldehyde solution was 
concentrated using a rotary evaporator and the crude aldehyde was used without further 
purification. 
 To as solution of diisopropylamine (15 µL, 0.11 mmol) in THF (1.1 mL) at 0 °C 
was added n-butyllithium (2.4 M in hexanes, 40 µL, 0.097 mmol).  The reaction was 
stirred at 0 °C for 20 min before cooling to -78 °C.  Methyl acetate (8.5 µL, 0.11 mmol) 
was then added to reaction and the reaction was stirred at -78 °C for 15 min.  A solution 
of crude aldehyde dissolved in THF (0.3 mL) was then added dropwise to the reaction.  
The vial containing the aldehyde solution was rinsed with additional THF (0.1 mL) which 
was added dropwise to the reaction.  The reaction was stirred at -78 °C for 30 min before 
warming to 0 °C and stirring for 30 min followed by warmed to room temperature and 
stirring for an additional 30 min.  The reaction was poured into pH 7 phosphate buffer 
and diluted with DCM.  The layers were separated and the aqueous phase was extracted 
three times with DCM and once with EtOAc.  During the extraction, the resulting 
emulsion mixture was filtered through Celite® to separate layers.  The combined organic 
layers were washed with brine and dried with anhydrous Na2SO4.  The salts were 
removed via gravity filtration and volatile materials were removed using a rotary 
evaporator.  The crude material was initially purified via silica gel flash chromatography 
(25% EtOAc in hexanes).  The impure material was further purified via silica gel flash 
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chromatography (30% EtOAc in hexanes) to yield 15.0 mg of product as a colorless oil 
(38% yield over 2 steps).  1H NMR (400 MHz, C6D6) δ 7.34 – 7.26 (m, 2H), 7.24 – 7.15 
(m, 3H), 6.17 (dd, J = 9.8, 6.0 Hz, 1H), 5.84 (dd, J = 9.8, 0.9 Hz, 1H), 5.62 (ddd, J = 7.9, 
5.8, 2.2 Hz, 1H), 4.31 (ddd, J = 8.4, 5.0, 3.5 Hz, 1H), 3.50 (s, 3H), 3.05 (dd, J = 9.3, 2.1 
Hz, 1H), 2.82 (dd, J = 13.4, 5.9 Hz, 1H), 2.66 (dd, J = 13.4, 9.0 Hz, 1H), 2.17 – 1.97 (m, 
3H), 1.85 (dt, J = 14.2, 5.4 Hz, 1H), 1.79 (s, 3H), 1.72 – 1.62 (m, 1H), 1.55 – 1.38 (m, 
1H), 1.37 – 1.16 (m, 1H), 1.05 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 7.0 Hz, 3H), 0.69 (t, J = 
7.5 Hz, 3H).  13C NMR (100 MHz, C6D6) δ 170.0, 162.9, 149.1, 141.6, 129.5, 128.6, 
126.2, 121.1, 85.6, 77.3, 71.5, 61.3, 41.9, 39.5, 38.4, 37.9, 34.5, 20.7, 20.6, 12.6, 10.9, 
10.6.  HRMS calc m/z [C24H34O5 + Na]+: 425.2298, found: 425.2246. 
 
(5R,6R)-5-Ethyl-6-((2R,3S,4R,5S)-2-hydroxy-4-methoxy-3,5-dimethyl-6-
phenylhexyl)-5,6-dihydro-2H-pyran-2-one (5.14).  To a solution of lactone 5.33 (13.6 
mg, 33.8 µmol) in MeOH (0.27 mL) was added HCl (3 M in MeOH, 50 µL, 150 µmol).  
The reaction was heated to 60 °C and stirred for 19 h.  The reaction was cooled to room 
temperature and quenched with saturated aqueous NaHCO3 and extracted three times 
with DCM and once with EtOAc.  The combined organic layers were washed with brine 
and dried with anhydrous Na2SO4.  The salts were removed via gravity filtration and 
volatile materials were removed using a rotary evaporator.  The crude material was 
initially purified via silica gel flash chromatography (40% EtOAc in hexanes).  The 
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impure material was further purified via silica gel flash chromatography (45% EtOAc in 
hexanes and 5% to 12.5% EtOAc in DCM) to yield 5.0 mg of product as a white solid 
(41% yield).  1H NMR (400 MHz, CD2Cl2) δ 7.41 – 7.25 (m, 2H), 7.19 (ddd, J = 6.2, 3.2, 
1.8 Hz, 3H), 7.01 (dd, J = 9.8, 5.9 Hz, 1H), 5.97 (dd, J = 9.8, 0.9 Hz, 1H), 4.71 (dt, J = 
9.2, 3.7 Hz, 1H), 4.30 – 4.11 (m, 1H), 3.51 (s, 3H), 3.14 – 3.01 (m, 2H), 2.81 (dd, J = 
13.3, 4.7 Hz, 1H), 2.39 (dd, J = 13.3, 9.7 Hz, 1H), 2.36 – 2.25 (m, 1H), 2.18 – 2.00 (m, 
1H), 1.84 (tt, J = 7.0, 6.1 Hz, 1H), 1.78 – 1.61 (m, 3H), 1.55 – 1.40 (m, 1H), 0.99 (d, J = 
7.1 Hz, 3H), 0.96 (7, J = 7.5 Hz, 3H), 0.90 (d, J = 6.7 Hz, 3H).  13C NMR (100 MHz, 
CD2Cl2) δ 164.8, 151.3, 141.5, 129.7, 128.8, 126.4, 121.2, 91.0, 78.3, 67.9, 61.8, 41.0, 
40.0, 39.6, 38.7, 37.2, 21.4, 15.0, 12.3, 11.3.  HRMS calc m/z [C22H32O4 + Na]+: 
383.2193, found: 383.2095.  99% pure by HPLC analysis. 
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